U.S. patent application number 14/439219 was filed with the patent office on 2015-10-22 for 2-substituted cephem compounds.
The applicant listed for this patent is GLAXO GROUP LIMITED, SHIONOGI & CO., LTD.. Invention is credited to Toshiaki AOKI, Hiroki KUSANO, Xiangmin LIAO, Neil David PEARSON, Israil PENDRAK, Jun SATO, Reema THALGI, Kenji YAMAWAKI, Katsuki YOKOO.
Application Number | 20150299223 14/439219 |
Document ID | / |
Family ID | 49955387 |
Filed Date | 2015-10-22 |
United States Patent
Application |
20150299223 |
Kind Code |
A1 |
AOKI; Toshiaki ; et
al. |
October 22, 2015 |
2-SUBSTITUTED CEPHEM COMPOUNDS
Abstract
The present invention relates to 2-substituted cephem compounds
of Formula (I) having a quaternary ammonium group on the 3-side
chain, preferably together with a cathechol group, or
pharmaceutically acceptable salts thereof, which exhibit potent
antimicrobial spectrum against a variety of bacteria including Gram
negative bacteria and/or Gram positive bacteria, corresponding
pharmaceutical compositions, methods of making, treatment methods
for bacterial infections or uses thereof.
Inventors: |
AOKI; Toshiaki; (Osaka,
JP) ; KUSANO; Hiroki; (Osaka, JP) ; LIAO;
Xiangmin; (Collegeville, PA) ; PEARSON; Neil
David; (Collegeville, PA) ; PENDRAK; Israil;
(Collegeville, PA) ; SATO; Jun; (Osaka, JP)
; THALGI; Reema; (Collegeville, PA) ; YAMAWAKI;
Kenji; (Osaka, JP) ; YOKOO; Katsuki; (Osaka,
JP) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
GLAXO GROUP LIMITED
SHIONOGI & CO., LTD. |
Middlesex
Osaka-shi |
|
GB
JP |
|
|
Family ID: |
49955387 |
Appl. No.: |
14/439219 |
Filed: |
October 29, 2013 |
PCT Filed: |
October 29, 2013 |
PCT NO: |
PCT/IB2013/002423 |
371 Date: |
April 28, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61719523 |
Oct 29, 2012 |
|
|
|
Current U.S.
Class: |
514/207 ;
544/47 |
Current CPC
Class: |
A61P 11/00 20180101;
A61P 1/16 20180101; A61P 1/02 20180101; A61P 31/04 20180101; A61P
17/02 20180101; Y02A 50/473 20180101; A61P 13/02 20180101; A61K
9/0019 20130101; C07D 501/48 20130101; A61P 27/16 20180101; C07D
505/24 20130101; Y02A 50/30 20180101; A61P 9/00 20180101; A61P
13/12 20180101; C07D 501/50 20130101; A61P 1/00 20180101 |
International
Class: |
C07D 501/48 20060101
C07D501/48 |
Claims
1. A compound of the Formula (I): ##STR00547## wherein, R.sup.1 is
an optionally substituted carbocyclic group or an optionally
substituted heterocyclic group; R.sup.2A and R.sup.2B is selected
from: a) R.sup.2A is hydrogen, optionally substituted amino,
--SO.sub.3H, optionally substituted amino sulfonyl, carboxyl,
optionally substituted (lower alkyl)oxycarbonyl, optionally
substituted carbamoyl, hydroxyl, or substituted carbonyloxy; and
R.sup.2B is hydrogen, provided that R.sup.2A and R.sup.2B are not
hydrogen at the same time, or b) R.sup.2A and R.sup.2B are taken
together to form optionally substituted methylidene or optionally
substituted hydroxyimino; R.sup.3 is hydrogen, --OCH.sub.3 or
--NH--CH(.dbd.O); R.sup.5A and R.sup.5B is selected from: a)
R.sup.5A and R.sup.5B are each independently hydrogen, or lower
alkyl and R.sup.5A and R.sup.5B are not hydrogen at the same time,
b) R.sup.5A and R.sup.5B may be taken together with the neighboring
atom to form optionally substituted carbocycle or a optionally
substituted heterocyclic group, or c) R.sup.5A and R.sup.5B may be
taken together to form optionally substituted methylidene; L is
--CH.sub.2--, --CH.dbd.CH--, --CH.sub.2--CH.dbd.CH--,
--CH.dbd.CH--CH.sub.2--, --S--, --CH.sub.2--S--, --CH.dbd.CH--S--
or --CH.dbd.CH--CH.sub.2--S--; E is an optionally substituted
divalent group having at least one quaternary ammonium ion;
R.sup.10 is hydrogen or a group represented by the formula (I-B):
##STR00548## wherein, ring A is a benzene ring, monocyclic
heterocycle or fused heterocycle; n is an integer from 0 to 2; each
R.sup.4 is independently hydrogen, halogen, oxo, --OH, --CN,
--NO.sub.2, --O--C(.dbd.O)--R.sup.9, --C(.dbd.O)--R.sup.9,
--C(.dbd.O)--OH, --C(.dbd.O)--OR.sup.9, --OR.sup.9',
--NR.sup.9R.sup.9, --SO.sub.2R.sup.9, --SR.sup.9,
--NR.sup.9--C(.dbd.O)--R.sup.9, optionally substituted lower alkyl,
optionally substituted cycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl; provided that two hydroxyl
groups on ring A bind respectively to carbon atoms each adjacently
locates; each R.sup.9 is independently lower alkyl or
halo(lower)alkyl; G is a single bond, optionally substituted lower
alkylene, optionally substituted alkenylene or optionally
substituted alkynylene; B is non-existent, a single bond or a 5- or
6-membered heterocyclic group containing at least 1-3 nitrogen
atoms; D is non-existent, a single bond, --C(.dbd.O)--,
--O--C(.dbd.O)--, --C(.dbd.O)--O--, --NR.sup.6--,
--NR.sup.6--C(.dbd.O)--, --C(.dbd.O)--NR.sup.6--,
--C(.dbd.O)--C(.dbd.O)--, --NR.sup.6--C(.dbd.O)--NR.sup.6--,
--C(.dbd.O)--C(.dbd.O)--NR.sup.6--,
--C(.dbd.O)--NR.sup.6--C(.dbd.O)--,
--NR.sup.6--C(.dbd.O)--C(.dbd.O)--,
--NR.sup.6--NR.sup.6--C(.dbd.O)--,
--C(.dbd.O)--NR.sup.6--NR.sup.6--, --N.dbd.N--C(.dbd.O)--,
--C(.dbd.O)--N.dbd.N--, --C.dbd.N--NR.sup.6--C(.dbd.O)--,
--C.dbd.N--C(.dbd.O)--, --N.dbd.C--C(.dbd.O)--,
--C.dbd.N--C(.dbd.O)--NR.sup.6--,
--NR.sup.6--C(.dbd.O)--C(.dbd.N--OR.sup.6)--,
--C(.dbd.N--OR.sup.6)--C(.dbd.O)--NR.sup.6--,
--NR.sup.6--C(.dbd.N--OR.sup.6)--,
--C(.dbd.N--OR.sup.6)--NR.sup.6--,
--C(.dbd.O)--C(.dbd.N--OR.sup.6)--,
--C(.dbd.N--OR.sup.6)--C(.dbd.O)--, --O--, --S--, --S(.dbd.O)--,
--S(.dbd.O).sub.2--NR.sup.6--, --NR.sup.6--S(.dbd.O).sub.2--,
--NR.sup.6--CH.sub.2--, --CH.sub.2--NR.sup.6-- or
--S(.dbd.O).sub.2--; each R.sup.6 is independently hydrogen or
optionally substituted lower alkyl; provided that: when R.sup.10 is
hydrogen, E is an optionally substituted divalent cyclic group
having at least one quanternary ammonium ion and at least two
hydroxyl groups which bind respectively to carbon atoms each
adjacently locates on the cyclic group-; or an ester at carboxyl
group, an amino-protected compound when the amino is present on a
ring in the 7-side chain; or a pharmaceutically acceptable salt
thereof.
2. The compound of Formula (I) according to claim 1 or an ester at
carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof, wherein R.sup.5A is hydrogen and R.sup.5B
is lower alkyl.
3. The compound of Formula (I) according to claim 1 or an ester at
carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof according to claim 1, wherein, R.sup.10 is
a group represented by the formula (I-B): ##STR00549## wherein each
symbol is as defined in claim 1.
4. The compound of Formula (I) according to claim 1 or an ester at
carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof according to claim 1, wherein ring A is a
benzene ring or monocyclic heterocycle.
5. The compound of Formula (I) according to claim 1 or an ester at
carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof according to claim 1, wherein, ring A is
fused heterocycle.
6. The compound of Formula (I) according to claim 1 or an ester at
carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof according to claim 1, wherein: R.sup.10 is
hydrogen; and E is an optionally substituted divalent cyclic group
having at least one quanternary ammonium ion and at least two
hydroxyl groups which bind respectively to carbon atoms each
adjacently locates on the cyclic group.
7. The compound of Formula (I) according to claim 1 or an ester at
carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof, wherein: G is a single bond, --CH.sub.2--,
--CH.sub.2--CH.sub.2--, --CH.sub.2--CH.sub.2--CH.sub.2--,
--CH.dbd.CH--, --CH.dbd.CH--CH.sub.2--, --CH.sub.2--CH.dbd.CH--,
--CH.sub.2--CH(CH.sub.3)--, --CH.sub.2--CH(.sup.iPr)- or
--CH.sub.2--CH(Ph)-; and wherein .sup.iPr is isopropyl and Ph is
phenyl.
8. The compound of Formula (I) according to claim 1 or an ester at
carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof, wherein: B is non-existent, a single bond
or a group represented by the formula: ##STR00550## and the bond of
the left side is attached to G and the bond of the right side is
attached to D.
9. The compound of Formula (I) according to claim 1 or an ester at
carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof, wherein: D is non-existent, a single bond,
--C(.dbd.O)--, --O--C(.dbd.O)--, --C(.dbd.O)--O--, --NR.sup.6--,
--O--, --C(.dbd.O)--C(.dbd.O), --NR.sup.6--C(.dbd.O)--NR.sup.6--,
--C(.dbd.O)--C(.dbd.O)--NR.sup.6--,
--C(.dbd.O)--NR.sup.6--C(.dbd.O)--,
--NR.sup.6--C(.dbd.O)--C(.dbd.O)--, --NR.sup.6--C(.dbd.O)--,
--C(.dbd.O)--NR.sup.6--, --NR.sup.6--NR.sup.6--C(.dbd.O)--,
--C(.dbd.O)--NR.sup.6--NR.sup.6--, --N.dbd.N--C(.dbd.O)--,
--C(.dbd.O)--N.dbd.N--, --C.dbd.N--NR.sup.6--C(.dbd.O)--,
--C.dbd.N--C(.dbd.O)--, --N.dbd.C--C(.dbd.O)--,
--C.dbd.N--C(.dbd.O)--NR.sup.6--,
--NR.sup.6--C(.dbd.O)--C(.dbd.N--OR.sup.6)--,
--C(.dbd.N--OR.sup.6)--C(.dbd.O)--NR.sup.6--,
--NR.sup.6--C(.dbd.N--OR.sup.6)--,
--C(.dbd.O)--C(.dbd.N--OR.sup.6)--,
--C(.dbd.N--OR.sup.6)--C(.dbd.O)-- or
--C(.dbd.N--OR.sup.6)--NR.sup.6--; and wherein R.sup.6 is as
defined in claim 1.
10. The compound of Formula (I) according to claim 1 or an ester at
carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof, wherein, the formula (I-C-1): ##STR00551##
is a group selected from the following formulae: ##STR00552##
##STR00553## ##STR00554## wherein: each R.sup.4a, R.sup.4b and
R.sup.4c is independently hydrogen, halogen, --OH, --CN,
--C(.dbd.O)--R.sup.9, --C(.dbd.O)--OH, --C(.dbd.O)--OR.sup.9,
--OR.sup.9, optionally substituted lower alkyl, or optionally
substituted cycloalkyl; each R.sup.6 and R.sup.9 independently are
as defined in claim 1; and the wavy line means that the bond is in
cis or trans configuration, or a mixture thereof.
11. The compound of Formula (I) according to claim 10 or an ester
at carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof, wherein, the Formula (I-C-1): ##STR00555##
is a group selected from the following formulae: ##STR00556##
##STR00557## ##STR00558## ##STR00559## ##STR00560## ##STR00561##
##STR00562## ##STR00563## ##STR00564## wherein: R.sup.6 is
hydrogen, methyl, ethyl, tert-buthyl, carboxymethyl,
0.2-carboxypropan-2-yl or 1-carboxyethyl; and the wavy line means
that the bond is in cis or trans configuration, or a mixture
thereof.
12. The compound of Formula (I) according to claim 1 or an ester at
carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof, wherein, the formula (I-C-1): ##STR00565##
is a group selected from the following formulae: ##STR00566##
##STR00567## ##STR00568## ##STR00569## ##STR00570## ##STR00571##
##STR00572## wherein: each R.sup.4a R.sup.4b and R.sup.4d is
independently hydrogen, halogen, --OH, --CN, --C(.dbd.O)--R.sup.9,
--C(.dbd.O)--OR.sup.9, --OR.sup.9, optionally substituted lower
alkyl, or optionally substituted cycloalkyl; and R.sup.6 and
R.sup.9 are as defined in claim 1; the wavy line means that the
bond is in cis or trans configuration, or a mixture thereof.
13. The compound of Formula (I) according to claim 12 or an ester
at carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof, wherein, the Formula (I-C-1): ##STR00573##
is a group selected from the following formulae: ##STR00574##
##STR00575## ##STR00576## ##STR00577## ##STR00578## ##STR00579##
##STR00580## ##STR00581## ##STR00582## ##STR00583##
14. The compound of Formula (I) according to claim 1 or an ester at
carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof, wherein E is an optionally substituted,
saturated or unsaturated, monocyclic or fused cyclic group having
at least one quaternary ammonium ion represented by the formula
(I-D): ##STR00584## wherein, the dashed line is a bond in the ring;
the bond to the cationic nitrogen atom binds to L, and the other
bond binds to R.sup.10; provided, when a cationic nitrogen atom
binds to R.sup.10, the dashed line is absent, and when a cationic
nitrogen atom does not bind to R.sup.10, the dashed line is a
single bond between the cationic nitrogen atom and a neighboring
atom or an alkylene group between the cationic nitrogen atom and a
ring member atom other than said neighboring atom.
15. The compound of Formula (I) according to claim 1 or an ester at
carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof according to, wherein E is an optionally
substituted, saturated or unsaturated, monocyclic or fused cyclic
group having at least one quaternary ammonium ion represented by
the formula (I-E): ##STR00585## wherein: the bond to the cationic
nitrogen atom binds to L, and the other bond binds to R.sup.10;
R.sup.x is optionally substituted lower alkyl.
16. The compound of Formula (I) according to claim 1 or an ester at
carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof, wherein L is --S--, --CH.sub.2--S--,
--CH.dbd.CH--S-- or --CH.dbd.CH--CH.sub.2--S-- and E is an
optionally substituted pyridinium group or an optionally
substituted fused pyridinium group.
17. The compound of Formula (I) according to claim 16 or an ester
at carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof, E is a group selected from the following
formulae which are optionally substituted on the ring; ##STR00586##
wherein the bond to the cationic nitrogen atom binds to R.sup.10,
the other bond binds to L.
18. The compound of Formula (I) according to claim 1 or an ester at
carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof according to, wherein E is a group selected
from the following formulae which are optionally substituted on the
ring: ##STR00587## ##STR00588## ##STR00589## ##STR00590##
##STR00591## ##STR00592## ##STR00593## ##STR00594## ##STR00595##
##STR00596## wherein, the bond to the quaternary nitrogen atom
binds to L, and the other bond binds to R.sup.10; p is an integer
from 1 to 3; n is an integer of 1 or 2; R.sup.x is optionally
substituted lower alkyl.
19. The compound of Formula (I) according to claim 13 or an ester
at carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof, wherein, E is selected from the group
consisting of the formulae (2), (3), (7), (10), (11), (26), (27),
(41), (42), (59), (60) and (77).
20. The compound of Formula (I) according to claim 1 or an ester at
carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof, wherein E is a group selected from the
following formulae which are optionally substituted on the ring:
##STR00597## ##STR00598## ##STR00599## ##STR00600## ##STR00601##
wherein, the bond to the quaternary nitrogen atom binds to L, and
the other bond binds to R.sup.10.
21. The compound of Formula (I) according to claim 20 or an ester
at carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof, wherein E-R.sup.10 is a group selected
from the following formulae: ##STR00602## wherein, the bond to the
quaternary nitrogen atom binds to L.
22. The compound of Formula (I) according to claim 21 or an ester
at carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof, wherein E-R.sup.10 is represented by the
formula: ##STR00603## wherein, the bond to the quaternary nitrogen
atom binds to L.
23. The compound of Formula (I) according to claim 16 or an ester
at carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof, wherein -L-E- is represented by the
formula; ##STR00604## wherein, the bond to the quaternary nitrogen
atom binds to R10, the other bond binds to cephem at 3
position.
24. The compound of Formula (I) according to claim 1 or an ester at
carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof, wherein R.sup.3 is hydrogen or
--OCH.sub.3.
25. The compound of Formula (I) according to claim 1 or an ester at
carboxyl group, an amino-protected compound when the aminos is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof according to, wherein R.sup.1 is an
optionally substituted phenyl.
26. The compound of Formula (I) according to claim 1 or an ester at
carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof, wherein R.sup.1 is represented by the
formula: ##STR00605## wherein, X is N, C(--H) or C(--Cl).
27. The compound of Formula (I) according to claim 26 or an ester
at carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof according, wherein, X is N.
28. The compound of Formula (I) according to claim 26 or an ester
at carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof, wherein, X is C(--H) or C(--Cl).
29. The compound of Formula (I) according to claim 1 or an ester at
carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof according to wherein, R.sup.2A is hydrogen,
optionally substituted amino, --SO.sub.3H, optionally substituted
amino sulfonyl, carboxyl, optionally substituted carbamoyl,
hydroxyl, or substituted carbonyloxy, and R.sup.2B is hydrogen.
30. The compound of Formula (I) according to claim 1 or an ester at
carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof according to, wherein, R.sup.2A is:
substituted amino shown below: ##STR00606## substituted amino
sulfonyl shown below: ##STR00607## wherein, ring B represents an
optionally substituted heterocyclic group; substituted carbamoyl
shown below: ##STR00608## wherein, ring B represents an optionally
substituted heterocyclic group; or substituted carbonyloxy shown
below: ##STR00609## wherein, ring B represents an optionally
substituted heterocyclic group.
31. The compound of Formula (I) according to claim 1 or an ester at
carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof according to, wherein, R.sup.2A and
R.sup.2B are taken together to form: substituted methylidene shown
below: ##STR00610## substituted hydroxyimino shown below:
##STR00611## wherein, R.sup.9 is optionally substituted lower
alkyl.
32. The compound of Formula (I) according to claim 1 or an ester at
carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof according to, wherein R.sup.2A and R.sup.2B
are taken together to form substituted hydroxyimino shown below:
##STR00612## wherein, R.sup.7 and R.sup.8 are each independently
hydrogen, halogen, hydroxyl, carboxyl, optionally substituted lower
alkyl, an optionally substituted carbocyclic group, or an
optionally substituted heterocyclic group, or R.sup.7 and R.sup.8
may be taken together with a neighboring atom to form an optionally
substituted carbocyclic group or an optionally substituted
heterocyclic group; Q is a single bond, an optionally substituted
carbocyclic group or an optionally substituted heterocyclic group;
and m is an integer from 0 to 3.
33. A compound of Formula (I-G-1): ##STR00613## an ester at
carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof, wherein, each symbol is as defined above
as in claim 1.
34. The compound of Formula (I-G-1) according to claim 33 or, an
ester at carboxyl group, an amino-protected compound when the amino
is present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt, wherein, R.sup.5A is hydrogen and R.sup.5B is
lower alkyl; R.sup.10 is a group represented by the Formula (I-B);
##STR00614## each symbol is as defined above as in claim 33.
35. The compound of Formula (I-G-1) according to claim 33 or, an
ester at carboxyl group, an amino-protected compound when the amino
is present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof, wherein: X is C(--H), C(--Cl) or N; each
R.sup.7 and R.sup.8 is independently hydrogen or lower alkyl; R3 is
hydrogen; m is 0 or 1; Q is a single bond; L is --CH2-; E is a
group selected from the following formulae; ##STR00615## wherein:
Rx is lower alkyl, p is an integer from 1 to 3; G is a single bond
or lower alkylene; B is non-existent, a single bond; D is
non-existent, a single bond, --C(.dbd.O)--,
--C(.dbd.O)--C(.dbd.O)--, --NR.sup.6--C(.dbd.O)--C(.dbd.O)--,
--NR.sup.6--C(.dbd.O)-- or --NH--C(.dbd.O)--C(.dbd.N--OR.sup.6a);
R.sup.6 is hydrogen or lower alkyl; R.sup.6a is hydrogen, methyl,
carboxymethyl, or 2-carboxypropane-2-yl; the formula (1-B-2);
##STR00616## is a group selected from the following formulae;
##STR00617## wherein: each R.sup.4a, R.sup.4b and R.sup.4c is
independently hydrogen, halogen or lower alkyl; and R.sup.4d is
hydrogen, lower alkyl or lower cycloalkyl.
36. A pharmaceutical composition, which comprises a compound of
Formula (I) according to claim 1, an ester at carboxyl group, an
amino-protected compound when the amino is present on the ring in
the 7-side chain, or a pharmaceutically acceptable salt
thereof.
37. The pharmaceutical composition according to claim 36, which
possesses antimicrobial activity.
38. The compound of Formula (I) according to claim 1, an ester at
carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof according to, wherein the Formula (I-C-1)
is: ##STR00618## wherein: ring A is defined as a fused heterocycle
ring system comprised of at least two (2) rings fused together;
R.sup.4 optionally is substituted on each of the at least two (2)
rings of the fused heterocycle ring system defined as ring A, such
that each R4 substituent on each ring of the fused heterocycle ring
system independently are selected from identical or different
substituents; wherein: each R.sup.4 as defined above optionally is
substituted independently on each ring of the fused heterocycle
ring is selected from hydrogen, halogen, oxo, --OH, --CN,
--NO.sub.2, --O--C(.dbd.O)--R.sup.9, --C(.dbd.O)--R.sup.9,
--C(.dbd.O)--OH, --C(.dbd.O)--OR.sup.9, --OR.sup.9',
--NR.sup.9R.sup.9, --SO.sub.2R.sup.9, --SR.sup.9,
--NR.sup.9--C(.dbd.O)--R.sup.9, optionally substituted lower alkyl,
optionally substituted cycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl; provided that two hydroxyl
groups on ring A bind respectively to carbon atoms each adjacently
locates; and n is an integer from 0 to 2.
39. A method for treating bacterial infections, which comprises
administering a compound of Formula (I) according to claim 1 to a
subject in need thereof.
40. The method according to claim 39, wherein the bacterial
infections are caused by Gram-Negative bacteria or Gram-Positive
bacteria.
41. The method according to claim 39, wherein the compounds of
Formula (I) exhibit potent antimicrobial activity against
beta-lactamase producing Gram negative bacteria;
42. The method according to claim 39, wherein the Gram negative
bacteria is selected from: Gram negative bacteria of enterobacteria
selected from E. coli, Klebsiella, Serratia, Enterobacter,
Citrobacter, Morganella, Providencia or Proteus; Gram negative
bacteria colonized in respiratory system selected from Haemophilus,
Moraxella; Gram negative bacteria of glucose non fermentation
selected from Pseudomonas aeruginosa, Pseudomonas other than P.
aeruginosa, Stenotrophomonas, Burkholderia or Acinetobacter; Gram
negative multidrug-resistant bacteria selected from Class B type
metallo-beta-lactamase producing Gram negative bacteria, and
extended-spectrum beta-lactamase (ESBL) producing bacteria; or Gram
beta-lactam drug resistant Gram negative bacteria selected from
ESBL producing bacteria.
43. The method according to claim 39, wherein the Gram positive
bacteria is selected from methicillin-resistant Staphylococcus
aureus (MRSA) or penicillin-resistant Streptococcus pneumoniae
(PRSP).
44. A method for treating biothreat organisms, which comprises
administering a compound of Formula (I) according to claim 1 to a
subject in need thereof.
45. The method according to claim 43, wherein the biothreat
organisms are selected from Yersinia pestis, Bacillus anthracis,
Francisella tularensis, Burkholderia mallei Burkholderia
pseudomallei, Brucella suis, Brucella melitensis or Brucella
abortus.
46. A method for treating Gram-negative bacterial infections, which
comprises administering a compound of Formula (I) according to
claim 1 to a subject in need thereof.
47. A method for treating Gram-positive bacterial infections, which
comprises administering a compound of Formula (I) according to
claim 1 to a subject in need thereof.
Description
TECHNICAL FIELD
[0001] The compounds of the subject invention are related to
2-substituted cephem compounds, which have a wide antimicrobial
spectrum, in particular exhibit potent antimicrobial activity
against beta-lactamase producing Gram negative bacteria, and
pharmaceutical compositions comprising the same.
BACKGROUND
[0002] To date, a variety of beta-lactam drugs have been developed
and beta-lactam drugs have become clinically extremely important
antimicrobial drugs. However, there are increasing number of
bacterial types which have obtained resistance against beta-lactam
drugs by producing beta-lactamase, which degrade beta-lactam
drugs.
[0003] According to the Ambler molecular classification,
beta-lactamases are largely classified into four classes.
Specifically, these are Class A (TEM type, SHV type, CTX-M type,
KPC type and the like), Class B (IMP type, VIM type, L-1 type and
the like), Class C (AmpC type) and Class D (OXA type and the like).
Amongst these, Classes A, C and D types are largely classified into
serine-beta-lactamase, on the other hand, Class B type is
classified into metallo-beta-lactamase. It has been known that both
have respectively different mechanisms to each other in terms of
hydrolysis of beta-lactam drugs.
[0004] Recently, clinical problem has been occurring due to the
existence of Gram negative bacteria which have become highly
resistant to a number of beta-lactam drugs including Cephems and
Carbapenems by producing Class A (ESBL) and D types
serine-beta-lactamases which have an extended substrate spectrum,
and Class B type metallo-beta-lactamase which have an extended
substrate spectrum. Particularly, metallo-beta-lactamase is known
to be one of the causes of obtaining multidrug-resistance in Gram
negative bacteria. Cephem compounds which exhibit intermediate
activity against metallo-beta-lactamase producing Gram negative
bacteria are known (e.g., International Publication No. 2007/119511
pamphlet and Applied Microbiology and Biotechnology (1994), 40(6),
892-7). However, there is a demand for development of Cephem
compounds which exhibit more potent antimicrobial activity, in
particular more effective against a variety of beta-lactamase
producing Gram negative bacteria.
[0005] One of the known antimicrobials having high anti-Gram
negative bactericidal activity is Cephem compounds having a
catechol group intramolecularly (e.g., The Journal of Antibiotics,
vol. 61, pp. 36-39 (2008); The Journal of Antibiotics, vol. 43, pp.
1617-1620 (1990) The Journal of Antibiotics, vol. 42, pp. 795-806
(1989)). The action thereof is that the catechol group forms a
chelate with Fe.sup.3+, thereby the compound is efficiently
incorporated into the bacterial body through the Fe.sup.3+
transportation system on the cellular membrane (tonB-dependent iron
transport system). Therefore, research has been conducted on
compounds having catechol or similar structure thereto, on the
3-side chain or 7-side chain moiety on the Cephem backbone.
[0006] Examples in the non-patent literature (i.e., e.g., see,
Applied Microbiology and Biotechnology (1994), 40(6), 892-7) and
patent literature (i.e., see Japanese Laid-Open Publication No.
4-364189; Japanese Laid-Open Publication No. 3-173893; Japanese
Laid-Open Publication No. 2-15090; Japanese Laid-Open Publication
No. 2-28187; Japanese Laid-Open Publication No. 2-117678; Japanese
Laid-Open Publication No. 2-28185), respectively, describe catechol
type derivatives having a catechol group on the 3-side chain moiety
on the Cephem backbone. Other patent documents (i.e., e.g.,
Japanese Laid-Open Publication No. 2-15090; Japanese Laid-Open
Publication No. 2-28187; Japanese Laid-Open Publication No.
6-510523; and Japanese Laid-Open Publication No. 5-213971) describe
pseudo-catechol type derivatives having a hydroxypyridone group on
the 3-side chain moiety on the Cephem backbone. Patent Documents,
International Publication No. 2007/096740 pamphlet and
International Publication No. 2003/078440 pamphlet disclose Cephem
compounds having a quaternary ammonium group, but do not describe a
catechol type derivative.
[0007] Moreover, in the above documents, which describe Cephem
compounds having a catechol group in their structure, there is no
description of Class B type metallo-beta-lactamase and specific
antimicrobial activity against a wide variety of Gram negative
bacteria including Class B type.
[0008] Additionally, specific patent literature documents (i.e.,
e.g., European Patent Publication No. 35357 and U.S. Pat. No.
3,487,079) and non-patent literature documents (i.e., e.g.,
Chemical & Pharmaceutical Bulletin, vol. 31, 1482-1493 (1983);
Journal of Medicinal Chemistry, vol. 14, 420-425 (1971); and
International Journal of Peptide & Protein Research, vol. 10,
51-59 (1977)), respectively, describe cephem compounds having a
substituent at position 2 of the cephem skeleton. However, these
compounds do not have a quaternary ammonium group and a cathechol
group at position 3 of the cephem skeleton.
[0009] Non-patent literature (e.g., The Journal of Antibiotics,
vol. 41, pp. 1154-1157 (1988); The Journal of Antibiotics, vol. 43,
pp. 357-371 (1989)) describe oxa-cephem compounds having a
substituent at position 2 of the oxa-cephem skeleton. However,
these compounds do not have a cathechol group at position 3 of the
oxa-cephem skeleton.
[0010] The present applicant has filed patent applications of
cephem compounds having catechol type substituents (e.g.,
International Publication No. 2010/050468 pamphlet; International
Publication No. 2011/125966 pamphlet; International Publication No.
2011/125967 pamphlet and International Publication No. 2011/136268
pamphlet). However, these applications do not disclose a compound
having a substituent at position 2 of the cephem skeleton.
SUMMARY OF INVENTION
Problems to be Solved by the Invention
[0011] The subject invention provides 2-substituted cephem
compounds having a quaternary ammonium group on the 3-side chain,
preferably together with a cathechol group, which exhibit potent
antimicrobial spectrum against a variety of bacteria including Gram
negative bacteria and/or Gram positive bacteria. Preferably, the
compounds are effective against beta-lactamase producing Gram
negative bacteria, including multidrug-resistant bacteria, in
particular, Class B type metallo-beta-lactamase producing Gram
negative bacteria, and extended-spectrum beta-lactamase (ESBL)
producing bacteria. Furthermore, the subject invention provides
preferably cephem compounds having antimicrobial activity against
strains resistant to 2-unsubstituted cephem compounds.
Means for Solving the Problem
[0012] The subject invention provides cephem compounds which have
solved the above-mentioned problems with the following structural
characteristics:
[0013] 1) a substituent group(s) at the position 2, preferably an
alkyl group.
[0014] 2) a quaternary ammonium group on the 3-side chain.
[0015] 3) a cathechol group at the terminal or in the quaternary
ammonium group of the 3-side chain as a preferable embodiment.
[0016] The subject invention provides the following inventions:
1. A compound of the formula (I):
##STR00001##
an ester at carboxyl group, an amino-protected compound when the
amino is present on a ring in the 7-side chain, or a
pharmaceutically acceptable salt thereof, wherein,
[0017] R.sup.1 is an optionally substituted carbocyclic group or an
optionally substituted heterocyclic group;
[0018] with regard to R.sup.2A and R.sup.2B,
[0019] a) R.sup.2A is hydrogen, optionally substituted amino,
--SO.sub.3H, optionally substituted amino sulfonyl, carboxyl,
optionally substituted (lower alkyl)oxycarbonyl, optionally
substituted carbamoyl, hydroxyl, or substituted carbonyloxy; and
R.sup.2B is hydrogen, provided that R.sup.2A and R.sup.2B are not
hydrogen at the same time, or
[0020] b) R.sup.2A and R.sup.2B are taken together to form
optionally substituted methylidene or optionally substituted
hydroxyimino;
[0021] R.sup.3 is hydrogen, --OCH.sub.3 or --NH--CH(.dbd.O);
[0022] with regard to R.sup.5A and R.sup.5B,
[0023] a) R.sup.5A and R.sup.5B are each independently hydrogen, or
lower alkyl and R.sup.5A and R.sup.5B are not hydrogen at the same
time,
[0024] b) R.sup.5A and R.sup.5B may be taken together with the
neighboring atom to form optionally substituted carbocycle or a
optionally substituted heterocyclic group, or
[0025] c) R.sup.5A and R.sup.5B may be taken together to form
optionally substituted methylidene;
[0026] L is --CH.sub.2--, --CH.dbd.CH--, --CH.sub.2--CH.dbd.CH--,
--CH.dbd.CH--CH.sub.2--, --S--, --CH.sub.2--S--, --CH.dbd.CH--S--
or --CH.dbd.CH--CH.sub.2--S--;
[0027] E is an optionally substituted divalent group having at
least one quaternary ammonium ion;
[0028] R.sup.10 is hydrogen or a group represented by the formula
(I-B)
##STR00002##
wherein,
[0029] ring A is a benzene ring, monocyclic heterocycle or fused
heterocycle;
[0030] n is an integer from 0 to 2;
[0031] each R.sup.4 is independently hydrogen, halogen, oxo, --OH,
--CN, --NO.sub.2, --O--C(.dbd.O)--R.sup.9, --C(.dbd.O)--R.sup.9,
--C(.dbd.O)--OH, --C(.dbd.O)--OR.sup.9, --OR.sup.9',
--NR.sup.9R.sup.9, --SO.sub.2R.sup.9, --SR.sup.9,
--NR.sup.9--C(.dbd.O)--R.sup.9, optionally substituted lower alkyl,
optionally substituted cycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl; provided that two hydroxyl
groups on ring A bind respectively to carbon atoms each adjacently
locates;
[0032] each R.sup.9 is independently lower alkyl or
halo(lower)alkyl;
[0033] G is a single bond, optionally substituted lower alkylene,
optionally substituted alkenylene or optionally substituted
alkynylene;
[0034] B is non-existent, a single bond or a 5- or 6-membered
heterocyclic group containing at least 1-3 nitrogen atoms;
[0035] D is non-existent, a single bond, --C(.dbd.O)--,
--O--C(.dbd.O)--, --C(.dbd.O)--O--, --NR.sup.6--C(.dbd.O)--,
--C(.dbd.O)--NR.sup.6--, --C(.dbd.O)--C(.dbd.O)--,
--NR.sup.6--C(.dbd.O)--NR.sup.6--,
--C(.dbd.O)--C(.dbd.O)--NR.sup.6--,
--C(.dbd.O)--NR.sup.6--C(.dbd.O)--,
--NR.sup.6--C(.dbd.O)--C(.dbd.O)--,
--NR.sup.6--NR.sup.6--C(.dbd.O)--,
--C(.dbd.O)--NR.sup.6--NR.sup.6--, --N.dbd.N--C(.dbd.O)--,
--C(.dbd.O)--N.dbd.N--, --C.dbd.N--NR.sup.6--C(.dbd.O)--,
--C.dbd.N--C(.dbd.O)--, --N.dbd.C--C(.dbd.O)--,
--C.dbd.N--C(.dbd.O)--NR.sup.6--,
--NR.sup.6--C(.dbd.O)--C(.dbd.N--OR.sup.6)--,
--C(.dbd.N--OR.sup.6)--C(.dbd.O)--NR.sup.6--, --NR.sup.6--,
C(.dbd.N--OR.sup.6)--, --C(.dbd.N--OR.sup.6)--NR.sup.6--,
--C(.dbd.O)--C(.dbd.N--OR.sup.6)--,
--C(.dbd.N--OR.sup.6)--C(.dbd.O)--, --O--, --S--, --S(.dbd.O)--,
--S(.dbd.O).sub.2--NR.sup.6--, --NR.sup.6--S(.dbd.O).sub.2--,
--NR.sup.6--CH.sub.2--, --CH.sub.2--NR.sup.6-- or
--S(.dbd.O).sub.2--;
[0036] each R.sup.6 is independently hydrogen or optionally
substituted lower alkyl;
provided that when R.sup.10 is hydrogen, E is an optionally
substituted divalent cyclic group having at least one quanternary
ammonium ion and at least two hydroxyl groups which bind
respectively to carbon atoms each adjacently locates on the cyclic
group.
[0037] In one aspect of the present invention Formula (I-B) is
defined as follows:
##STR00003##
where:
[0038] ring A is defined as a fused heterocycle ring system
comprised of at least two (2) rings fused together;
[0039] where:
[0040] R.sup.4 optionally is substituted on each of the at least
two (2) rings of the fused heterocycle ring system defined as ring
A, such that each R4 substituent on each ring of the fused
heterocycle ring system independently are selected from identical
or different substituents;
[0041] where: [0042] each R.sup.4 as defined above optionally is
substituted independently on each ring of the fused heterocycle
ring is selected from hydrogen, halogen, oxo, --OH, --CN,
--NO.sub.2, --O--C(.dbd.O)--R.sup.9, --C(.dbd.O)--R.sup.9,
--C(.dbd.O)--OH, --C(.dbd.O)--OR.sup.9, --OR.sup.9',
--NR.sup.9R.sup.9, --SO.sub.2R.sup.9, --SR.sup.9,
--NR.sup.9--C(.dbd.O)--R.sup.9, optionally substituted lower alkyl,
optionally substituted cycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl; [0043] provided that two
hydroxyl groups on ring A bind respectively to carbon atoms each
adjacently locates; and n is an integer from 0 to 2. 2. The
compound, an ester at carboxyl group, an amino-protected compound
when the amino is present on the ring in the 7-side chain, or a
pharmaceutically acceptable salt thereof according to the above 1,
wherein R.sup.5A is hydrogen and R.sup.5B is lower alkyl. 3. The
compound, an ester at carboxyl group, an amino-protected compound
when the amino is present on the ring in the 7-side chain, or a
pharmaceutically acceptable salt thereof according to the above 1
or 2, wherein, R.sup.10 is a group represented by the formula
(I-B):
##STR00004##
[0043] wherein, each symbol is as defined above in 1 and throughout
the instant specification. 4. The compound, an ester at carboxyl
group, an amino-protected compound when the amino is present on the
ring in the 7-side chain, or a pharmaceutically acceptable salt
thereof according to the above 1, 2 or 3, wherein, ring A is a
benzene ring or monocyclic heterocycle. 5. The compound, an ester
at carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof according to the above 1, 2 or 3, wherein,
ring A is fused heterocycle or an optionally substituted fused
heterocycle, where each ring of the fused heterocycle independently
is substituted with identical or different substituents.
[0044] In one aspect, ring A as defined herein is a fused
heterocycle ring system comprised of at least two (2) rings fused
together optionally substituted by substituents selected from
R.sup.4;
[0045] where:
[0046] R.sup.4 optionally is substituted on each of the at least
two (2) rings of the fused heterocycle ring system defined as ring
A, such that each R4 substituent on each ring of the fused
heterocycle ring system independently are selected from identical
or different substituents;
[0047] where: [0048] each R.sup.4 as defined above optionally is
substituted independently on each ring of the fused heterocycle
ring is selected from hydrogen, halogen, oxo, --OH, --CN,
--NO.sub.2, --O--C(.dbd.O)--R.sup.9, --C(.dbd.O)--R.sup.9,
--C(.dbd.O)--OH, --C(.dbd.O)--OR.sup.9, --OR.sup.9',
--NR.sup.9R.sup.9, --SO.sub.2R.sup.9, --SR.sup.9,
--NR.sup.9--C(.dbd.O)--R.sup.9, optionally substituted lower alkyl,
optionally substituted cycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl; [0049] provided that two
hydroxyl groups on ring A bind respectively to carbon atoms each
adjacently locates; and [0050] n is an integer from 0 to 2. 6. The
compound, an ester at carboxyl group, an amino-protected compound
when the amino is present on the ring in the 7-side chain, or a
pharmaceutically acceptable salt thereof according to the above 1
or 2, wherein, R.sup.10 is hydrogen; E is an optionally substituted
divalent cyclic group having at least one quanternary ammonium ion
and at least two hydroxyl groups which bind respectively to carbon
atoms each adjacently locates on the cyclic group. 7. The compound,
an ester at carboxyl group, an amino-protected compound when the
amino is present on the ring in the 7-side chain, or a
pharmaceutically acceptable salt thereof according to any one of
the above 1 to 5, wherein, G is a single bond, --CH.sub.2--,
--CH.sub.2--CH.sub.2--, --CH.sub.2--CH.sub.2--CH.sub.2--,
--CH.dbd.CH--, --CH.dbd.CH--CH.sub.2--, --CH.sub.2--CH.dbd.CH--,
--CH.sub.2--CH(CH.sub.3)--, --CH.sub.2--CH(.sup.iPr)- or
--CH.sub.2--CH(Ph)- wherein .sup.iPr is isopropyl and Ph is phenyl.
8. The compound, an ester at carboxyl group, an amino-protected
compound when the amino is present on the ring in the 7-side chain,
or a pharmaceutically acceptable salt thereof according to the
above 1, 2, 3, 4, 5 or 7, wherein, B is non-existent, a single bond
or a group represented by the formula:
##STR00005##
[0050] wherein, the bond of the left side is attached to G and the
bond of the right side is attached to D. 9. The compound, an ester
at carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof according to the above 1, 2, 3, 4, 5, 7 or
8, wherein, D is non-existent, a single bond, --C(.dbd.O)--,
--O--C(.dbd.O)--, --C(.dbd.O)--O--, --NR.sup.6--, --O--,
--C(.dbd.O)--C(.dbd.O)--, --NR.sup.6--C(.dbd.O)--NR.sup.6--,
--C(.dbd.O)--C(.dbd.O)--NR.sup.6--,
--C(.dbd.O)--NR.sup.6--C(.dbd.O)--,
--NR.sup.6--C(.dbd.O)--C(.dbd.O)--, --NR.sup.6--C(.dbd.O)--,
--C(.dbd.)--NR.sup.6--, --NR.sup.6--NR.sup.6--C(.dbd.O)--,
--C(.dbd.O)--NR.sup.6--NR.sup.6--, --N.dbd.N--C(.dbd.O)--,
--C(.dbd.O)--N.dbd.N--, --C.dbd.N--NR.sup.6--C(.dbd.O)--,
--C.dbd.N--C(.dbd.O)--, --N.dbd.C--C(.dbd.O)--,
--C.dbd.N--C(.dbd.O)--NR.sup.6--,
--NR.sup.6--C(.dbd.O)--C(.dbd.N--OR.sup.6)--,
--C(.dbd.N--OR.sup.6)--C(.dbd.O)--NR.sup.6--,
--NR.sup.6--C(.dbd.N--OR.sup.6)--,
--C(.dbd.O)--C(.dbd.N--OR.sup.6)--,
--C(.dbd.N--OR.sup.6)--C(.dbd.O)-- or
--C(.dbd.N--OR.sup.6)--NR.sup.6--, wherein R.sup.6 is as defined in
the above 1.
[0051] In one aspect, The compound, an ester at carboxyl group, an
amino-protected compound when the amino is present on the ring in
the 7-side chain, or a pharmaceutically acceptable salt thereof
according to the above 1, 2, 3, 5, 7, 8 or 9, wherein, the formula
I-C-1):
##STR00006##
wherein:
[0052] ring A is defined as a fused heterocycle ring system
comprised of at least two (2) rings fused together;
[0053] where:
[0054] R.sup.4 optionally is substituted on each of the at least
two (2) rings of the fused heterocycle ring system defined as ring
A, such that each R4 substituent on each ring of the fused
heterocycle ring system independently are selected from identical
or different substituents;
[0055] where: [0056] each R.sup.4 as defined above optionally is
substituted independently on each ring of the fused heterocycle
ring is selected from hydrogen, halogen, oxo, --OH, --CN,
--NO.sub.2, --O--C(.dbd.O)--R.sup.9, --C(.dbd.O)--R.sup.9,
--C(.dbd.O)--OH, --C(.dbd.O)--OR.sup.9, --OR.sup.9',
--NR.sup.9R.sup.9, --SO.sub.2R.sup.9, --SR.sup.9,
--NR.sup.9--C(.dbd.O)--R.sup.9, optionally substituted lower alkyl,
optionally substituted cycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl; [0057] provided that two
hydroxyl groups on ring A bind respectively to carbon atoms each
adjacently locates; and [0058] n is an integer from 0 to 2. 10. The
compound, an ester at carboxyl group, an amino-protected compound
when the amino is present on the ring in the 7-side chain, or a
pharmaceutically acceptable salt thereof according to the above 1,
2, 3, 4, 7, 8 or 9, wherein, the formula (I-C-1):
##STR00007##
[0058] is a group selected from the following formulae:
##STR00008## ##STR00009## ##STR00010## ##STR00011##
wherein, each R.sup.4a, R.sup.4b and R.sup.4c is independently
hydrogen, halogen, --OH, --CN, --C(.dbd.O)--R.sup.9,
--C(.dbd.O)--OH, --C(.dbd.O)--OR.sup.9, --OR.sup.9, optionally
substituted lower alkyl, or optionally substituted cycloalkyl and
R.sup.6 and R.sup.9 are as defined in the above 1, the wavy line
means that the bond is in cis or trans configuration, or a mixture
thereof. 11. The compound, an ester at carboxyl group, an
amino-protected compound when the amino is present on the ring in
the 7-side chain, or a pharmaceutically acceptable salt thereof
according to the above 10, wherein, the formula (I-C-1):
##STR00012##
is a group selected from the following formulae:
##STR00013## ##STR00014## ##STR00015## ##STR00016## ##STR00017##
##STR00018## ##STR00019## ##STR00020## ##STR00021##
##STR00022##
wherein, R.sup.6 is hydrogen, methyl, ethyl, tert-buthyl,
carboxymethyl, 0.2-carboxypropan-2-yl or 1-carboxyethyl, the wavy
line means that the bond is in cis or trans configuration, or a
mixture thereof. 12. The compound, an ester at carboxyl group, an
amino-protected compound when the amino is present on the ring in
the 7-side chain, or a pharmaceutically acceptable salt thereof
according to the above 1, 2, 3, 5, 7, 8 or 9, wherein, the formula
(I-C-1):
##STR00023##
is a group selected from the following formulae:
##STR00024## ##STR00025## ##STR00026## ##STR00027## ##STR00028##
##STR00029## ##STR00030##
wherein, each R.sup.4a, R.sup.4b and R.sup.4d is independently
hydrogen, halogen, --OH, --CN, --C(.dbd.O)--R.sup.9,
--C(.dbd.O)--OH, --C(.dbd.O)--OR.sup.9, --OR.sup.9, optionally
substituted lower alkyl, or optionally substituted cycloalkyl and
R.sup.6 and R.sup.9 are as defined in the above 1, 13. The
compound, an ester at carboxyl group, an amino-protected compound
when the amino is present on the ring in the 7-side chain, or a
pharmaceutically acceptable salt thereof according to the above 12,
wherein, the formula (I-C-1):
##STR00031##
is a group selected from the following formulae:
##STR00032## ##STR00033## ##STR00034## ##STR00035## ##STR00036##
##STR00037## ##STR00038## ##STR00039## ##STR00040##
##STR00041##
14. The compound, an ester at carboxyl group, an amino-protected
compound when the amino is present on the ring in the 7-side chain,
or a pharmaceutically acceptable salt thereof according to any one
of the above 1 to 13, wherein E is an optionally substituted,
saturated or unsaturated, monocyclic or fused cyclic group having
at least one quaternary ammonium ion represented by the formula
(I-D):
##STR00042##
wherein,
[0059] the dashed line is a bond in the ring;
[0060] the bond to the cationic nitrogen atom binds to L, and the
other bond binds to R.sup.10; provided,
[0061] when a cationic nitrogen atom binds to R.sup.10, the dashed
line is absent, and
[0062] when a cationic nitrogen atom does not bind to R.sup.10, the
dashed line is a single bond between the cationic nitrogen atom and
a neighboring atom or an alkylene group between the cationic
nitrogen atom and a ring member atom other than said neighboring
atom.
15. The compound, an ester at carboxyl group, an amino-protected
compound when the amino is present on the ring in the 7-side chain,
or a pharmaceutically acceptable salt thereof according to any one
of the above 1 to 13, wherein E is an optionally substituted,
saturated or unsaturated, monocyclic or fused cyclic group having
at least one quaternary ammonium ion represented by the formula
(I-E):
##STR00043##
wherein, the bond to the cationic nitrogen atom binds to L, and the
other bond binds to R.sup.10; R.sup.x is optionally substituted
lower alkyl. 16. The compound, an ester at carboxyl group, an
amino-protected compound when the amino is present on the ring in
the 7-side chain, or a pharmaceutically acceptable salt thereof
according to any one of the above 1 to 13, wherein L is --S--,
--CH.sub.2--S--, --CH.dbd.CH--S-- or --CH.dbd.CH--CH.sub.2--S-- and
E is an optionally substituted pyridinium group or an optionally
substituted fused pyridinium group. 17. The compound, an ester at
carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof according to the above 16, E is a group
selected from the following formulae which are optionally
substituted on the ring;
##STR00044##
wherein the bond to the cationic nitrogen atom binds to R.sup.10,
the other bond binds to L. 18. The compound, an ester at carboxyl
group, an amino-protected compound when the amino is present on the
ring in the 7-side chain, or a pharmaceutically acceptable salt
thereof according to any one of the above 1 to 15, wherein E is a
group selected from the following formulae which are optionally
substituted on the ring:
##STR00045## ##STR00046## ##STR00047## ##STR00048## ##STR00049##
##STR00050## ##STR00051## ##STR00052## ##STR00053##
##STR00054##
wherein,
[0063] the bond to the quaternary nitrogen atom binds to L, and the
other bond binds to R.sup.10;
[0064] p is an integer from 1 to 3;
[0065] n is an integer of 1 or 2;
[0066] R.sup.x is optionally substituted lower alkyl.
19. The compound, an ester at carboxyl group, an amino-protected
compound when the amino is present on the ring in the 7-side chain,
or a pharmaceutically acceptable salt thereof according to the
above 13, wherein, E is selected from the group consisting of the
formulae (2), (3), (7), (10), (11), (26), (27), (41), (42), (59),
(60) and (77). 20. The compound, an ester at carboxyl group, an
amino-protected compound when the amino is present on the ring in
the 7-side chain, or a pharmaceutically acceptable salt thereof
according to any one of the above 1 to 15, wherein E is a group
selected from the following formulae which are optionally
substituted on the ring:
##STR00055## ##STR00056## ##STR00057## ##STR00058##
##STR00059##
wherein, the bond to the quaternary nitrogen atom binds to L, and
the other bond binds to R.sup.10. 21. The compound, an ester at
carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof according to the above 20, wherein
E-R.sup.10 is a group selected from the following formulae:
##STR00060##
wherein, the bond to the quaternary nitrogen atom binds to L. 22.
The compound, an ester at carboxyl group, an amino-protected
compound when the amino is present on the ring in the 7-side chain,
or a pharmaceutically acceptable salt thereof according to the
above 21, wherein E-R.sup.10 is represented by the formula:
##STR00061##
wherein, the bond to the quaternary nitrogen atom binds to L. 23.
The compound, an ester at carboxyl group, an amino-protected
compound when the amino is present on the ring in the 7-side chain,
or a pharmaceutically acceptable salt thereof according to the
above 16, wherein -L-E- is represented by the formula;
##STR00062##
wherein, the bond to the quaternary nitrogen atom binds to
R.sup.10, the other bond binds to cephem at 3 position. 24. The
compound, an ester at carboxyl group, an amino-protected compound
when the amino is present on the ring in the 7-side chain, or a
pharmaceutically acceptable salt thereof according to any one of
the above 1 to 23, wherein R.sup.3 is hydrogen or --OCH.sub.3. 25.
The compound, an ester at carboxyl group, an amino-protected
compound when the amino is present on the ring in the 7-side chain,
or a pharmaceutically acceptable salt thereof according to any one
of the above 1 to 24, wherein R.sup.1 is an optionally substituted
phenyl. 26. The compound, an ester at carboxyl group, an
amino-protected compound when the amino is present on the ring in
the 7-side chain, or a pharmaceutically acceptable salt thereof
according to any one of the above 1 to 24, wherein R.sup.1 is
represented by the formula:
##STR00063##
wherein, X is N, C(--H) or C(--Cl). 27. The compound, an ester at
carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof according to the above 26, wherein, X is N.
28. The compound, an ester at carboxyl group, an amino-protected
compound when the amino is present on the ring in the 7-side chain,
or a pharmaceutically acceptable salt thereof according to the
above 26, wherein, X is C(--H) or C(--Cl). 29. The compound, an
ester at carboxyl group, an amino-protected compound when the amino
is present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof according to any one of the above 1 to 28,
wherein, R.sup.2A is hydrogen, optionally substituted amino,
--SO.sub.3H, optionally substituted amino sulfonyl, carboxyl,
optionally substituted carbamoyl, hydroxyl, or substituted
carbonyloxy, and R.sup.2B is hydrogen. 30. The compound, an ester
at carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof according to any one of the above 1 to 29,
wherein, R.sup.2A is: substituted amino shown below:
##STR00064##
substituted amino sulfonyl shown below:
##STR00065##
wherein, ring B represents an optionally substituted heterocyclic
group; substituted carbamoyl shown below:
##STR00066##
wherein, ring B represents an optionally substituted heterocyclic
group; or substituted carbonyloxy shown below:
##STR00067##
wherein, ring B represents an optionally substituted heterocyclic
group. 31. The compound, an ester at carboxyl group, an
amino-protected compound when the amino is present on the ring in
the 7-side chain, or a pharmaceutically acceptable salt thereof
according to any one of the above 1 to 29, wherein, R.sup.2A and
R.sup.2B are taken together to form: substituted methylidene shown
below:
##STR00068##
substituted hydroxyimino shown below:
##STR00069##
wherein, R.sup.9 is optionally substituted lower alkyl. 32. The
compound, an ester at carboxyl group, an amino-protected compound
when the amino is present on the ring in the 7-side chain, or a
pharmaceutically acceptable salt thereof according to any one of
the above 1 to 29, wherein R.sup.2A and R.sup.2B are taken together
to form substituted hydroxyimino shown below:
##STR00070##
wherein,
[0067] R.sup.7 and R.sup.8 are each independently hydrogen,
halogen, hydroxyl, carboxyl, optionally substituted lower alkyl, an
optionally substituted carbocyclic group, or an optionally
substituted heterocyclic group, or
[0068] R.sup.7 and R.sup.8 may be taken together with a neighboring
atom to form an optionally substituted carbocyclic group or an
optionally substituted heterocyclic group;
[0069] Q is a single bond, an optionally substituted carbocyclic
group or an optionally substituted heterocyclic group; and m is an
integer from 0 to 3.
33. A compound of the formula (I-G-1):
##STR00071##
an ester at carboxyl group, an amino-protected compound when the
amino is present on the ring in the 7-side chain, or a
pharmaceutically acceptable salt thereof according to any one of
the above 1 to 24, wherein, each symbol is as defined above. 34.
The compound, an ester at carboxyl group, an amino-protected
compound when the amino is present on the ring in the 7-side chain,
or a pharmaceutically acceptable salt thereof according to the
above 33, wherein, R.sup.5A is hydrogen and R.sup.5B is lower
alkyl; R.sup.10 is a group represented by the formula (I-B);
##STR00072##
each symbol is as defined above. 35. The compound, an ester at
carboxyl group, an amino-protected compound when the amino is
present on the ring in the 7-side chain, or a pharmaceutically
acceptable salt thereof according to the above 34, wherein,
X is C(--H), C(--Cl) or N;
[0070] each R.sup.7 and R.sup.8 is independently hydrogen or lower
alkyl; R3 is hydrogen; m is 0 or 1; Q is a single bond; L is
--CH2-; E is a group selected from the following formulae;
##STR00073##
wherein, Rx is lower alkyl, p is an integer from 1 to 3; G is a
single bond or lower alkylene; B is a single bond; D is a single
bond, --C(.dbd.O)--, --C(.dbd.O)--C(.dbd.O)--,
--NR.sup.6--C(.dbd.O)--C(.dbd.O)--, --NR.sup.6--C(.dbd.O)-- or
--NH--C(.dbd.O)--C(.dbd.N--OR.sup.6a); R.sup.6 is hydrogen or lower
alkyl; R.sup.6a is hydrogen, methyl, carboxymethyl, or
2-carboxypropane-2-yl; the formula (1-B-2);
##STR00074##
is a group selected from the following formulae;
##STR00075##
wherein each R.sup.4a, R.sup.4b and R.sup.4c is independently
hydrogen, halogen or lower alkyl; R.sup.4d is hydrogen, lower alkyl
or lower cycloalkyl. 36. A pharmaceutical composition, which
comprises a compound, an ester at carboxyl group, an
amino-protected compound when the amino is present on the ring in
the 7-side chain, or a pharmaceutically acceptable salt thereof
according to any one of the above 1 to 35. 37. The pharmaceutical
composition according to the above 36, which possesses
antimicrobial activity.
Effects of the Invention
[0071] The compounds of the subject invention are useful as a
pharmaceutical product having at least one of the following
features:
[0072] 1) the compounds exhibit potent antimicrobial spectrum
against a variety of bacteria including Gram negative bacteria
and/or Gram positive bacteria;
[0073] 2) the compounds exhibit potent antimicrobial activity
against beta-lactamase producing Gram negative bacteria;
[0074] 3) the compounds exhibit potent antimicrobial activity
against multidrug-resistant bacteria, in particular, Class B type
metallo-beta-lactamase producing Gram negative bacteria;
[0075] 4) the compounds exhibit potent antimicrobial activity
against extended-spectrum beta-lactamase (ESBL) producing
bacteria;
[0076] 5) the compounds do not exhibit cross resistance with known
cephem drugs and/or carbapenem drugs; and
[0077] 6) the compounds do not exhibit side effects such as
toxicity and fever after administration into the body;
[0078] 7) the compounds are stable for storage and/or well soluble
in water;
[0079] 8) the compounds of the present invention have excellent
features regarding kinetics in the body, such as high blood
concentration, high bioavailabity, long duration of effects, and/or
high tissue migration; and
[0080] 9) the compounds of the present invention also may exhibit
or have antimicrobial activity against biothreat organisms, which
may include, but are not limited to those biothreat organisms, such
as Yersinia pestis, Bacillus anthracis, Francisella tularensis,
Burkholderia mallei Burkholderia pseudomallei, Brucella suis,
Brucella melitensis or Brucella abortus.
Preferable Embodiments for Carrying Out the Invention
[0081] It should be understood that, throughout the present
specification, the expression of a singular form (e.g., "a", "an",
"the", and the like; and in other languages, corresponding
articles, adjectives, and the like) includes the concept of its
plural form unless specified otherwise. Furthermore, it should be
understood that the terms used herein are used in a meaning
normally used in the art unless specified otherwise. Thus, unless
defined otherwise, all technical and scientific terms used herein
have the same meaning as those generally understood by those
skilled in the art in the field to which the subject invention
pertains. Each specific definition of terms specifically used
herein is described below. Each term used herein means, alone or in
combination with another word, as below.
[0082] "Halogen" includes fluoro, chloro, bromo and iodo.
Preferably, halogen is fluoro, chloro or bromo, and more preferably
is chloro.
[0083] "Lower alkyl" includes linear or branched alkyl having 1-8
carbons, preferably 1-6 carbons, and more preferably 1-4 carbons,
for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,
sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl,
isohexyl, n-heptyl, isoheptyl, n-octyl, and the like.
[0084] "Lower alkylene" includes linear alkylene having 1-8
carbons, preferably 1-6 carbons, more preferably 1-4 carbons, and
most preferably one or two carbons, for example, methylene,
ethylene, n-propylene, n-butylene, n-pentylene, n-hexylene, and the
like.
[0085] "Lower alkenylene" includes linear alkenylene having 2-8
carbons, preferably 2-6 carbons, more preferably 2-4 carbons, and
at least one double bond at any position, and includes, for
example, vinylene, allylene, propenylene, butenylene, prenylene,
butadienylene, pentenylene, pentadienylene, hexenylene,
hexadienylene, and the like.
[0086] "Lower alkynylene" includes linear alkynylene having 2-8
carbons, preferably 2-6 carbons, more preferably 2-4 carbons, and
at least one triple bond at any position, for example, ethynylene,
propynylene, buthynylene, pentynylene, hexynylene, and the
like.
[0087] "Halo(lower)alkyl" refers to a group in which at least one
position of said "lower alkyl" is substituted with the above
"halogen", and includes, for example, monofluoromethyl,
difluoromethyl, ifluoromethyl, monochloromethyl, dichloromethyl,
trichloromethyl, monobromomethyl, monofluoroethyl, monochloroethyl,
chlorodifluoromethyl, and the like. Preferably is trifluoromethyl
or trichloromethyl.
[0088] "Aralkyl" includes the above lower alkyl substituted with
one to three groups selected from "aryl" mentioned below,
preferably wherein the carbon number of alkyl is 1 to 4, more
preferably is 1 or 2, for example, benzyl, phenethyl, phenylpropyl,
trityl, and the like.
[0089] "Heteroaralkyl" includes the above lower alkyl substituted
with one to three groups selected from "heteroaryl" mentioned
below, preferably wherein the carbon number of alkyl is 1 to 4,
more preferably is 1 or 2, for example, furylmethyl, thienylmethyl,
pyrolylmethyl, pyridylmethyl, thienylethyl, furylethyl,
imidazorylmethyl, benzotienylmethyl, thiazolylmethyl, and the
like.
[0090] "Acyl" includes formyl, optionally substituted lower
alkylcarbonyl (e.g., acetyl, propionyl, butylyl, isobutylyl,
valeryl, isovaleryl, pivaloyl, hexanoyl, octanoyl,
methoxyethylcarbonyl, 2,2,2-trifluoroethylcarbonyl), optionally
substituted alkenyloxycarbonyl (e.g., alloc, cinnamyloxy carbonyl),
alkoxycarbonylacetyl (e.g., ethoxycarbonylmethylcarbonyl),
(lower)alkoxy(lower)alkylcarbonyl (e.g., methoxyethylcarbonyl),
(lower)alkylcarbamoyl(lower)alkylcarbonyl (e.g.,
methylcarbamoylethylcarbonyl), optionally substituted arylcarbonyl
(e.g., benzoyl, toluoyl), optionally substituted cycloalkyloxy
carbonyl (e.g., cycrohexyloxycarbonyl), optionally substituted
aralkyloxy carbonyl (e.g., benzyloxycarbonyl,
p-nitrobenzyloxycarbonyl), optionally substituted heteroaralkyl
carbonyl (e.g., thienylmethyl carbonyl) and the like.
[0091] Substituents of "optionally substituted amino" or
"optionally substituted carbamoyl" include optionally substituted
lower alkyl (e.g., methyl, ethyl, isopropyl, benzyl, carbamoylalkyl
(e.g., carbamoylmethyl), mono- or
di-(lower)alkylcarbamoyl(lower)alkyl (e.g.,
dimethylcarbamoylethyl), hydroxy(lower)alkyl,
heterocyclyl(lower)alkyl (e.g., morpholinoethyl,
tetrahydropyranylethyl), alkoxycarbonyl(lower)alkyl (e.g.,
ethoxycarbonylmethyl, ethoxycarbonylethyl), mono- or
di-(lower)alkylamino(lower)alkyl (e.g., dimethylaminoethyl));
(lower)alkoxy(lower)alkyl (e.g., methoxyethyl, ethoxymethyl,
ethoxyethyl, isopropoxyethyl, and the like); acyl (e.g., formyl,
optionally substituted lower alkylcarbonyl (e.g., acetyl,
propionyl, butylyl, isobutylyl, valeryl, isovaleryl, pivaloyl,
hexanoyl, octanoyl, methoxyethylcarbonyl,
2,2,2-trifluoroethylcarbonyl, alkoxycarbonylacetyl (e.g.,
ethoxycarbonylmethylcarbonyl), (lower)alkoxy(lower)alkylcarbonyl
(e.g., methoxyethylcarbonyl),
(lower)alkylcarbamoyl(lower)alkylcarbonyl (e.g.,
methylcarbamoylethylcarbonyl), optionally substituted arylcarbonyl
(e.g., benzoyl, toluoyl);
optionally substituted aralkyl (e.g., benzyl, 4-fluorobenzyl);
hydroxy; optionally substituted lower alkylsulfonyl (e.g.,
methanesulfonyl, ethanesulfonyl, isopropylsulfonyl,
2,2,2-trifluoroethanesulfonyl, benzylsulfonyl,
methoxyethylsulfonyl); arylsulfonyl optionally having a lower alkyl
or halogen as a substituent (e.g., benzenesulfonyl,
toluenesulfonyl, 4-fluorobenzenesulfonyl), cycloalkyl (e.g.,
cyclopropyl); aryl optionally having lower alkyl as a substituent
(e.g., phenyl, tolyl); lower alkylaminosulfonyl (e.g.,
methylaminosulfonyl, dimethylaminosulfonyl); lower
alkylaminocarbonyl (e.g., dimethylaminocarbonyl); lower
alkoxycarbonyl (e.g., ethoxycarbonyl); cycloalkylcarbonyl (e.g.,
cyclopropylcarbonyl, cyclohexylcarbonyl); optionally substituted
sulfamoyl (e.g., sulfamoyl, methylsulfamoyl, dimethylsulfamoyl);
lower alkylcarbonylamino (e.g., methylcarbonylamino); heterocyclic
group (e.g., morpholino, tetrahydropyranyl); optionally substituted
amino (e.g., mono- or di-alkylamino (e.g., dimethylamino),
formylamino), and the like.
[0092] The above substituted amino or substituted carbamoyl may be
mono-substituted or di-substituted.
[0093] "Lower alkenyl" refers to a linear or branched alkenyl
having 2 to 8 carbons and having one or more double bonds on said
"lower alkyl". The examples include vinyl, 1-propenyl, 2-propenyl,
1-butenyl, 2-butenyl, 3-butenyl, 1,3-butadienyl,
3-methyl-2-butenyl, and the like. Preferred is alkenyl having 2 to
6 carbons, more preferably 2 to 4 carbons.
[0094] With regard to "optionally substituted amino" or "optionally
substituted carbamoyl", two substituents of the amino group may be
taken together with the adjacent nitrogen atom to form a
nitrogen-containing heterocycle which optionally includes a sulfur
atom and/or an oxygen atom in the ring (preferably, the heterocycle
is a 5- to 7-membered ring, and is preferably saturated). The
heterocycle is optionally substituted with oxo or hydroxy. When a
sulfur atom forms the heterocycle, said sulfur atom may be
substituted with oxo. Examples thereof include 5- or 6-membered
rings such as piperazinyl, piperidino, morpholino, pyrrolidino,
2-oxopiperidino, 2-oxopyrrolidino, 4-hydroxymorpholino, and the
like.
[0095] Substituents of "optionally substituted lower alkyl" include
at least one group selected from Substituent Group alpha. The
substitution may be of plurality and the substituents are same or
different.
[0096] Substituents of "optionally substituted lower alkylene",
"optionally substituted lower alkenylene" and "optionally
substituted lower alkynylene" include at least one group selected
from Substituent Group alpha. The substitution may be of plurality
and the substituents are same or different.
[0097] Substituents of "optionally substituted cycloalkyl" include
at least one group selected from Substituent Group alpha. The
substitution may be of plurality and the substituents are same or
different.
[0098] Substituents of "optionally substituted aryl" include at
least one group selected from Substituent Group alpha. The
substitution may be of plurality and the substituents are same or
different.
[0099] Substituents of "optionally substituted heteroaryl" include
at least one group selected from Substituent Group alpha.
[0100] The substitution may be of plurality and the substituents
are same or different.
[0101] Substituents of "optionally substituted aminosulfonyl"
include substituted lower alkyl and at least one group selected
from Substituent Group alpha.
[0102] Substituents of "optionally substituted lower
alkyloxycarbonyl" include at least one group selected from
Substituent Group alpha.
[0103] Substituents of "substituted carbonyloxy" means
"--O--C(.dbd.O)-substituent", including optionally substituted
lower alkyl, optionally substituted lower alkenyl, optionally
substituted lower alkynyl, an optionally substituted carbocyclic
group, an optionally substituted heterocyclic group, amino
optionally substituted with a heterocyclic group, and at least one
group selected from Substituent Group alpha.
[0104] Substituents of "optionally substituted carboxyl" include an
optionally substituted lower alkyl, optionally substituted lower
alkenyl, optionally substituted lower alkynyl, an optionally
substituted carbocyclic group, and an optionally substituted
heterocyclic group.
[0105] "Optionally substituted acyl group" includes carbonyl
substituted with optionally substituted lower alkyl, optionally
substituted lower alkenyl, optionally substituted lower alkynyl, an
optionally substituted carbocyclic group, or an optionally
substituted heterocyclic group.
[0106] Substituents of an "optionally substituted, saturated or
unsaturated, monocyclic or fused cyclic quaternary ammonium group"
include an optionally substituted lower alkyl, one group selected
from Substituent Group alpha, or any two substituents taken
together may form a carbocyclic group or heterocyclic group. Lower
alkylene, as a substituent in a heterocyle containing a quanternary
ammonium group, may form a bridged structure between the
quanternary ammonium group and any carbon atom in the
heterocyle.
[0107] "Substituent Group alpha" consists of halogen, hydroxy,
lower alkoxy, lower alkylene, hydroxy(lower)alkoxy,
(lower)alkoxy(lower)alkoxy, carboxy, amino, acylamino,
lower(alkyl)amino, imino, hydroxyimino, lower(alkoxy)imino,
lower(alkyl)thio, carbamoyl, lower(alkyl)carbamoyl,
hydroxy(lower)alkylcarbamoyl, sulfamoyl, lower (alkyl) sulfamoyl,
lower(alkyl)sulfinyl, cyano, nitro, a carbocyclic group, and a
heterocyclic group.
[0108] The lower alkyl moiety in "lower alkoxy",
"hydroxy(lower)alkoxy", "(lower)alkoxy(lower)alkoxy",
"lower(alkyl)amino", "lower(alkoxy)imino", "lower (alkyl)thio",
"lower (alkyl) carbamoyl", "hydroxy(lower)alkylcarbamoyl", and
"lower (alkyl)sulfamoyl", "lower(alkyl)sulfinyl",
"lower(alkyl)oxycarbonyl", "lower(alkyl) sulfonyl", is as defined
as the above "lower alkyl".
[0109] The lower alkenyl moiety in "lower(alkenyl)oxy", is as
defined as the above "lower alkenyl".
[0110] The aryl moiety in "aryloxy" is as defined as "aryl"
mentioned below.
[0111] Preferred embodiments of substituents in "optionally
substituted lower alkyl" include fluoro, chloro, bromo, hydroxy,
carboxy, methoxy, ethoxy, hydroxymethoxy, hydroxyethoxy,
methoxymethoxy, methoxyethoxy, amino, acetylamino, methylamino,
dimethylamino, imino, hydroxyimino, methoxyimino, methylthio,
carbamoyl, methylcarbamoyl, hydroxymethylcarbamoyl, sulfamoyl,
methylsulfamoyl, lower alkylsulfamoyl, cyano, nitro, phenyl,
cyclopropyl, cyclobutyl, cyclohexyl, pyridyl, morpholinyl, and the
like.
[0112] Preferred embodiments of "optionally substituted lower
alkyl" include methyl, ethyl, isopropyl, tert-butyl,
halo(lower)alkyl (e.g., monochloromethyl, dichloromethyl,
trichloromethyl, monofluoromethyl, difluoromethyl,
trifluoromethyl), carboxymethyl, carboxyethyl, carbamoylmethyl,
carbamoylethyl, hydroxymethyl, hydroxyethyl, methoxymethyl,
ethoxymethyl, methoxyethyl, ethoxyethyl, methylthiomethyl,
ethylthiomethyl, benzyl, phenethyl, 4-hydroxybenzyl,
4-methoxybenzyl, 4-carboxybenzyl, and the like.
[0113] Preferred embodiments of substituents in "optionally
substituted cycloalkyl" include fluoro, chloro, bromo, hydroxy,
carboxy, methoxy, ethoxy, hydroxymethoxy, hydroxyethoxy,
methoxymethoxy, methoxyethoxy, amino, acetylamino, methylamino,
dimethylamino, imino, hydroxyimino, methoxyimino, methylthio,
carbamoyl, methylcarbamoyl, hydroxymethylcarbamoyl, sulfamoyl,
methylsulfamoyl, lower alkylsulfamoyl, cyano, nitro, phenyl,
cyclopropyl, cyclobutyl, cyclohexyl, pyridyl, morpholinyl, and the
like.
[0114] "Carbocyclic group" includes cycloalkyl, cycloalkenyl, aryl
and non-aromatic fused carbocyclic groups, and the like.
[0115] "Cycloalkyl" has 3-10 carbons, preferably 3-8 carbons, and
more preferably 3-6 carbons, and includes, for example,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,
cyclooctyl, cyclononyl, cyclodecyl, and the like.
[0116] "Cycloalkenyl" is cycloalkyl which contains at least one
double bond at any position(s), and includes, for example,
cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl,
cycloheptynyl, cyclooctynyl, and cyclohexadienyl, and the like.
[0117] "Aryl" includes phenyl, naphthyl, anthryl, phenanthryl, and
the like, and phenyl is preferable.
[0118] "Aromatic carbocycle" means a ring derived from aryl as
described below.
[0119] "Aromatic heterocycle" means an aromatic ring, which is
monocyclic or bicyclic or more, having same or different one or
more hetero atom selected independently from O, S or N.
[0120] The aromatic heterocyclic group which is bicyclic or more
includes those wherein a monocyclic or bicyclic or more aromatic
heterocyle is condensed with "aromatic carbocyle" described
above.
[0121] "Non-aromatic carbocyclic group" includes the above
"cycloalkyl" and "cycloalkenyl", for example, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl,
cyclononyl, cyclodecyl, cyclopropenyl, cyclobutenyl, cyclopentenyl,
cyclohexenyl, cycloheptynyl, cyclooctynyl, and cyclohexadienyl and
the like.
[0122] "Non-aromatic fused carbocyclic group" includes a group in
which one or more cyclic group selected from said "cycloalkyl" and
"cycloalkenyl" is fused to said "cycloalkyl" "cycloalkenyl" or
"aryl", and includes, for example, indanyl, indenyl,
tetrahydronaphthyl, and fluorenyl, and the like.
[0123] "Heterocyclic group" includes heterocyclic groups having at
least one hetero atom arbitrarily selected from O, S, and N in the
ring, and includes, for example, 5- or 6-membered monocyclic
non-aromatic heterocyclic group such as pyrrolidyl, piperidinyl,
piperadinyl, morpholinyl, tetrahydrofuranyl, tetrohydrothienyl, and
the like; 5- or 6-membered monocyclic heteroaryl such as pyrrolyl,
imidazolyl, pyrazolyl, pyridyl, pyridazinyl, pyrimidinyl,
pyrazinyl, triazolyl, triazinyl, tetrazolyl, isoxazolyl, oxazolyl,
oxadiazolyl, isothiazolyl, thiazolyl, thiadiazolyl, furyl, thienyl,
and the like; 9- or 10-membered bicyclic fused heterocyclic groups
such as indolyl, isoindolyl, indazolyl, indolizinyl, indolinyl,
isoindolinyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl,
quinazolinyl, naphthyridinyl, quinoxalinyl, purinyl, pteridinyl,
benzopyranyl, benzimidazolyl, benzotriazolyl, benzisoxazolyl,
benzoxazolyl, benzoxadiazolyl, benzisothiazolyl, benzothiazolyl,
benzothiadiazolyl, benzofuryl, isobenzofuryl, benzothienyl,
benzotriazolyl, imidazopyridyl, pyrazolopyridine, triazolopyridyl,
imidazothiazolyl, pyrazinopyridazinyl, quinazolinyl, quinolyl,
isoquinolyl, naphthyridinyl, dihydrobenzofuryl, tetrahydroquinolyl,
tetrahydroisoquinolyl, dihydrobenzoxazine, tetrahydrobenzothienyl,
and the like; tricyclic fused heterocyclic groups such as
carbazolyl, acridinyl, xanthenyl, phenothiadinyl, phenoxathiinyl,
phenoxazinyl, dibenzofuryl, imidazoquinolyl, and the like;
non-aromatic heterocyclic groups such as dioxanyl, thiiranyl,
oxiranyl, oxathiolanyl, azetidinyl, thianyl, thiazolidine,
pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl,
pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, morpholinyl,
thiomorpholinyl, thiomorpholino, dihydropyridyl,
dihyrobenzimidazolyl, tetrahydropyridyl, tetrahydrofuryl,
tetrahydropyranyl, tetrahydrothiazolyl, tetrahydroisothiazolyl,
dihydrooxazinyl, hexahydroazepinyl, tetrahydrodiazepinyl, and the
like. Preferably, the heterocyclic group is a 5- or 6-membered
monocyclic heterocyclic group or 9- or 10-membered bicyclic fused
heterocyclic group, and more preferably, a 5- or 6-membered
heteroaryl or 9- or 10-membered bicyclic fused heterocyclic
group.
[0124] "Heteroaryl" means an aromatic heterocyclic group described
above. Preferred is 5- or 6-membered monocyclic heteroaryl or 9- or
10-membered bicyclic heteroaryl.
[0125] "Heterocycle" means a ring derived from a heterocyclic group
as described above. Preferred is 5- or 6-membered monocyclic
heterocycle or 9- or 10-membered bicyclic heterocycle.
[0126] "Fused heterocycle" means a ring condensed with at least one
heterocycle, includes those wherein monocyclic, bicyclic or more
heterocyle is condensed with "carbocyle" described above.
[0127] Preferred is 9- or 10-membered bicyclic heterocycle having
at least one nitrogen atom.
[0128] "Monocyclic heterocycle" is preferably 5- to 7-membered
heterocycle, and more preferably 6-membered heterocycle having at
least one nitrogen atom.
[0129] "Non-aromatic heterocyclic group" means a group which does
not show aromatic character of the "heterocyclic group".
[0130] Substituents of "optionally substituted carbocyclic group"
"optionally substituted heterocyclic group", "optionally
substituted non-aromatic carbocyclic group", and "optionally
substituted non-aromatic heterocyclic group" include optionally
substituted lower alkyl, and at least one group selected from
Substituent Group alpha.
[0131] Preferred embodiments of substituents in "optionally
substituted carbocyclic group", "optionally substituted
heterocyclic group", "optionally substituted non-aromatic
carbocyclic group" and "optionally substituted non-aromatic
heterocyclic group" include methyl, ethyl, isopropyl, tert-butyl, a
fluorine atom, a chlorine atom, a bromine atom, hydroxy, carboxy,
methoxy, ethoxy, hydroxymethoxy, hydroxyethoxy, methoxymethoxy,
methoxyethoxy, amino, acetylamino, methylamino, dimethylamino,
imino, hydroxyimino, methoxyimino, methylthio, carbamoyl,
methylcarbamoyl, hydroxymethylcarbamoyl, sulfamoyl,
methylsulfamoyl, lower alkylsulfamoyl, cyano, nitro, phenyl,
cyclopropyl, cyclobutyl, cyclohexyl, pyridyl, morpholinyl, and the
like.
[0132] "5- or 6-membered aromatic heterocyclic group having 1-3
nitrogen atoms" includes pyrrolyl, imidazolyl, pyrazolyl, pyridyl,
pyridazinyl, pyrimidinyl, pyrazinyl, triazolyl, triazinyl,
isoxazolyl, oxazolyl, oxadiazolyl, isothiazolyl, thiazolyl,
thiadiazolyl, furyl, thienyl, and the like.
[0133] Examples of "optionally substituted carbocyclic group" or
"optionally substituted heterocyclic group" of R1 include phenyl,
aminothiazole, aminothiadiazole, thiophene, furan, benzothiazole,
pyridine, pyrimidine, pyridazine, aminopyridine, and the like, each
optionally substituted with hydroxyl and/or halogen. Preferred
Examples include the followings:
##STR00076##
[0134] Examples of R.sup.2A include hydrogen, optionally
substituted amino, --COOH, --SO.sub.3H, optionally substituted
aminosulfonyl, carboxyl, optionally substituted carbamoyl,
hydroxyl, substituted carbonyloxy, and the like.
[0135] In Preferred examples of
##STR00077##
R.sup.2B is hydrogen and R.sup.2A is the following group: 1)
substituted amino group shown below:
##STR00078##
2) substituted aminosulfonyl group shown below:
##STR00079##
wherein ring B represents an optionally substituted heterocyclic
group; 3) substituted carbamoyl group shown below:
##STR00080##
wherein ring B represents an optionally substituted heterocyclic
group; or 4) substituted carbonyloxy shown below:
##STR00081##
wherein ring B represents an optionally substituted.
[0136] Alternatively, R.sup.2A and R.sup.2B may be taken together
to form a substituted methylidene group shown below:
##STR00082##
wherein R.sup.9 is optionally substituted lower alkyl,
preferably
##STR00083##
[0137] Also, R.sup.2A and R.sup.2B may be taken together to form
optionally substituted hydroxyimino shown below:
##STR00084##
wherein R.sup.9 is as defined above. Preferred is group shown
below.
##STR00085##
wherein each symbol is as defined above.
[0138] Examples of "R.sup.7 and R.sup.8" includes hydrogen, fluoro,
chloro, hydroxy, carboxy, methyl, ethyl, isopropyl, tert-butyl,
monofluoromethyl, difluoromethyl, trifluoromethyl, carboxymethyl,
carboxyethyl, carbamoylmethyl, carbamoylethyl, hydroxymethyl,
hydroxyethyl, methoxymethyl, ethoxymethyl, methoxyethyl,
ethoxyethyl, methylthiomethyl, ethylthiomethyl, benzyl,
4-hydroxybenzyl, 4-methoxybenzyl, 4-carboxybenzyl,
3,4-dihydroxybenzyl, phenyl, 4-hydroxyphenyl, 3,4-dihydroxyphenyl,
naphthyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyridazinyl, pyrimidinyl,
pyrazinyl, triazolyl, triazinyl, tetrazolyl, isoxazolyl, oxazolyl,
oxadiazolyl, isothiazolyl, thiazolyl, thiadiazolyl, furyl, thienyl,
and the like.
[0139] Preferred combinations of (R.sup.7, R.sup.8) include
(hydrogen, hydrogen), (methyl, hydrogen), (hydrogen, methyl),
(methyl, methyl), (ethyl, hydrogen), (hydrogen, ethyl), (ethyl,
ethyl), (phenyl, hydrogen), (hydrogen, phenyl), (dihydroxyphenyl,
hydrogen), (hydrogen, dihydroxyphenyl), (carboxymethyl, hydrogen),
(hydrogen, carboxymethyl), (carboxyethyl, hydrogen), (hydrogen,
carboxyethyl), (hydroxyethyl, hydrogen), (hydrogen, hydroxylethyl),
(carbamoylmethyl, hydrogen), (hydrogen, carbamoylmethyl),
(trifluoromethyl, hydrogen), (carboxy, hydrogen), (carbamoylethyl,
hydrogen), (benzyl, hydrogen), (dihydroxybenzyl, hydrogen), and the
like. More preferred combinations of (R.sup.7, R.sup.8) include,
(methyl, methyl), (hydrogen, carboxymethyl), and (carboxyethyl,
hydrogen).
[0140] Preferred examples of the above substituted hydroxyimino
include groups shown bellow.
##STR00086##
[0141] More preferred examples of the above substituted
hydroxyimino include groups shown bellow.
##STR00087##
[0142] In the case where "R.sup.7 and R.sup.8 may be taken together
with a neighboring atom to form an optionally substituted
carbocyclic group or an optionally substituted heterocyclic group"
in the formula:
##STR00088##
wherein each symbol is as defined,
[0143] R.sup.7 and R.sup.8 may form cycloalkane, cycloalkene, or a
non-aromatic heterocycle optionally substituted with a group
selected from Substituent Group alpha. For example, a group of the
formula:
##STR00089##
includes those shown below:
##STR00090##
wherein each ring is optionally substituted with a group selected
from Substituent Group alpha.
[0144] Examples of "Q" include a single bond, phenyl, pyridyl, and
the like. A single bond is particularly preferable.
[0145] "m" is preferably 0 or 1, and 0 is particularly
preferable.
[0146] Preferred examples of the above embodiments include:
##STR00091##
[0147] "R.sup.3" is preferably hydrogen or --OCH.sub.3, and more
preferably hydrogen.
[0148] Lower alkyl of R5.sup.A and R5.sup.B includes linear or
branched alkyl having 1-6 carbons, preferably 1-4 carbons, for
example, methyl, ethyl, n-propyl, isopropyl, n-buthyl, isobutyl,
sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl,
isohexyl, and the like.
[0149] Examples of combinations of (R.sup.5A, R.sup.5B) include
(hydrogen, methyl), (hydrogen, ethyl), (hydrogen, isopropyl),
(hydrogen, tert-butyl), (methyl, methyl), and the like. Preferably,
(R.sup.5A, R.sup.5B) is (hydrogen, methyl) or (methyl, methyl).
[0150] Carbocycle of "R5.sup.A and R5.sup.B may be taken together
with the neighboring atom to form optionally substituted
carbocycle" include cycloalkane and cycloalkene which have 3-8
carbons, preferably 3-6 carbons. Preferred embodiments include
cyclopropane, cyclobutane, cyclopentane, cyclopentene,
cyclohexcane, cyclohexcene, and the like, more preferably include
cyclopropane. Substituents of the carbocycle include halogen,
hydroxyl, lower alkyl, lower alkoxy, and the like. Preferred
embodiments include fluoro, chloro, hydroxyl, methyl, ethyl,
isopropyl, tert-buthyl, methoxy, ethoxy, isopropoxy, and the
like.
[0151] Heterocycle of "R5.sup.A and R5.sup.B may be taken together
with the neighboring atom to form optionally substituted
heterocycle" include an aromatic or non-aromatic, monocyclic or
fused cyclic ring. Preferred embodiments include non-aromatic 3- to
6-membered monocyclic ring. Substituents of the heterocycle include
halogen, hydroxyl, lower alkyl, lower alkoxy, and the like.
Preferred embodiments include fluoro, chloro, hydroxyl, methyl,
ethyl, isopropyl, tert-buthyl, methoxy, ethoxy, isopropoxy, and the
like.
[0152] Optionally substituted methylidene of "R5.sup.A and R5.sup.B
may be taken together to form optionally substituted methylidene"
is shown by the formula;
##STR00092##
wherein, R.sup.13 and R.sup.14 are each independently hydrogen,
halogen, or optionally substituted lower alkyl, and preferred
R.sup.13 and R.sup.14 are hydrogen.
[0153] "L" is --CH.sub.2--, --CH.dbd.CH--, --CH.sub.2--CH.dbd.CH--,
--CH.dbd.CH--CH.sub.2--, --S--, --CH.sub.2--S--, --CH.dbd.CH--S--
or --CH.dbd.CH--CH.sub.2--S--, preferably --CH.sub.2--,
--CH.sub.2--CH.dbd.CH--, --S-- or --CH.sub.2--S--.
[0154] E is an optionally substituted, saturated or unsaturated,
monocyclic or fused cyclic group having at least one quaternary
ammonium ion and is preferably selected from the above formulae (1)
to (77) which are optionally substituted on the ring. The
substituents on the ring include an optionally substituted lower
alkyl or one or more group selected from substituent Group alpha.
Preferred embodiments of such substitutent include methyl, ethyl,
isopropyl, tert-butyl, fluorine atom, chlorine atom, bromine atom,
hydroxyl, carboxyl, methoxy, ethoxy, hydroxymethoxy, hydroxyethoxy,
methoxymethoxy, methoxyethoxy, methylene, ethylene, propylene,
butylene, amino, acetylamino, methylamino, dimethylamino, imino,
hydroxyimino, methoxyimino, methylthio, carbamoyl, methylcarbamoyl,
hydroxymethylcarbamoyl, sulfamoyl, methylsulfamoyl,
(lower)alkylsulfamoyl, cyano, nitro, phenyl, cyclopropyl,
cyclobutyl, cyclohexyl, pyridyl, morpholinyl, and the like. More
preferred embodiments include a ring unsubstituted or mono- or
di-substituted with a hydroxyl group. Such ring mono- or
di-substituted with a hydroxyl group may be substituted
additionally with another substituent. Herein, when a substitutent
is lower alkylene such as ethylene, propylene, or butylene, the
lower alkylene may form a bridged structure between the quanternary
ammonium group and any carbon atom or between any two carbon atoms
in E.
[0155] Preferred embodiment of E is the formula (I-D):
##STR00093##
wherein,
[0156] the dashed line is a bond in the ring;
[0157] the bond to the cationic nitrogen atom binds to L, and the
other bond binds to R.sup.10;
provided,
[0158] when a cationic nitrogen atom binds to R.sup.10, the dashed
line is absent, and
[0159] when a cationic nitrogen atom does not bind to R.sup.10, the
dashed line is a single bond between the cationic nitrogen atom and
a neighboring atom or an alkylene group between the cationic
nitrogen atom and a ring member atom other than said neighboring
atom,
or the formula (I-E):
##STR00094##
wherein, the bond to the cationic nitrogen atom binds to L, and the
other bond binds to R.sup.10; R.sup.x is optionally substituted
lower alkyl.
[0160] When L is --S--, --CH.sub.2--S--, --CH.dbd.CH--S-- or
--CH.dbd.CH--CH.sub.2--S--, preferred embodiment of E is a
monocyclic or fused heterocyclic group represented by the formula
(I-D'):
##STR00095##
wherein,
[0161] the bond to the cationic nitrogen atom binds to R.sup.10,
and the other bond binds to L,
[0162] more preferred E is an optionally substituted pyridinium
group or an optionally substituted fused pyridinium group.
[0163] Preferred examples of E include the following formulae
optionally substituted on the ring:
##STR00096## ##STR00097## ##STR00098## ##STR00099## ##STR00100##
##STR00101## ##STR00102## ##STR00103## ##STR00104##
##STR00105##
[0164] wherein one bond to the quaternary nitrogen atom binds to L,
and the other bond binds to R.sup.10; p is an integer from 1 to 3;
n is 1 or 2; each Rx is independently an optionally substituted
lower alkyl group.
[0165] Among the above formulae, a group selected from the group
consisting of the formulae (1) to (7), (10) to (12), (14), (25) to
(29), (31), (41) to (44), (47), (50), (52), (53), (59), (60), (64),
(73) and (77) is more preferable.
[0166] Particularly, a group selected from the group consisting of
the formulae (2), (3), (5), (6), (7), (10), (11), (26), (27), (41),
(42), (59), (60) and (77) is preferable.
[0167] In the subject invention, E is an optionally substituted,
saturated or unsaturated, monocyclic or fused cyclic group having
at least one quaternary ammonium ion and includes the following
embodiment:
[0168] 1) E is an aromatic heterocyclic group wherein two hydroxyl
groups each binds to each of two adjacent carbon atoms on the
aromatic ring;
[0169] 2) E is a heterocyclic group wherein a hydroxyl group(s) do
not attached to the ring, or when a hydroxyl group(s) attached, two
hydroxyl group each do not bind to each of two adjacent carbon
atoms on the ring; and
[0170] 3) E is a non-cyclic group.
Preferred is 1) or 2).
[0171] Preferable examples of the above 1) include:
##STR00106## ##STR00107## ##STR00108## ##STR00109## ##STR00110##
##STR00111##
wherein one bond to the quaternary nitrogen atom binds to L, and
the other bond binds to R.sup.10.
[0172] Preferred examples of E-R.sup.10 include:
##STR00112##
[0173] wherein one bond to the quaternary nitrogen atom binds to L,
and R.sup.12 is as defined above.
[0174] More preferred examples of E-R.sup.10 include:
##STR00113##
wherein the bond to the quaternary nitrogen atom binds to L.
[0175] R.sup.6 is hydrogen or optionally substituted lower alkyl,
preferably hydrogen, linear or branched alkyl having 1-4 carbons or
linear or branched alkyl having 1-4 carbons substituted with
carboxy, halogen, hydroxyl or carbonyl, more preferably hydrogen,
methyl, ethyl, tert-buthyl,
##STR00114##
[0176] In accordance with the present invention, variable terms "B"
or "D", respectively. are as defined throughout the specification
and as below, i.e.:
[0177] B is non-existent, a single bond or a 5- or 6-membered
heterocyclic group containing at least 1-3 nitrogen atoms.
[0178] D is non-existent, a single bond, --C(.dbd.O)--,
--O--C(.dbd.O)--, --C(.dbd.O)--O--, --NR.sup.6--,
--NR.sup.6--C(.dbd.O)--, --C(.dbd.O)--NR.sup.6--,
--C(.dbd.O)--C(.dbd.O)--, --NR.sup.6--C(.dbd.O)--NR.sup.6--,
--C(.dbd.O)--C(.dbd.O)--NR.sup.6--,
--C(.dbd.O)--NR.sup.6--C(.dbd.)--,
--NR.sup.6--C(.dbd.O)--C(.dbd.O)--,
--NR.sup.6--NR.sup.6--C(.dbd.O)--, --C(.dbd.O)--NR--NR.sup.6--,
--N.dbd.N--C(.dbd.O)--, --C(.dbd.O)--N.dbd.N--,
--C.dbd.N--NR.sup.6--C(.dbd.O)--, --C.dbd.N--C(.dbd.O)--,
--N.dbd.C--C(.dbd.O)--, --C.dbd.N--C(.dbd.O)--NR.sup.6--,
--NR.sup.6--C(.dbd.O)--C(.dbd.N--OR.sup.6)--,
--C(.dbd.N--OR.sup.6)--C(.dbd.O)--NR.sup.6--,
--NR.sup.6--C(.dbd.N--OR.sup.6)--,
--C(.dbd.N--OR.sup.6)--NR.sup.6--,
--C(.dbd.O)--C(.dbd.N--OR.sup.6)--,
--C(.dbd.N--OR.sup.6)--C(.dbd.O)--, --O--, --S--, --S(.dbd.O)--,
--S(.dbd.O).sub.2--NR.sup.6--, --NR.sup.6--S(.dbd.O).sub.2--,
--NR.sup.6--CH.sub.2--, --CH.sub.2--NR.sup.6-- or
--S(.dbd.O).sub.2--.
[0179] In light of the above definitions and throughout the
specification, the terms "B" and "D" may respectively or
individually be non-existent, or if both "B" and "D" represent
single bonds, then "B" and "D" may be taken together or
collectively (i.e., "B-D" joined together) such that it may
represent one single bond attached to corresponding adjacent or
adjoining functional groups as defined by the present
invention.
[0180] Preferred embodiments of R.sup.10 as a group represented by
the formula:
##STR00115##
are provided below.
[0181] G is preferably a single bond or optionally substituted
lower alkylene, and more preferably a single bond, methylene or
ethylene.
[0182] B is non-existent, preferably a single bond or a group
represented by the formula:
##STR00116##
wherein the bond of the left side is attached to G and the bond of
the right side is attached to D.
[0183] B is more preferably a single bond. [0184] D is preferably a
single bond, --C(.dbd.O)--, --O--C(.dbd.O)--, --C(.dbd.O)--O--,
--NR6-, --O--, --C(.dbd.O)--C(.dbd.O)--, --NR6-C(.dbd.O)--NR6-,
--C(.dbd.O)--C(.dbd.O)--NR6-, --C(.dbd.O)--NR6-C(.dbd.O)--,
--NR6-C(.dbd.O)--C(.dbd.O)--, --NR6-C(.dbd.O)--, --C(.dbd.O)--NR6-,
--NR6-NR6-C(.dbd.O)--, --C(.dbd.O)--NR6-NR6-,
--N.dbd.N--C(.dbd.O)--, --C(.dbd.O)--N.dbd.N--,
--C.dbd.N--NR6-C(.dbd.O)--, --C.dbd.N--C(.dbd.O)--,
--N.dbd.C--C(.dbd.O)--, --C.dbd.N--C(.dbd.O)--NR.sup.6--,
--NR.sup.6--C(.dbd.O)--C(.dbd.N--OR6)-,
--C(.dbd.N--OR6)-C(.dbd.O)--NR6-, --NR6-C(.dbd.N--OR6)-,
--C(.dbd.O)--C(.dbd.N--OR6)-, --C(.dbd.N--OR6)-C(.dbd.O)-- or
--C(.dbd.N--OR6)-NR.sup.6--, wherein R.sup.6 is hydrogen, methyl,
carboxymethyl or 2-carboxypropane-2-yl, and more preferably a
single bond, --C(.dbd.O)--, --C(.dbd.O)--C(.dbd.O)--,
--NH--C(.dbd.O)--C(.dbd.O)--, --NH--C(.dbd.O)--,
--NH--C(.dbd.O)--C(.dbd.N--OR.sup.6)--,
--C(.dbd.O)--C(.dbd.N--OR.sup.6)--, --NH--, --O--, or
--C.dbd.N--NH--C(.dbd.O)--, R.sup.6 is hydrogen, methyl, ethyl,
tert-buthyl, carboxymethyl, 2-carboxypropan-2-yl or
1-carboxyethyl.
[0185] Preferred combinations of "-G-B-D-" include the formulae as
shown below:
##STR00117##
wherein, k is an integer of to 3, R6 is as defined above, the wavy
line means that the bond is in cis or trans configuration, or a
mixture thereof.
[0186] Preferable examples of "-E-G-B-D-" include the formulae as
shown below:
##STR00118## ##STR00119## ##STR00120## ##STR00121##
wherein, Me represents a methyl group, h is an integer 0 to 3,
R.sup.6 is hydrogen, methyl, ethyl, tert-buthyl, carboxymethyl,
2-carboxypropan-2-yl or 1-carboxyethyl, the wavy line means that
the bond is in cis or trans configuration, or a mixture
thereof.
[0187] In one aspect of the present invention with regard to
Formula (I-B):
##STR00122##
where:
[0188] ring A is defined as a fused heterocycle ring system
comprised of at least two (2) rings fused together;
[0189] where:
[0190] R.sup.4 optionally is substituted on each of the at least
two (2) rings of the fused heterocycle ring system defined as ring
A, such that each R4 substituent on each ring of the fused
heterocycle ring system independently are selected from identical
or different substituents;
[0191] where: [0192] each R.sup.4 as defined above optionally is
substituted independently on each ring of the fused heterocycle
ring is selected from hydrogen, halogen, oxo, --OH, --CN,
--NO.sub.2, --O--C(.dbd.O)--R.sup.9, --C(.dbd.O)--R.sup.9,
--C(.dbd.O)--OH, --C(.dbd.O)--OR.sup.9, --OR.sup.9',
--NR.sup.9R.sup.9, --SO.sub.2R.sup.9, --SR.sup.9,
--NR.sup.9--C(.dbd.O)--R.sup.9, optionally substituted lower alkyl,
optionally substituted cycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl; [0193] provided that two
hydroxyl groups on ring A bind respectively to carbon atoms each
adjacently locates; and n is an integer from 0 to 2.
[0194] Preferred embodiments of a group of the formula:
##STR00123##
[0195] wherein:
[0196] A is a benzene ring, monocyclic heterocycle or fused
heterocycle, respectively as defined throughout the
specification;
[0197] each R.sup.4 is independently hydrogen, halogen, oxo, --OH,
--CN, --NO2, --O--C(.dbd.O)--R.sup.9, --C(.dbd.O)--R.sup.9,
--C(.dbd.O)--OH, --C(.dbd.O)--OR.sup.9, --OR.sup.9,
--NR.sup.9R.sup.9, --SO.sub.2R.sup.9, --SR.sup.9,
--NR.sup.9--C(.dbd.O)--R.sup.9, lower alkyl, halo(lower)alkyl,
cycloalkyl, aryl, or heteroaryl; each R.sup.9 is independently
lower alkyl or halo(lower)alkyl; n is an integer from 0 to 2;
provided that two hydroxyl groups on the ring A bind respectively
to carbon atoms each adjacently locates.
[0198] Preferred examples of ring A include benzene, a 5- to
7-membered monocyclic heterocycle and a 8- to 12-membered fused
heterocycle and as defined throughout the instant
specification.
[0199] Preferred examples of 5- to 7-membered monocyclic
heterocycle of ring A include the ring having 1 to 3 nitrogen
atom(s), more preferably one nitrogen atom.
[0200] Preferred examples of 8- to 12-membered fused heterocycle of
ring A include the ring having 1 to 4 nitrogen atom(s), more
preferably one or two nitrogen atom(s).
[0201] More preferred examples of ring A include benzene, a 5- to
6-membered monocyclic heterocycle having one nitrogen atom and a 9-
to 10-membered fused heterocycle having one or two nitrogen
atom(s).
[0202] Preferred examples of a group of the formula:
##STR00124##
include the formulae as shown below:
##STR00125## ##STR00126## ##STR00127## ##STR00128##
##STR00129##
wherein, each R.sup.4a, R.sup.4b R.sup.4c and R.sup.4d is
independently hydrogen, halogen, --OH, --CN, --C(.dbd.O)--R.sup.9,
--C(.dbd.O)--OH, --C(.dbd.O)--OR.sup.9, --OR.sup.9, optionally
substituted lower alkyl, or optionally substituted cycloalkyl;
R.sup.9 is independently lower alkyl or halo(lower)alkyl; R.sup.6
is hydrogen, or optionally substituted lower alkyl.
[0203] More preferred examples of a group of the formula:
##STR00130##
include the formulae as shown below:
##STR00131## ##STR00132## ##STR00133## ##STR00134## ##STR00135##
##STR00136## ##STR00137## ##STR00138## ##STR00139##
##STR00140##
Wherein, Me represents a methyl group.
[0204] Preferred examples of a group of the formula (1-C-1):
##STR00141##
include the formulae as shown below:
##STR00142## ##STR00143## ##STR00144## ##STR00145## ##STR00146##
##STR00147## ##STR00148## ##STR00149## ##STR00150##
##STR00151##
wherein, each R.sup.4a, R.sup.4b R.sup.4c and R.sup.4d is
independently hydrogen, halogen, --OH, --CN, --C(.dbd.O)--R.sup.9,
--C(.dbd.O)--OH, --C(.dbd.O)--OR.sup.9, --OR.sup.9, optionally
substituted lower alkyl, or optionally substituted cycloalkyl;
R.sup.9 is independently lower alkyl or halo(lower)alkyl; R.sup.6
is hydrogen, or optionally substituted lower alkyl; the wavy line
means that the bond is in cis or trans configuration, or a mixture
thereof.
[0205] Examples of R.sup.4a, R.sup.4b R.sup.4c and R.sup.4d include
hydrogen, chloro, fluoro, bromo, cyano, hydroxy, carboxy, acetyl,
methoxy, ethoxy, trifluoromethyl, and the like. Preferably, each
R.sup.4a, R.sup.4b R.sup.4c and R.sup.4d is independently hydrogen,
hydroxy, carboxy, methoxy, fluoro, trifluoromethyl, or chloro.
[0206] More preferred examples of a group of the formula
(1-C-1):
##STR00152##
include the formulae as shown below:
##STR00153## ##STR00154## ##STR00155## ##STR00156## ##STR00157##
##STR00158## ##STR00159## ##STR00160## ##STR00161## ##STR00162##
##STR00163## ##STR00164## ##STR00165## ##STR00166## ##STR00167##
##STR00168## ##STR00169## ##STR00170## ##STR00171##
##STR00172##
wherein, R.sup.6 is hydrogen, methyl, ethyl, tert-buthyl,
carboxymethyl, 2-carboxypropan-2-yl or 1-carboxyethyl, the wavy
line means that the bond is in cis or trans configuration, or a
mixture thereof.
[0207] The nomenclature of the substitution position on the cephem
skeleton of Formula (I) is as follows. As used herein, 3-side
chain, 4-side chain and 7-side chain respectively refer to groups
binding to the 3-position, 4-position and the 7-position of the
cephem skeleton
##STR00173##
[0208] Esters of Formula (I) preferably include those at the 7-side
chain. Esters at the carboxyl group on the 7-side chain include
compounds, wherein any carboxyl group of optionally substituted
amino, optionally substituted aminosulfonyl, carboxyl, optionally
substituted (lower)alkyloxycarbonyl, optionally substituted
carbamoyl, substituted carbonyloxy, or the like at the terminal of
R.sup.1, R.sup.2A or R.sup.2B shown in the formula:
##STR00174##
wherein each symbol is as defined above, is esterified. For
example, in the case of carboxyl (--COOH), such esters are
represented by the structural formula --COOR.sup.a, wherein R.sup.a
is an ester residue such as a carboxyl-protecting group or the
like. Such esters include those easily metabolized in the body to
form a carboxylic state.
[0209] The aforementioned protecting groups for carboxyl or the
like may be any group as long as it can be protected and/or
deprotected by a method described in Protective Groups in Organic
Synthesis, written by T. W. Greene, John Wiley & Sons Inc.
(1991), or the like. Examples thereof include lower alkyl (e.g.,
methyl, ethyl, t-butyl), (lower)alkylcarbonyloxymethyl (e.g.,
pivaloyl), optionally substituted aralkyl (e.g., benzyl,
benzhydryl, phenethyl, p-methoxybenzyl, p-nitrobenzyl), silyl
groups (t-butyldimethylsilyl, diphenyl(t-butyl)silyl), and the
like.
[0210] Amino-protected compounds at the amino on the 7-side chain
of Formula (I) refer to the structures in which the amino on the
ring (e.g., thiazole, thiadiazole) has been protected.
[0211] The amino protected group is represented by the formula
--NHR.sup.c wherein R.sup.c represents an amino-protecting group.
Such amino-protecting groups include those groups that are readily
metabolized in the body to form amino. The aforementioned
amino-protecting groups may be any group as long as it can be
protected and/or deprotected by a method described in Protective
Groups in Organic Synthesis, written by T. W. Greene, John Wiley
& Sons Inc. (1991), or the like. Examples thereof include
(lower)alkoxycarbonyl (e.g., t-butoxycarbonyl, benzyloxycarbonyl,
p-nitrobenzyloxycarbonyl), optionally substituted aralkanoyl (e.g.,
benzoyl, p-nitrobenzoyl), acyl (e.g., formyl, chloroacetyl), and
the like.
[0212] The Compound (I) of the subject invention is not limited to
particular isomers, but includes any possible isomers (e.g.,
keto-enol isomer, imine-enamine isomer, diastereoisomer,
geometrical isomer, optical isomer, rotamer, etc.), racemates and a
mixture thereof.
[0213] For example, the Formula (I):
##STR00175##
includes
##STR00176##
[0214] For example, the formula:
##STR00177##
wherein each symbol is as defined above, includes the following
resonance structures:
##STR00178##
wherein R.sup.4 is as defined above.
[0215] Also, the group "E" in Formula (I), for example, includes
the following resonance structures:
##STR00179##
wherein each symbol is as defined above.
[0216] For example, the formula:
##STR00180##
wherein, R6 is as defined above; includes
##STR00181##
and a mixture thereof.
[0217] At least one hydrogen atom, carbon atom and/or another atom
may be replaced with an isotope of said hydrogen atom, carbon atom
and/or another atom. Examples of such isotope include hydrogen,
carbon, nitrogen, oxygen, sulfur, fluorine, iodine and chlorine,
such as .sup.2H, .sup.3H, .sup.11C, .sup.13C, .sup.14C, .sup.15N,
.sup.18O, .sup.17O, .sup.31P, .sup.32P, .sup.35S, .sup.18F,
.sup.123I and .sup.36Cl. The compound of Formula (I) include
compounds having an atom replaced with such isotope. Such compound
replaced with an isotope are useful as a pharmaceutical product,
and such compound include all of radiolabeled compound of Formula
(I). Also, the subject invention includes any method of radioactive
labeling for the production of such radiolabeled compound, and
thus, it is useful in a research for metabolic pharmacokinetics,
binding assay and/or as a diagnostic tool.
[0218] A radiolabeled compound of Formula (I) may be prepared
according to the technique well known in the art. For example,
tritium can be introduced into a specific compound of Formula (I)
by catalytic dehalogenation using tritium to prepare a
tritium-labeled compound of Formula (I). This method comprises
reaction of a precursor which is a compound of Formula (I)
appropriately halogenated with tritium gas in the presence of
appropriate catalyst, such as Pd/C, in the presence or absence of a
base. For another method for the preparation of a tritium-labeled
compound, see the literature, Isotopes in the Physical and
Biomedical Sciences, Vol. 1, Labeled Compounds (Part A), Chapter 6
(1987). .sup.14C-labeled compound can be prepared using a starting
material having .sup.14C.
[0219] Salts of a compound of Formula (I) include those formed with
an inorganic or organic acid by a carboxyl group in the 7-side
chain and/or an amino group in the 7-side chain; and those formed
with a counter anion by a quaternary amine moiety in the 3-side
chain.
[0220] Pharmaceutically acceptable salts of a compound of Formula
(I) include, for example, salts formed with alkali metal (e.g.
lithium, sodium, potassium, etc.), alkaline earth metal (e.g.
calcium, barium, etc.), magnesium, transition metal (e.g. zinc,
ferrum, etc.), ammonia, organic base (e.g. trimethylamine,
triethylamine, dicyclohexylamine, ethanolamine, diethanolamine,
triethanolamine, meglumine, diethanolamine, ethylenediamine,
pyrydine, picoline, quinoline, etc.) and amino acid, or salts
formed with inorganic acid (e.g. hydrochloric acid, sulphuric acid,
nitric acid, carbonic acid, hydrobromic acid, phosphoric acid,
hydroiodic acid, etc.), and organic acid (e.g. formic acid, acetic
acid, propionic acid, trifluoroacetic acid, citric acid, lactic
acid, tartaric acid, oxalic acid, maleic acid, fumaric acid,
mandelic acid, glutaric acid, malic acid, benzoic acid, phthalic
acid, ascorbic acid, benzenesulphonic acid, p-toluenesulfonic acid,
methanesulphonic acid, ethanesulphonic acid, etc, particularly,
salts formed with hydrochloric acid, sulphuric acid, phosphoric
acid, tartaric acid, methanesulphonic acid. These salts can be
formed according to the conventional method.
[0221] The compound of Formula (I) or pharmaceutically acceptable
salts thereof may form a solvate (e.g., hydrate) and/or a
crystalline polymorphism, and the subject invention also includes
such solvates and crystalline polymorphisms. In such "solvate", any
number of solvent molecules (e.g., water molecule, etc.) may be
coordinated to the compound of Formula (I). By leaving the compound
of Formula (I) or pharmaceutically acceptable salt thereof in the
atmosphere, it may absorb moisture to adhere with absorbed water or
form a hydrate thereof. Also, a crystalline polymorphism of the
compound of Formula (I) or pharmaceutically acceptable salt thereof
can be formed by recrystallization.
[0222] The compound of Formula (I) or pharmaceutically acceptable
salt thereof may form a prodrug, and the subject invention includes
such prodrugs. Prodrug is a derivative of the compound of the
invention having a group chemically- or metabolically-degradable to
be transformed into a pharamacologically active compound by
solvolysis or under physiological condition in vivo. Prodrug
includes compounds which can be transformed into the compound of
Formula (I) by enzymatically oxidization, reduction or hydrolysis
under physiological condition in vivo, or transformed into the
compound of Formula (I) by hydrolysis with gastric acid, etc.
Methods for selection and production of appropriate prodrug
derivative can be found, for example, in Design of Prodrugs,
Elsevier, Amsterdam 1985.
[0223] Prodrug may be active compound in itself.
[0224] When the compound of Formula (I) or pharmaceutically
acceptable salt thereof has hydroxyl, acyloxy derivatives or
sulfonyloxy derivatives can be prepared as a prodrug. For example,
such compound having hydroxyl may be reacted with an appropriate
acyl halide, acid anhydrate or an appropriate sulfonyl chloride,
sulfonyl anhydrate, mixed anhydrate, etc., or may be reacted using
a coupling agent, such as for examples, those having CH.sub.3COO--,
C.sub.2H.sub.5COO--, t-BuCOO--, C.sub.15H.sub.31COO--, PhCOO--,
(m-NaOOCPh)COO--, NaOOCCH.sub.2CH.sub.2COO--,
CH.sub.3CH(NH.sub.2)COO--, CH.sub.2N (CH.sub.3).sub.2COO--,
CH.sub.3SO.sub.3--, CH.sub.3CH.sub.2SO.sub.3--, CF.sub.3SO.sub.3--,
CH.sub.2FSO.sub.3--, CF.sub.3CH.sub.2SO.sub.3--,
p-CH.sub.3--O-PhSO.sub.3--, PhSO.sub.3--,
p-CH.sub.3PhSO.sub.3--.
[0225] For the synthesis of a compound of Formula (I), A compound
of the formula (I-H):
##STR00182##
wherein,
[0226] Y is a leaving group; P.sup.2 is a protecting group;
[0227] R.sup.5A, R.sup.5B and L are as defined above,
or a pharmaceutically acceptable salt thereof is preferred as an
intermediate.
[0228] The compound of the formula (I-H), or a salt thereof,
wherein P.sup.2 is benzhydryl group, p-methoxybenzyl group, trityl
group, 2,6-dimethoxybenzyl group, methoxymethyl group,
benzyloxymethyl group or 2-(trimethylsilyl)ethoxymethyl group is
preferred as an intermediate.
[0229] The compound of the formula (I-H), or a salt thereof,
wherein R5.sup.A is methyl and R5.sup.B is hydrogen is preferred as
an intermediate.
[0230] For the synthesis of a compound of Formula (I), a compound
of the formula (I-I):
##STR00183##
or a salt thereof, wherein,
[0231] Y is a leaving group; P.sup.2 is a protecting group;
[0232] R5.sup.A and L are as defined above,
or a pharmaceutically acceptable salt thereof is preferred as an
intermediate.
[0233] For the synthesis of a compound of Formula (I), a compound
of the formula:
##STR00184##
wherein, Y is a leaving group; P2 is a protecting group; R5A, R5B
and L are as defined above, or a pharmaceutically acceptable salt
thereof is preferred as an intermediate. The 7-amino can be formed
with a counter anion (Z.sup.-) to be a salt
(--NH.sub.3+Z.sup.-)
[0234] The leaving group includes halogen (Cl, Br, I, F), acetoxy,
methanesulfonyloxy, p-toluenesulfonyloxy,
trifluoromethanesulfonyloxy, etc.
[0235] Preferred example of a compound of the formula:
##STR00185##
wherein, Y is a leaving group; P2 is a protecting group; R5A, R5B
and L are as defined above, is a compound of the formula:
##STR00186##
wherein, Y is a leaving group; P2 is a protecting group; L is as
defined above.
[0236] As described in the following General Synthesis and
Examples, an intermediate compound described above is reacted with
side chain moieties at the 3-, 4- and 7-positions of the cephem
skeleton to obtain a compound of Formula (I). Examples of the
protecting group "P.sup.2" include those described in the following
General Synthesis, and preferably, benzhydryl, p-methoxybenzyl,
trityl, 2,6-dimethoxybenzyl, methoxymethyl, benzyloxymethyl or
2-(trimethylsilyl)ethoxymethyl, etc.
(General Synthesis Method)
[0237] Scheme 1 represents a general scheme for the preparation of
compounds of the present invention.
##STR00187## ##STR00188## ##STR00189##
wherein, P.sup.1 and P.sup.2 are protecting groups; Y is a leaving
group (e.g., a halogen (Cl, Br, I, F), methanesulfonyloxy,
pe-toluenesulfoxy); R5 is hydrogen or lower alkyl; other symbols
are as defined above.
1) Formation of 2-Methyl Cephem: Synthesis of Compound (X)
Step 1
[0238] The 4-carboxyl group of the compound (II) is protected with
a carboxyl-protecting group by a conventional method to give the
compound (III). The carboxyl-protecting group is exemplified by
diphenyl methyl, p-methoxybenzyl etc.
[0239] The reaction solvents include, for example, ethers (e.g.,
dioxane, tetrahydrofuran, diethyl ether, tert-butyl methyl ether,
diisopropyl ether), esters (e.g., ethyl formate, ethyl acetate,
isopropyl acetate), halogenated hydrocarbons (e.g.,
dichloromethane, chloroform, carbon tetarachloride), hydrocarbons
(e.g., n-hexane, benzene, toluene), amides (e.g., formamide,
N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone),
ketones (e.g., acetone, methyl ethyl ketone), nitriles (e.g., MeCN,
propionitrile), dimethylsulfoxide, water and a mixed solvent
thereof.
[0240] The reaction temperature is usually in the range of from
about -100.degree. C. to 100.degree. C., preferably from about
-80.degree. C. to 80.degree. C., more preferably from about
-60.degree. C. to 60.degree. C. The reaction time may vary
according to the reagents, solvents or reaction temperature to be
employed, but usually is 0.5 to 24 hours.
Step 2
[0241] The compound (IV) is obtained by subjecting the compound
(III) to oxidation reaction using an oxidation agent well-known to
those skilled in the art (e.g., m-chloroperbenzoic acid, acetic
peroxide).
[0242] The reaction solvents include, for example, ethers (e.g.,
anisole, dioxane, tetrahydrofuran, diethyl ether, tert-butyl methyl
ether, diisopropyl ether), esters (e.g., ethyl formate, ethyl
acetate, n-butyl acetate, isopropyl acetate), halogenated
hydrocarbons (e.g., dichloromethane, chloroform, carbon
tetarachloride), hydrocarbons (e.g., n-hexane, benzene, toluene),
amides (e.g., formamide, N,N-dimethylformamide,
N,N-dimethylacetamide, N-methylpyrrolidone), ketones (e.g.,
acetone, methyl ethyl ketone), nitriles (e.g., MeCN,
propionitrile), nitros (e.g., nitromethane, nitorethane,
nitrobenzene), dimethylsulfoxide, water, and a mixed solvent
selected from two or more of these solvents. The reaction
temperature is usually in the range of from about -100.degree. C.
to 100.degree. C., preferably from about -80.degree. C. to
50.degree. C., more preferably about -60.degree. C. to -30.degree.
C. The reaction time may vary according to the reagents, solvents
or reaction temperature to be employed, but usually is carried out
for 0.5 to 24 hours.
Step 3
[0243] The compound (IV) is reacted with aldehyde (i.e. R.sup.5CHO)
and a primary or secondary amine to give the compound (V).
[0244] Aldehyde include, for example, formaldehyde and lower alkyl
aldehyde (e.g. acetaldehyde, propionaldehyde). Aldehyde is
generally used in an amount of about 1 to 100 moles, preferably 1
to 30 moles, for 1 mole of the compound (IV).
[0245] A primary or secondary amine include, for example,
methylamine, dimethylamine, ethylamine and diethylamine. A primary
or secondary amine, including its salt, is generally used in an
amount of about 1 to 100 moles, preferably 1 to 30 moles, for 1
mole of the compound (IV).
[0246] The reaction solvents include, for example, ethers (e.g.,
dioxane, tetrahydrofuran, diethyl ether, tert-butyl methyl ether,
diisopropyl ether), esters (e.g., ethyl formate, ethyl acetate,
isopropyl acetate), halogenated hydrocarbons (e.g.,
dichloromethane, chloroform, carbon tetarachloride), hydrocarbons
(e.g., n-hexane, benzene, toluene), amides (e.g., formamide,
N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone),
ketones (e.g., acetone, methyl ethyl ketone), nitriles (e.g., MeCN,
propionitrile), dimethylsulfoxide, water, and a mixed solvent
thereof.
[0247] The reaction temperature is usually in the range of from
about -100.degree. C. to 100.degree. C., preferably from about
-80.degree. C. to 80.degree. C., more preferably from about
0.degree. C. to 80.degree. C. The reaction time may vary according
to the reagents, solvents or reaction temperature to be employed,
but usually is 0.5 to 24 hours.
Step 4
[0248] The compound (V) is reacted with a reductant (e.g., zinc,
copper, mixture thereof) and an acid (e.g., Hydrochloric acid,
acetic acid, formic acid) to give the compound (VI).
[0249] Zinc is generally used in an amount of about 1 to 100 moles,
preferably 1 to 30 moles, for 1 mole of the compound (V). Acid
(e.g., Hydrochloric acid, acetic acid, formic acid) is generally
used in an amount of about 1 to 100 moles, preferably 1 to 30
moles, for 1 mole of the compound (V).
[0250] The reaction solvents include, for example, ethers (e.g.,
dioxane, tetrahydrofuran, diethyl ether, tert-butyl methyl ether,
diisopropyl ether), esters (e.g., ethyl formate, ethyl acetate,
isopropyl acetate), halogenated hydrocarbons (e.g.,
dichloromethane, chloroform, carbon tetarachloride), hydrocarbons
(e.g., n-hexane, benzene, toluene), amides (e.g., formamide,
N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone),
ketones (e.g., acetone, methyl ethyl ketone), nitriles (e.g., MeCN,
propionitrile), acid (e.g., Hydrochloric acid, acetic acid, formic
acid), dimethylsulfoxide, water, and a mixed solvent thereof.
[0251] The reaction temperature is usually in the range of from
about -100.degree. C. to 100.degree. C., preferably from about
-80.degree. C. to 80.degree. C., more preferably from about
-20.degree. C. to 60.degree. C. The reaction time may vary
according to the reagents, solvents or reaction temperature to be
employed, but usually is 0.5 to 24 hours.
Step 5
[0252] The compound (VI) is reacted with hydrohalic acid such as
hydrochloric acid, etc. to give the compound (VII). Hydrohalic acid
is generally used in an amount of about 1 to 100 moles, preferably
1 to 30 moles, for 1 mole of the compound (VI). The reaction
solvents include, for example, ethers (e.g., dioxane,
tetrahydrofuran, diethyl ether, tert-butyl methyl ether,
diisopropyl ether), esters (e.g., ethyl formate, ethyl acetate,
isopropyl acetate), halogenated hydrocarbons (e.g.,
dichloromethane, chloroform, carbon tetarachloride), hydrocarbons
(e.g., n-hexane, benzene, toluene), amides (e.g., formamide,
N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone),
ketones (e.g., acetone, methyl ethyl ketone), nitriles (e.g., MeCN,
propionitrile), dimethylsulfoxide, water, and a mixed solvent
thereof.
[0253] The reaction temperature is usually in the range of from
about -100.degree. C. to 100.degree. C., preferably from about
-80.degree. C. to 80.degree. C., more preferably from about
-20.degree. C. to 60.degree. C. The reaction time may vary
according to the reagents, solvents or reaction temperature to be
employed, but usually is 0.5 to 24 hours.
Step 6
[0254] The compound (VII) is reacted with a peroxyacid (e.g.,
meta-Chloroperoxybenzoic acid, peroxyacetic acid), etc. to give the
crude sulfoxide compound. Furthermore, the crude sulfoxide compound
is reacted with a base (e.g. triethylamine, sodium acetate, sodium
bicarbonate, sodium hydrogen carbonete) to give the single
stereoisomer sulfoxide compound (VIII).
[0255] Peroxyacid is generally used in an amount of about 1 to 100
moles, preferably 1 to 30 moles, for 1 mole of Compound (III). The
reaction solvents include, for example, alcohols (e.g., methanol,
ethanol), halogenated hydrocarbons (e.g., dichloromethane,
chloroform, carbon tetarachloride), hydrocarbons (e.g., n-hexane,
benzene, toluene), amides (e.g., formamide, N,N-dimethylformamide,
N,N-dimethylacetamide, N-methylpyrrolidone). The reaction
temperature is usually in the range of from about -100.degree. C.
to 100.degree. C., preferably from about -80.degree. C. to
50.degree. C., more preferably from about -20.degree. C. to
0.degree. C. The reaction time may vary according to the reagents,
solvents or reaction temperature to be employed, but usually is 0.5
to 24 hours.
Step 7
[0256] The compound (VIII) is reacted with a reductant (e.g.,
phosphorus trichloride, phosphorus tribromide) to give the compound
(IX).
[0257] The reductant (e.g., phosphorus trichloride, phosphorus
tribromide) is generally used in an amount of about 1 to 100 moles,
preferably 1 to 30 moles, for 1 mole of Compound (VIII).
[0258] The reaction solvents include, for example, halogenated
hydrocarbons (e.g., dichloromethane, chloroform, carbon
tetarachloride), hydrocarbons (e.g., n-hexane, benzene, toluene),
amides (e.g., formamide, N,N-dimethylformamide,
N,N-dimethylacetamide, N-methylpyrrolidone). The reaction
temperature is usually in the range of from about -100.degree. C.
to 100.degree. C., preferably from about -80.degree. C. to
50.degree. C., more preferably from about -60.degree. C. to
0.degree. C. The reaction time may vary according to the reagents,
solvents or reaction temperature to be employed, but usually is 0.5
to 24 hours.
Step 8
[0259] The compound (X) is obtained by subjecting Compound (IX) to
a hydrolysis reaction to make amide on 7-side chain to an amino
group, followed by treating the compound with a hydrohalic acid
such as hydrochloric acid. The reaction solvents include, for
example, ethers (e.g., anisole, dioxane, tetrahydrofuran, diethyl
ether, tert-butyl methyl ether, diisopropyl ether), esters (e.g.,
ethyl formate, ethyl acetate, n-butyl acetate, isopropyl acetate),
halogenated hydrocarbons (e.g., dichloromethane, chloroform, carbon
tetarachloride), hydrocarbons (e.g., n-hexane, benzene, toluene),
amides (e.g., formamide, N,N-dimethylformamide,
N,N-dimethylacetamide, N-methylpyrrolidone), ketones (e.g.,
acetone, methyl ethyl ketone), nitriles (e.g., MeCN,
propionitrile), nitros (e.g., nitromethane, nitorethane,
nitrobenzene), dimethylsulfoxide, water, and a mixed solvent
selected from two or more thereof. The reaction temperature is
usually in the range of from about -100.degree. C. to 100.degree.
C., preferably from about -50.degree. C. to 50.degree. C., more
preferably from about -40.degree. C. to 30.degree. C. The reaction
time may vary according to the reagents, solvents or reaction
temperature to be employed, but usually is 0.5 to 24 hours.
2) Formation of the 7-Saide Chain: Synthesis of the Compound
(XII)
Step 9
[0260] The compound (X) is subjected to condensation reaction with
the compound (XI) to give the compound (XII). The reaction solvents
include, for example, water, ethers (e.g., dioxane,
tetrahydrofuran, diethyl ether, tert-butyl methyl ether,
diisopropyl ether), esters (e.g., ethyl formate, ethyl acetate,
isopropyl acetate), halogenated hydrocarbons (e.g.,
dichloromethane, chloroform, carbon tetarachloride), hydrocarbons
(e.g., n-hexane, benzene, toluene), amides (e.g., formamide,
N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone),
ketones (e.g., acetone, methyl ethyl ketone), nitriles (e.g., MeCN,
propionitrile), dimethylsulfoxide, water, and a mixed solvent
thereof.
[0261] The reaction temperature is usually in the range of from
about -100.degree. C. to 100.degree. C., preferably from about
-80.degree. C. to 80.degree. C., more preferably from about
-60.degree. C. to 50.degree. C. The reaction time may vary
according to the reagents, solvents or reaction temperature to be
employed, but usually is 0.5 to 24 hours.
3) Formation of the 3-Side Chain: Synthesis of the Compound (I)
Step 10
[0262] The compound (I') is obtained by subjecting the compound
(XII) to a substitution reaction with the compound (XIII) and then
subjecting it to deprotection reaction. The reaction solvents used
in the reaction between the compound (XII) and the compound (XIII)
include, for example, ethers (e.g., dioxane, tetrahydrofuran,
diethyl ether, tert-butyl methyl ether, diisopropyl ether), esters
(e.g., ethyl formate, ethyl acetate, isopropyl acetate),
halogenated hydrocarbons (e.g., dichloromethane, chloroform, carbon
tetarachloride), hydrocarbons (e.g., n-hexane, benzene, toluene),
amides (e.g., formamide, N,N-dimethylformamide,
N,N-dimethylacetamide, N-methylpyrrolidone), ketones (e.g.,
acetone, methyl ethyl ketone), nitriles (e.g., MeCN,
propionitrile), dimethylsulfoxide, water, and a mixed solvent
thereof. The reaction temperature is usually in the range of from
about -100.degree. C. to 100.degree. C., preferably from about
-80.degree. C. to 80.degree. C., more preferably from about
-20.degree. C. to 30.degree. C. The reaction time may vary
according to the reagents, solvents or reaction temperature to be
employed, but usually is 0.5 to 24 hours.
[0263] The protecting group to be used in the above reaction such
as amino-protecting groups, hydroxy-protecting groups, etc.
includes, for example, protecting groups described in Protective
Groups in Organic Synthesis, written by T. W. Greene, John Wiley
& Sons Inc. (1991), etc. Methods for the introduction and
removal of a protecting group are methods commonly used in
synthetic organic chemistry (see, for example, methods described in
Protective Groups in Organic Synthesis, written by T. W. Greene,
John Wiley & Sons Inc. (1991)), etc., or can be obtained by a
modified method thereof. Furthermore, a functional group included
in each substituent can be converted by a known method (e.g., those
described in Comprehensive Organic Transformations, written by R.
C. Larock (1989), etc.) in addition to the above production
methods. Some of the compounds of the present invention can be used
as a synthetic intermediate, leading to a new derivative.
Intermediates and desired compounds produced in each of the above
production methods can be isolated and purified by a purification
method commonly used in synthetic organic chemistry, for example,
neutralization, filtration, extraction, washing, drying,
concentration, recrystallization, any kind of chromatography, etc.
Furthermore, intermediates can be subjected to a next reaction
without any purification.
[0264] Examples of an amino-protecting group include phthalimide,
lower alkoxycarbonyl (butoxycarbonyl (Boc) etc.), lower
alkenyloxycarbonyl (allyloxycarbonyl (Alloc), etc.),
benzyloxycarbonyl, p-nitrobenzyloxycarbonyl, optionally substituted
aralkanoyl (p-nitrobenzoyl, etc.), acyl (formyl, chloroacetyl,
etc.), optionally substituted aralkyl (trityl, etc.), benzhydryl
(BH), and the like.
[0265] Examples of a hydroxy-protecting group include lower
alkoxycarbonyl such as a C1-C4 alkoxycarbonyl (e.g.,
t-butyloxycarbonyl), halogenated lower alkoxycarbonyl such as a
halogenated (C1-C3) alkoxycarbonyl (e.g., 2-iodo ethyloxycarbonyl,
2,2,2-trichloroethyloxycarbonyl), aryl-(lower) alkoxycarbonyl such
as a phenyl-(C1-C4) alkoxycarbonyl having optionally a substituent
(s) on the benzene ring (benzyloxycarbonyl,
o-nitrobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl,
p-methoxybenzyloxycarbonyl), p-methoxybenzyl (PMB), tri-lower
alkylsilyl such as tri-(C1-C4) alkylsilyl (e.g., trimethylsilyl,
t-butyldimethylsilyl), a substituted methyl such as C1-C4
alkoxymethyl (e.g., methoxymethyl), C1-C4 alkoxy-(C1-C4)
alkoxymethyl (e.g., 2-methoxyethoxymethyl), C1-C4 alkylthiomethyl
(e.g., methylthiomethyl), tetrahydropyranyl, and the like.
[0266] The above-mentioned deprotecting reaction is carried out in
a solvent such as tetrahydrofuran, dimethylformamide, diethyl
ether, dichloromethane, toluene, benzene, xylene, cyclohexane,
hexane, chloroform, ethyl acetate, butyl acetate, pentane, heptane,
dioxane, acetone, acetonitrile, or a mixed solvent thereof, using a
Lewis acid (e.g., AlCl3, SnCl4, TiCl4), a protonic acid (e.g., HCl,
HBr, H2SO4, HCOOH), and the like.
[0267] The obtained compound is further chemically modified, and
thereby an ester, or a compound of which amino on the thiazole or
thiadiazole ring at the 7-position thereof is protected, or a
pharmaceutically acceptable salt, or a solvate thereof can be
synthesized.
##STR00190## ##STR00191##
wherein, P.sup.1 and P.sup.2 are protecting groups; Y is a leaving
group (e.g., a halogen (Cl, Br, I, F), methanesulfonyloxy,
pe-toluenesulfoxy); R5 is lower alkyl; other symbols are as defined
above.
(1) Synthesis of the Compound (XV)
Step 1
[0268] The compound (V) is reacted with a reductant (e.g.,
phosphorus trichloride, phosphorus tribromide), followed by
treating the resultant with a hydrohalic acid such as hydrochloric
acid, etc. to give the compound (IX)
[0269] The reaction solvents include, for example, ethers (e.g.,
dioxane, tetrahydrofuran, diethyl ether, tert-butyl methyl ether,
diisopropyl ether), esters (e.g., ethyl formate, ethyl acetate,
isopropyl acetate), halogenated hydrocarbons (e.g.,
dichloromethane, chloroform, carbon tetarachloride), hydrocarbons
(e.g., n-hexane, benzene, toluene), amides (e.g., formamide,
N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone),
ketones (e.g., acetone, methyl ethyl ketone), nitriles (e.g., MeCN,
propionitrile), dimethylsulfoxide, water, and a mixed solvent
thereof.
[0270] The reaction temperature is usually in the range of from
about -100.degree. C. to 100.degree. C., preferably from about
-80.degree. C. to 80.degree. C., more preferably from about
-20.degree. C. to 60.degree. C. The reaction time may vary
according to the reagents, solvents or reaction temperature to be
employed, but usually is 0.5 to 24 hours.
Step 2
[0271] The compound (XV) is obtained by subjecting Compound (XIV)
to a hydrolysis reaction to make amide on 7-side chain to an amino
group, followed by treating the compound with a hydrohalic acid
such as hydrochloric acid. The reaction solvents include, for
example, ethers (e.g., anisole, dioxane, tetrahydrofuran, diethyl
ether, tert-butyl methyl ether, diisopropyl ether), esters (e.g.,
ethyl formate, ethyl acetate, n-butyl acetate, isopropyl acetate),
halogenated hydrocarbons (e.g., dichloromethane, chloroform, carbon
tetarachloride), hydrocarbons (e.g., n-hexane, benzene, toluene),
amides (e.g., formamide, N,N-dimethylformamide,
N,N-dimethylacetamide, N-methylpyrrolidone), ketones (e.g.,
acetone, methyl ethyl ketone), nitriles (e.g., MeCN,
propionitrile), nitros (e.g., nitromethane, nitorethane,
nitrobenzene), dimethylsulfoxide, water, and a mixed solvent
selected from two or more thereof.
[0272] The reaction temperature is usually in the range of from
about -100.degree. C. to 100.degree. C., preferably from about
-50.degree. C. to 50.degree. C., more preferably from about
-40.degree. C. to 30.degree. C. The reaction time may vary
according to the reagents, solvents or reaction temperature to be
employed, but usually is 0.5 to 24 hours.
2) Formation of the 7-Saide Chain: Synthesis of the Compound
(XVII)
Step 3
[0273] The compound (XV) is subjected to condensation reaction with
the compound (XI) to give the compound (XVI). The reaction solvents
include, for example, water, ethers (e.g., dioxane,
tetrahydrofuran, diethyl ether, tert-butyl methyl ether,
diisopropyl ether), esters (e.g., ethyl formate, ethyl acetate,
isopropyl acetate), halogenated hydrocarbons (e.g.,
dichloromethane, chloroform, carbon tetarachloride), hydrocarbons
(e.g., n-hexane, benzene, toluene), amides (e.g., formamide,
N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone),
ketones (e.g., acetone, methyl ethyl ketone), nitriles (e.g., MeCN,
propionitrile), dimethylsulfoxide, water, and a mixed solvent
thereof.
[0274] The reaction temperature is usually in the range of from
about -100.degree. C. to 100.degree. C., preferably from about
-80.degree. C. to 80.degree. C., more preferably from about
-60.degree. C. to 50.degree. C. The reaction time may vary
according to the reagents, solvents or reaction temperature to be
employed, but usually is 0.5 to 24 hours.
Step 4
[0275] The compound (XVII) is obtained by subjecting the compound
(XVI) to oxidation reaction using an oxidation agent well-known to
those skilled in the art (e.g., m-chloroperbenzoic acid, acetic
peroxide).
[0276] The reaction solvents include, for example, ethers (e.g.,
anisole, dioxane, tetrahydrofuran, diethyl ether, tert-butyl methyl
ether, diisopropyl ether), esters (e.g., ethyl formate, ethyl
acetate, n-butyl acetate, isopropyl acetate), halogenated
hydrocarbons (e.g., dichloromethane, chloroform, carbon
tetarachloride), hydrocarbons (e.g., n-hexane, benzene, toluene),
amides (e.g., formamide, N,N-dimethylformamide,
N,N-dimethylacetamide, N-methylpyrrolidone), ketones (e.g.,
acetone, methyl ethyl ketone), nitriles (e.g., MeCN,
propionitrile), nitros (e.g., nitromethane, nitorethane,
nitrobenzene), dimethylsulfoxide, water, and a mixed solvent
selected from two or more thereof. The reaction temperature is
usually in the range of from about -100.degree. C. to 100.degree.
C., preferably from about -80.degree. C. to 50.degree. C., more
preferably from about -60.degree. C. to -30.degree. C. The reaction
time may vary according to the reagents, solvents or reaction
temperature to be employed, but usually is carried out for 0.5 to
24 hours.
[0277] The obtained compound (XVII) can be purified by column
chromatography to obtain each 2-methyl stereoisomer.
3) Formation of the 3-Side Chain: Synthesis of the Compound (I)
Step 5
[0278] Compound (I') is obtained by subjecting Compound (XVII) to a
substitution reaction with Compound (XIII) by a method well-known
to those skilled in the art, followed by reducing it with a
reduction agent well-known to those skilled in the art (e.g.,
phosphorus chloride, phosphorus tribromide), and then subjecting it
to a deprotection reaction. The reaction solvents include, for
example, ethers (e.g., anisole, dioxane, tetrahydrofuran, diethyl
ether, tert-butyl methyl ether, diisopropyl ether), esters (e.g.,
ethyl formate, ethyl acetate, n-butyl acetate, isopropyl acetate),
halogenated hydrocarbons (e.g., dichloromethane, chloroform, carbon
tetarachloride), hydrocarbons (e.g., n-hexane, benzene, toluene),
amides (e.g., formamide, N,N-dimethylformamide,
N,N-dimethylacetamide, N-methylpyrrolidone), ketones (e.g.,
acetone, methyl ethyl ketone), nitriles (e.g., MeCN,
propionitrile), nitros (e.g., nitromethane, nitorethane,
nitrobenzene), dimethylsulfoxide, water, and a mixed solvent
selected from two or more thereof. The reaction temperature is
usually in the range of from about -100.degree. C. to 100.degree.
C., preferably from about -80.degree. C. to 50.degree. C., more
preferably from about -40.degree. C. to 00.degree. C. The reaction
time may vary according to the reagents, solvents or reaction
temperature to be employed, but usually is 0.5 to 24 hours.
##STR00192##
wherein, P2 is protecting groups; Y is a leaving group (e.g., a
halogen (Cl, Br, I, F), methanesulfonyloxy, pe-toluenesulfoxy);
other symbols are as defined above.
(1) Synthesis of the Compound (I)
Step 1
[0279] The compound (XVIII) is obtained by reaction of the compound
(XI) and the compound (I-H) as the similar procedure described in
Step 9 of Scheme 1.
Step 2
[0280] The compound (I) is obtained by reaction of the compound
(XVIII) and the compound (XIII) as the similar procedure described
in Step 10 of Scheme 1.
[0281] The compounds of the present invention have a wide
antimicrobial activity spectrum, and may be used for prevention or
therapy against a variety of diseases caused by causative bacteria
in a variety of mammals including humans, for example, airway
infectious diseases, urinary system infectious diseases,
respiratory system infectious diseases, sepsis, nephritis,
cholecystitis, oral cavity infectious diseases, endocarditis,
pneumonia, bone marrow membrane myelitis, otitis media, enteritis,
empyema, wound infectious diseases, opportunistic infection,
etc.
[0282] The compounds of the present invention exhibit high
antimicrobial activity in particular against Gram negative
bacteria, preferably, Gram negative bacteria of enterobacteria (E.
coli, Klebsiella, Serratia, Enterobacter, Citrobacter, Morganella,
Providencia, Proteus, etc.), Gram negative bacteria colonized in
respiratory system (Haemophilus, Moraxella, etc.), and Gram
negative bacteria of glucose non fermentation (Pseudomonas
aeruginosa, Pseudomonas other than P. aeruginosa, Stenotrophomonas,
Burkholderia, Acinetobacter, etc.). The compounds are stable
against beta-lactamase belonging to Classes A, B, C and D which is
produced by these Gram negative bacteria, and have high
antimicrobial activity against a variety of beta-lactam drug
resistant Gram negative bacteria, such as ESBL producing bacteria,
etc. These are extremely stable against metallo-beta-lactamase
belonging to Class B including in particular IMP type, VIM type,
L-1 type, etc. Thus, these are effective against a variety of
beta-lactam drug resistant Gram negative bacteria including Cephem
and Carbapenem. Moreover, the compounds of the present invention
have antimicrobial activity against Gram positive bacteria
including methicillin-resistant Staphylococcus aureus (MRSA),
penicillin-resistant Streptococcus pneumoniae (PRSP), etc. Still
more preferable compounds have features regarding kinetics in the
body, such as high blood concentration, long duration of effects,
and/or significant tissue migration. More preferable compounds are
safe in terms of side effects, such as fever and nephrotoxty. More
preferable compounds have high water solubility, and thus
preferable as an injecting drug, in particular.
[0283] The compounds of the present invention can be administered
either orally or parenterally. The compounds of the present
invention, when administered orally, can be used in any dosage form
of normal formulations, for example, solid drug such as tablet,
powder, granule, capsule, etc.; solution drug; oleaginous
suspension drug; or liquid drug such as syrup or elixir.
[0284] The compounds of the present invention, when administered
parenterally, can be used as an aqueous or oleaginous suspended
injecting agent, or nasal drops. In preparation thereof, a
conventional excipient, binder, lubricant, aqueous solvent,
oleaginous solvent, emulsifier, suspending agent, preservative,
stabilizer, etc. can be optionally used. A formulation of the
present invention is produced by combining (for example, mixing) a
therapeutically effective amount of a compound of the present
invention with a pharmaceutically acceptable carrier or
diluent.
[0285] The compounds of the present invention may be administered
either parenterally or orally as an injecting agent, capsules,
tablets, and granules, and preferably administered as an injecting
agent. The dosage of the present compound may usually be, per 1 kg
of body weight of a patient or animal, about 0.1 to 100 mg/day,
preferably, about 0.5 to 50 mg/day, if desired, divided into 2-4
times per day. Carriers when used in an injecting agent are, for
example, distilled water, brine, etc., and a base and the like may
be used for pH adjustment. When used as capsules, granules, or
tablets, carriers may be known excipients (e.g., starch, lactose,
sucrose, calcium carbonate, calcium phosphate, etc.), binders
(e.g., starch, acacia gum, carboxymethyl cellulose, hydroxypropyl
cellulose, crystalline cellulose, etc.), lubricants (e.g.,
magnesium stearate, talc, etc.), etc.
General Method
[0286] Unless otherwise noted, all starting materials were obtained
from commercial suppliers and used without further purification.
Unless otherwise indicated, all temparatures are expressed in
.degree. C. (degrees Centigrade). Unless otherwise indicated, all
reactions are conducted under an inert atmosphere at ambient
temperature.
[0287] All temperatures are given in degrees Celsius, all solvents
are highest available purity and all reactions run under anhydrous
conditions in an argon (Ar) or nitrogen (N2) atmosphere where
necessary.
[0288] 1H NMR (hereinafter also "NMR") spectra were recorded on
Brucker AVANCE-400 spectrometers. CDCI3 is deuteriochloroform,
d6-DMSO is hexadeuteriodimethylsulfoxide, D20 is Deuterium oxide,
and CD3OD is tetradeuteriomethanol. Chemical shifts are expressed
in parts per million (ppm, 8 units). Coupling constants are in
units of hertz (Hz). Splitting patterns describe apparent
multiplicities and are designated as s (singlet), d (doublet), t
(triplet), q (quartet), quint (quintet), m (muitiplet), br
(broad)..quadrature.
[0289] Mass spectra were run on Waters Open Architecture System,
UPLC SQD MS analytical system. The compound is analyzed using a
reverse phase column, e.g., Xbridge-C18, Sunfire-C18, Thermo
Aquasil/Aquasil C18, Acquity HPLC C18, Acquity UPLC BEH C18,
Shim-pack XR-ODS, Thermo Hypersil Gold eluted using an acetonitrile
and water gradient with a iow percentage of an acid modifier such
as 0.02% TFA or 0.1% formic acid.
[0290] Analytical HPLC was run using an Agilent system (1100
series) with variable wavelength UV detection using Luna C18 column
and eluting with an acetonitrile/water gradient containing a 0.05%
or 0.1% TFA modifier (added to each solvent).
[0291] Unless otherwise indicated, flash chromatography was run on
a Teledyne Isco Combiflash RF using disposable Redi-Sep flash
columns (normal or reverse stationary phase as indicated), and a
detector with UV wavelength at 254 nm. A styrenic adsorbent resin,
DIAION.TM. HP20SS, was used in the workup and purification of
cephalosporin analogs, and is referred to simply as HP20SS resin in
the following examples.
EXAMPLES
[0292] Hereinafter, the present invention is described in more
details with Examples, Reference Examples, Experiments and
Formulation Examples. However, the present invention is not
construed to be limited thereto.
[0293] The meaning of each abbreviation is as described below.
Ac: Acetyl
Allooc: Allyloxycarbonyl
BH or Bzh: Benzhydryl
[0294] Boc: tert-Butoxycarbonyl
Bn: Benzyl
[0295] Bt: benzotriazole Cbz: carbobenzoxy
DMF: N,N-dimethylformamide
[0296] EDC: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
Et: Ethyl
[0297] HOBt: 1-hydroxybenzotriazole i-Pr: isopropyl mCPBA:
m-chloroperoxybenzoic acid Me: methyl
ODS: Octadecylsilyl
[0298] PMB: para-Methoxybenzyl TBS: tert-butyldimethylsilyl t-Bu:
tert-butyl TFA: trifluoroacetic acid
Tr: Trityl
[0299] WSCD: N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide rt:
room temperature TFA: trifluoroacetic acid THF: tetrahydrofuran
DCM: dichloromethane MeOH: methanol EA or EtOAc: ethyl acetate
Pd/C: palladium on carbon NaBH(OAc).sub.3: sodium
triacetoxyborohydride Pd.sub.2(dba).sub.3:
tris(dibenzylideneacetone)dipalladium (0)
XPhos:
[0300]
dicyclohexyl[2',4',6'-tris(1-methylethyl)-2-biphenylyl]phosphane
SEMCl: 2-(trimethylsilyl)ethoxymethyl chloride CDI:
1,1'-carbonyldiimidazole AlCl.sub.3: aluminum chloride LAH: lithium
aluminium hydride DIBAL-H: diisobutylaluminium hydride PyBOP:
(benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate
HATU:
2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisouronium
hexafluorophosphate (V) DIPEA or DIEA: diisopropylethylamine
K.sub.2CO.sub.3: potassium carbonate TMS: tetramethylsilane
CDCl.sub.3: deuteriochloroform CD.sub.3OD: tetradeuteriomethanol
DMSO-d.sub.6: hexadeuteriodimethylsulfoxide
Reference Example 1
Synthesis of Compound X-1
##STR00193##
[0301] Step (1): Compound X-1a.fwdarw.Compound X-1b
[0302] Compound X-1a (26.47 g, 51.2 mmol) which was synthesized
according to the synthesis in U.S. Pat. No. 4,463,172A1 was
dissolved into dioxane (200 mL), and thereto was then added 4 mol/L
hydrochloric acid solution in dioxane (25.6 ml, 102 mmol) at rt.
The mixture was stirred at rt for 1 hour. The reaction mixture was
concentrated under reduced pressure. The precipitated solid was
then collected by filtration, and washed with diisopropyl
ether/dichloromethane to yield compound X-1b (21.1 g, 75%).
[0303] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.37-7.26 (11H, m),
7.03-6.99 (2H, m), 6.87 (1H, s), 6.36 (1H, d, J=8.7 Hz), 5.63-5.59
(1H, m), 5.23-5.20 (2H, m), 4.31 (1H, d, J=12.3 Hz), 4.09 (1H, d,
J=12.3 Hz), 3.86 (2H, s), 1.99 (3H, s).
Step (2): Compound X-1b.fwdarw.Compound X-1c
[0304] Compound X-1b (5.53 g, 10 mmol) was dissolved into
dichloromethane (60 mL), and thereto was then added dropwise a
solution of m-chloroperoxybenzoic acid (3.45 g, 13 mmol) in
dichloromethane (40 mL) at -40.degree. C. The mixture was stirred
at -40.degree. C. for 1 hour. The reaction mixture was diluted with
an aqueous sodium thiosulfate solution, then separated and washed
with saturated sodium hydrogen carbonate solution, and dried over
magnesium sulfate. Magnesium sulfate was filtrated off, and then
the liquid was concentrated under reduced pressure. The
precipitated solid was then collected by filtration, and washed
with methanol to yield compound X-1c (3.79 g, 67%).
[0305] MS (M+1)=569
Step (3): Compound X-1c.fwdarw.Compound X-1d
[0306] Compound X-1c (3.79 g, 6.6 mmol) was dissolved into
dimethylformamide (35 mL), and thereto was then added phosphorus
trichloride (1.7 mL, 20 mmol) at -50.degree. C. The mixture was
stirred at -20.degree. C. for 30 minutes. The reaction mixture was
diluted with water and ethyl acetate, then separated and washed
with water and a saturated salt solution, and dried over magnesium
sulfate. Magnesium sulfate was filtrated off, and then the liquid
was concentrated under reduced pressure. The compound-containing
liquid was subjected to silica gel column chromatography to elute
out the desired compound with hexane/ethyl acetate. The
desired-compound-containing fraction was concentrated under reduced
pressure to yield compound X-1d (1.98 g, 54%).
[0307] MS (M+1)=553
Step (4): Compound X-1d.fwdarw.Compound X-1e
[0308] Phorphorus pentachloride (1.47 g, 7.1 mmol) was suspended
into dichloromethane (20 mL), and thereto were then added pyridine
(0.63 ml, 7.8 mmol) and compound X-1d (1.95 g, 3.5 mmol) at
0.degree. C. The mixture was stirred at 0.degree. C. for 1 hour.
Thereto was then added methanol (10 mL) at -40.degree. C. The
mixture was stirred at 0.degree. C. for 30 minutes. The mixture was
diluted with a saturated sodium hydrogen carbonate solution and
dichloromethane, then separated and dried over magnesium sulfate.
Magnesium sulfate was filtrated off, and then ethyl acetate (20 ml)
was added and concentrated under reduced pressure to yield the
ethyl acetate solution of compound X-1e. This solution was used as
it was, without being purified, in the next reaction.
Step (5): Compound X-1e+Compound X-1f.fwdarw.Compound X-1g,
Compound X-1h
[0309] Compound X-1f (1.82 g, 4.2 mmol) and triethylamine (0.68 mL,
4.9 mmol) were dissolved into dimethylacetoamide (20 mL), and
thereto was then added methanesulfonyl chloride (0.36 mL, 4.6 mmol)
at -20.degree. C. The mixture was stirred at -10.degree. C. for 20
minutes. Pyridine (0.57 mL, 7.1 mmol) and the reaction mixture were
added to the ethyl acetate solution of compound X-1e (3.5 mmol) at
0.degree. C. The mixture was stirred at 0.degree. C. for 20
minutes. The reaction mixture was diluted with water and ethyl
acetate, then separated and washed with water and a saturated salt
solution, and dried over magnesium sulfate. Magnesium sulfate was
filtrated off, and then the liquid was concentrated under reduced
pressure. The compound-containing liquid was subjected to silica
gel column chromatography to elute out the desired compound with
hexane/ethyl acetate. The desired-compound-containing fraction was
concentrated under reduced pressure to yield Compound X-1g (0.13 g,
4.4%), compound X-1h (1.17 g, 40%).
[0310] Compound X-1g
[0311] .sup.1H-NMR (CDCl.sub.3) .delta.: 8.18-8.16 (2H, m),
7.42-7.30 (11H, m), 6.93 (1H, s), 6.03 (1H, dd, J=9.0, 5.0 Hz),
5.23 (1H, d, J=5.0 Hz), 4.83 (1H, d, J=12.3 Hz), 4.21 (1H, d,
J=12.3 Hz), 4.01 (1H, q, J=7.2 Hz), 1.64 (3H, s), 1.61 (3H, s),
1.57 (3H, d, J=7.2 Hz), 1.53 (9H, s), 1.41 (9H, s).
[0312] Compound X-1h
[0313] .sup.1H-NMR (CDCl.sub.3) .delta.: 8.22-8.19 (2H, m),
7.46-7.30 (11H, m), 7.01 (1H, s), 6.13 (1H, dd, J=9.0, 5.1 Hz),
5.19 (1H, d, J=5.1 Hz), 4.43 (1H, d, J=11.5 Hz), 4.18 (1H, d,
J=11.5 Hz), 3.85 (1H, q, J=7.3 Hz), 1.63 (3H, s), 1.60 (3H, s),
1.58 (3H, d, J=7.3 Hz), 1.53 (9H, s), 1.39 (9H, s).
Step (6): Compound X-1g.fwdarw.Compound X-1 Compound X-1g (77.6 g,
92 mmol) was dissolved into tetrahydrofuran (770 mL), and thereto
was then added sodium iodide (41.5 g, 277 mmol) at 15.degree. C.
The resultant solution was stirred at 15.degree. C. for 1 day. The
reaction mixture was diluted with an aqueous sodium bisulfite
solution and ethyl acetate, then separated and washed with water
and a saturated salt solution, and dried over magnesium sulfate.
Magnesium sulfate was filtrated off, and then the liquid was
concentrated under reduced pressure to yield compound X-1 (85.2 g,
99%). Compound X-1g yielded was used as it was, without being
purified, in the next reaction.
[0314] .sup.1H-NMR (CDCl.sub.3) .delta.: 8.24 (1H, d, J=8.8 Hz),
7.42-7.29 (12H, m), 6.94 (1H, s), 5.94 (1H, dd, J=8.8, 4.9 Hz),
5.27 (1H, d, J=4.9 Hz), 4.97 (1H, d, J=9.8 Hz), 4.07-4.00 (2H, m),
1.64 (3H, s), 1.61 (3H, s), 1.55-1.53 (12H, m), 1.41 (9H, s).
Reference Example 2
Synthesis of Compound X-2
##STR00194##
[0315] Step (1): Compound X-1e+Compound X-2a.fwdarw.Compound
X-2b
[0316] Compound X-1e (8.3 g, 15 mmol) and compound X-2a (10.4 g, 18
mmol) were used to synthesize the target compound in the same way
as in step 4 and 5 of Reference Example 1.
[0317] Yielded amount: 10.4 g, (70%)
[0318] .sup.1H-NMR (CDCl.sub.3) .delta.: 8.27 (1H, d, J=8.1 Hz),
8.09 (1H, s), 7.43-7.29 (11H, m), 7.23 (2H, d, J=8.5 Hz), 6.94 (1H,
s), 6.82 (2H, d, J=8.5 Hz), 5.92 (1H, dd, J=8.1, 4.9 Hz), 5.36 (1H,
dd, J=8.4, 4.6 Hz), 5.23 (1H, d, J=4.9 Hz), 5.14 (1H, d, J=11.9
Hz), 5.05 (1H, d, J=11.9 Hz), 4.85 (1H, d, J=12.3 Hz), 4.23 (1H, d,
J=12.3 Hz), 4.00 (1H, q, J=7.4 Hz), 3.76 (3H, s), 2.92 (1H, dd,
J=16.4, 8.4 Hz), 2.83 (1H, dd, J=16.4, 4.6 Hz), 1.57 (3H, d, J=7.4
Hz), 1.54 (9H, s), 1.41 (9H, s).
Step (2): Compound X-2b.fwdarw.Compound X-2
[0319] Compound X-2b (10.4 g, 11 mmol) was used to synthesize the
target compound in the same way as in step 6 of Reference Example
1.
[0320] Yielded amount: 10.7 g, (95%) .sup.1H-NMR (CDCl.sub.3)
.delta.: 8.30 (1H, d, J=7.9 Hz), 8.11 (1H, s), 7.44-7.29 (11H, m),
7.23 (2H, d, J=8.7 Hz), 6.95 (1H, s), 6.82 (2H, d, J=8.7 Hz), 5.84
(1H, dd, J=7.9, 4.8 Hz), 5.37 (1H, dd, J=8.3, 4.8 Hz), 5.27 (1H, d,
J=4.8 Hz), 5.14 (1H, d, J=11.8 Hz), 5.05 (1H, d, J=11.8 Hz), 4.99
(1H, d, J=9.8 Hz), 4.06-4.01 (2H, m), 3.76 (3H, s), 2.92 (1H, dd,
J=16.4, 8.3 Hz), 2.84 (1H, dd, J=16.4, 4.8 Hz), 1.54-1.52 (12H, m),
1.41 (9H, s).
Reference Example 3
Synthesis of Compound X-3 and X-24
##STR00195##
[0321] Step (1): Compound X-3a.fwdarw.Compound X-3b.fwdarw.Compound
X-3c
[0322] To a pre-cooled solution of compound X-3a (50 g, 97 mmol),
which was synthesized according to the synthesis in Tetrahedron
Letter, 37, 1971-1974 (1996), in dichloromethane (450 mL) at
-10.degree. C. was added peracetic acid (19.82 g, 102 mmol, 37%
Wt). The mixture was stirred at -10 to -5.degree. C. To the
resulting mixture was added a solution of sodium bisulfite (12.1 g,
116 mmol) in water (200 mL). Water (150 mL) was added to the
mixture, and then an organic layer was separated. The organic layer
was washed with water (250 mL), 10% aqueous solution of sodium
chloride (250 mL). The aqueous layers were successively extracted
with dichloromethane (150 mL). The combined organic layers were
dried over magnesium sulfate and filtered. To the filtrated was
added dimethylformamide (200 mL) and then the solution was
concentrated. The residue was placed in a reaction bottle with
dimethylformamide (30 mL) and then to the solution was added
formaldehyde (15.7 g, 194 mmol, 37% Wt) and dimethylamine
hydrochloride (7.89 g, 97 mmol). The mixture was stirred at
60.degree. C. for 3 hours and then cooled in ice bath. To the
mixture was added water (250 mL) dropwise over 8 minutes. The
resulting mixture was stirred for 3.5 hr. The precipitated material
was collected by filtration and washed with water (250 mL) and
ethanol (250 mL). The solid was dried under air for 3 days to
afford compound X-3c (48.5 g, 92%).
[0323] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 8.61 (1H, d, J=8.3 Hz),
7.39-7.35 (3H, m), 6.98-6.93 (4H, m), 6.40 (1H, s), 6.21 (1H, s),
5.95 (1H, dd, J=8.3, 5.1 Hz), 5.31-5.26 (2H, m), 5.21 (1H, d,
J=11.9 Hz), 5.07 (1H, d, J=5.1 Hz), 4.74 (1H, d, J=12.5 Hz), 3.91
(1H, d, J=15.4 Hz), 3.83 (1H, d, J=15.4 Hz), 3.75 (3H, s), 1.96
(3H, s).
Step (2): Compound X-3c.fwdarw.Compound X-3d.fwdarw.Compound
X-3e
[0324] To a pre-cooled suspension of compound X-3c (25.0 g, 45.9
mmol) in 1,4-dioxane (175 mL) and dichloromethane (50 mL) in ice
bath was added zinc (15.01 g, 230 mmol) with dichloromethane (15
mL). To the mixture in ice bath was added concentrated hydrochloric
acid (19.1 mL, 230 mmol, 12 M) dropwise over 45 minutes and then
washed with dichloromethane (10 mL). The mixture was stirred in ice
bath for 1 hour, and then filtered through Celite and it washed
with dichloromethane (300 mL). The filtrate was washed with water
(500 mL) and water (125 mL) successively. The aqueous layers were
successively extracted with dichloromethane (75 mL). The combined
organic layers were dried over magnesium sulfate, filtered and
concentrated. The residue was dissolved with 1,4-dioxane (75 mL) to
remove dichloromethane and then cooled in ice bath. To the mixture
was added hydrochloric acid in 1,4-dioxane (23.0 mL, 4M) and then
stirred in ice bath for 2 hr. To the resulting mixture was added
isopropyl ether (122 mL) and stirred in ice bath for 1.5 hr. The
precipitated material was collected by filtration and washed with
isopropyl ether. The solid was dried under air over night to afford
compound X-3e (15.3g, 58%).
[0325] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 9.27 (1H, d, J=7.8 Hz),
7.38-7.34 (3H, m), 6.97-6.92 (4H, m), 5.48 (1H, dd, J=7.8, 3.8 Hz),
5.19 (1H, d, J=3.8 Hz), 5.15-5.08 (3H, m), 4.64 (1H, d, J=12.2 Hz),
4.31 (1H, d, J=12.2 Hz), 3.77-3.74 (5H, m), 2.04 (3H, s).
Step (3): Compound X-3e.fwdarw.Compound X-3f
[0326] To a pre-cooled suspension of compound X-3e (50.0 g, 94
mmol) in dichloromethane (500 mL) in ice bath was added peracetic
acid (18.4 g, 94 mmol, 39% Wt) dropwise over 10 minutes. The
mixture was stirred in ice bath for 3 hours. An aqueous solution of
sodium bisulfite (11.8 g, 113 mmol) in water (250 mL) was added.
Water (250 mL) was further added. The organic layer was washed with
water (500 mL) and 10% aqueous solution of sodium chloride (500
mL). The aqueous layers were successively extracted with
dichloromethane (50 mL). The combined organic layers were
concentrated while replaced a solvent to acetonitrile by adding
twice (250 mL, 100 mL). To the residual suspension (approx. 250 mL)
was added acetonitrile (612 mL) and water (150 mL). To the mixture
was added 10% aqueous solution of sodium acetate (100 mL) and then
pH showed 6.29. The mixture was stirred at room temperature with
monitoring pH for 1.5 hours. 2 mol/L hydrochloric acid (24.5 mL)
was added to quench. The insoluble material was collected by
filtration and washed with water (200 mL) and acetonitrile (150
mL). The solid was dried under air over 3 days to afford compound
X-3f (32.6 g, 66%).
[0327] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 8.53 (1H, d, J=8.3 Hz),
7.38-7.36 (3H, m), 6.97-6.93 (4H, m), 5.88 (1H, dd, J=8.3, 4.9 Hz),
5.30 (1H, d, J=12.0 Hz), 5.21 (1H, d, J=12.0 Hz), 5.10 (1H, d,
J=4.9 Hz), 4.81 (1H, d, J=12.3 Hz), 4.42 (1H, d, J=12.3 Hz),
3.90-3.79 (3H, m), 3.76 (3H, s), 1.61 (3H, d, J=7.5 Hz).
Step (4): Compound X-3f.fwdarw.Compound X-3g
[0328] To a pre-cooled suspension of compound X-3f (30.0 g, 57.4
mmol) in dimethylformamide (240 mL) with stirring at -40.degree. C.
was added phosphorus trichloride (23.6 g, 172 mmol) over 10
minutes. The mixture was stirred at -35.degree. C. for 1 hour. To
the resulting mixture was added dichloromethane (300 mL) and water
(300 mL). The organic layer was separated, and then washed with
water (300 mL) and 10% aqueous solution of sodium chloride (300
mL). The aqueous layers were successively extracted with
dichloromethane (90 mL). The combined organic layers were dried
over magnesium sulfate, filtered and concentrated to approx. 150
mL. To the residual suspension was added 2-propanol (180 mL) and
then the suspension was concentrated to approx. 150 mL again. To
the residue was added 2-propanol (14 mL) and diisopropyl ether (120
mL). The mixture was stirred for 3 hours. The insoluble material
was collected by filtration and dried under air for 3 days to
afford compound X-3g (20.8g, 71%).
[0329] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 9.21 (1H, d, J=8.4 Hz),
7.38-7.34 (3H, m), 6.96-6.91 (4H, m), 5.73 (1H, dd, J=8.4, 5.0 Hz),
5.33 (1H, d, J=5.0 Hz), 5.27 (1H, d, J=11.9 Hz), 5.17 (1H, d,
J=11.9 Hz), 4.66 (1H, d, J=12.0 Hz), 4.49 (1H, d, J=12.0 Hz), 4.08
(1H, q, J=7.2 Hz), 3.75 (5H, s), 1.53 (3H, d, J=7.2 Hz).
Step (5): Compound X-3g.fwdarw.Compound X-3h
[0330] To a pre-cooled suspension of phosphorus pentachloride (8.21
g, 39.4 mmol) in dichloromethane (90 mL) with stirring at
-5.degree. C. was added pyridine (3.43 g, 43.4 mmol) and compound
X-3g (10.0 g, 19.7 mmol). The mixture was stirred at 10 to
15.degree. C. for 1 hour. The resulting mixture was poured into
pre-cooled methanol (25 mL) in ice bath, and then water (50 mL) was
added. The organic layer was separated and washed with water (100
mL). The aqueous layers were successively extracted with
dichloromethane (40 mL). The combined organic layers were dried
over magnesium sulfate, filtered. To the filtrate was added
p-toluenesulfonic acid mono-hydrate (3.75 g, 19.7 mmol) and ethyl
acetate (60 mL). The mixture was concentrated to remove
dichloromethane. To the residual suspension was added ethyl acetate
(50 mL). The mixture was stirred at 35.degree. C., and then stirred
in ice bath for 2.5 hours. The insoluble material was collected by
filtration and washed with ethyl acetate. The solid was dried
through air circulation to afford compound X-3h (7.30 g, 63%).
[0331] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 9.02 (3H, br s), 7.48
(2H, d, J=7.7 Hz), 7.36 (2H, d, J=8.3 Hz), 7.12 (2H, d, J=7.7 Hz),
6.94 (2H, d, J=8.3 Hz), 5.45 (1H, d, J=5.0 Hz), 5.29-5.17 (3H, m),
4.68 (1H, d, J=12.0 Hz), 4.51 (1H, d, J=12.0 Hz), 4.21 (1H, q,
J=7.2 Hz), 3.75 (3H, s), 2.29 (3H, s), 1.57 (3H, d, J=7.2 Hz).
Step (6): Compound X-3h+Compound X-1f.fwdarw.Compound X-3
[0332] To a pre-cooled suspension of compound X-1f (9.29 g, 21.6
mmol) and compound X-3h (12.0 g, 21.6 mmol) in ethyl acetate (120
mL) at -40.degree. C. was added phenyl dichlorophosphate (6.84 g,
4.82 mmol) and N-methyl morpholine (7.65 g, 76 mmol). The mixture
was stirred at -40.degree. C. for 1.5 hours. 0.5 mol/L hydrochloric
acid (130 mL) was added to quench. The organic layer was separated
and washed with water (120 mL), 5% aqueous solution of sodium
bicarbonate (120 mL), and 10% aqueous solution of sodium chloride
(120 mL). The aqueous layers were successively extracted with ethyl
acetate (60 mL). The combine organic layers were dried over
magnesium sulfate, filtered and concentrated to give a crude
material (19.7g) 6.58 g of the crude residue was purified by silica
gel column chromatography eluted with n-hexane and ethyl acetate to
afford compound X-3 (5.77 g).
[0333] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 11.84 (1H, s), 9.58 (1H,
d, J=8.3 Hz), 7.36 (2H, d, J=8.2 Hz), 7.26 (1H, s), 6.94 (2H, d,
J=8.2 Hz), 5.87 (1H, dd, J=8.1, 5.0 Hz), 5.40 (1H, d, J=4.9 Hz),
5.26 (1H, d, J=11.8 Hz), 5.18 (1H, d, J=11.8 Hz), 4.67 (1H, d,
J=12.2 Hz), 4.48 (1H, d, J=12.0 Hz), 4.06 (1H, q, J=7.2 Hz), 3.76
(3H, s), 1.52 (3H, d, J=7.2 Hz), 1.46-1.44 (15H, m), 1.39 (9H,
s).
Step (7): Compound X-3.fwdarw.Compound X-24
[0334] Compound X-3 (25.6 g, 30.0 mmol) was used to synthesize
Compound X-24 in the same way as in step (6) of Reference Example
1.
[0335] Yielded amount: 28.08 g, (106%)
[0336] .sup.1H-NMR (CDCl.sub.3) .delta.: 8.14 (1H, d, J=8.9 Hz),
7.35-7.33 (3H, m), 6.91 (2H, d, J=8.4 Hz), 5.91 (1H, dd, J=8.9, 4.9
Hz), 5.27 (1H, d, J=11.9 Hz), 5.21-5.18 (2H, m), 5.05 (1H, d,
J=10.4 Hz), 4.09-4.07 (2H, m), 3.82 (3H, s), 1.62 (3H, s), 1.60
(3H, s), 1.55 (3H, d, J=7.3 Hz), 1.53 (9H, s), 1.41 (9H, s).
Reference Example 4
Synthesis of Compound X-4
##STR00196##
[0337] Step (1): Compound X-3h+Compound X-2a.fwdarw.Compound
X-4a
[0338] Compound X-3h (6.3 g, 11 mmol) and compound X-2a (6.0 g, 11
mmol) were used to synthesize the target compound in the same way
as in step 6 of Reference example 3.
[0339] Yielded amount: 6.7 g, (65%)
[0340] .sup.1H-NMR (DMSO-DE) .delta.: 11.87 (1H, s), 9.68 (1H, d,
J=8.2 Hz), 7.36 (2H, d, J=8.0 Hz), 7.31-7.29 (3H, m), 6.94 (2H, d,
J=8.0 Hz), 6.87 (2H, d, J=8.0 Hz), 5.84 (1H, dd, J=8.2, 4.8 Hz),
5.39 (1H, d, J=4.8 Hz), 5.26 (1H, d, J=12.0 Hz), 5.18 (1H, d,
J=12.0 Hz), 5.10 (2H, s), 4.96 (1H, t, J=6.4 Hz), 4.68 (1H, d,
J=12.0 Hz), 4.49 (1H, d, J=12.0 Hz), 4.07 (1H, q, J=7.2 Hz), 3.75
(3H, s), 3.73 (3H, s), 2.92-2.80 (2H, m), 1.51 (3H, d, J=7.2 Hz),
1.47 (9H, s), 1.35 (9H, s).
Step (2): Compound X-4a.fwdarw.Compound X-4
[0341] Compound X-4a (28.3 g, 30 mmol) was used to synthesize the
target compound X-4 in the same way as in step 6 of Reference
Example 1.
[0342] Yielded amount: 32 g, (103%)
[0343] .sup.1H-NMR (CDCl.sub.3) .delta.: 8.21 (1H, d, J=8.0 Hz),
8.11 (1H, s), 7.37-7.35 (3H, m), 7.23 (2H, d, J=8.7 Hz), 6.92 (2H,
d, J=8.7 Hz), 6.83 (2H, d, J=8.7 Hz), 5.81 (1H, dd, J=8.0, 4.8 Hz),
5.36 (1H, dd, J=8.2, 5.0 Hz), 5.30-5.04 (7H, m), 4.09-4.03 (1H, m),
3.82 (3H, s), 3.79 (3H, s), 2.89 (1H, dd, J=16.4, 8.2 Hz), 2.82
(1H, dd, J=16.4, 5.0 Hz), 1.55-1.54 (12H, m), 1.40 (9H, s).
Reference Example 5
Synthesis of Compound X-5
##STR00197##
[0344] Step (1): Compound X-5a.fwdarw.Compound X-5
[0345] Compound X-5a (2.1 g, 5 mmol) was suspended into toluene (20
mL), and thereto was then added quinuclidin-4-ylmethanamine (0.74
g, 5.3 mmol) at 0.degree. C. The mixture was stirred at 50.degree.
C. for 1 hour. Thereto was added acetic acid (0.57 mL, 10 mmol).
The resultant was stirred at reflux for 3 days. The reaction
mixture was diluted with ethyl acetate and aqueous sodium hydroxide
solution, then separated and washed with water and a saturated salt
solution, and dried over magnesium sulfate. Magnesium sulfate was
filtrated off, and then the liquid was concentrated under reduced
pressure. The precipitated solid was then collected by filtration,
and washed with diisopropyl ether to yield compound X-5 (2.6 g,
95%).
[0346] .sup.1H-NMR (CDCl3) .delta.: 7.35 (4H, d, J=8.7 Hz), 7.33
(2H, s), 6.90 (4H, d, J=8.7 Hz), 5.18 (4H, s), 3.82 (6H, s), 3.38
(2H, br s), 2.85-2.81 (6H, m), 1.42-1.38 (6H, m).
Reference Example 6
Synthesis of Compound X-6
##STR00198##
[0347] Step (1): Compound X-5a.fwdarw.Compound X-6
[0348] Compound X-5a (2.1 g, 5 mmol) was used to synthesize
Compound X-6 in the same way as Reference Example 5.
[0349] Yielded amount: 2.18 g (80%)
[0350] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.36-7.32 (4H, m), 7.27
(2H, s), 6.91-6.87 (4H, m), 5.16 (4H, s), 4.59-4.49 (1H, m), 3.81
(6H, s), 3.24-3.20 (2H, m), 2.32-2.24 (2H, m), 2.20 (3H, s),
2.15-2.11 (2H, m), 1.88-1.82 (2H, m), 1.72-1.67 (2H, m).
Reference Example 7
Synthesis of Compound X-7
##STR00199##
[0351] Step (1): Compound X-7a.fwdarw.Compound X-7
[0352] Compound X-7a (0.48 mg, 4.2 mmol) and triethylamine (0.58
ml, 4.2 mmol) were dissolved into dimethylacetamide (12 mL), and
thereto was then added Methanesulfonyl chloride (0.3 ml, 3.9 mmol)
at -20.degree. C. The mixture was stirred at -20.degree. C. for 30
minutes. Thereto was then added aminoethylpyrrolidine (0.48 g, 4.2
mmol) at 0.degree. C. The mixture was stirred at 0.degree. C. for 1
hours. The reaction mixture was diluted with ethyl acetate, washed
with an aqueous sodium hydroxide solution, water and a saturated
salt solution, and dried over magnesium sulfate. Magnesium sulfate
was filtrated off, and then the liquid was concentrated under
reduced pressure. The compound-containing liquid was subjected to
silica gel column chromatography to elute out the desired compound
with hexane/ethyl acetate (containing 3% triethyl amine). The
desired-compound-containing fraction was concentrated under reduced
pressure to yield compound X-7 (0.75 g, 45%).
[0353] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.62 (1H, d, J=8.7 Hz),
7.47-7.42 (1H, m), 7.34 (4H, dd, J=8.7, 2.3 Hz), 6.95-6.90 (3H, m),
6.85-6.81 (2H, m), 5.11 (2H, s), 4.96 (2H, s), 3.83 (3H, s), 3.80
(3H, s), 3.49 (2H, q, J=5.9 Hz), 2.72-2.65 (2H, m), 2.58-2.50 (4H,
m), 1.83-1.74 (4H, m).
Reference Example 8
Synthesis of Compound X-8
##STR00200##
[0354] Step (1): Compound X-7a.fwdarw.Compound X-8
[0355] Compound X-7a (0.5 g, 3.9 mmol) was used to synthesize
Compound X-7 in the same way as Reference Example 7.
[0356] Yielded amount: 0.62 g (39%)
[0357] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 7.69-7.65 (1H, m),
7.47-7.45 (2H, m), 7.39 (1H, d, J=8.8 Hz), 7.31-7.26 (2H, m),
7.01-6.97 (2H, m), 6.87-6.83 (2H, m), 5.25 (2H, s), 4.91 (2H, s),
3.78 (3H, s), 3.74 (3H, s), 3.08-2.89 (7H, m), 1.97-1.69 (6H,
m).
Reference Example 9
Synthesis of Compound X-9
##STR00201##
[0358] Step (1): Compound X-7a.fwdarw.Compound X-9
[0359] Compound X-7a (0.5 g, 3.9 mmol) was used to synthesize
Compound X-9 in the same way as Reference Example 7.
[0360] Yielded amount: 0.64 g (43%)
[0361] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.69 (1H, d, J=8.9 Hz),
7.34 (4H, t, J=8.2 Hz), 6.99 (1H, d, J=8.9 Hz), 6.93 (2H, d, J=8.7
Hz), 6.83 (2H, d, J=8.7 Hz), 5.13 (2H, s), 4.95 (2H, s), 4.72-4.55
(1H, m), 3.84 (3H, s), 3.80 (3H, s), 3.77-3.61 (1H, m), 3.14-2.94
(3H, m), 2.32-2.03 (3H, m), 1.92-1.76 (3H, m), 1.50-1.34 (1H,
m).
Reference Example 10
Synthesis of Compound X-10
##STR00202##
[0362] Step (1): Compound X-21.fwdarw.Compound X-10
[0363] Compound X-21 (1.9 g, 5.0 mmol) and diisopropylethylamine
(1.3 ml, 7.5 mmol) were dissolved into dichloromethane (25 mL), and
thereto was then added diphenyl chlorophosphate (1.2 ml, 6.5 mmol)
at 0.degree. C. The mixture was stirred at 0.degree. C. for 1 hour.
Thereto was then added aminoethylpyrrolidine (0.68 g, 6 mmol) at
0.degree. C. The mixture was stirred at rt for 2 hours. The
reaction mixture was diluted with ethyl acetate, washed with an
aqueous sodium hydroxide solution, water and a saturated salt
solution, and dried over magnesium sulfate. Magnesium sulfate was
filtrated off, and then the liquid was concentrated under reduced
pressure. The compound-containing liquid was subjected to silica
gel column chromatography to elute out the desired compound with
hexane/ethyl acetate (containing 3% triethyl amine). The
desired-compound-containing fraction was concentrated under reduced
pressure to yield compound X-10 (0.56 g, 19%).
[0364] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 8.85 (1H, t, J=5.8 Hz),
7.58-7.32 (12H, m), 5.25 (2H, s), 5.22 (2H, s), 3.37-3.35 (2H, m),
2.56-2.54 (2H, m), 1.72-1.65 (3H, m).
[0365] The compounds shown below were used to synthesize the each
target compound in the same way as Reference Example 10.
Reference Example 11
Synthesis of Compound X-11
##STR00203##
[0367] Yielded amount: 0.37 g (15%)
[0368] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 7.49-7.21 (15H, m), 5.28
(2H, s), 5.23 (2H, s), 2.99-2.72 (7H, m), 2.02-1.55 (6H, m).
Reference Example 12
Synthesis of Compound X-12
##STR00204##
[0370] Yielded amount: 0.52 g (20%)
[0371] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 8.82 (1H, t, J=6.3 Hz),
7.57-7.20 (10H, m), 5.24 (2H, s), 5.23 (2H, s), 3.02 (2H, d, J=6.4
Hz), 2.74-2.70 (6H, br m), 1.33-1.29 (6H, br m).
Reference Example 13
Synthesis of Compound X-13
##STR00205##
[0373] Yielded amount: 0.88 g (36%)
[0374] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 7.49-7.32 (12H, m), 5.28
(2H, s), 5.24 (2H, s), 3.41-2.82 (8H, m), 2.14-1.63 (5H, m).
Reference Example 14
Synthesis of Compound X-14
##STR00206##
[0376] Yielded amount: 1.0 g (39%)
[0377] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.97 (1H, br s), 7.93-7.90
(1H, m), 7.56-7.30 (10H, m), 5.25 (2H, s), 5.16 (2H, s), 4.16-4.11
(1H, m), 3.24 (1H, br s), 2.34-2.18 (6H, m), 1.84-1.71 (5H, m).
Reference Example 15
Synthesis of Compound X-15
##STR00207##
[0379] Yielded amount: 0.85 g (50%)
[0380] [M+H]=537.25
Reference Example 16
Synthesis of Compound X-16
##STR00208##
[0382] Yielded amount: 2.0 g (71%)
[0383] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.41 (1H, s), 7.36-7.27
(5H, m), 6.91 (2H, d, J=8.4 Hz), 6.81 (2H, d, J=8.4 Hz), 6.28 (1H,
br s), 5.06 (2H, s), 5.02 (2H, s), 3.82 (3H, s), 3.78 (3H, s), 3.19
(2H, d, J=6.3 Hz), 2.90-2.86 (6H, m), 1.41-1.38 (6H, m).
Reference Example 17
Synthesis of Compound X-17
##STR00209##
[0385] Yielded amount: 1.3 g (49%)
[0386] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.34 (4H, dd, J=8.8, 2.6
Hz), 7.11 (1H, d, J=1.9 Hz), 7.02 (1H, d, J=1.9 Hz), 6.91 (2H, d,
J=8.5 Hz), 6.83 (2H, d, J=8.5 Hz), 5.06 (2H, br s), 5.00 (2H, br
s), 3.98 (1H, s), 3.83 (3H, d, J=10.2 Hz), 3.80 (3H, s), 3.54 (2H,
s), 3.25 (1H, s), 2.82 (2H, s), 2.42 (6H, dd, J=53.5, 20.3 Hz).
Reference Example 18
Synthesis of Compound X-18
##STR00210##
[0388] Yielded amount: 0.39 g (32%)
[0389] [M+H]=521.35
Reference Example 19
Synthesis of Compound X-19
##STR00211##
[0391] Yielded amount: 1.3 g (50%)
[0392] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.34 (2H, dd, J=11.5, 2.8
Hz), 7.31-7.27 (2H, m), 7.24 (1H, d, J=1.6 Hz), 7.01 (1H, dd,
J=10.4, 1.9 Hz), 6.92 (2H, dt, J=9.3, 2.4 Hz), 6.82 (2H, dt, J=9.2,
2.4 Hz), 5.95 (1H, t, J=6.1 Hz), 5.08 (4H, s), 3.82 (3H, s), 3.79
(3H, s), 3.20 (2H, d, J=6.4 Hz), 2.91-2.87 (6H, m), 1.42-1.38 (6H,
m).
Reference Example 20
Synthesis of Compound X-20
##STR00212##
[0394] Yielded amount: 1.1 g (42%)
[0395] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.33 (4H, dd, J=13.7, 8.6
Hz), 6.91-6.79 (6H, m), 5.05 (4H, s), 4.00-3.89 (1H, m), 3.82 (3H,
s), 3.77 (3H, dd, J=18.3, 6.6 Hz), 3.59 (1H, t, J=20.3 Hz), 3.21
(1H, d, J=28.7 Hz), 2.85 (1H, s), 2.57 (1H, d, J=39.9 Hz), 2.35
(3H, s), 1.81 (5H, s).
Reference Example 21
Synthesis of Compound X-21
##STR00213##
[0396] Step (1): Compound X-21a.fwdarw.Compound X-21b
[0397] Compound X-21a (13.5 g, 38 mmol) was suspended into
dichloromethane (100 mL), and thereto were then added
N,O-Dimethylhydroxylamine hydrochloride (5.6 g, 57 mmol),
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (11 g,
57 mmol) and triethylamine (7.94 ml, 57 mmol) in turn. The mixture
was stirred at rt for 1 hours. The reaction mixture was diluted
with dichloromethane and water. The resultant solution was then
separated and washed with water and a saturated salt solution, and
dried over magnesium sulfate. Magnesium sulfate was filtrated off,
and then the liquid was concentrated under reduced pressure. The
precipitated solid was then collected by filtration, and washed
with diisopropyl ether to yield compound X-21b (15.1 g, 100%).
[0398] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.42-7.26 (12H, m), 7.16
(2H, d, J=10.4 Hz), 5.17 (2H, s), 5.13 (2H, s), 3.48 (3H, s), 3.32
(3H, s).
Step (2): Compound X-21b.fwdarw.Compound X-21c
[0399] Compound X-21b (15.1 g, 38 mmol) was suspended into
tetrahydrofurane (320 mL), and thereto was then added methyl
magnesium bromide (0.99 mol/L in tetrahydrofurane, 77 ml 76 mmol)
at 0.degree. C. The mixture was stirred at rt for 1 hours. The
reaction mixture was diluted with saturated ammonium chloride
solution, then extracted ethyl acetate and washed with water and a
saturated salt solution, and dried over magnesium sulfate.
Magnesium sulfate was filtrated off, and then the liquid was
concentrated under reduced pressure. The precipitated solid was
then collected by filtration, and washed with diisopropyl ether to
yield compound X-21c (13 g, 97%).
[0400] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.44-7.26 (12H, m), 5.21
(2H, s), 5.16 (2H, s), 2.52 (3H, s).
Step (2): Compound X-21c.fwdarw.Compound X-21
[0401] Compound X-21c (13 g, 37 mmol) was dissolved into pyridine
(200 mL), and thereto was then added selenium dioxide (10.3 g, 93
mmol).
[0402] The mixture was stirred at 80.degree. C. for 1 day. The
reaction mixture was filtered and evaporated. The residue was
diluted with aqueous hydrochloric acid solution and ethyl acetate,
then separated and washed with water and a saturated salt solution,
and dried over magnesium sulfate. Magnesium sulfate was filtrated
off, and then the liquid was concentrated under reduced pressure.
The precipitated solid was then collected by filtration, and washed
with diisopropyl ether to yield compound X-21 (11.5 g, 82%).
[0403] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 7.52-7.48 (3H, m),
7.44-7.32 (9H, m), 5.27 (2H, s), 5.23 (2H, s).
Reference Example 22
Synthesis of Compound X-22
##STR00214##
[0404] Step (1): Compound X-1g.fwdarw.Compound X-22
[0405] A solution of the Compound X-1g (4.20 g, 5.0 mmol) in
dichloromethane (20 ml) was cooled to -40.degree. C. A solution of
m-chloroperbenzoic acid (1.46 g, 5.5 mmol) in dichloromethane (20
ml) was added drop-wise. After stirring at -40.degree. C. for 30
minutes, aqueous 15% sodium thiosulfate solution was added thereto,
dichloromethane was evaporated under reduced pressure, followed by
extraction with ethyl acetate. The organic layer was washed with
aqueous 5% sodium hydrogen carbonate, then saturated brine, and
then dried with anhydrous magnesium sulfate. The inorganic
substance was removed by filtration, followed by concentration in
vacuo. The resulting crude product was purified by silica gel
column chromatography to yield Compound X-22 as a yellow form.
[0406] Yield: 2.59 g, (60%)
[0407] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.43 (9H, s), 1.59 (3H,
s), 1.60 (3H, s), 1.61 (9H, s), 1.78 (3H, d, J=7.53 Hz), 3.48 (1H,
q, J=7.53 Hz), 4.05 (1H, d, J=12.67 Hz), 4.74 (1H, dd, J=4.96, 1.38
Hz), 5.17 (1H, d, J=12.67 Hz), 6.25 (1H, dd, J=9.98, 4.96 Hz), 6.95
(1H, s), 7.28-7.44 (11H, m), 8.09 (1H, d, J=9.98 Hz), 8.30 (1H,
s).
Reference Example 23
Synthesis of Compound X-23
##STR00215##
[0408] Step (1): Compound X-1h.fwdarw.Compound X-23
[0409] From Compound X-1h (4.20 g, 5.0 mmol), Compound X-23 was
obtained as a white solid using the same method as Reference
Example 22.
[0410] Yield: 2.26 g, (53%)
[0411] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.39 (3H, d, J=7.47 Hz),
1.42 (9H, s), 1.53 (9H, s), 1.59 (3H, s), 1.60 (3H, s), 3.88 (1H,
q, J=7.47 Hz), 4.34 (1H, d, J=12.05 Hz), 4.59 (1H, d, J=5.03 Hz),
4.63 (1H, d, J=12.05 Hz), 6.31 (1H, dd, J=9.76, 5.03 Hz), 7.00 (1H,
s), 7.25-7.48 (11H, m), 7.95 (1H, d, J=9.76 Hz), 8.19 (1H, s).
Reference Example 25
Synthesis of Compound X-25
[Chemical Formula 142]
[0412] compound X-25:
5-chloro-1-cyclopropyl-6,7-bis((4-methoxybenzyl)oxy)-N-((1R,3r,5S)-8-meth-
yl-8-azabicyclo[3.2.1]octan-3-yl)-4-oxo-1,4-dihydroquinoline-3-carboxamide
##STR00216##
[0413] To a solution of
5-chloro-1-cyclopropyl-6,7-bis((4-methoxybenzyl)oxy)-4-oxo-1,4-dihydroqui-
noline-3-carboxylic acid (WO2013052568A1, 8 g, 14.93 mmol) and
(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-amine, 2 Hydrochloride
(3.34 g, 15.7 mmol) in DCM (700 mL) were added DIPEA (9.12 mL, 52.2
mmol) and PyBOP (9.32 g, 17.9 mmol) at room temperature. The
reaction mixture was stirred overnight and then concentrated, and
the resulting residue was purified via automated silica gel
chromatography (120 g column, 0-10% MeOH in DCM). The isolated
product was purified again via automated silica gel chromatography
(24 g column, 0-10% MeOH in DCM) to afford compound X-25 (4.64 g,
47% yield) as a white solid. LCMS: (M+H).sup.+: 658.2. .sup.1H NMR
(DMSO-d.sub.6): 10.46 (d, J=7.3 Hz, 1H), 8.57 (s, 1H), 7.67 (s,
1H), 7.50 (d, J=8.6 Hz, 2H), 7.33 (d, J=8.6 Hz, 2H), 7.02 (d, J=8.6
Hz, 2H), 6.87 (d, J=8.6 Hz, 2H), 5.35 (s, 2H), 4.91 (s, 2H), 4.04
(q, J=6.8 Hz, 1H), 3.79 (s, 3H), 3.75 (s, 3H), 3.62-3.69 (m, 1H),
3.02-3.16 (m, 2H), 2.21 (s, 3H), 1.90-2.15 (m, 6H), 1.60 (d, J=13.9
Hz, 2H), 1.25-1.35 (m, 2H), 0.99-1.07 (m, 2H).
Reference Example 26
Synthesis of Compound X-26
[Chemical Formula 144]
[0414] Compound X-26:
5-chloro-1-ethyl-6,7-bis((4-methoxybenzyl)oxy)-N-((R,3r,5S)-8-methyl-8-az-
abicyclo[3.2.1]octan-3-yl)-4-oxo-1,4-dihydroquinoline-3-carboxamide
##STR00217##
[0415] To a solution of
5-chloro-1-ethyl-6,7-bis((4-methoxybenzyl)oxy)-4-oxo-1,4-dihydroquinoline-
-3-carboxylic acid (WO2013052568A1, 10.0 g, 19.1 mmol) and
(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-amine, 2 Hydrochloride
(4.07 g, 19.1 mmol) in DCM (800 mL) were added DIPEA (11.7 mL, 66.8
mmol) and PyBOP (11.92 g, 22.90 mmol) at room temperature, and the
reaction mixture was stirred for 0.5 h. The mixture was
concentrated and the obtained residue was purified via automated
silica gel chromatography (120 g column, 0-10% MeOH in DCM). The
fractions containing product were combined and washed with
saturated NaHCO.sub.3 aq, brine, and water successively. The
product was repurified via automated silica gel chromatography (24
g column, 0-10% MeOH in DCM) to afford compound X-26 (5.95 g, 48%
yield) as a white solid. LCMS: (M+H).sup.+: 646.2. .sup.1H NMR
(CDCl.sub.3) .delta.: 10.71 (d, J=6.6 Hz, 1H), 8.64 (s, 1H), 7.41
(d, J=8.6 Hz, 2H), 7.37 (d, J=8.6 Hz, 2H), 6.96 (d, J=9.1 Hz, 2H),
6.87 (d, J=8.6 Hz, 1H), 6.81 (s, 1H), 5.22 (s, 2H), 5.01 (s, 2H),
4.31 (q, J=6.4 Hz, 1H), 4.17 (q, J=7.3 Hz, 2H), 3.85 (s, 3H), 3.83
(s, 3H), 3.40-3.55 (m, 2H), 2.58-2.73 (m, 2H), 2.55 (s, 3H),
2.31-2.41 (m, 2H), 2.20-2.30 (m, 2H), 2.01 (d, J=14.9 Hz, 2H), 1.41
(t, J=7.2 Hz, 3H).
Example 1
Synthesis of Compound I-1
##STR00218##
[0416] Step (1): Compound 1a.fwdarw.Compound 1b
[0417] Compound 1a (14.53 g, 74.8 mmol) was dissolved into
dichloromethane (150 m), and thereto was then added dropwise boron
tribromide (50g, 200 mmol) at 0.degree. C. The mixture was stirred
at rt for 1 if mixture was diluted with ice water and evaporated.
The precipitated solid was then collected by filtration, and washed
with water. In this way, compound 1b was yielded (11.2 g, 90%).
[0418] .sup.1H-NMR (DMSO-D) .delta.: 10.18 (1H, s), 9.66 (1H, s),
7.06 (1H, s), 6.92 (1H, s), 5.16 (2H, s).
Step (2): Compound 1a.fwdarw.Compound 1b
[0419] Compound 1a (14.53 g, 74.8 mmol) was dissolved into
dichloromethane (150 mL), and thereto was then added dropwise boron
tribromide (50g, 200 mmol) at 0.degree. C. The mixture was stirred
at rt for 1 hour. The reaction mixture was diluted with ice water,
and evaporated. The precipitated solid was then collected by
filtration, and washed with water. In this way, compound 1b was
yielded (11.2g, 90%).
[0420] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 10.18 (1H, s), 9.66 (1H,
s), 7.06 (1H, s), 6.92 (1H, s), 5.16 (2H, s).
Step (2): Compound 1b.fwdarw.Compound 1c
[0421] Compound 1b (13.20 g, 79 mmol) was dissolved into
dimethylacetoamide (130 mL), and thereto were then added potassium
carbonate (32.9 g, 238 mmol), p-methoxybenzyl chloride (26.0 ml,
191 mmol) and sodium iodide (11.91 g, 79 mmol) in turn. The mixture
was stirred at 50.degree. C. for 1 hour. The reaction mixture was
poured into water. The precipitated solid was then collected by
filtration, and washed with water and diisopropyl ether. In this
way, compound 1c was yielded (37.32 g 116%).
[0422] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.37-7.33 (5H, m),
6.92-6.88 (5H, m), 5.16 (2H, s), 5.16 (2H, s), 5.12 (2H, s), 3.82
(3H, s), 3.81 (3H, s).
Step (3): Compound 1c.fwdarw.Compound 1d
[0423] A 2 mol/L aqueous sodium hydroxide solution (119 ml, 237
mmol) was added to a solution of the total amount of compound 1c
yielded (37.32g, 79 mmol) in tetrahydrofuran (30 mL) and methanol
(30 mL). The resultant solution was stirred at 70.degree. C. for 1
hour. To the reaction mixture was added water and 2 mol/L aqueous
hydrochloric acid solutions (120 mL). The precipitated solid was
then collected by filtration, and washed with water to yield
compound 1d (42.71 g, 127%).
[0424] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.69 (1H, s), 7.36-7.34
(4H, m), 7.02 (1H, s), 6.91-6.87 (4H, m), 5.15 (2H, s), 5.09 (2H,
s), 4.73 (2H, s), 4.69 (1H, br s), 3.81 (3H, s), 3.80 (3H, s).
Step (4): Compound 1d.fwdarw.Compound 1e
[0425] The total amount of compound 1d yielded (42.71 g, 79 mmol)
was suspended into acetone (350 mL), and thereto was then added
Jone's reagent (2.67 mol/L, 71.0 mL, 190 mmol) at 0.degree. C. The
mixture was stirred at 0.degree. C. for 1 hour. The reaction
mixture was diluted with dichloromethane and water, then added
sodium bisulfite at 0.degree. C. The resultant solution was then
separated and washed with water and a saturated salt solution, and
dried over magnesium sulfate. Magnesium sulfate was filtrated off,
and then the liquid was concentrated under reduced pressure. The
precipitated solid was then collected by filtration, and washed
with diisopropyl ether to yield compound 1e (26.94 g, 81%).
[0426] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.38 (2H, s), 7.35 (4H, d,
J=8.1 Hz), 6.92 (4H, d, J=8.1 Hz), 5.21 (4H, s), 3.82 (6H, s).
Step (5): Compound 1e.fwdarw.Compound 1f
[0427] Compound 1e (1.88 g, 4.5 mmol) was suspended into toluene
(20 mL), and thereto was then added aminoethylpyrrolidine (0.60 mL,
4.7 mmol) at 0.degree. C. The mixture was stirred at rt for 30
minutes. Thereto was added acetic acid (0.28 mL, 4.9 mmol). The
resultant mixture was stirred at reflux for 30 minutes. The
reaction mixture was diluted with ethyl acetate and aqueous sodium
hydroxide solution, then separated and washed with water and a
saturated salt solution, and dried over magnesium sulfate.
Magnesium sulfate was filtrated off, and then the liquid was
concentrated under reduced pressure. The precipitated solid was
then collected by filtration, and washed with diisopropyl ether to
yield compound if (2.10 g, 91%).
[0428] .sup.1H-NMR (CDCl3) .delta.: 7.36-7.32 (6H, m), 6.92-6.89
(4H, m), 5.17 (4H, s), 3.81 (6H, s), 3.78-3.73 (2H, m), 2.72-2.68
(2H, m), 2.56 (4H, br s), 1.74 (4H, br s).
Step (6): Compound X-1+Compound 1f.fwdarw.Compound
1g.fwdarw.Compound I-1
[0429] Compound if (517 mg, 1.0 mmol) was added to a solution of
compound X-1 (932 mg, 1.00 mmol) in dimethylformamide (2 mL) at
0.degree. C., and the resultant solution was stirred at 0.degree.
C. for 1 day. The reaction mixture was slowly added to a 5% salt
solution (30 ml) (containing 1.5 g of sodium bisulfite) at
0.degree. C. The precipitated solid was collected by filtration,
washed with water, and then suspended into water. The suspension
was freeze-dried to yield compound 1g as an orange solid. Compound
1g yielded was used as it was, without being purified, in the next
reaction.
[0430] The total amount of compound 1g yielded was dissolved in
dichloromethane (10 mL), and the solution was cooled to -40.degree.
C. Thereto were then added anisole (1.3 mL, 12 mmol) and a 2 mol/L
aluminum chloride solution (6.00 mL, 12 mmol) in nitromethane in
turn. The resultant was stirred at 0.degree. C. for 30 minutes. The
reaction mixture was dissolved in water, a 2 mol/L aqueous
hydrochloric acid solution, and acetonitrile. The resultant
solution was then washed with diisopropyl ether. To the water phase
was added HP20-SS resin, and then acetonitrile was distilled off
under reduced pressure. The resultant mixed liquid was purified by
ODS column chromatography. To the resultant target-compound
solution was added HP20-SS resin, and then acetonitrile was
distilled off under reduced pressure. The resultant mixed liquid
was purified by HP20-SS column chromatography. To the resultant
target-compound solution was added a 0.2 N aqueous sodium hydroxide
solution until the whole gave a pH of 6.0. Thereafter, a piece of
dry ice was added thereto. The resultant solution was concentrated
under reduced pressure, and then freeze-dried to yield compound I-1
as an orange powder.
[0431] Yielded amount: 163.5 mg, (18%).
[0432] .sup.1H-NMR (D.sub.2O) .delta.: 6.99 (3H, s), 5.80 (1H, d,
J=4.6 Hz), 5.47 (1H, d, J=4.6 Hz), 5.07 (1H, d, J=14.1 Hz), 4.30
(1H, d, J=14.1 Hz), 4.11 (1H, d, J=6.3 Hz), 4.00 (2H, br s),
3.69-3.52 (6H, m), 2.23 (4H, br s), 1.59 (3H, d, J=5.8 Hz), 1.53
(3H, s), 1.51 (3H, s).
[0433] Elem. Anal.: C32H34N7O11S2Na(H2O) 4.8
[0434] Calcd.: C, 44.37; H, 5.07; N, 11.32; S, 7.40; Na,
2.65(%).
[0435] Found: C, 44.29; H, 4.98; N, 11.52; S, 7.27; Na,
2.76(%).
Example 2
Synthesis of Compound I-2
##STR00219##
[0436] Step (1): Compound 2a.fwdarw.Compound 2b
[0437] Compound 2a (2.33 g, 10.2 mmol) was used to synthesize the
target compound in the same way as step 1 of Example 1.
[0438] Yielded amount: 2.00 g, (98%)
[0439] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 10.55 (2H, br s), 7.09
(1H, s), 5.22 (2H, s).
Step (2): Compound 2b.fwdarw.Compound 2c
[0440] Compound 2b (2.00 g, 9.97 mmol) was used to synthesize the
target compound in the same way as step 2 of Example 1.
[0441] Yielded amount: 4.85 g (110%)
[0442] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.39-7.37 (3H, m), 7.31
(2H, d, J=8.7 Hz), 6.94 (2H, d, J=8.7 Hz), 6.83 (2H, d, J=8.7 Hz),
5.18 (2H, s), 5.11 (2H, s), 5.09 (2H, s), 3.84 (3H, s), 3.80 (3H,
s).
Step (3): Compound 2c.fwdarw.Compound 2d
[0443] The total amount of compound 2c yielded (4.85 g, 9.97 mmol)
was used to synthesize the target compound in the same way as step
3 of Example 1.
[0444] Yielded amount: 4.46 g, (98%)
[0445] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.62 (1H, s), 7.36 (2H, d,
J=8.5 Hz), 7.33 (2H, d, J=8.5 Hz), 6.92 (2H, d, J=8.5 Hz), 6.83
(2H, d, J=8.5 Hz), 5.09 (2H, s), 5.04 (2H, s), 4.99 (2H, s), 3.83
(3H, s), 3.80 (3H, s).
Step (4): Compound 2d.fwdarw.Compound 2e
[0446] Compound 2d (4.46 g, 9.72 mmol) was used to synthesize the
target compound in the same way as step 4 of Example 1.
[0447] Yielded amount: 3.32 g, (75%, containing compound 2c)
[0448] Compound 2e yielded was used as it was, without being
purified, in the next reaction.
Step (5): Compound 2e.fwdarw.Compound 2f
[0449] Compound 2e (2.36 g, 5.19 mmol) was used to synthesize the
target compound in the same way as in step 5 of Example 1.
[0450] Yielded amount: 0.98 g, (34%)
[0451] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.39-7.36 (3H, m), 7.30
(2H, d, J=8.7 Hz), 6.94 (2H, d, J=8.7 Hz), 6.82 (2H, d, J=8.7 Hz),
5.16 (2H, s), 5.03 (2H, s), 3.84 (3H, s), 3.80-3.77 (5H, m), 2.73
(2H, t, J=6.8 Hz), 2.61-2.56 (4H, m), 1.77-1.74 (4H, m).
Step (6): Compound X-1+Compound 2f.fwdarw.Compound 2g
[0452] Compound X-1 (932 mg, 1.00 mmol) and compound 2f (551 mg,
1.00 mmol) were used to synthesize the target compound in the same
way as step 6 of Example 1.
[0453] Yielded amount: 124.3 mg (13%)
[0454] .sup.1H-NMR (D.sub.2O) .delta.: 7.31 (1H, dd, J=7.78, 1.53
Hz), 7.07 (1H, dd, J=7.78, 1.53 Hz), 6.98 (1H, s), 6.83 (1H, t,
J=7.78 Hz), 5.89 (1H, d, J=4.96 Hz), 5.38 (1H, d, J=4.96 Hz), 4.31
(1H, t, J=7.32 Hz), 4.11-3.94 (4H, m), 3.51 (1H, d, J=17.23 Hz),
3.11 (3H, br s), 2.83-2.72 (2H, m), 2.61-2.41 (5H, m), 2.19 (1H, br
s), 2.13 (1H, br s), 1.52 (3H, s), 1.50 (3H, s).
[0455] Elem. Anal.: C32H32.8ClN7O11S2Na1.2(H2O) 6.7
[0456] Calcd.: C, 40.92; H, 4.96; Cl, 3.77; N, 10.44; S, 6.83; Na,
2.94(%).
[0457] Found: C, 40.77; H, 4.91; Cl, 3.53; N, 10.72; S, 6.99; Na,
2.94(%).
Example 3
Synthesis of Compound I-3
##STR00220##
[0458] Step (1): Compound 3a.fwdarw.Compound 3b
[0459] Compound 3a (60 g, 140 mmol) was suspended into
dichloromethane (300 mL), and thereto were then added
N,O-Dimethylhydroxylamine hydrochloride (16.5 g, 169 mmol) and
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (32.2
g, 168 mmol) in turn. The mixture was stirred at rt for 1 day.
Thereto were then added N,O-Dimethylhydroxylamine hydrochloride
(4.10 g, 42 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
hydrochloride (8.05 g, 42 mmol) in turn. The mixture was stirred at
rt for 3 hours. Thereto were then added N,O-Dimethylhydroxylamine
hydrochloride (4.10 g, 42 mmol) and
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (8.05
g, 42 mmol) in turn. The mixture was stirred at rt for 2 hours. The
reaction mixture was diluted with dichloromethane and water. The
resultant solution was then separated and washed with water and a
saturated salt solution, and dried over magnesium sulfate.
Magnesium sulfate was filtrated off, and then the liquid was
concentrated under reduced pressure. The precipitated solid was
then collected by filtration, and washed with diisopropyl ether to
yield compound 3b (62.07 g, 94%).
[0460] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.36-7.32 (4H, m), 7.02
(1H, d, J=8.4 Hz), 6.93-6.89 (3H, m), 6.81 (2H, d, J=8.5 Hz), 5.06
(2H, s), 4.98 (2H, s), 3.83 (3H, s), 3.79 (3H, s), 3.45-3.31 (6H,
br m).
Step (2): Compound 3b.fwdarw.Compound 3c
[0461] Compound 3b (18.88 g, 40 mmol) was suspended into
tetrahydrofurane (380 mL), and thereto was then added methyl
magnesium bromide (0.99 mol/L in tetrahydrofurane, 81 ml 80 mmol)
at 0.degree. C. The mixture was stirred at rt for 3 hours. The
reaction mixture was diluted with a saturated ammonium chloride
solution, then extracted ethyl acetate and washed with water and a
saturated salt solution, and dried over magnesium sulfate.
Magnesium sulfate was filtrated off, and then the liquid was
concentrated under reduced pressure. The precipitated solid was
then collected by filtration, and washed with diisopropyl ether to
yield compound 3c (13.19 g, 77%).
[0462] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.39-7.33 (5H, m),
6.93-6.91 (3H, m), 6.83 (2H, d, J=8.5 Hz), 5.09 (2H, s), 4.96 (2H,
s), 3.83 (3H, s), 3.80 (3H, s), 2.62 (3H, s).
Step (3): Compound 3c.fwdarw.Compound 3d
[0463] Compound 3c (13.19 g, 31 mmol) was dissolved into pyridine
(130 mL), and thereto was then added selenium dioxide (8.57 g, 77
mmol). The mixture was stirred at 80.degree. C. for 1 day. The
reaction mixture was filtered and evaporated. The residue was
diluted with an aqueous hydrochloric acid solution and ethyl
acetate, then separated and washed with water and a saturated salt
solution, and dried over magnesium sulfate. Magnesium sulfate was
filtrated off, and then the liquid was concentrated under reduced
pressure. The precipitated solid was then collected by filtration,
and washed with diisopropyl ether to yield compound 3d (12.41 g,
88%).
[0464] .sup.1H-NMR (DMSO-D) .delta.: 7.60 (1H, d, J=8.8 Hz), 7.46
(2H, d, J=8.5 Hz), 7.37 (1H, d, J=8.8 Hz), 7.28 (2H, d, J=8.5 Hz),
6.99 (2H, d, J=8.5 Hz), 6.85 (2H, d, J=8.5 Hz), 5.24 (2H, s), 4.92
(2H, s), 3.78 (3H, s), 3.74 (3H, s).
Step (4): Compound 3d.fwdarw.Compound 3e
[0465] Compound 3d (2.28 g, 5.0 mmol) was dissolved into
dimethylacetoamide (20 mL), and thereto were then added
4-aminomethylquinuclidine (2.10 g, 15.0 mmol), hydroxybenzotriazole
(0.74 g, 5.50 mmol) and
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (1.05
g, 5.50 mmol) in turn. The mixture was stirred at rt for 1 day and
40.degree. C. for 1 day. The reaction mixture was diluted with an
aqueous hydrochloric acid solution and stirred at rt for 30
minutes. The reaction mixture was diluted with ethyl acetate and
aqueous sodium hydroxide solution, then separated and washed with
water and a saturated salt solution, and dried over magnesium
sulfate. Magnesium sulfate was filtrated off, and then the liquid
was concentrated under reduced pressure. The precipitated solid was
then collected by filtration, and washed with ethyl acetate to
yield compound 3e (0.50 g, 17%).
[0466] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 8.80 (1H, t, J=6.4 Hz),
7.50 (1H, d, J=8.8 Hz), 7.46 (2H, d, J=8.7 Hz), 7.33 (1H, d, J=8.8
Hz), 7.28 (2H, d, J=8.7 Hz), 6.99 (2H, d, J=8.7 Hz), 6.85 (2H, d,
J=8.7 Hz), 5.22 (2H, s), 4.90 (2H, s), 3.78 (3H, s), 3.74 (3H, s),
3.01 (2H, d, J=6.4 Hz), 2.81 (6H, t, J=7.6 Hz), 1.37 (6H, t, J=7.6
Hz).
Step (2): Compound X-1+Compound 3e.fwdarw.Compound 3f
[0467] Compound X-1 (745 mg, 0.80 mmol) and compound 3e (463 mg,
0.80 mmol) were used to synthesize the target compound in the same
way as step 6 of Example 1.
[0468] Yielded amount: 284.2 mg (35%)
[0469] .sup.1H-NMR (D.sub.2O) .delta.: 7.31 (1H, d, J=8.7 Hz), 7.01
(1H, s), 6.88 (1H, d, J=8.7 Hz), 5.84 (1H, d, J=4.8 Hz), 5.45 (1H,
d, J=4.8 Hz), 4.65 (1H, d, J=14.4 Hz), 4.11-4.05 (2H, m), 3.60-3.42
(6H, m), 3.36 (2H, s), 1.95 (6H, t, J=7.8 Hz), 1.57 (3H, d, J=6.9
Hz), 1.52 (3H, s), 1.51 (3H, s).
[0470] Elem. Anal.: C34H37ClN7O11S2Na(H2O) 6.4
[0471] Calcd.: C, 42.65; H, 5.24; Cl, 3.70; N, 10.24; S, 6.70; Na,
2.40(%).
[0472] Found: C, 42.61; H, 5.26; Cl, 3.83; N, 10.32; S, 6.71; Na,
2.43(%).
Example 4
Synthesis of Compound I-4
##STR00221##
[0473] Step (1): Compound 1e+Compound 4a.fwdarw.Compound 4b
[0474] Compound 1e (1.88 g, 4.5 mmol) was dissolved into ethanol
(10 mL), and thereto was then added Compound 4a (0.58 g, 4.5 mmol).
The mixture was stirred at rt for 1 day. The precipitated solid was
then collected by filtration, and washed with ethanol and
diisopropyl ether to yield compound 4b (2.00 g, 84%).
[0475] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.80 (1H, s), 7.32 (2H, d,
J=8.5 Hz), 7.08 (2H, d, J=8.5 Hz), 6.73 (2H, d, J=8.5 Hz), 6.69
(2H, d, J=8.5 Hz), 6.49 (1H, br s), 5.01 (2H, s), 4.65 (2H, s),
4.35 (2H, br s), 3.78 (3H, s), 3.76 (3H, s), 3.27-3.01 (6H, br m),
1.90 (4H, br s).
Step (2): Compound X-1+Compound 4b.fwdarw.Compound 4c
[0476] Compound X-1 (932 mg, 1.00 mmol) and compound 4b (532 mg,
1.00 mmol) were used to synthesize the target compound in the same
way as step 6 of Example 1.
[0477] Yielded amount: 64.5 mg (6%)
[0478] .sup.1H-NMR (D.sub.2O) .delta.: 7.31 (1H, s), 7.15 (1H, s),
6.98 (1H, s), 5.79 (1H, d, J=4.8 Hz), 5.45 (1H, d, J=4.8 Hz), 5.03
(1H, d, J=14.2 Hz), 4.45 (2H, d, J=4.6 Hz), 4.25 (1H, d, J=14.2
Hz), 4.01 (1H, q, J=7.0 Hz), 3.81-3.43 (6H, m), 2.24-2.06 (4H, m),
1.51-1.49 (9H, m).
[0479] Elem. Anal.: C32H34.5N8011S2Na1.5(H2O) 10.3
[0480] Calcd.: C, 38.77; H, 5.60; N, 11.30; S, 6.47; Na,
3.48(%).
[0481] Found: C, 38.76; H, 5.45; N, 11.42; S, 6.34; Na,
3.49(%).
Example 5
Synthesis of Compound I-5
##STR00222##
[0482] Step (1): Compound 5a.fwdarw.Compound 5b
[0483] Compound 5a (8.50 g, 50 mmol) and hydroxylamine
hydrochloride (5.21 g, 75 mmol) were dissolved into ethanol (50 mL)
and water (25 ml), and thereto was then added sodium carbonate
(10.6 g, 100 mmol) at 0.degree. C. The mixture was stirred at
reflux for 1 hour. The reaction mixture was diluted with ethyl
ether and aqueous sodium hydroxide solution, then separated and
dried over magnesium sulfate. Magnesium sulfate was filtrated off,
and then the liquid was concentrated under reduced pressure. The
residue was distilled by vacuum distillation (4 mmHg, 116.degree.
C.) to yield compound 5b (1.88 g, 29%).
[0484] .sup.1H-NMR (CDCl.sub.3) .delta.: 3.09 (2H, br s), 2.75 (2H,
br s), 2.57 (4H, br s), 1.78 (4H, br s).
Step (2): Compound 5b+Compound 1e.fwdarw.Compound 5c
[0485] Compound 1e (2.10 g, 5.0 mmol) was dissolved into ethanol
(10 mL), and thereto was then added Compound 5b (0.65 g, 5.0 mmol).
The mixture was stirred at rt for 1 day, 50.degree. C. for 2 hours
and 80.degree. C. for 4 hours. The precipitated solid was then
collected by filtration, and washed with ethanol and diisopropyl
ether to yield compound 5c (1.81 g, 68%).
[0486] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.69 (1H, s), 7.61 (1H,
s), 7.39-7.36 (4H, m), 6.92-6.89 (4H, m), 5.23 (2H, s), 5.19 (2H,
s), 4.19 (2H, t, J=6.7 Hz), 3.81 (6H, s), 2.90 (2H, br s), 2.60
(4H, br s), 1.77 (4H, br s).
Step (3): Compound X-1+Compound 5c.fwdarw.Compound 5d
[0487] Compound X-1 (932 mg, 1.00 mmol) and compound 5c (533 mg,
1.00 mmol) were used to synthesize the target compound in the same
way as step 6 of Example 1.
[0488] Yielded amount: 158.9 mg, (14%)
[0489] .sup.1H-NMR (D.sub.2O) .delta.: 7.47 (1H, s), 7.40 (1H, s),
7.02 (1H, s), 5.81 (1H, d, J=4.8 Hz), 5.48 (1H, d, J=4.8 Hz), 5.04
(1H, d, J=14.3 Hz), 4.63-4.58 (1H, m), 4.32 (1H, d, J=14.2 Hz),
4.08 (1H, q, J=7.0 Hz), 3.89-3.49 (6H, m), 2.22 (4H, br s), 1.58
(3H, d, J=7.2 Hz), 1.52 (3H, s), 1.50 (3H, s).
[0490] Elem. Anal.: C32H33.8N7O12S2Na1.2(H2O) 8.3
[0491] Calcd.: C, 40.47; H, 5.35; N, 10.32; S, 6.75; Na,
2.90(%).
[0492] Found: C, 40.39; H, 5.30; N, 10.59; S, 6.64; Na,
3.02(%).
Example 6
Synthesis of Compound I-6
##STR00223##
[0493] Step (1): Compound 6a.fwdarw.Compound 6b
[0494] Compound 6a (2.81 g, 9.11 mmol) was dissolved into
dichloromethane (30 mL), and thereto was then added dropwise boron
tribromide (2.5 ml, 26.4 mmol) at 0.degree. C. The mixture was
stirred at rt for 1 hour. Thereto was then added dropwise methanol
(10 ml, 247 mmol) at 0.degree. C. The mixture was stirred at
0.degree. C. for 10 minutes. The reaction mixture was evaporated.
In this way, compound 6b was yielded (5.53g, 168%). Compound 6b
yielded was used as it was, without being purified, in the next
reaction.
Step (2): Compound 6b.fwdarw.Compound 6c
[0495] The total amount of compound 6b yielded (5.53g, 9.11 mmol)
and triethylamine (5.68 mL, 41.0 mmol) were dissolved into
dichloromethane (30 mL), and thereto were then added di-t-butyl
dicarbonate (6.35 ml, 27.3 mmol) and N,N-dimethyl-4-aminopyridine
(0.06 g, 0.5 mmol) in turn at 0.degree. C. The mixture was stirred
at rt for 1 day. The reaction mixture was diluted with
dichloromethane, washed with an aqueous sodium hydroxide solution,
water and a saturated salt solution, and dried over magnesium
sulfate. Magnesium sulfate was filtrated off, and then the liquid
was concentrated under reduced pressure. The compound-containing
liquid was subjected to silica gel column chromatography to elute
out the desired compound with hexane/ethyl acetate (containing 3%
triethyl amine). The desired-compound-containing fraction was
concentrated under reduced pressure to yield compound 6c (1.27 g,
29%).
[0496] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.89 (1H, s), 7.47 (1H,
s), 4.00 (2H, t, J=6.0 Hz), 2.82 (2H, t, J=6.0 Hz), 2.62 (4H, br
s), 1.82 (4H, br s), 1.56 (18H, s).
Step (3): Compound X-1+Compound 5c.fwdarw.Compound 5d
[0497] Compound X-1 (932 mg, 1.00 mmol) and compound 5c (481 mg,
1.00 mmol) were used to synthesize the target compound in the same
way as step 6 of Example 1.
[0498] Yielded amount: 175.2 mg (18%)
[0499] .sup.1H-NMR (D.sub.2O) .delta.: 7.33 (1H, s), 7.15 (1H, s),
7.02 (1H, s), 5.80 (1H, d, J=4.8 Hz), 5.46 (1H, d, J=4.8 Hz),
4.47-4.25 (3H, m), 4.04 (1H, br s), 3.72-3.47 (6H, m), 2.22 (4H, br
s), 1.56-1.50 (9H, m).
[0500] Elem. Anal.: C31H34N7O10S3Na(H2O) 7.4
[0501] Calcd.: C, 40.60; H, 5.36; N, 10.69; S, 10.49; Na,
2.51(%).
[0502] Found: C, 40.65; H, 5.22; N, 10.88; S, 10.20; Na,
2.51(%).
Example 7
Synthesis of Compound I-7
##STR00224##
[0503] Step (1): Compound 7a+Compound 7b.fwdarw.Compound 7c
[0504] Compound 7a (10.0 g, 41.6 mmol) was suspended into
dichloromethane (100 mL), and thereto was then added 1-chloro-N,N,
2-trimethyl-1-propenylamine (6.1 mL, 45.8 mmol) at 0.degree. C. The
mixture was stirred at rt for 1 hour. The reaction mixture was
added to the mixture of Compound 7b (23.90 g, 125 mmol) and sodium
bicarbonate (17.65 g, 167 mmol) in tetrahydrofurane (100 ml) and
water (100 ml) at 0.degree. C. The mixture was stirred at rt for 1
hour. The reaction mixture was diluted with an aqueous hydrochloric
acid solution (adjusted pH=5) and ethyl acetate, then separated and
washed with water and a saturated salt solution, and dried over
magnesium sulfate. Magnesium sulfate was filtrated off, and then
the liquid was concentrated under reduced pressure.
[0505] The compound-containing liquid was subjected to silica gel
column chromatography to elute out the desired compound with
hexane/ethyl acetate. The desired-compound-containing fraction was
concentrated under reduced pressure to yield compound 7c (15.5 g,
101%).
[0506] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.39 (1H, s), 6.51 (1H,
s), 4.02-3.98 (4H, m), 3.89 (3H, s), 3.82 (3H, s), 0.89 (9H, s),
0.09 (6H, s).
Step (2): Compound 7c.fwdarw.Compound 7d
[0507] Compound 7c (14.5 g, 39.0 mmol) and triphenylphosphine
(12.28 g, 46.8 mmol) were dissolved into tetrahydrofurane (150 mL),
and thereto was then added dropwise dimethyl azodicarboxylate (2.7
mol/L in toluene, 17.35 ml, 46.8 mmol) at 0.degree. C. The mixture
was stirred at rt for 2 hour. Thereto was then added dropwise a
mixture of acetic acid and methanol (1:1) at 0.degree. C. The
mixture was stirred at 0.degree. C. for 10 minutes. The reaction
mixture was diluted with a saturated sodium hydrogen carbonate
solution and toluene, then separated and washed with a saturated
salt solution, and dried over magnesium sulfate. Magnesium sulfate
was filtrated off, and then the liquid was concentrated under
reduced pressure. The residue was dissolved into toluene (150 mL)
and hexane (100 ml) and stored at -20.degree. C. for over night.
The reaction mixture was filtered and washed with toluene/hexane
(1/1).
[0508] The compound-containing liquid was subjected to silica gel
column chromatography to elute out the desired compound with
hexane/ethyl acetate. The desired-compound-containing fraction was
concentrated under reduced pressure to yield compound 7d (6.37 g,
46%)
[0509] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.17 (1H, s), 6.67 (1H,
s), 4.11 (2H, t, J=5.8 Hz), 3.95 (3H, s), 3.93-3.90 (5H, m), 0.83
(9H, s), -0.01 (6H, s).
Step (3): Compound 7d.fwdarw.Compound 7e
[0510] Triphenylphosphine (7.09 g, 27.0 mmol) was dissolved into
dichloromethane (60 ml), and thereto was then added dropwise
bromine (1.30 ml, 25.3 mmol) at 0.degree. C. The mixture was
stirred at rt for 20 min. Thereto was then added a solution of
Compound 7d (6.37 g, 18.0 mmol) in dichloromethane (20 ml) at
0.degree. C. The resulting mixture was stirred at rt. for 2 hr. The
reaction mixture was diluted with water and dichloromethane, then
separated and washed with a saturated sodium hydrogen carbonate
solution and a saturated salt solution, and dried over magnesium
sulfate.
[0511] Magnesium sulfate was filtrated off, and then the liquid was
concentrated under reduced pressure. The compound-containing liquid
was subjected to silica gel column chromatography to elute out the
desired compound with hexane/ethyl acetate. The
desired-compound-containing fraction was concentrated under reduced
pressure to yield compound 7e (4.41 g, 81%).
[0512] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.17 (1H, s), 6.69 (1H,
s), 4.37 (2H, t, J=6.8 Hz), 3.96 (3H, s), 3.91 (3H, s), 3.64 (2H,
t, J=6.8 Hz).
Step (4): Compound 7e.fwdarw.Compound 7f
[0513] Compound 7e (4.41 g, 14.6 mmol) was used to synthesize the
target compound in the same way as step 1 of Example 1.
[0514] Yielded amount: 3.80 g, (95%)
[0515] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 9.91 (2H, br s), 6.94
(1H, s), 6.73 (1H, s), 4.24 (2H, br s), 3.76 (2H, br s).
Step (5): Compound 7f.fwdarw.Compound 7g
[0516] Compound 7f (3.80 g, 13.87 mmol) was used to synthesize the
target compound in the same way as step 2 of Example 1.
[0517] Yielded amount: 7.25 g, (102%)
[0518] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.36-7.33 (4H, m), 7.23
(1H, s), 6.93-6.87 (4H, m), 6.71 (1H, s), 5.13 (2H, s), 5.06 (2H,
s), 4.33 (2H, t, J=6.8 Hz), 3.82 (3H, s), 3.81 (3H, s), 3.60 (2H,
t, J=6.8 Hz).
Step (6): Compound 7g.fwdarw.Compound 7h
[0519] Compound 7g (3.50 g, 6.80 mmol) was dissolved into
dimethylacetoamide (35 ml), and thereto were then added pyrrolidine
(1.13 ml, 13.61 mmol) and sodium iodide (1.02 g, 6.80 mmol) at
0.degree. C. The mixture was stirred at rt for 1 day. The reaction
mixture was diluted with ethyl acetate and an aqueous sodium
hydroxide solution, then separated and washed with water and a
saturated salt solution, and dried over magnesium sulfate.
Magnesium sulfate was filtrated off, and then the liquid was
concentrated under reduced pressure. The compound-containing liquid
was subjected to amino silica gel column chromatography to elute
out the desired compound with hexane/ethyl acetate. The
desired-compound-containing fraction was concentrated under reduced
pressure to yield compound 7h (0.62 g, 18%).
[0520] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.36-7.33 (4H, m), 7.22
(1H, s), 6.92-6.86 (4H, m), 6.70 (1H, s), 5.12 (2H, s), 5.06 (2H,
s), 4.08 (2H, t, J=6.7 Hz), 3.82 (3H, s), 3.81 (3H, s), 2.84 (2H,
t, J=6.7 Hz), 2.57 (4H, br s), 1.76 (4H, br s).
Step (7): Compound X-1+Compound 7h.fwdarw.Compound 7i
[0521] Compound X-1 (932 mg, 1.00 mmol) and compound 7h (505 mg,
1.00 mmol) were used to synthesize the target compound in the same
way as step 6 of Example 1.
[0522] Yielded amount: 292.8 mg, (33%)
[0523] .sup.1H-NMR (D.sub.2O) .delta.: 7.13 (1H, s), 7.01 (1H, s),
6.83 (1H, s), 5.81 (1H, d, J=4.8 Hz), 5.46 (1H, d, J=4.8 Hz), 5.05
(1H, d, J=14.3 Hz), 4.62-4.45 (2H, m), 4.29 (1H, d, J=14.3 Hz),
4.06 (1H, q, J=7.0 Hz), 3.91-3.71 (3H, m), 3.58 (2H, br s),
3.51-3.44 (1H, m), 2.22 (4H, br s), 1.56 (3H, d, J=7.0 Hz), 1.52
(3H, s), 1.50 (3H, s).
[0524] Elem. Anal.: C31H34N7O11S2Na(H2O) 5.7
[0525] Calcd.: C, 42.77; H, 5.26; N, 11.26; S, 7.37; Na,
2.64(%).
[0526] Found: C, 42.50; H, 5.22; N, 11.55; S, 7.40; Na,
2.70(%).
Example 8
Synthesis of Compound I-8
##STR00225##
[0527] Step (1): Compound 8a.fwdarw.Compound 8b
[0528] Compound 8a (21.4 g, 50 mmol) was used to synthesize the
target compound in the same way as step 1 of Example 3.
[0529] Yielded amount: 21.27 g, (90%)
[0530] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.40 (1H, d, J=1.9 Hz),
7.37-7.33 (4H, m), 7.29 (1H, d, J=1.9 Hz), 6.92 (2H, d, J=8.7 Hz),
6.83 (2H, d, J=8.5 Hz), 5.07 (2H, s), 5.03 (2H, s), 3.83 (3H, s),
3.80 (3H, s), 3.52 (3H, s), 3.34 (3H, s).
Step (2): Compound 8b.fwdarw.Compound 8c
[0531] Compound 8b (21.27 g, 45 mmol) was used to synthesize the
target compound in the same way as step 2 of Example 3.
[0532] Yielded amount: 17.17 g, (89%)
[0533] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.58 (1H, d, J=2.0 Hz),
7.52 (1H, d, J=2.0 Hz), 7.38 (2H, d, J=8.7 Hz), 7.32 (2H, d, J=8.7
Hz), 6.93 (2H, d, J=8.7 Hz), 6.82 (2H, d, J=8.7 Hz), 5.09 (2H, s),
5.07 (2H, s), 3.83 (3H, s), 3.80 (3H, s), 2.54 (3H, s).
Step (3): Compound 8c.fwdarw.Compound 8d
[0534] Compound 8c (21.27 g, 45 mmol) was used to synthesize the
target compound in the same way as step 3 of Example 3.
[0535] Yielded amount: 17.58 g, (96%)
[0536] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 7.64 (1H, s), 7.57 (1H,
s), 7.46 (2H, d, J=7.1 Hz), 7.28 (2H, d, J=7.3 Hz), 6.99 (2H, d,
J=7.3 Hz), 6.86 (2H, d, J=7.1 Hz), 5.21 (2H, s), 5.09 (2H, s), 3.78
(3H, s), 3.74 (3H, s).
Step (4): Compound 8d.fwdarw.Compound 8e
[0537] Compound 8d (2.28 g, 5.0 mmol) and diisopropylethylamine
(1.3 ml, 7.5 mmol) were dissolved into dichloromethane (20 mL), and
thereto was then added diphenyl chlorophosphate (1.6 ml, 7.5 mmol)
at 0.degree. C. The mixture was stirred at 0.degree. C. for 1 hour.
Thereto was then added aminoethylpyrrolidine (0.7 ml, 5.5 mmol) at
0.degree. C. The mixture was stirred at rt for 2 hours. The
reaction mixture was diluted with ethyl acetate, washed with an
aqueous sodium hydroxide solution, water and a saturated salt
solution, and dried over magnesium sulfate. Magnesium sulfate was
filtrated off, and then the liquid was concentrated under reduced
pressure. The compound-containing liquid was subjected to silica
gel column chromatography to elute out the desired compound with
hexane/ethyl acetate (containing 3% triethyl amine). The
desired-compound-containing fraction was concentrated under reduced
pressure to yield compound 8e (0.58 g, 21%).
[0538] .sup.1H-NMR (CDCl.sub.3) .delta.: 8.11 (1H, s), 8.00 (1H,
s), 7.50 (1H, br s), 7.38 (2H, d, J=7.7 Hz), 7.31 (2H, d, J=7.7
Hz), 6.93 (2H, d, J=7.7 Hz), 6.82 (2H, d, J=7.7 Hz), 5.10 (4H, s),
3.83 (3H, s), 3.79 (3H, s), 3.47 (2H, t, J=6.0 Hz), 2.68 (2H, t,
J=6.0 Hz), 2.55 (4H, br s), 1.79 (4H, br s).
Step (5): Compound X-1+Compound 8e.fwdarw.Compound 8f
[0539] Compound X-1 (932 mg, 1.00 mmol) and compound 8e (553 mg,
1.00 mmol) were used to synthesize the target compound in the same
way as step 6 of Example 1.
[0540] Yielded amount: 434.5 mg, (44%)
[0541] .sup.1H-NMR (D.sub.2O) .delta.: 7.73 (1H, s), 7.39 (1H, s),
7.03 (1H, s), 5.80 (1H, d, J=4.6 Hz), 5.48 (1H, d, J=4.6 Hz), 4.28
(1H, d, J=13.8 Hz), 4.14-4.08 (1H, m), 3.99-3.92 (1H, m), 3.85-3.79
(1H, m), 3.74-3.69 (1H, m), 3.58 (5H, br s), 2.24 (4H, br s), 1.58
(3H, d, J=6.4 Hz), 1.52 (3H, s), 1.50 (3H, s).
[0542] Elem. Anal.: C32H34.8ClN7O11S2Na1.2(H2O) 5.5
[0543] Calcd.: C, 41.79; H, 5.02; Cl, 3.85; N, 10.66; S, 6.97; Na,
3.00(%).
[0544] Found: C, 41.69; H, 4.95; Cl, 3.83; N, 10.81; S, 7.10; Na,
2.96(%).
Example 9
Synthesis of Compound I-9
##STR00226##
[0545] Step (1): Compound X-4+Compound 8e.fwdarw.Compound I-9
[0546] Compound X-4 (1082 mg, 1.00 mmol) and compound 8e (553 mg,
1.00 mmol) were used to synthesize the target compound in the same
way as step 6 of Example 1.
[0547] Yielded amount: 414.9 mg, (38%)
[0548] .sup.1H-NMR (D.sub.2O) .delta.: 7.71 (1H, d, J=2.1 Hz), 7.37
(1H, d, J=2.1 Hz), 7.08 (1H, s), 5.74 (1H, d, J=4.6 Hz), 5.46 (1H,
d, J=4.6 Hz), 5.09 (1H, d, J=14.2 Hz), 4.96 (1H, dd, J=9.9, 3.6
Hz), 4.27 (1H, d, J=14.2 Hz), 4.03 (1H, q, J=7.0 Hz), 3.98-3.91
(1H, m), 3.85-3.45 (7H, m), 2.77-2.64 (2H, m), 2.24 (4H, br s),
1.56 (3H, d, J=7.0 Hz).
[0549] Elem. Anal.: C32H31.4ClN7O13S2Na2.6(H2O) 6.9
[0550] Calcd.: C, 38.22; H, 4.53; Cl, 3.53; N, 9.75; S, 6.38; Na,
5.94(%).
[0551] Found: C, 38.22; H, 4.53; Cl, 3.67; N, 9.84; S, 6.35; Na,
6.04(%).
Example 10
Synthesis of Compound I-10
##STR00227##
[0552] Step (1): Compound 8d.fwdarw.Compound 10a
[0553] Compound 8d (2.28 g, 5.00 mmol) was used to synthesize the
target compound in the same way as step 5 of Example 8.
[0554] Yielded amount: 0.81 g, (29%)
[0555] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.55 (1H, s), 7.52 (1H,
s), 7.37 (2H, d, J=7.8 Hz), 7.30 (2H, d, J=7.8 Hz), 6.93 (2H, d,
J=7.8 Hz), 6.82 (2H, d, J=7.8 Hz), 5.10 (4H, s), 4.78-4.61 (1H, m),
3.84 (3H, s), 3.80 (3H, s), 3.58-3.43 (1H, m), 3.29-2.96 (3H, m),
2.92-2.59 (1H, m), 2.28-2.12 (2H, m), 1.99-1.75 (4H, m), 1.51-1.31
(1H, m).
Step (2): Compound X-1+Compound 10a.fwdarw.Compound I-10
[0556] Compound X-1 (932 mg, 1.00 mmol) and compound 10a (565 mg,
1.00 mmol) were used to synthesize the target compound in the same
way as step 6 of Example 1.
[0557] Yielded amount: 415.5 mg, (42%)
[0558] .sup.1H-NMR (D.sub.2O) .delta.: 7.58-7.56 (1H, m), 7.29 (1H,
s), 7.02-7.01 (1H, m), 5.83-5.81 (1H, m), 5.46-5.44 (1H, m),
5.17-5.07 (1H, m), 4.37-4.25 (2H, m), 4.08-3.48 (8H, m), 2.50-2.00
(4H, m), 1.60-1.54 (3H, m), 1.53-1.52 (3H, m), 1.50-1.50 (3H,
m).
[0559] Elem. Anal.: C33H34.5ClN7O11S2Na1.5(H2O) 6.4
[0560] Calcd.: C, 41.52; H, 4.99; Cl, 3.71; N, 10.27; S, 6.72; Na,
3.61(%).
[0561] Found: C, 41.32; H, 5.00; Cl, 3.42; N, 10.56; S, 6.72; Na,
3.62(%).
Example 11
Synthesis of Compound I-11
##STR00228##
[0562] Step (1): Compound X-4+Compound 10a.fwdarw.Compound I-11
[0563] Compound X-4 (1082 mg, 1.00 mmol) and compound 10a (565 mg,
1.00 mmol) were used to synthesize the target compound in the same
way as step 6 of Example 1.
[0564] Yielded amount: 379.3 mg, (35%)
[0565] .sup.1H-NMR (D.sub.2O) .delta.: 7.58-7.56 (1H, m), 7.26 (1H,
s), 7.07-7.06 (1H, m), 5.78-5.76 (1H, m), 5.44-5.43 (1H, m),
5.22-5.10 (1H, m), 4.97-4.95 (1H, m), 4.39-4.27 (2H, m), 4.00-3.48
(8H, m), 2.76-2.64 (2H, m), 2.50-2.01 (4H, m), 1.59-1.53 (3H,
m).
[0566] Elem. Anal.: C33H31.2ClN7O13S2Na2.8(H2O) 8.2
[0567] Calcd.: C, 37.91; H, 4.59; Cl, 3.39; N, 9.38; S, 6.13; Na,
6.16(%).
[0568] Found: C, 37.92; H, 4.61; Cl, 3.41; N, 9.52; S, 6.02; Na,
6.21(%).
Example 12
Synthesis of Compound I-12
##STR00229##
[0569] Step (1): Compound 8d.fwdarw.8 Compound 12a
[0570] Compound 8d (2.28 g, 5.00 mmol) was used to synthesize the
target compound in the same way as step 4 of Example 8.
[0571] Yielded amount: 0.95 g, (33%)
[0572] .sup.1H-NMR (CDCl.sub.3) .delta.: 8.15 (1H, s), 8.08 (1H,
s), 7.56 (1H, d, J=7.3 Hz), 7.38 (2H, d, J=8.1 Hz), 7.31 (2H, d,
J=8.1 Hz), 6.93 (2H, d, J=8.1 Hz), 6.82 (2H, d, J=8.1 Hz), 5.10
(4H, s), 4.13 (1H, t, J=6.7 Hz), 3.83 (3H, s), 3.79 (3H, s), 3.19
(2H, br s), 2.30-2.17 (7H, m), 1.81-1.79 (2H, m), 1.72-1.69 (2H,
m).
Step (2): Compound X-1+Compound 12a.fwdarw.Compound 12b
[0573] Compound X-1 (745 mg, 0.80 mmol) and compound 12a (463 mg,
0.80 mmol) were used to synthesize the target compound in the same
way as step 6 of Example 1.
[0574] Yielded amount: 321 mg, (39%)
[0575] .sup.1H-NMR (D.sub.2O) .delta.: 7.65 (1H, d, J=2.3 Hz), 7.34
(1H, d, J=2.3 Hz), 7.03 (1H, s), 5.82 (1H, d, J=4.8 Hz), 5.47 (1H,
d, J=4.8 Hz), 4.31-4.27 (1H, m), 4.12-4.05 (2H, m), 3.95 (1H, br
s), 3.12-3.00 (3H, m), 2.86-2.74 (2H, m), 2.61-2.30 (4H, m),
2.19-2.15 (2H, m), 1.58 (3H, d, J=7.0 Hz), 1.53 (3H, s), 1.51 (3H,
s).
[0576] Elem. Anal.: C34H36.8ClN7O11S2Na1.2(H2O) 6.7
[0577] Calcd.: C, 42.21; H, 5.23; Cl, 3.66; N, 10.14; S, 6.63; Na,
2.85(%).
[0578] Found: C, 42.22; H, 5.26; Cl, 3.54; N, 10.28; S, 6.74; Na,
2.92(%).
Example 13
Synthesis of Compound I-13
##STR00230##
[0579] Step (1): Compound X-4+Compound 12a.fwdarw.Compound I-13
[0580] Compound X-4 (829 mg, 0.80 mmol) and compound 12a (463 mg,
0.80 mmol) were used to synthesize the target compound in the same
way as in step 6 of Example 1.
[0581] Yielded amount: 370.4 mg, (41%)
[0582] .sup.1H-NMR (D.sub.2O) .delta.: 7.64 (1H, d, J=2.4 Hz), 7.32
(1H, d, J=2.4 Hz), 7.07 (1H, s), 5.77 (1H, d, J=4.6 Hz), 5.45 (1H,
d, J=4.6 Hz), 4.96 (1H, dd, J=9.3, 4.0 Hz), 4.31-4.27 (1H, m),
4.09-4.02 (2H, m), 3.95 (2H, br s), 3.11-3.02 (3H, m), 2.86-2.65
(4H, m), 2.61-2.12 (7H, m), 1.56 (3H, d, J=7.0 Hz).
[0583] Elem. Anal.: C34H33.5ClN7O13S2Na2.5(H2O) 7.5
[0584] Calcd.: C, 39.25; H, 4.70; Cl, 3.41; N, 9.42; S, 6.16; Na,
5.52(%).
[0585] Found: C, 39.51; H, 4.83; Cl, 3.68; N, 9.30; S, 5.78; Na,
5.46(%).
Example 14
Synthesis of Compound I-14
##STR00231##
[0586] Step (1): Compound 8d.fwdarw.Compound 14a
[0587] Compound 8d (2.28 g, 5.00 mmol) was used to synthesize the
target compound in the same way as step 4 of Example 8.
[0588] Yielded amount: 0.90 g, (31%)
[0589] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 8.81 (1H, t, J=5.3 Hz),
7.64 (1H, s), 7.59 (1H, s), 7.45 (2H, d, J=7.1 Hz), 7.28 (2H, d,
J=7.1 Hz), 6.99 (2H, d, J=7.1 Hz), 6.86 (2H, d, J=7.1 Hz), 5.18
(2H, s), 5.08 (2H, s), 3.78 (3H, s), 3.74 (3H, s), 3.02 (2H, d,
J=5.3 Hz), 2.72 (6H, br s), 1.31 (6H, br s).
Step (2): Compound X-1+Compound 14a.fwdarw.Compound 14b
[0590] Compound X-1 (745 mg, 0.80 mmol) and compound 14a (450 mg,
0.78 mmol) were used to synthesize the target compound in the same
way as in step 6 of Example 1.
[0591] Yielded amount: 447 mg, (%)
[0592] .sup.1H-NMR (D.sub.2O) .delta.: 7.66 (1H, d, J=2.0 Hz), 7.37
(1H, d, J=2.0 Hz), 7.00 (1H, s), 5.84 (1H, d, J=4.8 Hz), 5.44 (1H,
d, J=4.8 Hz), 4.64 (1H, d, J=14.3 Hz), 4.08-4.05 (2H, m), 3.59-3.40
(6H, m), 3.36 (2H, s), 1.94 (6H, t, J=7.6 Hz), 1.56 (3H, d, J=7.2
Hz), 1.52 (3H, s), 1.51 (3H, s).
Example 15
Synthesis of Compound I-15
##STR00232##
[0593] Step (1): Compound X-4+Compound 14a.fwdarw.Compound I-15
[0594] Compound X-4 (829 mg, 0.80 mmol) and compound 14a (450 mg,
0.78 mmol) were used to synthesize the target compound in the same
way as in step 6 of Example 1.
[0595] Yielded amount: 388 mg
[0596] .sup.1H-NMR (D.sub.2O) .delta.: 7.67 (1H, d, J=2.3 Hz), 7.35
(1H, d, J=2.3 Hz), 7.05 (1H, s), 5.80 (1H, d, J=4.8 Hz), 5.43 (1H,
d, J=4.8 Hz), 4.96 (1H, dd, J=9.2, 4.1 Hz), 4.68 (1H, d, J=14.2
Hz), 4.08-3.99 (2H, m), 3.60-3.43 (6H, m), 3.37 (2H, s), 2.74-2.71
(2H, m), 1.95 (6H, t, J=7.7 Hz), 1.55 (3H, d, J=7.0 Hz).
Example 16
Synthesis of Compound I-16
##STR00233##
[0597] Step (1): Compound 8d.fwdarw.Compound 16a
[0598] Compound 8d (2.28 g, 5.00 mmol) was used to synthesize the
target compound in the same way as step 4 of Example 8.
[0599] Yielded amount: 0.75 g, (27%)
[0600] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 7.54 (1H, s), 7.46-7.44
(3H, m), 7.29 (2H, d, J=6.3 Hz), 7.00 (2H, d, J=6.3 Hz), 6.87 (2H,
d, J=6.3 Hz), 5.22 (2H, s), 5.09 (2H, s), 4.54 (1H, s), 3.78-3.66
(8H, m), 3.01-2.78 (6H, m), 1.99-1.62 (4H, m).
Step (1): Compound X-1+Compound 16a.fwdarw.Compound I-16
[0601] Compound X-1 (606 mg, 0.65 mmol) and compound 16a (367 mg,
0.65 mmol) were used to synthesize the target compound in the same
way as in step 6 of Example 1.
[0602] Yielded amount: 213.1 mg, (33%)
[0603] .sup.1H-NMR (D.sub.2O) .delta.: 7.54 (1H, s), 7.23 (1H, s),
7.00 (1H, s), 5.87-5.84 (1H, m), 5.47-5.45 (1H, m), 4.38-4.08 (4H,
m), 3.88 (2H, br s), 3.82-3.46 (6H, m), 2.42-2.23 (4H, m),
1.61-1.57 (3H, m), 1.53-1.52 (3H, m), 1.51-1.50 (3H, m).
[0604] Elem. Anal.: C33H34.4ClN7O11S2Na1.6(H2O) 6.7
[0605] Calcd.: C, 41.20; H, 5.01; Cl, 3.68; N, 10.19; S, 6.67; Na,
3.82(%).
[0606] Found: C, 40.92; H, 5.00; Cl, 3.48; N, 10.50; S, 6.87; Na,
3.77(%).
Example 17
Synthesis of Compound I-17
##STR00234##
[0607] Step (1): Compound X-4+Compound 16a.fwdarw.Compound I-17
[0608] Compound X-4 (673 mg, 0.65 mmol) and compound 16a (367 mg,
0.65 mmol) were used to synthesize the target compound in the same
way as step 6 of Example 1.
[0609] Yielded amount: 225.6 mg, (31%)
[0610] .sup.1H-NMR (D.sub.2O) .delta.: 7.54 (1H, s), 7.23 (1H, s),
7.04 (1H, s), 5.82-5.80 (1H, m), 5.44-5.43 (1H, m), 4.98-4.94 (1H,
m), 4.38-4.07 (3H, m), 3.89 (2H, br s), 3.81-3.44 (6H, m),
2.75-2.65 (2H, m), 2.46-2.24 (4H, m), 1.60-1.56 (3H, m).
[0611] Elem. Anal.: C33H31ClN7O13S2Na3(H2O) 7.9
[0612] Calcd.: C, 37.95; H, 4.52; Cl, 3.39; N, 9.39; S, 6.14; Na,
6.60(%).
[0613] Found: C, 37.93; H, 4.43; Cl, 3.34; N, 9.56; S, 6.18; Na,
6.59(%).
Example 18
Synthesis of Compound I-18
##STR00235## ##STR00236##
[0614] Step (1): Compound 18a.fwdarw.Compound 18b
[0615] Compound 18a (59.1 g, 100 mmol) which was synthesized
according to the synthesis in U.S. Pat. No. 4,463,172A1 was
dissolved into dichloromethane (600 ml) and thereto was then
bubbled a diazomethane (170 mmol), prepared from
N-methyl-N-nitroso-p-toluenesulfonamide (36.4 g, 170 mmol) at
0.degree. C. The mixture was concentrated under reduced pressure.
The precipitated solid was then collected by filtration, and washed
with diisopropyl ether. In this way, compound 18b was yielded
(64.98g, 103%). Compound 18b yielded was used as it was, without
being purified, in the next reaction.
[0616] MS (m+1)=633
Step (2): Compound 18b.fwdarw.Compound 18c
[0617] The total amount of compound 18b yielded (64.98 g, 100 mmol)
was suspended into toluene (650 mL), and then stirred at 90.degree.
C. for 2 hours. The mixture was concentrated under reduced
pressure. The compound-containing liquid was subjected to silica
gel column chromatography to elute out the desired compound with
chloroform/ethyl acetate. The desired-compound-containing fraction
was concentrated under reduced pressure to yield compound 18c (23.5
g, 39%).
[0618] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.41-7.29 (12H, m),
7.01-6.96 (3H, m), 6.85 (1H, d, J=10.0 Hz), 6.13 (1H, dd, J=10.0,
4.8 Hz), 4.87 (1H, d, J=12.8 Hz), 4.64 (1H, d, J=4.8 Hz), 4.38 (1H,
d, J=12.8 Hz), 3.84 (2H, s), 1.91-1.75 (5H, m), 1.46-1.41 (1H, m),
0.92-0.86 (1H, m).
Step (3): Compound 18c.fwdarw.Compound 18d
[0619] Compound 18c (23.5 g, 39 mmol) was dissolved into
dimethylacetoamide (230 ml) and thereto were then added potassium
iodide (38.7 g, 233 mmol) and acetyl chloride (11.10 ml, 156 mmol)
in turn at 0.degree. C. The mixture was stirred at 0.degree. C. for
4 hours. The reaction mixture was diluted with ethyl acetate and an
aqueous sodium thiosulfate solution, then separated and washed with
a saturated sodium hydrogen carbonate solution and a saturated salt
solution, and dried over magnesium sulfate. Magnesium sulfate was
filtrated off, and then the liquid was concentrated under reduced
pressure. The compound-containing liquid was subjected to silica
gel column chromatography to elute out the desired compound with
hexane/ethyl acetate. The desired-compound-containing fraction was
concentrated under reduced pressure to yield compound 18d (15.6 g,
68%). .sup.1H-NMR (CDCl.sub.3) .delta.: 7.38-7.26 (11H, m),
7.03-6.95 (3H, m), 6.25-6.19 (1H, m), 5.93-5.89 (1H, m), 5.21-5.16
(1H, m), 4.44-4.35 (2H, m), 3.86-3.82 (2H, m), 1.95-1.91 (3H, m),
1.45-1.30 (3H, m),
Step (4): Compound 18d.fwdarw.Compound 18e
[0620] Compound 18d (15.6 g, 26.5 mmol) and anisole (5.79 mL, 53.0
mmol) were dissolved into dichloromethane (70 mL), and thereto was
then added trifluoroacetic acid (70 mL) at 0.degree. C. The mixture
was stirred at 0.degree. C. for 30 minutes. The reaction mixture
was concentrated under reduced pressure. The precipitated solid was
then collected by filtration, and washed with diisopropyl ether to
yield compound 18e (10.5 g, 94%).
[0621] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 13.66 (1H, s), 9.17 (1H,
d, J=8.2 Hz), 7.38-7.35 (1H, m), 6.96-6.90 (2H, m), 5.81-5.78 (1H,
m), 5.29-5.26 (1H, m), 4.48 (2H, s), 3.74 (2H, s), 2.00 (3H, s),
1.54-1.41 (2H, m), 1.35-1.30 (1H, m), 0.95-0.90 (1H, m).
Step (5): Compound 18e.fwdarw.Compound 18f
[0622] Compound 18e (8.9 g, 21.1 mmol) and sodium hydrogen
carbonate (2.3 g, 27.4 mmol) were dissolved into boronic
acid-ammonia buffer (150 mL, pH=8), and thereto was then added CAH
immobilized enzyme (8.90 ml, 21.07 mmol) at rt (pH was adjusted ca.
8 with 7% NH3 aq.). The mixture was stirred at rt for 5 hours (pH
was adjusted ca. 8 with 7% NH3 aq.). The reaction mixture was
diluted with acetone (300 ml), then pH was adjusted ca. 3 with 2N
HCl at 0.degree. C. The reaction mixture was filtered and washed
with acetone. To the filtrate diphenyl diazomethane (9.00 g, 46.3
mmol) in Acetone (10 ml) was added at 0.degree. C. The resulting
mixture was stirred at 0.degree. C. for 2 hr. The reaction mixture
was concentrated under reduced pressure. The precipitated solid was
then collected by filtration, and washed with water and diisopropyl
ether to yield compound 18f (10.19 g, 89%).
[0623] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.42-7.28 (11H, m), 7.01
(1H, dd, J=5.1, 3.6 Hz), 6.96 (1H, d, J=3.3 Hz), 6.91 (1H, s), 6.22
(1H, d, J=8.9 Hz), 5.94 (1H, dd, J=9.0, 4.8 Hz), 5.12 (1H, d, J=4.8
Hz), 3.99 (1H, dd, J=12.8, 3.9 Hz), 3.84 (2H, s), 3.27-3.21 (1H,
m), 2.61 (1H, dd, J=11.2, 3.9 Hz), 1.77-1.71 (1H, m), 1.39-1.31
(2H, m), 1.05-1.01 (1H, m).
Step (6): Compound 18f.fwdarw.Compound 18g
[0624] Compound 18f (10.2 g, 18.6 mmol) was suspended into
dichloromethane (100 mL), and thereto were then added 2,6-lutidine
(8.7 ml, 74.6 mmol) and triphosgene (2.8 g, 9.3 mmol) in turn at
0.degree. C. The mixture was stirred at rt for 2 hours. The mixture
was diluted with an aqueous hydrochloric acid solution and ethyl
acetate, then separated and washed with a saturated sodium hydrogen
carbonate and a saturated salt solution, and dried over magnesium
sulfate. Magnesium sulfate was filtrated off, and then the liquid
was concentrated under reduced pressure. The compound-containing
liquid was subjected to silica gel column chromatography to elute
out the desired compound with chloroform/ethyl acetate. The
desired-compound-containing fraction was concentrated under reduced
pressure to yield compound 18g (5.63 g, 53%).
[0625] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.42-7.26 (11H, m),
7.02-6.95 (3H, m), 6.23 (1H, d, J=8.8 Hz), 5.90 (1H, dd, J=8.8, 4.9
Hz), 5.18 (1H, d, J 4.9 Hz), 4.15 (1H, d, J=11.8 Hz), 3.83 (2H, s),
3.77 (1H, d, J=11.8 Hz), 1.75-1.69 (1H, m), 1.45-1.38 (2H, m),
1.04-0.98 (1H, m).
Step (7): Compound 18g.fwdarw.Compound 18h
[0626] Phorphorus pentachloride (2.08 g, 10 mmol) was suspended
into dichloromethane (30 mL), and thereto were then added pyridine
(0.89 ml, 11 mmol) and compound 18g (2.83 g, 5.0 mmol) in turn at
0.degree. C. The mixture was stirred at 0.degree. C. for 1 hour.
Thereto was then added methanol (6.1 mL, 150 mmol) at -40.degree.
C. The mixture was stirred at rt for 30 minutes. The mixture was
diluted with water and dichloromethane, then separated and washed
with a saturated sodium hydrogen carbonate solution and a saturated
salt solution, and dried over magnesium sulfate. Magnesium sulfate
was filtrated off, and then the liquid was concentrated under
reduced pressure to yield compound 18h (2.98 g, 135%). Compound 18h
yielded was used as it was, without being purified, in the next
reaction.
[0627] MS (m+1)=633
Step (8): Compound X-1f+Compound 18h.fwdarw.Compound 18i
[0628] Compound 18h and compound X-1f were dissolved into
dichloromethane (25 mL), and thereto were then added phenyl
phosphorodichloridate (1.121 ml, 7.50 mmol) and NMM (1.924 ml,
17.50 mmol) in turn at -40.degree. C. The mixture was stirred at
-40.about.-20.degree. C. for 1 hour. The mixture was diluted with a
0.2 mol/L aqueous hydrochloric acid solution and ethyl acetate,
then separated and washed with a saturated sodium hydrogen
carbonate and a saturated salt solution, and dried over magnesium
sulfate. Magnesium sulfate was filtrated off, and then the liquid
was concentrated under reduced pressure. The compound-containing
liquid was subjected to silica gel column chromatography to elute
out the desired compound with hexane/ethyl acetate. The
desired-compound-containing fraction was concentrated under reduced
pressure to yield compound 18i (2.28 g, 54%).
[0629] .sup.1H-NMR (CDCl.sub.3) .delta.: 8.23 (1H, d, J=8.7 Hz),
7.45-7.30 (13H, m), 7.00 (1H, s), 6.08 (1H, dd, J=8.7, 5.0 Hz),
5.29 (1H, d, J=5.0 Hz), 4.14 (1H, d, J=11.8 Hz), 3.81 (1H, d,
J=11.8 Hz), 1.77-1.71 (1H, m), 1.53-1.37 (26H, m), 1.07-0.99 (1H,
m).
Step (9): Compound 18i+Compound 18j.fwdarw.Compound I-18
[0630] Compound 18i (852 mg, 1.00 mmol), compound 18j (551 mg, 1.05
mmol) and sodium iodide (300 mg, 2.00 mmol) were used to synthesize
the target compound in the same way as in step 6 of Example 1.
[0631] Yielded amount: 320.3 mg, (34%)
[0632] .sup.1H-NMR (D.sub.2O) .delta.: 6.93-6.91 (2H, m), 6.84 (1H,
d, J=8.3 Hz), 5.66-5.63 (2H, m), 4.30 (1H, br s), 3.90-3.63 (9H,
m), 2.28-2.16 (4H, m), 1.60-1.40 (9H, m), 1.22-1.17 (1H, m).
[0633] Elem. Anal.: C32H35ClN7O10S2Na (H2O) 5
[0634] Calcd.: C, 43.17; H, 5.09; Cl, 3.98; N, 11.01; S, 7.20; Na,
2.58(%).
[0635] Found: C, 43.12; H, 5.08; Cl, 4.24; N, 11.03; S, 7.08; Na,
2.47(%).
Example 19
Synthesis of Compound I-19
##STR00237##
[0636] Step (1): Compound 18i+Compound 19a.fwdarw.Compound I-19
[0637] Compound 18i (852 mg, 1.00 mmol), compound 19a (542 mg, 1.05
mmol) and sodium iodide (300 mg, 2.00 mmol) were used to synthesize
the target compound in the same way as step 6 of Example 1.
[0638] Yielded amount: 202.9 mg, (21%)
[0639] .sup.1H-NMR (D.sub.2O) .delta.: 7.12 (1H, d, J=7.5 Hz), 7.01
(1H, d, J=7.5 Hz), 6.94 (1H, s), 5.74-5.66 (2H, m), 4.36 (1H, br
s), 4.09 (2H, br s), 3.94-3.58 (7H, m), 2.25-2.17 (4H, m),
1.63-1.43 (9H, m), 1.31-1.14 (1H, m).
[0640] Elem. Anal.: C33H34N7O11S2Na (H2O) 5.6
[0641] Calcd.: C, 44.40; H, 5.10; N, 10.98; S, 7.18; Na,
2.58(%).
[0642] Found: C, 44.40; H, 5.01; N, 11.02; S, 7.08; Na,
2.55(%).
Example 20
Synthesis of Compound I-20
##STR00238##
[0643] Step (1): Compound 20a+Compound 20b.fwdarw.Compound 20c
[0644] A solution of Compound 20a (1.00 g, 2.19 mmol) in 1
dichloromethane (10 mL) was cooled with ice, and thereto was added
DIEA (573 .mu.L, 3.28 mmol), and Diphenyl chlorophosphate (681
.mu.L, 3.28 mmol). The liquid was stirred at 0.degree. C. for 30
minutes.
[0645] A solution of Compound 20b (513 g, 2.41 mmol) in 1
dichloromethane (10 mL) was cooled with ice, and thereto was added
triethylamine (698 .mu.L, 5.03 mmol), and phosphate solution. After
stirring at room temperature for 1 hour, aqueous sodium hydroxide
was added to the reaction mixture, followed by extraction with
ethyl acetate twice time. The combined organic layer was washed
with water, then saturated brine, and then dried with anhydrous
magnesium sulfate. The inorganic substance was removed by
filtration, and then concentrated and subsequently drying under
reduced pressure to yield Compound 20c as a yellow powder oil.
[0646] Yielded amount: 1.00 g (79%)
[0647] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.75 (3H, d, J=14.56 Hz),
1.86 (2H, dd, J=15.31, 6.65 Hz), 2.18-2.21 (2H, m), 2.28-2.30 (2H,
m), 2.33 (3H, s), 3.23 (2H, s), 3.80 (3H, s), 3.83 (3H, s), 4.96
(2H, s), 5.11 (2H, s), 6.83 (2H, d, J=8.53 Hz), 6.91-6.96 (3H, m),
7.33-7.36 (4H, m), 7.65 (1H, d, J=8.78 Hz).
Step (2): Compound X-1+Compound 20c.fwdarw.Compound
20d.fwdarw.Compound I-20
[0648] A solution of Compound 20c (579 mg, 1.0 mmol) in
dimethylformamide (2.0 mL) was cooled with ice. The reaction vessel
was then degassed under reduced pressure, and thereto was added
Compound X-1 (932 mg, 1.0 mmol). After stirring at 0.degree. C. for
7 hours, the reaction mixture was slowly added to 5% aqueous sodium
chloride and sodium hydrogen sulfite cooled with ice. The
precipitated solid was collected by filtration, washed with water,
and suspended into water. The suspension was freeze-dried to yield
Compound 20d as a brown solid. Compound 20d yielded was used as it
was, without being purified, in the next reaction.
[0649] The total amount of compound 20d yielded was dissolved in
dichloromethane (12 mL), and the solution was cooled to -40.degree.
C. Thereto were then added anisole (1.09 mL, 10 mmol) and a 2 mol/L
aluminum chloride solution (5.0 mL, 10 mmol) in nitromethane in
turn. The liquid was stirred at 0.degree. C. for 30 minutes. To the
reaction liquid were added diisopropyl ether and a small amount of
water, and the resultant was stirred to generate a precipitate. The
supernatant was removed by decantation. To the insoluble matter
adhering to the vessel were added a diluted aqueous hydrochloric
acid solution, and acetonitrile. The resultant was stirred to
dissolve the matter completely. Thereto was then added diisopropyl
ether, and the water phase was separated to be collected. The
organic phase was again subjected to extraction with water, and
then all of the resultant water phases were combined with each
other. Thereto was added HP20-SS resin. Acetonitrile was then
distilled off therefrom under reduced pressure. The resultant mixed
liquid was purified by ODS column chromatography. The
desired-compound-containing fraction was concentrated under reduced
pressure, and then freeze-dried to yield compound I-20 as a yellow
powder.
[0650] Yielded amount: 385 mg (43%)
[0651] .sup.1H-NMR (D.sub.2O) .delta.: 1.51 (3H, s), 1.53 (3H, s),
1.58 (3H, d, J=7.15 Hz), 2.17 (2H, d, J=16.81 Hz), 2.37-2.61 (5H,
m), 2.71-2.85 (2H, m), 3.10 (3H, s), 3.95 (1H, s), 4.04-4.11 (3H,
m), 4.24 (1H, t, J=7.53 Hz), 5.46 (1H, d, J=4.89 Hz), 5.83 (1H, d,
J=4.89 Hz), 6.90 (1H, d, J=8.66 Hz), 7.02 (1H, s), 7.37 (1H, d,
J=8.66 Hz).
[0652] MS (m+1)=820.28
Example 21
Synthesis of Compound I-21
##STR00239##
[0653] Step (1): Compound X-2+Compound 20c.fwdarw.Compound I-21
[0654] From Compound X-2 (1.082 g, 1.0 mmol) and Compound 20c (579
mg, 1.0 mmol), Compound I-21 was obtained as a yellow powder using
the same method as Example 20.
[0655] Yield: 385 mg, (43%)
[0656] .sup.1H-NMR (D.sub.2O) .delta.: 1.56 (3H, d, J=7.15 Hz),
2.18 (2H, d, J=16.81 Hz), 2.27-2.83 (9H, m), 3.11 (3H, s), 3.95
(1H, s), 3.99-4.09 (3H, m), 4.24 (1H, t, J=7.47 Hz), 4.97 (1H, dd,
J=9.22, 4.08 Hz), 5.44 (1H, d, J=4.77 Hz), 5.77 (1H, d, J=4.77 Hz),
6.87 (1H, d, J=8.66 Hz), 7.07 (1H, s), 7.37 (1H, d, J=8.66 Hz).
[0657] MS (m+1)=850.27
Example 22
Synthesis of Compound I-22
##STR00240##
[0658] Step (1): Compound X-2+Compound 22a.fwdarw.Compound I-22
[0659] From Compound X-2 (866 mg, 0.80 mmol) and Compound 22a (442
mg, 0.80 mmol), Compound I-22 was obtained as a yellow powder using
the same method as Example 20.
[0660] Yield: 85 mg, (12%)
[0661] .sup.1H-NMR (D.sub.2O) .delta.: 1.56 (3H, d, J=7.03 Hz),
2.24 (4H, s), 2.65-2.77 (2H, m), 3.53-4.04 (9H, m), 4.26 (1H, d,
J=14.18 Hz), 4.96 (1H, dd, J=9.60, 3.58 Hz), 5.07 (1H, d, J=14.18
Hz), 5.45 (1H, d, J=4.64 Hz), 5.74 (1H, d, J=4.64 Hz), 6.87 (1H, d,
J=8.66 Hz), 7.07 (1H, s), 7.34 (1H, d, J=8.66. Hz).
[0662] MS (m+1)=824.31
Example 23
Synthesis of Compound I-23
##STR00241##
[0663] Step (1): Compound X-2+Compound 23a.fwdarw.Compound I-23
[0664] From Compound X-2 (1.082 g, 1.0 mmol) and Compound 23a (565
mg, 1.0 mmol), Compound I-23 was obtained as a yellow powder using
the same method as Example 20.
[0665] Yield: 369 mg, (42%)
[0666] .sup.1H-NMR (D.sub.2O) .delta.: 1.57 (3H, dd, J=10.73, 7.09
Hz), 2.06-2.48 (4H, m), 2.70-2.74 (3H, m), 3.57-4.03 (8H, m),
4.29-4.35 (2H, m), 4.95-4.98 (1H, m), 5.12-5.21 (1H, m), 5.44 (1H,
d, J=4.64 Hz), 5.77 (1H, dd, J=4.64, 2.13 Hz), 6.83 (1H, d, J=8.78
Hz), 7.06 (1H, d, J=2.26 Hz), 7.48 (1H, d, J=8.78 Hz).
[0667] MS (m+1)=836.19
Example 24
Synthesis of Compound I-24
##STR00242##
[0668] Step (1): Compound X-2+Compound 24a.fwdarw.Compound I-24
[0669] From Compound X-2 (1.082 g, 1.0 mmol) and Compound 24a (579
mg, 1.0 mmol), Compound I-24 was obtained as a yellow powder using
the same method as Example 20.
[0670] Yield: 442 mg, (49%)
[0671] .sup.1H-NMR (D.sub.2O) .delta.: 1.55 (3H, d, J=7.15 Hz),
1.94 (6H, t, J=7.72 Hz), 2.72 (2H, t, J=5.77 Hz), 3.35 (2H, s),
3.50 (6H, dt, J=29.32, 7.75 Hz), 3.98-4.08 (2H, m), 4.68 (1H, d,
J=14.18 Hz), 4.96 (1H, dd, J=9.10, 4.33 Hz), 5.42 (1H, d, J=4.89
Hz), 5.80 (1H, d, J=4.89 Hz), 6.90 (1H, d, J=8.53 Hz), 7.05 (1H,
s), 7.31 (1H, d, J=8.53 Hz).
[0672] MS (m+1)=850.20
Example 25
Synthesis of Compound I-25
##STR00243##
[0673] Step (1): Compound X-4+Compound 25a.fwdarw.Compound I-25
[0674] From Compound X-4 (1.036 g, 1.0 mmol) and Compound 25a (565
mg, 1.0 mmol), Compound I-25 was obtained as a yellow powder using
the same method as Example 20.
[0675] Yield: 550 mg, (63%)
[0676] .sup.1H-NMR (D.sub.2O) .delta.: 1.58 (3H, dd, J=9.35, 7.22
Hz), 2.29-2.42 (4H, m), 2.70-2.74 (2H, m), 3.54-3.95 (7H, m),
4.02-4.10 (1H, m), 4.22-4.38 (2H, m), 4.87 (2H, d, J=13.93 Hz),
4.95-4.98 (1H, m), 5.43 (1H, d, J=4.77 Hz), 5.81 (1H, t, J=4.83
Hz), 6.83 (1H, dd, J=8.78, 6.84 Hz), 7.04 (1H, s), 7.48 (1H, d,
J=8.78 Hz).
[0677] MS (m+1)=836.19
Example 26
Synthesis of Compound I-26
##STR00244##
[0678] Step (1): Compound 26a.fwdarw.Compound 26b.fwdarw.Compound
26d
[0679] A solution of Compound 26a (1.29 g, 10 mmol) in ethanol (10
mL) was cooled with ice, and thereto was added Boc.sub.2O solution
(2.44 mL, 10.5 mmol) in ethanol (10 mL) dropwise. After stirring at
room temperature for over night, the reaction mixture was
concentrated and subsequently drying under reduced pressure to
yield Compound 26b as colorless oil. The obtained Compound 26b was
used in the next reaction without purification.
[0680] The total amount of Compound 26b yielded was dissolved in
toluene (40 mL), and the solution was cooled with ice. Thereto was
added Compound 26c (4.20 g, 10 mmol). After stirring at room
temperature for 1 hour, then stirring at reflux for 6 hours,
aqueous sodium hydroxide was added to the reaction mixture,
followed by extraction with ethyl acetate. The inorganic substance
was removed by filtration, and then concentrated under reduced
pressure. The resulting crude product was purified by silica gel
column chromatography (3% triethylamine in ethyl acetate/hexane) to
yield Compound 26d as a white solid.
[0681] Yielded amount: 3.60 g (57%)
[0682] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.51 (4H, s), 1.56 (9H,
s), 2.42-2.46 (4H, m), 2.71 (2H, q, J=7.24 Hz), 3.71-3.79 (2H, m),
3.82 (6H, s), 5.18 (4H, s), 6.89-6.92 (4H, m), 7.33-7.37 (6H,
m).
Step (2): Compound X-1+Compound 26d.fwdarw.Compound I-26
[0683] From Compound X-1 (932 mg, 1.0 mmol) and Compound 26d (632
mg, 1.0 mmol), Compound I-26 was obtained as a white powder using
the same method as Example 20.
[0684] Yield: 449 mg, (57%)
[0685] .sup.1H-NMR (D.sub.2O) .delta.: 1.50 (3H, s), 1.51 (3H, s),
1.53 (3H, d, J=7.07 Hz), 2.22 (4H, s), 3.45-3.53 (6H, m), 3.64-3.77
(2H, m), 3.97 (1H, q, J=7.07 Hz), 4.26 (1H, d, J=14.31 Hz), 4.92
(1H, d, J=14.31 Hz), 5.39 (1H, d, J=4.77 Hz), 5.77 (1H, d, J=4.77
Hz), 6.98 (1H, s), 7.20 (2H, s).
[0686] MS (m+1)=773.33
Example 27
Synthesis of Compound I-27
##STR00245##
[0687] Step (1): Compound 27a.fwdarw.Compound 27b
[0688] A solution of Compound 27a (911 mg, 7.0 mmol) in toluene (30
mL) was cooled with ice, and thereto was added Compound 26c (2.94
g, 7.0 mmol). After stirring at room temperature for 30 minutes,
thereto was added acetic acid (440 .mu.L, 7.7 mmol). After stirring
at reflux for 1 hour, aqueous sodium hydroxide was added to the
reaction mixture, followed by extraction with ethyl acetate. The
inorganic substance was removed by filtration, and then
concentrated under reduced pressure. Thereto was added diisopropyl
ether to precipitate a solid. The solid was collected by
filtration, so as to yield compound 27b as a white solid.
[0689] Yielded amount: 2.60 g (70%)
[0690] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.71-1.74 (4H, m), 2.58
(4H, s), 2.89 (2H, t, J=5.71 Hz), 3.81 (6H, s), 4.29 (2H, t, J=5.71
Hz), 5.17 (4H, s), 6.90 (4H, d, J=8.66 Hz), 7.32 (2H, s), 7.34 (4H,
d, J=8.66 Hz).
Step (2): Compound 1a+Compound 9a.fwdarw.Compound (I-9)
[0691] From Compound 1a (932 mg, 1.0 mmol) and Compound 9a (632 mg,
1.0 mmol), Compound I-9 was obtained as a white powder using the
same method as Example 1.
[0692] Yield: 453 mg, (57%)
[0693] .sup.1H-NMR (D.sub.2O) .delta.: 1.51 (3H, s), 1.53 (3H, s),
1.61 (3H, d, J=7.03 Hz), 2.27 (4H, s), 3.52-3.62 (2H, m), 3.71-3.78
(2H, m), 3.84-3.95 (2H, m), 4.10 (1H, q, J=7.03 Hz), 4.38 (1H, d,
J=14.43 Hz), 4.56-4.69 (2H, m), 5.00 (1H, d, J=14.43 Hz), 5.47 (1H,
d, J=4.77 Hz), 5.82 (1H, d, J=4.77 Hz), 7.01 (1H, s), 7.12 (2H,
s).
[0694] MS (m+1)=774.34
Example 28
Synthesis of Compound I-28
##STR00246## ##STR00247##
[0695] Step (1): Compound 28a.fwdarw.Compound 28b.fwdarw.Compound
28c
[0696] A solution of Compound 28a (24.4 g, 93 mmol) in
dichloromethane (120 mL) was cooled with ice, and thereto was added
N,O-dimethylhydroxylamine hydrochloride (16.4 g, 168 mmol) and
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (32.2
g, 168 mmol). After stirring at room temperature for 4.5 hours,
water was added to the reaction mixture, followed by extraction
with dichloromethane. The organic layer was washed with saturated
brine, and then dried with anhydrous magnesium sulfate. The
inorganic substance was removed by filtration, and then
concentrated and subsequently drying under reduced pressure to
yield Compound 28b as an orange oil. The obtained Compound 28b was
used in the next reaction without purification.
[0697] The total amount of Compound 28b yielded was dissolved in
tetrahydrofuran (500 mL), and the solution was cooled to 0.degree.
C. Thereto was added a 1 mol/L methylmagnesium bromide solution
(186 mL, 186 mmol) in tetrahydrofuran. After stirring at room
temperature for 5 hours, aqueous ammonium chloride was added to the
reaction mixture, followed by extraction with ethyl acetate.
[0698] The organic layer was washed with water, then saturated
brine, and then dried with anhydrous magnesium sulfate. The
inorganic substance was removed by filtration, and then
concentrated under reduced pressure. Thereto was added diisopropyl
ether to precipitate a solid. The solid was collected by
filtration, so as to yield compound 28c.
[0699] Yielded amount: 23.5 g (97%)
[0700] .sup.1H-NMR (CDCl.sub.3) .delta.: 2.68 (3H, s), 3.90 (3H,
s), 3.92 (3H, s), 7.05 (1H, s), 7.15 (1H, s).
Step (2): Compound 28c.fwdarw.Compound 28d
[0701] A solution of Copper bromide (7.97 g, 35.7 mmol) in ethyl
acetate (20 mL) was heated to reflux, and thereto was added a
solution of Compound 28c (5.0 g, 19.3 mmol) in chloroform (20 mL).
After stirring at reflux for 2.5 hours, the insoluble matter was
removed by filtration, and then concentrated under reduced
pressure. The resulting crude product was purified by silica gel
column chromatography (ethyl acetate/hexane) to yield Compound 28d
as a yellow oil.
[0702] Yielded amount: 4.61 g (71%)
[0703] .sup.1H-NMR (CDCl.sub.3) .delta.: 3.90 (3H, s), 3.93 (3H,
s), 4.59 (2H, s), 7.06 (1H, s), 7.13 (1H, s).
Step (3): Compound 28d.fwdarw.Compound 28e.fwdarw.Compound 28f
[0704] A solution of Compound 28d (4.61 g, 13.6 mmol) in methanol
(180 mL) and water (30 mL) was added hydroxylamine hydrochloride
(7.58 g, 109 mmol). After stirring at room temperature for over
night, aqueous hydrochloric acid was added to the reaction mixture,
followed by extraction with ethyl acetate. The organic layer was
washed with water, then saturated brine, and then dried with
anhydrous magnesium sulfate. The inorganic substance was removed by
filtration, and then concentrated and subsequently drying under
reduced pressure to yield Compound 28e as a yellow oil. The
obtained Compound 28e was used in the next reaction without
purification.
[0705] The total amount of Compound 28e yielded was dissolved in
tetrahydrofuran (50 mL), and thereto was added pyrrolidine (3.38
mL, 40.9 mmol). After stirring at room temperature for 1 hour,
water was added to the reaction mixture, followed by extraction
with ethyl acetate. The organic layer was washed with water, then
saturated brine, and then dried with anhydrous magnesium
sulfate.
[0706] The inorganic substance was removed by filtration, and then
concentrated and subsequently drying under reduced pressure to
yield Compound 28f as a yellow powder.
[0707] Yielded amount: 4.63 g (99%)
[0708] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.77-1.80 (4H, m), 2.64
(4H, br s), 3.49 (2H, s), 3.86 (3H, s), 3.88 (3H, s), 6.68 (1H, s),
7.06 (1H, s).
Step (4): Compound 28f.fwdarw.Compound 28g
[0709] A solution of Compound 28f (4.29 g, 12.5 mmol) in
1,4-dioxane (300 mL) was added sodium tert-butoxide (1.80 g, 18.8
mmol). The reaction vessel was then degassed under reduced
pressure, and thereto was added palladium acetate (421 mg, 1.88
mmol) and 1,3-bis(diphenylphosphino) propane (1.19 mg, 2.88 mmol).
After stirring at 80.degree. C. for 4.5 hours, water was added to
the reaction mixture, followed by extraction with ethyl acetate
twice time. The combined organic layer was washed saturated brine,
and then dried with anhydrous sodium sulfate. The inorganic
substance was removed by filtration, and then concentrated under
reduced pressure. The resulting crude product was purified by
silica gel column chromatography (ethyl acetate/hexane) to yield
Compound 28g as a yellow oil.
[0710] Yielded amount: 1.82 g (56%)
[0711] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.79-1.83 (4H, m),
2.60-2.63 (4H, m), 3.94 (3H, s), 3.97 (3H, s), 3.98 (2H, s), 7.02
(1H, s), 7.18 (1H, s).
Step (5): Compound 28g.fwdarw.Compound 28h.fwdarw.Compound 28i
[0712] A solution of Compound 28g (1.82 g, 6.94 mmol) in
dichloromethane (20 mL) was cooled with ice, and thereto was added
boron tribromide (1.97 mL, 20.8 mmol) dropwise. After stirring at
room temperature for 1.5 hour, methanol was added to the reaction
mixture at 0.degree. C., and thereto was concentrated and
subsequently drying under reduced pressure to yield Compound 28h as
a brown solid. The obtained Compound 28h was used in the next
reaction without purification.
[0713] The total amount of Compound 28h yielded was suspended in
dichloromethane (20 mL), and the suspension was cooled with ice,
and thereto was added triethylamine (1.44 mL, 10.4 mmol), DMAP (42
mg, 0.35 mmol), and Boc.sub.2O (4.83 mL, 20.8 mmol). After stirring
at room temperature for over night, water was added to the reaction
mixture, followed by extraction with ethyl acetate. The organic
layer was washed with water, then saturated brine, and then dried
with anhydrous sodium sulfate. The inorganic substance was removed
by filtration, and then concentrated under reduced pressure. The
resulting crude product was purified by silica gel column
chromatography (3% triethylamine in ethyl acetate/hexane) to yield
Compound 28i as a yellow solid.
[0714] Yielded amount: 602 mg (20%)
[0715] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.57 (18H, s), 1.78-1.81
(4H, m), 2.58-2.61 (4H, m), 4.00 (2H, s), 7.51 (1H, s), 7.78 (1H,
s).
Step (6): Compound X-1+Compound 28i.fwdarw.Compound I-28
[0716] From Compound X-1 (932 mg, 1.0 mmol) and Compound 28i (434
mg, 1.0 mmol), Compound I-18 was obtained as a white powder using
the same method as Example 20.
[0717] Yield: 344 mg, (47%)
[0718] .sup.1H-NMR (D.sub.2O) .delta.: 1.42 (3H, d, J=7.03 Hz),
1.48 (3H, s), 1.50 (3H, s), 2.28 (4H, s), 3.52-3.65 (3H, m),
3.81-3.84 (1H, m), 4.01 (1H, q, J=7.15 Hz), 4.40 (1H, d, J=14.05
Hz), 4.90 (2H, dd, J=32.12, 14.68 Hz), 5.07 (1H, d, J=14.05 Hz),
5.40 (1H, d, J=4.77 Hz), 5.79 (1H, d, J=4.77 Hz), 6.97 (1H, s),
7.18 (1H, s), 7.22 (1H, s).
[0719] MS (m+1)=716.06
Example 29
Synthesis of Compound I-29
##STR00248##
[0720] Step (1): Compound 29a.fwdarw.Compound 29b
[0721] To a solution of Compound 29a (12.6 g, 76 mmol) in DMF (120
mL) was added potassium carbonate (23.0 g, 166 mmol),
4-methoxybenzylchloride (22.7 mL, 166 mmol) and sodium iodide (5.67
g, 38 mmol), and the mixture was stirred at 70 degree for 1.5 hr.
The solvent was removed by evaporation and the residue was diluted
with water and ethyl acetate. The organic layer was washed with
water and brine, dried over magnesium sulfate, filtered, and
concentrated. The precipitated material was collected by filtration
with diisopropyl ether and dried under high vacuum to afford
Compound 29b (22.7 g, 74%) as a yellowish solid.
[0722] .sup.1H-NMR (CDCl.sub.3) .delta.: 3.79 (3H, s), 3.82 (3H,
s), 5.05 (2H, s), 5.17 (2H, s), 5.26 (2H, s), 6.82 (2H, d, J=8.5
Hz), 6.89 (2H, d, J=8.5 Hz), 7.00 (1H, d, J=8.2 Hz), 7.22 (1H, d,
J=8.2 Hz), 7.30 (2H, d, J=8.2 Hz), 7.42 (2H, d, J=8.4 Hz).
Step (2): Compound 29b.fwdarw.Compound 29c
[0723] To a solution of Compound 29b (22.4 g, 55 mmol) in methanol
(55 mL) and tetrahydrofuran (55 mL) was added 2 mol/L sodium
hydroxide (83 mL, 166 mmol), and the mixture was stirred at 70
degree for 1.5 hr. The resulting mixture was cooled to room
temperature and then diluted with diethyl ether. The aqueous layer
was separated and adjusted pH at 3.0 by adding 2 mol/L hydrochloric
acid. The mixture was extracted with dichloromethane. The organic
layer was washed with water and brine, dried over magnesium
sulfate, evaporated and dried under high vacuum to afford Compound
29c (20.5 g, 88%) as a pale pink solid.
[0724] .sup.1H-NMR (CDCl.sub.3) .delta.: 3.80 (3H, s), 3.84 (3H,
s), 4.67 (2H, s), 5.11 (2H, s), 5.12 (2H, s), 6.82 (2H, d, J=8.7
Hz), 6.95 (2H, d, J=8.7 Hz), 7.19-7.24 (4H, m), 7.39 (2H, d, J=8.7
Hz).
Step (3): Compound 29c.fwdarw.Compound 29d.fwdarw.Compound 29e
[0725] To a solution of Compound 29c (45.7 g, 108 mmol) in
tetrahydrofuran (350 mL) was added a solution of
diphenyldiazomethane (23.0 g, 118 mmol) in tetrahydrofuran (100 mL)
over 20 min at room temperature. The mixture was stirred at room
temperature over night and then the solvent was removed by
evaporation. The residue was dried under high vacuum to give a
crude material containing 13e as a major product which was used for
the next step without further purification.
[0726] To a solution of Compound 29d prepared above in
dichloromethane (640 mL) with stirring at 0 degree was added
Dess-Martin periodinane (50.4 g, 119 mmol) and then the mixture was
stirred at 0 degree for 2 hr. The mixture was diluted with water
and the organic solvent was removed by evaporation. The resulting
aqueous mixture was extracted with ethyl acetate. The organic layer
was washed with water and brine, dried over magnesium sulfate,
filtered and concentrated. The residue was triturated with
diisopropyl ether and the solid was collected by filtration and
dried under high vacuum to afford Compound 29e (51.1 g, 80%) was a
colorless solid.
[0727] .sup.1H-NMR (CDCl.sub.3) .delta.: 3.79 (3H, s), 3.84 (3H,
s), 4.86 (2H, s), 5.14 (2H, s), 6.68 (2H, d, J=8.66 Hz), 6.93 (2H,
d, J=8.78 Hz), 6.97 (2H, d, J=8.66 Hz), 7.14 (1H, d, J=8.41 Hz),
7.19 (1H, s), 7.25-7.27 (5H, m), 7.36-7.38 (7H, m), 7.61 (1H, d,
J=8.41 Hz), 9.74 (1H, s).
Step (4): Compound 29e.fwdarw.Compound 29f
[0728] To a solution of Compound 29e (51.1 g, 87 mmol) in
1,4-dioxane (600 mL) and water (200 mL) was added amidosulfuric
acid (16.9 g, 174 mmol) and sodium chlorite (19.6 g, 174 mmol). The
mixture was stirred at 0 degree for 30 min before an aqueous
solution of sodium bisulfite (36.2 g, 348 mmol) was added. The
mixture was extracted with ethyl acetate. The organic layer was
washed with water and brine, dried over magnesium sulfate, filtered
and concentrated. The solid precipitated by adding diisopropyl
ether was collected by filtration and dried under high vacuum to
afford Compound 29f (51.4 g, 98%) as a colorless solid.
[0729] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 3.73 (3H, s), 3.77 (3H,
s), 4.71 (2H, s), 5.20 (2H, s), 6.69 (2H, d, J=8.59 Hz), 6.85 (2H,
d, J=8.59 Hz), 6.97-6.99 (3H, m), 7.26-7.28 (6H, m), 7.36-7.38 (5H,
m), 7.45 (2H, d, J=8.59 Hz), 7.75 (1H, d, J=8.84 Hz).
Step (5): Compound 29f.fwdarw.Compound 29g
[0730] To a solution of Compound 29f (9.07 g, 15 mmol) in DMF (90
mL) with stirring at 0 degree was added 1-hydroxybenzotriazole
(2.23 g, 16.5 mmol), 1-(2-aminoethyl)pyrrolidine (2.26 mL, 18 mmol)
and EDC hydrochloride (3.74 g, 19.5 mmol) and then the mixture was
stirred at room temperature for 3.5 hr. The organic solvent was
removed by evaporation, and the residue was diluted with water. The
mixture was extracted with ethyl acetate. The organic layer was
washed with 1 mol/L sodium hydroxide, water and brien, and then
dried over magnesium sulfate, filtered and concentrated. The
precipitated material was collected by filtration and dried under
high vacuum to afford Compound 29g (6.73 g, 87%) as a colorless
solid.
[0731] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.74-1.77 (4H, m),
2.57-2.60 (4H, m), 2.73 (2H, t, J=6.96 Hz), 3.78-3.81 (5H, m), 3.83
(3H, s), 5.09 (2H, s), 5.28 (2H, s), 6.82 (2H, d, J=8.66 Hz), 6.92
(2H, d, J=8.66 Hz), 7.12 (1H, d, J=8.03 Hz), 7.31 (2H, d, J=8.66
Hz), 7.38 (2H, d, J=8.66 Hz), 7.47 (1H, d, J=8.03 Hz).
Step (6): Compound 29g.fwdarw.Compound 29h
[0732] A solution of Compound 29g (1.55 g, 3.0 mmol) in acetic acid
(60 mL) was added zinc powder (3.92 g, 60 mmol). After stirring at
80.degree. C. for 3 hours, the insoluble matter was removed by
filtration, and then water was added to the filtrate, followed by
extraction with ethyl acetate. The organic layer was washed with
aqueous sodium hydroxide, then saturated brine, and then dried with
anhydrous magnesium sulfate. The inorganic substance was removed by
filtration, and then concentrated under reduced pressure. The
resulting crude product was purified by silica gel column
chromatography (3% triethylamine in ethyl acetate/hexane) to yield
Compound 29h as a colorless oil.
[0733] Yield: 870 mg, (58%)
[0734] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.74-1.78 (4H, m),
2.52-2.55 (4H, m), 2.64 (2H, t, J=6.90 Hz), 3.64 (2H, t, J=6.90
Hz), 3.79 (3H, s), 3.83 (3H, s), 4.09 (2H, s), 5.04 (2H, s), 5.14
(2H, s), 6.81 (2H, d, J=6.65 Hz), 6.93 (2H, d, J=8.66 Hz), 7.09
(1H, d, J=8.28 Hz), 7.20 (2H, d, J=8.66 Hz), 7.40 (2H, d, J=8.53
Hz), 7.50 (1H, d, J=8.28 Hz).
Step (7): Compound X-1+Compound 29h.fwdarw.Compound I-29
[0735] From Compound X-1 (745 mg, 0.80 mmol) and Compound 29h (402
mg, 0.80 mmol), Compound I-29 was obtained as a white powder using
the same method as Example 20.
[0736] Yield: 244 mg, (40%)
[0737] .sup.1H-NMR (D.sub.2O) .delta.: 1.50 (3H, s), 1.52 (3H, s),
1.57 (3H, d, J=6.06 Hz), 2.22 (4H, s), 3.51-3.73 (6H, m), 4.05-4.10
(3H, m), 4.29 (1H, d, J=14.15 Hz), 4.49 (2H, s), 5.04 (1H, d,
J=14.15 Hz), 5.47 (1H, d, J=2.53 Hz), 5.80 (1H, d, J=2.53 Hz),
7.00-7.04 (2H, m), 7.22 (1H, d, J=8.08 Hz).
[0738] MS (m+1)=744.21
Example 30
Synthesis of Compound I-30
##STR00249##
[0739] Step (1): Compound 30a.fwdarw.Compound 30b
[0740] From Compound 30a (1.03 g, 2.0 mmol), Compound 30b was
obtained as a white solid using the same method as Example 29.
[0741] Yield: 585 mg, (58%)
[0742] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.76 (4H, s), 2.56 (4H,
s), 2.72 (2H, t, J=6.32 Hz), 3.70 (2H, t, J=6.32 Hz), 3.81 (6H, s),
4.34 (2H, s), 5.12 (4H, s), 6.89 (4H, d, J=8.59 Hz), 6.93 (1H, s),
7.33-7.38 (5H, m).
Step (2): Compound X-1+Compound 30b.fwdarw.Compound I-30
[0743] From Compound X-1 (745 mg, 0.80 mmol) and Compound 30b (402
mg, 0.80 mmol), Compound I-30 was obtained as a white powder using
the same method as Example 20.
[0744] Yield: 236 mg, (39%)
[0745] .sup.1H-NMR (D.sub.2O) .delta.: 1.50 (3H, s), 1.52 (3H, s),
1.56 (3H, d, J=6.57 Hz), 2.23 (4H, s), 3.49-3.73 (6H, m), 4.02-4.10
(3H, m), 4.28 (1H, d, J=14.15 Hz), 4.42 (2H, s), 5.02 (1H, d,
J=14.15 Hz), 5.46 (1H, d, J=3.28 Hz), 5.80 (1H, d, J=3.28 Hz), 7.01
(1H, s), 7.03 (1H, s), 7.17 (1H, s).
[0746] MS (m+1)=744.21
Example 31
Synthesis of Compound I-31
##STR00250##
[0747] Step (1): Compound 31a.fwdarw.Compound 31b
[0748] A solution of Compound 31a (6.31 g, 32.5 mmol) in
acetonitrile (60 mL) was added NCS (4.77 g, 35.7 mmol). After
stirring at 60.degree. C. for 1 hour, the insoluble matter was
collected by filtration, so as to yield compound 31b.
[0749] Yield: 6.15 g, (83%)
[0750] .sup.1H-NMR (CDCl.sub.3) .delta.: 3.91 (3H, s), 4.09 (3H,
s), 5.15 (2H, s), 7.16 (1H, s).
Step (2): Compound 31b.fwdarw.Compound 31c
[0751] A solution of Compound 31b (6.83 g, 30 mmol) in
dichloromethane (60 mL) was cooled with ice, and thereto was added
boron tribromide (9.43 mL, 100 mmol) dropwise. After stirring at
room temperature for 2 hours, the reaction mixture was poured to
ice, and thereto was concentrated dichloromethane. Then the solid
was collected by filtration, so as to yield compound 31c.
[0752] Yield: 5.57 g, (93%)
[0753] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 5.15 (2H, s), 7.10 (1H,
s).
Step (3): Compound 31c.fwdarw.Compound 31d
[0754] From Compound 31c (5.57 g, 27.8 mmol), Compound 31d was
obtained as a white solid using the same method as Example 29.
[0755] Yield: 8.45 g, (69%)
[0756] .sup.1H-NMR (CDCl.sub.3) .delta.: 3.79 (3H, s), 3.83 (3H,
s), 5.03 (2H, s), 5.12 (2H, s), 5.24 (2H, s), 6.81 (2H, d, J=8.54
Hz), 6.91 (2H, d, J=8.54 Hz), 7.17 (1H, s), 7.30 (2H, d, J=8.39
Hz), 7.37 (2H, d, J=8.54 Hz).
Step (4): Compound 31d.fwdarw.Compound 31e
[0757] From Compound 31d (8.45 g, 19.2 mmol), Compound 31e was
obtained as a white solid using the same method as Example 29.
[0758] Yield: 8.08 g, (92%)
[0759] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 3.74 (3H, s), 3.77 (3H,
s), 4.49 (2H, s), 4.85 (2H, s), 5.15 (2H, s), 6.85 (2H, d, J=8.54
Hz), 6.97 (2H, d, J=8.54 Hz), 7.23 (2H, d, J=8.54 Hz), 7.30 (1H,
s), 7.42 (2H, d, J=8.54 Hz).
Step (5): Compound 31e.fwdarw.Compound 31f
[0760] A solution of Compound 31e (8.23 g, 17.9 mmol) in
dichloromethane (80 mL) was cooled with ice, and thereto was added
Dess-Martin Periodinane (8.37 g, 19.7 mmol). After stirring at room
temperature for 30 minutes, water was added to the reaction
mixture, followed by extraction with ethyl acetate. The organic
layer was washed with water, then saturated brine, and then dried
with anhydrous sodium sulfate. The inorganic substance was removed
by filtration, and then concentrated under reduced pressure.
Thereto was added diisopropyl ether to precipitate a solid. The
solid was collected by filtration, so as to yield compound 31f.
[0761] Yield: 6.38 g, (78%)
[0762] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 3.73 (3H, s), 3.77 (3H,
s), 5.06 (2H, s), 5.15 (2H, s), 6.85 (2H, d, J=8.54 Hz), 6.97 (2H,
d, J=8.54 Hz), 7.30 (2H, d, J=8.54 Hz), 7.38 (2H, d, J=8.39 Hz),
7.58 (1H, s).
Step (6): Compound 31f.fwdarw.Compound 31g.fwdarw.Compound 31h
[0763] A solution of Compound 31f (6.38 g, 14.0 mmol) in
tetrahydrofuran (30 mL) was added drop-wise diphenyldiazomethane
solution (2.98 g, 15.4 mmol) in tetrahydrofuran (30 mL). After
stirring at room temperature for over night, the reaction mixture
was concentrated under reduced pressure. Thereto was added
diisopropyl ether to precipitate a solid. The solid was collected
by filtration, so as to yield compound 31g.
[0764] From Compound 31g, Compound 31h was obtained as a white
solid using the same method as Example 29.
[0765] Yield: 8.72 g, (98%)
[0766] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 3.71 (3H, s), 3.77 (3H,
s), 4.72 (2H, s), 5.19 (2H, s), 6.67 (2H, d, J=8.73 Hz), 6.79 (2H,
d, J=8.73 Hz), 6.91 (1H, s), 6.98 (2H, d, J=8.73 Hz), 7.26-7.47
(13H, m).
Step (7): Compound 31h.fwdarw.Compound 31i
[0767] From Compound 31h (4.16 g, 6.51 mmol), Compound 31i was
obtained as a white solid using the same method as Example 29.
[0768] Yield: 2.36 g, (66%)
[0769] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.76 (4H, s), 2.58 (4H,
s), 2.73 (2H, t, J=6.82 Hz), 3.78-3.81 (5H, m), 3.84 (3H, s), 5.06
(2H, s), 5.22 (2H, s), 6.81 (2H, d, J=8.59 Hz), 6.93 (2H, d, J=8.59
Hz), 7.03 (1H, s), 7.30-7.35 (4H, m).
Step (8): Compound 31i.fwdarw.Compound 31j
[0770] From Compound 31i (1.10 g, 2.0 mmol), Compound 31j was
obtained as a colorless oil using the same method as Example
29.
[0771] Yield: 381 mg, (36%)
[0772] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.76 (4H, s), 2.53 (4H,
s), 2.63 (2H, t, J=6.19 Hz), 3.60 (2H, t, J=6.69 Hz), 3.79 (3H, s),
3.84 (3H, s), 4.00 (2H, s), 5.01 (2H, s), 5.11 (2H, s), 6.81 (2H,
d, J=8.34 Hz), 6.94 (2H, d, J=8.08 Hz), 7.02 (1H, s), 7.17 (2H, d,
J=7.33 Hz), 7.39 (2H, d, J=7.83 Hz).
Step (9): Compound X-1+Compound 31j.fwdarw.Compound I-31
[0773] From Compound X-1(745 mg, 0.80 mmol) and Compound 31j (430
mg, 0.80 mmol), Compound I-31 was obtained as a white powder using
the same method as Example 20.
[0774] Yield: 155 mg, (24%)
[0775] .sup.1H-NMR (D.sub.2O) .delta.: 1.50 (3H, s), 1.52 (3H, s),
1.58 (3H, d, J=7.03 Hz), 2.23 (4H, s), 3.49-3.64 (5H, m), 3.74-3.78
(1H, m), 4.00-4.11 (3H, m), 4.27 (1H, d, J=14.18 Hz), 4.39 (2H, s),
5.05 (1H, d, J=14.18 Hz), 5.48 (1H, d, J=4.77 Hz), 5.80 (1H, d,
J=4.77 Hz), 6.87 (1H, s), 7.01 (1H, s).
[0776] MS (m+1)=778.23
Example 32
Synthesis of Compound I-32
##STR00251##
[0777] Step (1): Compound 29f.fwdarw.Compound 32a
[0778] From Compound 29f (3.02 g, 5.0 mmol) and
1-(2-aminoethyl)piperidine (775 .mu.L, 5.5 mmol), Compound 32a was
obtained as a white solid using the same method as Example 29.
[0779] Yield: 2.51 g, (95%)
[0780] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.38-1.43 (2H, m),
1.51-1.56 (4H, m), 2.46 (4H, s), 2.57 (2H, t, J=6.96 Hz), 3.76-3.79
(5H, m), 3.83 (3H, s), 5.09 (2H, s), 5.28 (2H, s), 6.82 (2H, d,
J=8.53 Hz), 6.92 (2H, d, J=8.53 Hz), 7.11 (1H, d, J=8.16 Hz),
7.30-7.39 (4H, m), 7.47 (1H, d, J=8.16 Hz).
Step (2): Compound X-2+Compound 32a.fwdarw.Compound I-32
[0781] From Compound X-2 (1.082 g, 1.0 mmol) and Compound 32a (624
mg, 1.0 mmol), Compound I-32 was obtained as a yellow powder using
the same method as Example 20.
[0782] Yield: 176 mg, (21%)
[0783] .sup.1H-NMR (D.sub.2O) .delta.: 1.59 (3H, d, J=7.03 Hz),
1.80-1.99 (6H, m), 2.69-2.73 (2H, m), 3.29-3.39 (3H, m), 3.60-3.81
(3H, m), 4.05-4.09 (3H, m), 4.29 (1H, d, J=13.93 Hz), 4.96 (1H, dd,
J=9.66, 3.76 Hz), 5.11 (1H, d, J=13.93 Hz), 5.49 (1H, d, J=4.64
Hz), 5.78 (1H, d, J=4.64 Hz), 7.02 (1H, d, J=7.78 Hz), 7.09 (1H,
s), 7.19 (1H, d, J=7.78 Hz).
[0784] MS (m+1)=801.88
Example 33
Synthesis of Compound I-33
##STR00252##
[0785] Step (1): Compound X-2+Compound 33a.fwdarw.Compound I-33
[0786] From Compound X-2 (1.082 g, 1.0 mmol) and Compound 33a (539
mg, 1.0 mmol), Compound I-33 was obtained as a white powder using
the same method as Example 20.
[0787] Yield: 181 mg, (21%)
[0788] .sup.1H-NMR (D.sub.2O) .delta.: 1.57 (3H, d, J=7.03 Hz),
1.82-2.01 (5H, m), 2.68-2.72 (2H, m), 3.29-3.35 (3H, m), 3.61-3.96
(5H, m), 4.03 (1H, q, J=7.03 Hz), 4.23 (1H, d, J=13.93 Hz), 4.96
(1H, dd, J=9.47, 3.83 Hz), 5.05 (1H, d, J=13.93 Hz), 5.46 (1H, d,
J=4.64 Hz), 5.77 (1H, d, J=4.64 Hz), 6.91 (1H, d, J=8.41 Hz), 7.00
(1H, d, J=8.41 Hz), 7.06 (1H, s).
[0789] MS (m+1)=809.98
Example 34
Synthesis of Compound I-34
##STR00253##
[0790] Step (1): Compound X-2+Compound 29g.fwdarw.Compound I-34
[0791] From Compound X-2 (1.082 g, 1.0 mmol) and Compound 29g (517
mg, 1.0 mmol), Compound I-34 was obtained as a yellow powder using
the same method as Example 20.
[0792] Yield: 414 mg, (50%)
[0793] .sup.1H-NMR (D.sub.2O) .delta.: 1.59 (3H, d, J=7.03 Hz),
2.23 (4H, s), 2.70-2.74 (2H, m), 3.53-3.71 (6H, m), 4.04-4.09 (3H,
m), 4.32 (1H, d, J=14.18 Hz), 4.96 (1H, dd, J=9.79, 3.64 Hz), 5.12
(1H, d, J=14.18 Hz), 5.47 (1H, d, J=4.64 Hz), 5.76 (1H, d, J=4.64
Hz), 7.02 (1H, d, J=7.78 Hz), 7.08 (1H, s), 7.17 (1H, d, J=7.78
Hz).
[0794] MS (m+1)=788.02
Example 35
Synthesis of Compound I-35
##STR00254##
[0795] Step (1): Compound X-2+Compound 35a.fwdarw.Compound I-35
[0796] From Compound X-2 (1.082 g, 1.0 mmol) and Compound 35a (525
mg, 1.0 mmol), Compound I-35 was obtained as a white powder using
the same method as Example 20.
[0797] Yield: 441 mg, (53%)
[0798] .sup.1H-NMR (D.sub.2O) .delta.: 1.56 (3H, d, J=7.15 Hz),
2.24 (4H, s), 2.69-2.72 (2H, m), 3.47-3.96 (9H, m), 4.01 (1H, q,
J=7.07 Hz), 4.27 (1H, d, J=14.18 Hz), 4.96 (1H, dd, J=9.66, 3.76
Hz), 5.07 (1H, d, J=14.18 Hz), 5.44 (1H, d, J=4.64 Hz), 5.75 (1H,
d, J=4.64 Hz), 6.90 (1H, d, J=8.41 Hz), 6.99 (1H, d, J=8.41 Hz),
7.06 (1H, s).
[0799] MS (m+1)=795.97
Example 36
Synthesis of Compound I-36
##STR00255##
[0800] Step (1): Compound 29f.fwdarw.Compound 36a
[0801] From Compound 29f (3.63 g, 6.0 mmol) and
N,N-diethylethylenediamine (1.01 mL, 7.2 mmol), Compound 36a was
obtained as a white solid using the same method as Example 29.
[0802] Yield: 1.98 g, (64%)
[0803] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.47 (1H, d, J=8.03 Hz),
7.38 (2H, d, J=8.53 Hz), 7.31 (2H, d, J=8.53 Hz), 7.11 (1H, d,
J=8.03 Hz), 6.92 (2H, d, J=8.50 Hz), 6.82 (2H, d, J=8.53 Hz), 5.28
(2H, s), 5.08 (2H, s), 3.83 (3H, s), 3.79 (3H, s), 3.73 (2H, t,
J=7.10 Hz), 2.69 (2H, t, J=7.09 Hz), 2.58 (4H, q, J=7.11 Hz), 1.01
(6H, t, J=7.09 Hz).
Step (2): Compound X-1+Compound 36a.fwdarw.Compound I-36
[0804] From Compound X-1 (559 mg, 0.60 mmol) and Compound 36a (311
mg, 0.60 mmol), Compound I-36 was obtained as a yellow powder using
the same method as Example 20.
[0805] Yield: 110 mg, (24%)
[0806] .sup.1H-NMR (D.sub.2O) .delta.: 1.45 (6H, q, J=7.40 Hz),
1.50 (3H, s), 1.52 (3H, s), 1.59 (3H, d, J=6.90 Hz), 3.45-3.52 (6H,
m), 3.95-4.11 (3H, m), 4.20 (1H, d, J=14.31 Hz), 5.03 (1H, d,
J=14.31 Hz), 5.48 (1H, d, J=4.64 Hz), 5.77 (1H, d, J=4.64 Hz), 7.00
(1H, d, J=7.78 Hz), 7.04 (1H, s), 7.15 (1H, d, J=7.78 Hz).
[0807] MS (m+1)=760.08
Example 37
Synthesis of Compound I-37
##STR00256##
[0808] Step (1): Compound 37a.fwdarw.Compound 37b
[0809] To a suspension of Compound 37a (4.29 g, 10 mmol) in
dichloromethane (40 ml) with stirring in ice bath was added
N,N-diethylethylenediamine (1.69 ml, 12 mmol), HOBt (1.62 g, 12
mmol) and EDC (2.30 g, 12 mmol), and then the mixture was stirred
at room temperature over night. The resulting mixture was diluted
with ethyl acetate and washed with a diluted aqueous solution of
sodium hydroxide, water and brine. The organic layer was dried over
magnesium sulfate, filtered and concentrated. The precipitated
material was collected by filtration to afford Compound 37b (4.55g,
86%).
[0810] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.47 (1H, d, J=8.7 Hz),
7.35-7.34 (4H, m), 7.03 (1H, br s), 6.94-6.92 (3H, m), 6.83 (2H, d,
J=8.4 Hz), 5.08 (2H, s), 4.95 (2H, s), 3.83 (3H, s), 3.80 (3H, s),
3.50 (2H, q, J=5.8 Hz), 2.64 (2H, t, J=5.8 Hz), 2.55 (4H, q, J=7.1
Hz), 1.01 (6H, t, J=7.1 Hz).
Step (2): Compound X-1+Compound 37b.fwdarw.Compound I-37
[0811] From Compound X-1 (932 mg, 1.0 mmol) and Compound 37b (527
mg, 1.0 mmol), Compound I-37 was obtained as a white powder using
the same method as Example 20.
[0812] Yield: 320 mg, (41%)
[0813] .sup.1H-NMR (D.sub.2O) .delta.: 1.43 (6H, dd, J=10.73, 6.84
Hz), 1.49 (3H, s), 1.52 (3H, s), 1.57 (3H, d, J=7.03 Hz), 3.48 (6H,
q, J=7.07 Hz), 3.74-3.95 (2H, m), 3.99 (1H, q, J=6.86 Hz), 4.17
(1H, d, J=14.31 Hz), 5.00 (1H, d, J=14.31 Hz), 5.45 (1H, d, J=4.64
Hz), 5.76 (1H, d, J=4.64 Hz), 6.90 (1H, d, J=8.41 Hz), 6.98 (1H, d,
J=8.41 Hz), 7.03 (1H, s).
[0814] MS (m+1)=768.22
Example 38
Synthesis of Compound I-38
##STR00257##
[0815] Step (1): Compound 29f.fwdarw.Compound 38a
[0816] From Compound 29f (3.02 g, 5.0 mmol), 20b (1.17 g, 5.5
mmol), and DIEA (1.92 mL, 11 mmol), Compound 38a was obtained as a
colorless oil using the same method as Example 29.
[0817] Yield: 100 mg, (4%)
[0818] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.74 (2H, dd, J=13.93,
6.27 Hz), 1.87-1.93 (2H, m), 2.13-2.16 (2H, m), 2.21 (3H, s),
2.26-2.34 (2H, m), 3.24 (2H, s), 3.79 (3H, s), 3.83 (3H, s),
4.55-4.65 (1H, m), 5.08 (2H, s), 5.25 (2H, s), 6.81 (2H, d, J=8.53
Hz), 6.91 (2H, d, J=8.53 Hz), 7.09 (1H, d, J=8.16 Hz), 7.30 (2H, d,
J=8.66 Hz), 7.37 (2H, d, J=8.66 Hz), 7.42 (1H, d, J=8.16 Hz).
Step (2): Compound X-1+Compound 38a.fwdarw.Compound I-38
[0819] From Compound X-1 (466 mg, 0.50 mmol) and Compound 38a (271
mg, 0.50 mmol), Compound I-38 was obtained as a yellow powder using
the same method as Example 20.
[0820] Yield: 126 mg, (31%)
[0821] .sup.1H-NMR (D.sub.2O) .delta.: 1.51 (3H, s), 1.53 (3H, s),
1.59 (3H, d, J=7.15 Hz), 2.21 (2H, t, J=19.39 Hz), 2.51-2.66 (4H,
m), 2.83-2.99 (2H, m), 3.12 (3H, s), 4.00 (1H, s), 4.07-4.15 (3H,
m), 4.75 (2H, d, J=14.68 Hz), 5.47 (1H, d, J=4.89 Hz), 5.84 (1H, d,
J=4.89 Hz), 7.02 (1H, s), 7.04 (1H, d, J=7.78 Hz), 7.17 (1H, d,
J=7.78 Hz).
[0822] MS (m+1)=786.06
Example 39
Synthesis of Compound I-39
##STR00258##
[0823] Step (1): Compound 29f.fwdarw.Compound 39b
[0824] From Compound 29f (3.02 g, 5.0 mmol) and Compound 39a (771
mg, 5.5 mmol), Compound 39b was obtained as a white solid using the
same method as Example 29.
[0825] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.41 (6H, t, J=7.65 Hz),
2.85 (6H, t, J=7.65 Hz), 3.79 (3H, s), 3.83 (3H, s), 5.11 (2H, s),
5.28 (2H, s), 6.81 (2H, d, J=8.66 Hz), 6.92 (2H, d, J=8.66 Hz),
7.14 (1H, d, J=8.03 Hz), 7.33 (2H, d, J=8.66 Hz), 7.37 (2H, d,
J=8.66 Hz), 7.48 (1H, d, J=8.03 Hz).
Step (2): Compound 39b+Compound X-2.fwdarw.Compound 39c
[0826] Compound 39b (543 mg, 1.0 mmol) was added to a solution of
compound X-2 (932 mg, 1.0 mmol) in dimethylformamide (2 mL) at
0.degree. C., and the resultant solution was stirred at 0.degree.
C. for 1 hour. The reaction mixture was slowly added to a 5% salt
solution (30 ml) (containing 1.5 g of sodium bisulfite) at
0.degree. C. The precipitated solid was collected by filtration,
washed with water, and then suspended into water. The suspension
was freeze-dried to yield compound 39c as an orange solid. Compound
39c yielded was used as it was, without being purified, in the next
reaction.
Step (3): Compound 39c.fwdarw.Compound I-39
[0827] The total amount of compound 39c yielded was dissolved in
dichloromethane (10 mL), and the solution was cooled to -40.degree.
C. Thereto were then added anisole (1.1 mL, 10 mmol) and a 2 M
aluminum chloride solution (5.00 mL, 10 mmol) in nitromethane in
turn. The resultant was stirred at 00.degree. C. for 30 minutes.
The reaction mixture was dissolved in water, a 2 mol/L aqueous
hydrochloric acid solution, and acetonitrile. The resultant
solution was then washed with diisopropyl ether. To the water phase
was added HP20-SS resin, and then acetonitrile was distilled off
under reduced pressure. The resultant mixed liquid was purified by
ODS column chromatography. To the resultant target-compound
solution was added HP20-SS resin, and then acetonitrile was
distilled off under reduced pressure. The resultant mixed liquid
was purified by HP20-SS column chromatography. To the resultant
target-compound solution was added a 0.2 N aqueous sodium hydroxide
solution until the whole gave a pH of 6.0. Thereafter, a piece of
dry ice was added thereto. The resultant solution was concentrated
under reduced pressure, and then freeze-dried to yield compound
I-39 as an orange powder.
[0828] Yielded amount: 168 mg (20%).
[0829] .sup.1H-NMR (D.sub.2O) .delta.: 1.50 (3H, s), 1.52 (3H, s),
1.55 (3H, d, J=7.15 Hz), 1.93 (6H, t, J=7.72 Hz), 3.41-3.53 (8H,
m), 4.03-4.10 (2H, m), 4.61 (1H, d, J=14.43 Hz), 5.43 (1H, d,
J=4.89 Hz), 5.84 (1H, d, J=4.89 Hz), 6.99 (1H, s), 7.04 (1H, d,
J=7.91 Hz), 7.17 (1H, d, J=7.91 Hz).
[0830] MS (m+1)=784.06
Example 40
Synthesis of Compound I-40
##STR00259##
[0831] Step (1): Compound X-1+Compound 40a.fwdarw.Compound I-40
[0832] From Compound X-1 (932 mg, 1.0 mmol) and Compound 40a (543
mg, 1.0 mmol), Compound I-40 was obtained as a white powder using
the same method as Example 20.
[0833] Yield: 523 mg, (64%)
[0834] .sup.1H-NMR (D.sub.2O) .delta.: 1.51 (3H, s), 1.53 (3H, s),
1.56 (3H, d, J=7.15 Hz), 1.96 (6H, t, J=7.59 Hz), 3.35 (2H, s),
3.45-3.57 (6H, m), 4.05-4.09 (2H, m), 4.64 (1H, d, J=14.31 Hz),
5.45 (1H, d, J=4.89 Hz), 5.85 (1H, d, J=4.89 Hz), 6.90 (1H, d,
J=8.41 Hz), 6.95 (1H, d, J=8.41 Hz), 7.00 (1H, s).
[0835] MS (m+1)=792.01
Example 41
Synthesis of Compound I-41
##STR00260##
[0836] Step (1): Compound X-1+Compound 41a.fwdarw.Compound I-41
[0837] From Compound X-1 (932 mg, 1.0 mmol) and Compound 41a (537
mg, 1.0 mmol), Compound I-41 was obtained as a white powder using
the same method as Example 20.
[0838] Yield: 443 mg, (55%)
[0839] .sup.1H-NMR (D.sub.2O) .delta.: 1.50 (3H, d, J=1.63 Hz),
1.52 (3H, d, J=1.88 Hz), 1.57 (3H, dd, J=17.69, 6.90 Hz), 2.02-2.46
(4H, m), 3.46-4.08 (9H, m), 4.25-4.53 (2H, m), 5.11 (1H, dd,
J=19.89, 15.00 Hz), 5.45 (1H, d, J=4.64 Hz), 5.83 (1H, d, J=4.64
Hz), 6.83-6.88 (1H, m), 6.95-6.98 (1H, m), 7.01 (1H, s).
[0840] MS (m+1)=778.04
Example 42
Synthesis of Compound I-42
##STR00261##
[0841] Step (1): Compound X-1+Compound 32a.fwdarw.Compound I-42
[0842] From Compound X-1 (932 mg, 1.0 mmol) and Compound 32a (624
mg, 1.0 mmol), Compound I-42 was obtained as a yellow powder using
the same method as Example 20.
[0843] Yield: 192 mg, (24%)
[0844] .sup.1H-NMR (D.sub.2O) .delta.: 1.51 (3H, s), 1.53 (3H, s),
1.61 (3H, d, J=7.03 Hz), 1.81-2.00 (6H, m), 3.28-3.39 (3H, m),
3.59-3.80 (3H, m), 4.02-4.07 (2H, m), 4.16 (1H, q, J=7.03 Hz), 4.29
(1H, d, J=14.05 Hz), 5.07 (1H, d, J=14.05 Hz), 5.50 (1H, d, J=4.77
Hz), 5.83 (1H, d, J=4.77 Hz), 7.02-7.04 (2H, m), 7.17 (1H, d,
J=7.78 Hz).
[0845] MS (m+1)=772.07
Example 43
Synthesis of Compound I-43
##STR00262##
[0846] Step (1): Compound X-1+Compound 33a.fwdarw.Compound I-43
[0847] From Compound X-1 (932 mg, 1.0 mmol) and Compound 33a (539
mg, 1.0 mmol), Compound I-43 was obtained as a white powder using
the same method as Example 20.
[0848] Yield: 272 mg, (29%)
[0849] .sup.1H-NMR (D.sub.2O) .delta.: 1.50 (3H, s), 1.52 (3H, s),
1.59 (3H, d, J=7.03 Hz), 1.82-2.01 (6H, m), 3.28-3.36 (3H, m), 3.62
(1H, d, J=11.92 Hz), 3.69-3.82 (3H, m), 3.89-3.96 (1H, m), 4.11
(1H, q, J=7.03 Hz), 4.23 (1H, d, J=14.18 Hz), 5.00 (1H, d, J=14.18
Hz), 5.48 (1H, d, J=4.77 Hz), 5.83 (1H, d, J=4.77 Hz), 6.87 (1H, d,
J=8.28 Hz), 6.95 (1H, d, J=8.28 Hz), 7.02 (1H, s).
Example 44
Synthesis of Compound I-44
##STR00263##
[0850] Step (1): Compound X-1h+Compound 44b.fwdarw.Compound
44c.fwdarw.Compound I-44
[0851] A solution of Compound 44b (404 mg, 0.80 mmol) in
dimethylacetamide (2.0 mL) was cooled with ice, and thereto was
added Compound X-1h (672 mg, 0.80 mmol). The reaction vessel was
then degassed under reduced pressure, and thereto was added sodium
iodide (240 mg, 1.6 mmol). After stirring at 15.degree. C. for 7
hours, the reaction mixture was slowly added to 5% aqueous sodium
chloride and sodium hydrogen sulfite cooled with ice. The
precipitated solid was collected by filtration, washed with water,
and suspended into water. The suspension was freeze-dried to yield
Compound 44c as a brown solid. Compound 44c yielded was used as it
was, without being purified, in the next reaction.
[0852] From Compound 44c, Compound I-44 was obtained as a white
powder using the same method as Example 20.
[0853] Yield: 359 mg, (58%)
[0854] .sup.1H-NMR (D.sub.2O) .delta.: 1.44 (3H, s), 1.45 (3H, s),
1.61 (3H, d, J=6.78 Hz), 3.49 (1H, q, J=6.78 Hz), 5.12 (1H, d,
J=14.68 Hz), 5.43-5.46 (2H, m), 5.92 (1H, d, J=4.39 Hz), 6.87 (1H,
d, J=8.41 Hz), 6.90 (1H, s), 7.12 (1H, d, J=8.41 Hz), 8.09 (2H, d,
J=6.53 Hz), 8.76 (2H, d, J=6.53 Hz).
[0855] MS (m+1)=745.97
Example 45
Synthesis of Compound I-45
##STR00264##
[0856] Step (1): Compound X-1h+Compound 45a.fwdarw.Compound
I-45
[0857] From Compound X-1h (672 mg, 0.80 mmol) and Compound 45a (300
mg, 1.0 mmol), Compound I-45 was obtained as a white powder using
the same method as Example 44.
[0858] Yield: 332 mg, (61%)
[0859] .sup.1H-NMR (D.sub.2O) .delta.: 1.39 (3H, d, J=7.15 Hz),
1.47 (6H, s), 2.69 (3H, s), 3.46 (1H, q, J=6.94 Hz), 5.22 (1H, d,
J=15.31 Hz), 5.33 (1H, d, J=15.31 Hz), 5.47 (1H, d, J=4.89 Hz),
5.91 (1H, d, J=4.89 Hz), 6.88 (1H, s), 6.90 (1H, s), 7.29 (1H, s),
7.54 (1H, s), 8.83 (1H, s).
[0860] MS (m+1)=657.01
Example 46
Synthesis of Compound I-46
##STR00265##
[0861] Step (1): Compound X-1h+Compound 46a.fwdarw.Compound
I-46
[0862] From Compound X-1h (672 mg, 0.80 mmol) and Compound 46a (289
mg, 1.0 mmol), Compound I-46 was obtained as a white powder using
the same method as Example 44.
[0863] Yield: 356 mg, (67%)
[0864] .sup.1H-NMR (D.sub.2O) .delta.: 1.43 (3H, s), 1.45 (3H, s),
1.57 (3H, d, J=7.15 Hz), 3.40 (1H, q, J=7.15 Hz), 5.12 (1H, d,
J=14.68 Hz), 5.43-5.47 (2H, m), 5.88 (1H, d, J=4.77 Hz), 6.79 (1H,
s), 7.06 (1H, s), 7.36 (1H, s), 7.72 (1H, d, J=6.90 Hz), 8.11 (1H,
d, J=6.90 Hz), 9.01 (1H, s).
[0865] MS (m+1)=643.01
Example 47
Synthesis of Compound I-47
##STR00266##
[0866] Step (1): Compound X-1g+Compound 44b.fwdarw.Compound
I-47
[0867] From Compound X-1g (672 mg, 0.80 mmol) and Compound 44b (404
mg, 0.80 mmol), Compound I-47 was obtained as a white powder using
the same method as Example 44.
[0868] Yield: 367 mg, (60%)
[0869] .sup.1H-NMR (D.sub.2O) .delta.: 1.27 (3H, d, J=7.16 Hz),
1.45 (3H, s), 1.48 (3H, s), 3.95 (1H, q, J=7.16 Hz), 5.28 (1H, d,
J=15.16 Hz), 5.35-5.39 (2H, m), 5.74 (1H, d, J=4.80 Hz), 6.88 (1H,
s), 6.91 (1H, d, J=8.34 Hz), 7.15 (1H, d, J=8.34 Hz), 8.19 (2H, d,
J=7.33 Hz), 8.76 (2H, d, J=7.33 Hz).
[0870] MS (m+1)=745.93
Example 48
Synthesis of Compound I-48
##STR00267##
[0871] Step (1): Compound X-1g+Compound 48a.fwdarw.Compound
I-48
[0872] From Compound X-1g (672 mg, 0.80 mmol) and Compound 48a (395
mg, 0.80 mmol), Compound I-48 was obtained as a white powder using
the same method as Example 44.
[0873] Yield: 320 mg, (53%)
[0874] .sup.1H-NMR (D.sub.2O) .delta.: 1.50 (3H, s), 1.52 (3H, s),
1.56 (3H, d, J=7.15 Hz), 4.11 (1H, q, J=7.15 Hz), 4.17 (1H, d,
J=13.80 Hz), 4.75 (1H, d, J=13.80 Hz), 5.30 (1H, d, J=4.64 Hz),
5.73 (1H, d, J=4.64 Hz), 7.00-7.02 (2H, m), 7.08 (1H, d, J=8.78
Hz), 7.91 (2H, d, J=6.90 Hz), 8.52 (2H, d, J=6.90 Hz).
[0875] MS (m+1)=734.92
Example 49
Synthesis of Compound I-49
##STR00268##
[0876] Step (1): Compound X-1g+Compound 45a.fwdarw.Compound
I-49
[0877] From Compound X-1g(672 mg, 0.80 mmol) and Compound 45a (300
mg, 1.0 mmol), Compound I-49 was obtained as a white powder using
the same method as Example 44.
[0878] Yield: 244 mg, (45%)
[0879] .sup.1H-NMR (D.sub.2O) .delta.: 1.25 (3H, d, J=7.15 Hz),
1.50 (3H, s), 1.51 (3H, s), 2.71 (3H, s), 3.95 (1H, q, J=7.15 Hz),
5.22 (1H, d, J=15.69 Hz), 5.44 (1H, d, J=15.69 Hz), 5.51 (1H, d,
J=4.77 Hz), 5.80 (1H, d, J=4.77 Hz), 6.97-6.98 (2H, m), 7.34 (1H,
s), 7.58 (1H, s), 8.83 (1H, s).
[0880] MS (m+1)=657.01
Example 50
Synthesis of Compound I-50
##STR00269##
[0881] Step (1): Compound X-1g+Compound 46a.fwdarw.Compound
I-50
[0882] From Compound X-1g (672 mg, 0.80 mmol) and Compound 46a (289
mg, 1.0 mmol), Compound I-50 was obtained as a white powder using
the same method as Example 44.
[0883] Yield: 294 mg, (55%)
[0884] .sup.1H-NMR (D.sub.2O) .delta.: 1.35 (3H, d, J=7.33 Hz),
1.49 (3H, s), 1.51 (3H, s), 3.89 (1H, q, J=7.33 Hz), 5.30 (1H, d,
J=14.91 Hz), 5.43 (1H, d, J=4.80 Hz), 5.46 (1H, d, J=14.91 Hz),
5.82 (1H, d, J=4.80 Hz), 6.98 (1H, s), 7.10 (1H, s), 7.41 (1H, s),
7.76 (1H, d, J=6.82 Hz), 8.00 (1H, d, J=6.82 Hz), 8.91 (1H, s).
[0885] MS (m+1)=643.01
Example 51
Synthesis of Compound I-51
##STR00270##
[0886] Step (1): Compound X-1+Compound 29g.fwdarw.Compound I-51
[0887] From Compound X-1 (932 mg, 1.0 mmol) and Compound 29g (517
mg, 1.0 mmol), Compound I-51 was obtained as a yellow powder using
the same method as Example 20.
[0888] Yield: 222 mg, (29%)
[0889] .sup.1H-NMR (D.sub.2O) .delta.: 1.50 (3H, s), 1.53 (3H, s),
1.60 (3H, d, J=7.03 Hz), 2.23 (4H, s), 3.52-3.71 (6H, m), 3.99-4.16
(3H, m), 4.32 (1H, d, J=14.18 Hz), 5.07 (1H, d, J=14.18 Hz), 5.48
(1H, d, J=4.77 Hz), 5.81 (1H, d, J=4.77 Hz), 7.00-7.02 (2H, m),
7.15 (1H, d, J=7.78 Hz).
[0890] MS (m+1)=758.25
Example 52
Synthesis of Compound I-52
##STR00271##
[0891] Step (1): Compound X-22+Compound 35a.fwdarw.Compound
52b.fwdarw.Compound I-52
[0892] A solution of Compound X-22 (420 mg, 0.80 mmol) in
dimethylacetoamide (2.0 mL) was cooled with ice, and thereto was
added compound 35a (685 mg, 0.80 mmol). The reaction vessel was
then degassed under reduced pressure. Thereto was added sodium
iodide (240 mg, 1.6 mmol), and the solution was stirred at
15.degree. C. for 6 hours. Dimethylformamide (5.0 mL) was added
thereto, and the solution was cooled to -40.degree. C. Thereto was
added phosphorus tribromide (151 .mu.L, 1.6 mmol). The solution was
stirred at 0.degree. C. for 30 minutes. The reaction mixture was
slowly added to a 5% salt solution cooled with ice. The
precipitated solid was collected by filtration, washed with water,
and suspended into water. The suspension was freeze-dried to yield
compound 52b as a brown solid. Compound 52b yielded was used as it
was, without being purified, in the next reaction.
[0893] From Compound 52b, Compound I-52 was obtained as a white
powder using the same method as Example 20.
[0894] Yield: 269 mg, (43%)
[0895] .sup.1H-NMR (D.sub.2O) .delta.: 1.50 (3H, s), 1.52 (3H, s),
1.58 (3H, d, J=7.02 Hz), 2.23 (4H, s), 3.55-3.59 (2H, m), 3.73-3.88
(5H, m), 4.04-4.10 (1H, m), 4.22-4.29 (2H, m), 5.02 (1H, d, J=13.88
Hz), 5.45 (1H, d, J=5.03 Hz), 5.73 (1H, d, J=5.03 Hz), 6.88-6.90
(2H, m), 7.00 (1H, s).
[0896] MS (m+1)=766.62
Example 53
Synthesis of Compound I-53
##STR00272##
[0897] Step (1): Compound X-23+Compound 35a.fwdarw.Compound
I-53
[0898] From Compound X-23 (514 mg, 0.60 mmol) and Compound 35a (315
mg, 0.60 mmol), Compound I-53 was obtained as a white powder using
the same method as Example 52.
[0899] Yield: 198 mg, (42%)
[0900] .sup.1H-NMR (D.sub.2O) .delta.: 1.48 (6H, s), 1.64 (3H, d,
J=6.86 Hz), 2.23 (4H, s), 3.55-3.59 (2H, m), 3.73-3.88 (6H, m),
4.22-4.29 (2H, m), 4.50 (1H, d, J=14.03 Hz), 5.47 (1H, d, J=5.03
Hz), 5.79 (1H, d, J=5.03 Hz), 6.82 (1H, d, J=8.39 Hz), 6.89 (1H,
s), 6.98 (1H, d, J=8.39 Hz).
[0901] MS (m+1)=766.36
Example 54
Synthesis of Compound I-54
##STR00273##
[0902] Step (1): Compound X-22+Compound 54a.fwdarw.Compound
I-54
[0903] From Compound X-22 (685 mg, 0.80 mmol) and Compound 54a (441
mg, 0.80 mmol), Compound I-54 was obtained as a white powder using
the same method as Example 51.
[0904] Yield: 164 mg, (25%)
[0905] .sup.1H-NMR (D.sub.2O) .delta.: 1.50 (3H, s), 1.52 (3H, s),
1.62 (3H, d, J=7.02 Hz), 2.17 (2H, dd, J=16.01, 6.86 Hz), 2.36-2.79
(7H, m), 3.14 (3H, s), 3.80 (1H, q, J=6.66 Hz), 4.01 (1H, s),
4.10-4.23 (3H, m), 5.43 (1H, d, J=4.88 Hz), 5.91 (1H, d, J=4.88
Hz), 6.89 (1H, d, J=8.39 Hz), 6.94 (1H, d, J=8.39 Hz), 6.98 (1H,
s).
[0906] MS (m+1)=792.62
Example 55
Synthesis of Compound I-55
##STR00274##
[0907] Step (1): Compound X-23+Compound 54a.fwdarw.Compound
I-55
[0908] From Compound X-23 (514 mg, 0.60 mmol) and Compound 54a (331
mg, 0.60 mmol), Compound I-55 was obtained as a white powder using
the same method as Example 51.
[0909] Yield: 30 mg, (6%)
[0910] .sup.1H-NMR (D.sub.2O) .delta.: 1.50 (3H, s), 1.52 (3H, s),
1.62 (3H, d, J=7.02 Hz), 2.17 (2H, dd, J=16.01, 6.86 Hz), 2.36-2.79
(7H, m), 3.14 (3H, s), 3.80 (1H, q, J=6.66 Hz), 4.01 (1H, s),
4.10-4.23 (3H, m), 5.43 (1H, d, J=4.88 Hz), 5.91 (1H, d, J=4.88
Hz), 6.89 (1H, d, J=8.39 Hz), 6.94 (1H, d, J=8.39 Hz), 6.98 (1H,
s).
[0911] MS (m+1)=792.44
Example 56
Synthesis of Compound I-56
##STR00275##
[0912] Step (1): Compound 56a.fwdarw.Compound 56c
[0913] To a solution of Compound 56a (10.19g, 24.0 mmol) in
dichloromethane (100 mL) was added Compound 56b (9.62g, 48.0 mmol),
and then the mixture was stirred at room temperature over night.
The solvent was removed by evaporation and to the residue was added
water and ethyl acetate. The organic layer separated was washed
with water and brine, and then dried over MgSO4, filtered and
concentrated. The residue was purified by column chromatography on
silica gel eluted with n-hexane/ethyl acetate to afford Compound
56c (4.45g, 39%) as an oil substance.
[0914] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.55 (9H, s), 2.54 (1H, t,
J=6.65 Hz), 3.80 (3H, s), 3.83 (3H, s), 4.52 (2H, d, J=6.65 Hz),
5.00 (2H, s), 5.05 (2H, s), 6.81 (2H, d, J=8.66 Hz), 6.90 (2H, d,
J=8.66 Hz), 7.00 (1H, d, J=8.28 Hz), 7.08 (1H, d, J=8.28 Hz), 7.29
(2H, d, J=8.53 Hz), 7.35 (2H, d, J=8.53 Hz).
Step (2): Compound 56c.fwdarw.Compound 56d
[0915] To a solution of Compound 56c (4.45 g, 9.26 mmol) in
dichloromethane (45 mL) was added Dess-Martin periodinane (4.32 g,
10.19 mmol) at 0 degree, and then the mixture was stirred at room
temperature over night. To the resulting mixture was added water.
The organic solvent was removed by evaporation and the aqueous
residue was extracted with ethyl acetate. The organic layer was
washed with water and brine, dried over magnesium sulfate, filtered
and concentrated. The residue was purified by column chromatography
on silica gel eluted with n-hexane/ethyl acetate to afford Compound
56d (2.91 g, 66%) as a colorless solid.
[0916] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.56 (9H, s), 3.80 (3H,
s), 3.84 (3H, s), 4.97 (2H, s), 5.14 (2H, s), 6.80 (2H, d, J=8.08
Hz), 6.93 (2H, d, J=8.34 Hz), 7.10 (1H, d, J=8.34 Hz), 7.26-7.28
(2H, m), 7.37 (2H, d, J=8.34 Hz), 7.60 (1H, d, J=8.34 Hz), 9.88
(1H, s).
Step (3): Compound 56d.fwdarw.Compound 56e
[0917] To a solution of Compound 56d (2.91 g, 6.08 mmol) in
1,4-dioxane (30 mL) and water (10 mL) with stirring in ice bath was
added amidosulfuric acid (1.18 g, 12.16 mmol) and sodium chlorite
(1.38 g, 12.16 mmol), and then the mixture was stirred at 0 degree
for 30 min. To the resulting mixture was added sodium bisulfate
(2.53 g, 24.32 mmol). The mixture was extracted with ethyl acetate.
The organic layer was washed with water and brine, dried over
magnesium sulfate, filtered, and concentrated. The residue was
triturated with diisopropyl ether and the solid was collected by
filtration and dried under high vacuum to afford Compound 56e (2.79
g, 93%) as a colorless solid.
[0918] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 1.45 (9H, s), 3.74 (3H,
s), 3.78 (3H, s), 4.84 (2H, s), 5.19 (2H, s), 6.83 (2H, d, J=8.66
Hz), 6.98 (2H, d, J=8.78 Hz), 7.20 (2H, d, J=8.66 Hz), 7.31 (1H, d,
J=8.78 Hz), 7.46 (2H, d, J=8.66 Hz), 7.69 (1H, d, J=8.66 Hz).
Step (4): Compound 56e.fwdarw.Compound 56f
[0919] To a solution of Compound 56e (989 mg, 2.0 mmol) in
dimethylformamide (3 mL) was added 1-hydroxybenzotriazole (324 mg,
2.4 mmol), 1-(2-aminoethyl)pyrrolidine (0.30 mL, 2.4 mmol) and EDC
hydrochloride (460 mg, 2.4 mmol) at 0 degree. The mixture was
stirred at room temperature for 4.5 hr. To the resulting mixture
was added ice water and extracted with ethyl acetate. The organic
layer was washed with 1 mol/L sodium hydroxide solution, water and
brine, and then dried over magnesium sulfate, filtered, evaporated
at 25 degree. The residue was dried under high vacuum to afford
Compound 56f (1.16g, 98%) as a yellowish oil.
[0920] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.53 (9H, s), 1.79 (4H, br
s), 2.58 (4H, br s), 2.70 (2H, t, J=5.81 Hz), 3.52 (2H, q, J=5.56
Hz), 3.79 (3H, s), 3.83 (3H, s), 4.97 (2H, s), 5.07 (2H, s), 6.80
(2H, d, J=8.34 Hz), 6.91 (2H, d, J=8.34 Hz), 6.96 (1H, d, J=8.59
Hz), 7.29 (2H, d, J=8.34 Hz), 7.33-7.36 (3H, m).
Step (5): Compound X-22+Compound 56f.fwdarw.Compound I-56
[0921] From Compound X-22 (475 mg, 0.59 mmol) and Compound 56f (346
mg, 0.59 mmol), Compound I-56 was obtained as a white powder using
the same method as Example 52.
[0922] Yield: 51 mg, (11%)
[0923] .sup.1H-NMR (D.sub.2O) .delta.: 1.50 (3H, s), 1.52 (3H, s),
1.59 (3H, d, J=7.03 Hz), 2.24 (4H, s), 3.35-3.87 (8H, m), 4.11 (1H,
q, J=7.03 Hz), 4.28 (1H, d, J=14.31 Hz), 5.00 (1H, d, J=14.31 Hz),
5.48 (1H, d, J=4.77 Hz), 5.82 (1H, d, J=4.77 Hz), 6.74 (1H, d,
J=8.16 Hz), 6.96 (1H, d, J=8.16 Hz), 7.03 (1H, s).
[0924] MS (m+1)=776.03
Example 57
Synthesis of Compound I-57
##STR00276##
[0925] Step (1): Compound X-23+Compound 56f.fwdarw.Compound
I-57
[0926] From Compound X-23 (685 mg, 0.80 mmol) and Compound 56f (473
mg, 0.80 mmol), Compound I-57 was obtained as a white powder using
the same method as Example 52.
[0927] Yield: 52 mg, (8%)
[0928] .sup.1H-NMR (D.sub.2O) .delta.: 1.50 (6H, s), 1.65 (3H, d,
J=6.82 Hz), 2.22 (4H, s), 3.58-3.87 (9H, m), 4.31 (1H, d, J=14.40
Hz), 4.46 (1H, d, J=14.40 Hz), 5.48 (1H, d, J=4.80 Hz), 5.83 (1H,
d, J=4.80 Hz), 6.68 (1H, d, J=8.08 Hz), 6.93 (1H, d, J=8.08 Hz),
6.96 (1H, s).
[0929] MS (m+1)=776.06
Example 58
Synthesis of Compound I-58
##STR00277##
[0930] Step (1): Compound X-23+Compound 29g.fwdarw.Compound
I-58)
[0931] From Compound X-23 (685 mg, 0.80 mmol) and Compound 29g (413
mg, 0.80 mmol), Compound I-58 was obtained as a yellow powder using
the same method as Example 52.
[0932] Yield: 46 mg, (7%)
[0933] .sup.1H-NMR (D.sub.2O) .delta.: 1.46 (3H, s), 1.47 (3H, s),
1.68 (3H, d, J=6.78 Hz), 2.21 (4H, s), 3.49-3.55 (1H, m), 3.74-3.93
(6H, m), 4.02-4.05 (2H, m), 4.27 (1H, d, J=14.43 Hz), 4.55 (1H, d,
J=13.93 Hz), 5.52 (1H, d, J=4.77 Hz), 5.87 (1H, d, J=4.77 Hz), 6.91
(1H, s), 6.96 (1H, s), 7.04 (1H, d, J=7.53 Hz).
[0934] MS (m+1)=758.03
[0935] The compounds shown below were obtained from Compound X-1g
and the each corresponding amine in the same way as example 39.
Example 59
Synthesis of Compound I-59
##STR00278##
[0937] Yielded amount: 423 g (52%)
[0938] .sup.1H-NMR (D.sub.2O) .delta.: 6.93-6.91 (1H, m), 6.93-6.91
(1H, m), 6.81-6.77 (1H, m), 5.86-5.83 (1H, m), 5.47-5.44 (1H, m),
4.13-3.98 (4H, m), 3.69-3.63 (2H, m), 3.49-2.95 (7H, m), 1.59-1.56
(3H, m), 1.52 (3H, s), 1.50 (3H, s).
[0939] [M+H]=778.23
Example 60
Synthesis of Compound I-60
##STR00279##
[0941] Yielded amount: 516 g (62%)
[0942] .sup.1H-NMR (D.sub.2O) .delta.: 7.39 (1H, s), 7.19 (1H, s),
7.01 (1H, s), 5.84 (1H, d, J=5.0 Hz), 5.45 (1H, d, J=5.0 Hz), 4.63
(1H, d, J=14.9 Hz), 4.09-4.04 (2H, m), 3.55-3.43 (6H, m), 3.35 (2H,
br s), 1.93 (6H, t, J=7.8 Hz), 1.56 (3H, d, J=7.3 Hz), 1.52 (3H,
s), 1.50 (3H, s).
[0943] [M+H]=792.27
Example 61
Synthesis of Compound I-61
##STR00280##
[0945] Yielded amount: 346 mg (42%)
[0946] .sup.1H-NMR (D.sub.2O) .delta.: 7.39 (1H, s), 7.23 (1H, s),
7.01 (1H, s), 5.80 (1H, d, J=4.8 Hz), 5.45 (1H, d, J=4.8 Hz), 5.03
(1H, d, J=14.3 Hz), 4.25 (1H, d, J=14.3 Hz), 4.09-4.04 (1H, m),
3.92-3.85 (1H, m), 3.79-3.70 (2H, m), 3.60-3.44 (5H, m), 2.29-2.15
(4H, m), 1.57 (3H, d, J=7.0 Hz), 1.52 (3H, s), 1.50 (3H, s).
[M+H]=766.24
Example 62
Synthesis of Compound I-62
##STR00281##
[0948] Yielded amount: 396 mg (48%)
[0949] .sup.1H-NMR (D.sub.2O) .delta.: 7.02-7.00 (1H, m), 6.92 (1H,
d, J=8.3 Hz), 6.81-6.77 (1H, m), 5.86-5.83 (1H, m), 5.47-5.44 (1H,
m), 4.13-3.98 (5H, m), 3.69-2.95 (11H, m), 1.58 (3H, t, J=6.6 Hz),
1.52 (3H, s), 1.50 (3H, s). [M+H]=778.20
Example 63
Synthesis of Compound I-63
##STR00282##
[0951] Yielded amount: 405 mg (50%)
[0952] .sup.1H-NMR (D.sub.2O) .delta.: 7.14 (1H, br s), 7.02-6.98
(2H, br m), 5.85-5.81 (1H, m), 5.45 (1H, d, J=4.9 Hz), 4.14-3.67
(8H, m), 3.42-2.95 (8H, m), 1.58-1.55 (3H, m), 1.52 (3H, br s),
1.50 (3H, br s). [M+H]=778.20
Example 64
Synthesis of Compound I-64
##STR00283##
[0954] Yielded amount: 279 mg (35%)
[0955] .sup.1H-NMR (D.sub.2O) .delta.: 7.11 (1H, s), 7.02 (1H, s),
6.94 (1H, s), 5.83 (1H, d, J=4.8 Hz), 5.46 (1H, d, J=4.8 Hz), 5.12
(1H, d, J=14.3 Hz), 4.28 (1H, d, J=14.3 Hz), 4.07-3.55 (8H, m),
2.21-2.00 (4H, br m), 1.58 (3H, d, J=6.8 Hz), 1.53 (3H, s), 1.51
(3H, s). [M+H]=778.20
Example 65
Synthesis of Compound I-65
##STR00284##
[0957] Yielded amount: 406 mg (50%)
[0958] .sup.1H-NMR (D.sub.2O) .delta.: 7.08-7.04 (1H, m), 6.99 (1H,
br s), 6.93 (1H, br s), 5.89-5.84 (1H, br m), 5.47-5.44 (1H, br m),
4.31-3.47 (11H, m), 2.37-2.23 (4H, br m), 1.57 (3H, d, J=6.5 Hz),
1.52 (3H, br s), 1.50 (3H, br s).
[0959] [M+H]=778.23
Example 66
Synthesis of Compound I-66
##STR00285##
[0961] Yielded amount: 272 mg (33%)
[0962] .sup.1H-NMR (D.sub.2O) .delta.: 7.32 (1H, d, J=2.0 Hz), 7.17
(1H, s), 7.02 (1H, s), 5.82 (1H, d, J=4.8 Hz), 5.46 (1H, d, J=4.8
Hz), 4.21-3.94 (5H, m), 3.11 (3H, br s), 2.81-2.32 (7H, m), 2.19
(2H, d, J=17.2 Hz), 1.58 (3H, d, J=7.0 Hz), 1.53 (3H, s), 1.51 (3H,
s). [M+H]=792.24
Example 67
Synthesis of Compound I-67
##STR00286##
[0964] Yielded amount: 321 mg (40%)
[0965] .sup.1H-NMR (D.sub.2O) .delta.: 7.00 (1H, s), 6.89-6.81 (2H,
m), 5.85 (1H, d, J=4.6 Hz), 5.45 (1H, d, J=4.6 Hz), 4.37-4.27 (1H,
m), 4.11-4.03 (3H, m), 3.85-3.62 (7H, m), 2.35 (4H, br s), 1.58
(3H, d, J=6.0 Hz), 1.52 (3H, s), 1.50 (3H, s).
[0966] [M+H]=762.32
Example 68
Synthesis of Compound I-68
##STR00287##
[0968] Yielded amount: 319 mg (40%)
[0969] .sup.1H-NMR (D.sub.2O) .delta.: 7.01 (1H, s), 6.92-6.89 (1H,
br m), 6.84 (1H, s), 5.83 (1H, d, J=4.9 Hz), 5.46 (1H, d, J=4.9
Hz), 5.12 (1H, d, J=14.4 Hz), 4.30-3.52 (10H, m), 2.21-2.02 (4H, br
m), 1.58 (3H, d, J=7.0 Hz), 1.53 (3H, s), 1.50 (3H, s).
[0970] [M+H]=762.32
Example 69
Synthesis of Compound I-69
##STR00288##
[0972] Yielded amount: 369 mg (47%)
[0973] .sup.1H-NMR (D.sub.2O) .delta.: 7.01 (1H, d, J=6.1 Hz),
6.95-6.92 (1H, m), 6.88 (1H, br s), 5.85-5.81 (1H, m), 5.45 (1H, d,
J=4.9 Hz), 4.14-2.94 (16H, m), 1.57 (3H, d, J=7.0 Hz), 1.52 (3H,
s), 1.50 (3H, s). [M+H]=762.50
Example 70
Synthesis of Compound I-70
##STR00289##
[0975] Yielded amount: 300 mg (37%)
[0976] .sup.1H-NMR (D.sub.2O) .delta.: 7.19-7.15 (2H, m), 7.01 (1H,
s), 5.81 (1H, d, J=4.8 Hz), 5.46 (1H, d, J=4.8 Hz), 5.03 (1H, d,
J=14.3 Hz), 4.25 (1H, d, J=14.3 Hz), 4.07 (1H, q, J=7.1 Hz),
3.92-3.86 (1H, m), 3.81-3.71 (2H, m), 3.62-3.44 (5H, m), 2.27-2.17
(4H, m), 1.57 (3H, d, J=7.2 Hz), 1.52 (3H, s), 1.50 (3H, s).
[M+H]=750.47
Example 71
Synthesis of Compound I-71
##STR00290##
[0978] Yielded amount: 143 mg (17%)
[0979] .sup.1H-NMR (D.sub.2O) .delta.: 7.14-7.09 (2H, m), 7.02 (1H,
s), 5.83 (1H, d, J=4.8 Hz), 5.47 (1H, d, J=4.8 Hz), 4.20 (1H, t,
J=7.2 Hz), 4.13-4.05 (3H, m), 3.95 (1H, br s), 3.11 (3H, s),
2.81-2.41 (7H, m), 2.19 (2H, d, J=16.9 Hz), 1.58 (3H, d, J=7.0 Hz),
1.53 (3H, s), 1.51 (3H, s).
[0980] [M+H]=776.25
Example 72
Synthesis of Compound I-72
##STR00291##
[0982] Yielded amount: 486 mg (60%)
[0983] .sup.1H-NMR (D.sub.2O) .delta.: 7.18-7.13 (2H, m), 7.00 (1H,
s), 5.84 (1H, d, J=4.8 Hz), 5.44 (1H, d, J=4.8 Hz), 4.64 (1H, d,
J=14.6 Hz), 4.07 (2H, dd, J=14.6, 8.2 Hz), 3.57-3.40 (6H, m), 3.35
(2H, s), 1.93 (6H, t, J=7.7 Hz), 1.56 (3H, d, J=7.2 Hz), 1.52 (3H,
s), 1.50 (3H, s).
[0984] [M+H]=776.22
Example 73
Synthesis of Compound I-73
##STR00292##
[0986] Yielded amount: 379 mg (45%)
[0987] .sup.1H-NMR (D.sub.2O) .delta.: 7.16 (2H, br s), 6.99 (1H,
s), 5.83 (1H, d, J=4.8 Hz), 5.42 (1H, d, J=4.8 Hz), 4.62 (1H, d,
J=14.4 Hz), 4.08-4.02 (2H, m), 3.52-3.40 (8H, m), 1.92 (6H, t,
J=7.7 Hz), 1.54 (3H, d, J=7.2 Hz), 1.52 (3H, s), 1.50 (3H, s).
[0988] [M+H]=784.32
Example 74
Synthesis of Compound I-74
##STR00293##
[0990] Yielded amount: 203 mg (23%)
[0991] .sup.1H-NMR (D.sub.2O) .delta.: 7.33 (1H, d, J=8.7 Hz), 7.02
(1H, d, J=2.4 Hz), 6.89 (1H, d, J=8.7 Hz), 5.80 (1H, d, J=4.8 Hz),
5.47 (1H, d, J=4.8 Hz), 5.03 (1H, d, J=14.3 Hz), 4.26 (1H, d,
J=14.3 Hz), 4.07 (1H, q, J=7.1 Hz), 3.97-3.90 (1H, m), 3.84-3.77
(1H, m), 3.70-3.48 (6H, m), 2.27-2.18 (4H, br m), 1.57 (3H, d,
J=7.0 Hz), 1.52 (3H, s), 1.50 (3H, s).
[0992] [M+H]=794.36
Example 75
Synthesis of Compound I-75
##STR00294##
[0994] Yielded amount: 410 mg (45%)
[0995] .sup.1H-NMR (D.sub.2O) .delta.: 7.47 (1H, d, J=8.4 Hz), 7.00
(1H, br s), 6.81 (1H, br s), 5.86-5.83 (1H, br m), 5.46 (1H, br s),
4.86-4.83 (1H, br m), 4.38-4.31 (1H, m), 4.24 (1H, br s), 4.10-3.52
(8H, m), 2.41-2.27 (4H, br m), 1.60-1.56 (3H, m), 1.52 (3H, br s),
1.45 (3H, br s).
[0996] [M+H]=806.35
Example 76
Synthesis of Compound I-76
##STR00295##
[0998] Yielded amount: 424 mg (48%)
[0999] .sup.1H-NMR (D.sub.2O) .delta.: 7.47 (1H, d, J=8.7 Hz), 7.02
(1H, s), 6.84 (1H, d, J=8.7 Hz), 5.82-5.81 (1H, br m), 5.46-5.45
(1H, br m), 5.17-5.08 (1H, m), 4.33-4.23 (2H, m), 4.07-3.56 (9H,
m), 2.48-2.06 (4H, m), 1.60-1.55 (3H, m), 1.53 (3H, s), 1.51 (3H,
s).
[1000] [M+H]=806.35
Example 77
Synthesis of Compound I-77
##STR00296##
[1002] Yielded amount: 102 mg (12%)
[1003] .sup.1H-NMR (D.sub.2O) .delta.: 7.19 (2H, s), 7.02 (1H, s),
5.83 (1H, d, J=4.8 Hz), 5.47 (1H, d, J=4.8 Hz), 4.14-4.06 (3H, m),
3.99 (1H, br s), 3.12 (3H, s), 2.98-2.14 (10H, m), 1.59 (3H, d,
J=7.2 Hz), 1.53 (3H, s), 1.51 (3H, s).
[1004] [M+H]=784.39
Example 78
Synthesis of Compound I-78
##STR00297##
[1006] Compound X-5 (543 mg, 1.0 mmol) and Compound X-2b (1.3 g,
1.0 mmol) were used to synthesize the target compound I-78 in the
same way as Example 39.
[1007] Yielded amount: 231 mg (25%)
[1008] .sup.1H-NMR (D.sub.2O) .delta.: 7.22 (2H, s), 7.03 (1H, s),
5.78 (1H, d, J=4.8 Hz), 5.41 (1H, d, J=4.8 Hz), 4.96 (1H, dd,
J=9.1, 4.2 Hz), 4.67 (1H, t, J=12.9 Hz), 4.06-3.98 (2H, m),
3.54-3.33 (8H, m), 2.72-2.69 (2H, m), 1.93 (6H, t, J=7.7 Hz), 1.54
(3H, d, J=7.2 Hz).
[1009] [M+H]=814.27
[1010] The compounds shown below were obtained from Compound X-2b
and the each corresponding amine in the same way as Example 78.
Example 79
Synthesis of Compound I-79
##STR00298##
[1012] Yielded amount: 75 mg (8%)
[1013] .sup.1H-NMR (D.sub.2O) .delta.: 7.27 (2H, s), 7.08 (1H, s),
5.75 (1H, d, J=4.6 Hz), 5.46 (1H, d, J=4.6 Hz), 5.12 (1H, d, J=14.2
Hz), 4.96 (1H, dd, J=9.6, 3.8 Hz), 4.31 (1H, d, J=14.2 Hz),
4.13-4.02 (3H, m), 3.69-3.51 (6H, m), 2.77-2.65 (2H, m), 2.22-2.07
(4H, m), 1.58 (3H, d, J=7.0 Hz).
[1014] [M+H]=788.24
Example 80
Synthesis of Compound I-80
##STR00299##
[1016] Yielded amount: 59 mg (5%)
[1017] .sup.1H-NMR (D.sub.2O) .delta.: 7.24 (2H, s), 7.07 (1H, s),
5.77 (1H, d, J=4.8 Hz), 5.45 (1H, d, J=4.8 Hz), 4.97 (2H, dd,
J=9.2, 3.9 Hz), 4.10-3.99 (4H, m), 3.13 (3H, s), 3.03-2.46 (9H, m),
2.28-2.12 (2H, m), 1.58 (3H, d, J=7.2 Hz).
[1018] [M+H]=814.20
Example 81
Synthesis of Compound I-81
##STR00300##
[1020] Yielded amount: 427 mg (49%)
[1021] .sup.1H-NMR (D.sub.2O) .delta.: 7.44-7.41 (1H, m), 7.33 (1H,
s), 7.01 (1H, s), 5.84 (1H, d, J=4.8 Hz), 5.45 (1H, d, J=4.8 Hz),
4.65 (1H, d, J=14.3 Hz), 4.07 (2H, t, J=6.9 Hz), 3.59-3.42 (6H, m),
3.37 (2H, s), 1.95 (6H, t, J=7.6 Hz), 1.56 (3H, d, J=7.0 Hz), 1.52
(3H, s), 1.51 (3H, s).
[1022] [M+H]=804.3
Example 82
Synthesis of Compound I-82
##STR00301##
[1024] Yielded amount: 325 mg (51%)
[1025] .sup.1H-NMR (D.sub.2O) .delta.: 7.33-7.29 (1H, m), 7.22 (1H,
br s), 7.00 (1H, br s), 5.85 (1H, t, J=5.5 Hz), 5.45 (1H, t, J=4.6
Hz), 4.38-4.27 (1H, m), 4.19-4.07 (2H, m), 3.88-3.49 (7H, m),
2.43-2.27 (4H, m), 1.61-1.56 (3H, m), 1.52 (3H, d, J=2.5 Hz), 1.50
(3H, d, J=1.9 Hz).
[1026] [M+H]=790.26
Example 83
Synthesis of Compound I-83
##STR00302##
[1028] Yielded amount: 333 mg (40%)
[1029] .sup.1H-NMR (D.sub.2O) .delta.: 7.44-7.41 (1H, m), 7.34 (1H,
s), 7.02 (1H, s), 5.82 (1H, d, J=4.9 Hz), 5.46 (1H, d, J=4.9 Hz),
4.29 (1H, t, J=7.4 Hz), 4.12-4.04 (3H, m), 3.95 (1H, br s), 3.11
(3H, s), 2.87-2.72 (2H, m), 2.55-2.32 (4H, m), 2.17 (2H, d, J=16.8
Hz), 1.58 (3H, d, J=7.0 Hz), 1.53 (3H, s), 1.51 (3H, s).
[1030] [M+H]=804.3
Example 84
Synthesis of Compound I-84
##STR00303##
[1032] Yielded amount: 307 mg (38%)
[1033] .sup.1H-NMR (D.sub.2O) .delta.: 7.51-7.48 (1H, m), 7.40 (1H,
s), 7.02 (1H, s), 5.80 (1H, d, J=4.8 Hz), 5.47 (1H, d, J=4.8 Hz),
5.04 (1H, d, J=14.3 Hz), 4.27 (1H, d, J=14.3 Hz), 4.09 (1H, dd,
J=13.9, 6.8 Hz), 3.97-3.38 (8H, m), 2.23 (4H, dd, J=12.4, 7.5 Hz),
1.58 (3H, d, J=7.0 Hz), 1.52 (3H, s), 1.50 (3H, s).
[1034] [M+H]=778.27
Example 85
Synthesis of Compound I-85
##STR00304##
[1036] Yielded amount: 395 mg (49%)
[1037] .sup.1H-NMR (D.sub.2O) .delta.: 7.37-7.33 (1H, m), 7.25 (1H,
s), 7.02-7.00 (1H, br m), 5.83-5.81 (1H, br m), 5.45 (1H, d, J=4.9
Hz), 5.13 (1H, dd, J=22.5, 14.3 Hz), 4.39-4.26 (2H, m), 4.09-3.52
(9H, m), 2.26-2.04 (4H, m), 1.60-1.54 (3H, br m), 1.52-1.52 (3H, br
m), 1.50 (3H, br s).
[1038] [M+H]=790.26
Example 86
Synthesis of Compound I-86
##STR00305##
[1039] Step (1): Compound X-1+Compound 86a.fwdarw.Compound I-86
[1040] Compound X-1 (932 mg, 1.0 mmol) was added to a solution of
compound 86a (564 mg, 1.00 mmol) in dimethylformamide (2 mL) at
0.degree. C., and the resultant solution was stirred at 0.degree.
C. for 5 hours. The reaction mixture was slowly added to a 5% salt
solution (30 ml) (containing 1.5 g of sodium bisulfite) at
0.degree. C. The precipitated solid was collected by filtration,
washed with water, and then suspended into water. The suspension
was freeze-dried to yield compound 86b as an orange solid. Compound
86b yielded was used as it was, without being purified, in the next
reaction.
[1041] The total amount of compound 86b yielded was dissolved in
dichloromethane (10 mL), and the solution was cooled to -40.degree.
C. Thereto were then added anisole (1.1 mL, 10 mmol) and a 2 mol/L
aluminum chloride solution (5.00 mL, 10 mmol) in nitromethane in
turn. The resultant was stirred at 0.degree. C. for 30 minutes. The
reaction mixture was dissolved in water, a 2 mol/L aqueous
hydrochloric acid solution, and acetonitrile. The resultant
solution was then washed with diisopropyl ether. To the water phase
was added HP20-SS resin, and then acetonitrile was distilled off
under reduced pressure. The resultant mixed liquid was purified by
ODS column chromatography. To the resultant target-compound
solution was added HP20-SS resin, and then acetonitrile was
distilled off under reduced pressure. The resultant mixed liquid
was purified by HP20-SS column chromatography. To the resultant
target-compound solution was added a 0.2 N aqueous sodium hydroxide
solution until the whole gave a pH of 6.0. Thereafter, a piece of
dry ice was added thereto. The resultant solution was concentrated
under reduced pressure, and then freeze-dried to yield compound
I-86 as a yellow powder.
[1042] Yielded amount: 472 mg (53%).
[1043] .sup.1H-NMR (D.sub.2O) .delta.: 7.00 (1H, s), 6.80 (1H, s),
5.82 (1H, d, J=4.8 Hz), 5.49 (1H, d, J=4.8 Hz), 4.99 (1H, d, J=14.3
Hz), 4.56 (2H, br s), 4.41-4.39 (3H, br m), 4.14 (1H, br s), 3.73
(1H, br s), 3.52-3.50 (3H, br m), 2.24 (4H, br s), 1.55-1.44 (12H,
m).
[1044] [M+H]=805.4
Example 87
Synthesis of Compound I-87
##STR00306##
[1045] Step (1): Compound X-1+Compound 87a.fwdarw.Compound I-87
[1046] Compound X-1 (932 mg, 1.0 mmol) and compound 87a (541 mg,
1.0 mmol) were used to synthesize the target compound in the same
way as Example 86.
[1047] Yielded amount: 298 mg (35%)
[1048] .sup.1H-NMR (D.sub.2O) .delta.: 8.24 (1H, s), 7.48 (2H, d,
J=7.3 Hz), 6.98 (1H, s), 5.82 (1H, d, J=4.9 Hz), 5.48 (1H, d, J=4.9
Hz), 4.89 (1H, d, J=14.3 Hz), 4.46-4.38 (2H, br m), 4.23 (1H, d,
J=14.3 Hz), 4.16-4.10 (1H, br m), 3.59 (2H, br s), 3.36 (3H, br s),
2.22 (4H, d, J=7.2 Hz), 1.55-1.47 (9H, m), 1.44 (1H, d, J=5.6 Hz),
1.33-1.32 (2H, br m), 1.11 (2H, br s).
[1049] [M+H]=782.42
Example 88
Synthesis of Compound I-88
##STR00307##
[1050] Step (1): Compound X-1+Compound 88a.fwdarw.Compound I-88
[1051] Compound X-1 (533 mg, 0.57 mmol) and compound 88a (329 mg,
0.57 mmol) were used to synthesize the target compound in the same
way as Example 86.
[1052] Yielded amount: 136 mg (27%)
[1053] .sup.1H-NMR (D.sub.2O) .delta.: 8.19 (1H, s), 7.41 (1H, s),
7.00 (1H, s), 5.83 (1H, d, J=4.9 Hz), 5.49 (1H, d, J=4.9 Hz), 4.89
(1H, d, J=14.2 Hz), 4.39 (2H, s), 4.22 (1H, d, J=14.2 Hz), 4.13
(1H, d, J=7.0 Hz), 3.56 (2H, s), 3.36 (3H, s), 2.21 (4H, s),
1.55-1.51 (9H, m), 1.32 (2H, s), 1.07 (2H, s).
[1054] [M+H]=816.21
Example 89
Synthesis of Compound I-89
##STR00308##
[1055] Step (1): Compound X-1+Compound 89a.fwdarw.Compound I-89
[1056] Compound X-1 (932 mg, 1 mmol) and compound 89a (620 mg, 1
mmol) were used to synthesize the target compound in the same way
as Example 86.
[1057] Yielded amount: 135 mg (14%)
[1058] .sup.1H-NMR (D.sub.2O) .delta.: 8.45 (1H, s), 7.00 (1H, s),
6.79 (1H, s), 5.82 (1H, d, J=4.6 Hz), 5.48 (1H, d, J=4.6 Hz), 5.03
(1H, d, J=14.4 Hz), 4.33-4.21 (3H, m), 4.07-3.91 (2H, m), 3.73-3.48
(6H, m), 2.24 (4H, br s), 1.57 (3H, d, J=7.0 Hz), 1.51-1.49 (9H,
m), 1.42 (3H, t, J=6.4 Hz).
[1059] [M+H]=782.42
Example 90
Synthesis of Compound I-90
##STR00309##
[1060] Step (1): Compound X-1+Compound 90a.fwdarw.Compound I-90
[1061] Compound X-1 (932 mg, 1 mmol) and compound 90a (632 mg, 1
mmol) were used to synthesize the target compound in the same way
as Example 86.
[1062] Yielded amount: 234 mg (25%)
[1063] .sup.1H-NMR (D.sub.2O) .delta.: 8.36 (1H, s), 7.23 (1H, s),
6.99 (1H, s), 5.83 (1H, d, J=4.6 Hz), 5.48 (1H, d, J=4.6 Hz), 5.03
(1H, d, J=14.2 Hz), 4.30 (1H, d, J=14.2 Hz), 4.06 (1H, br s),
3.90-3.36 (10H, m), 2.24 (4H, br s), 1.58 (3H, d, J=6.8 Hz), 1.51
(3H, s), 1.49 (3H, s), 1.44 (1H, d, J=5.6 Hz), 1.29 (2H, d, J=6.5
Hz), 1.03 (2H, br s).
[1064] [M+H]=873.35
Example 91
Synthesis of Compound I-91
##STR00310##
[1065] Step (1): Compound X-1+Compound 91a.fwdarw.Compound I-91
[1066] Compound X-1 (932 mg, 1 mmol) and compound 91a (557 mg, 1
mmol) were used to synthesize the target compound in the same way
as Example 86.
[1067] Yielded amount: 334 mg (38%)
[1068] .sup.1H-NMR (D.sub.2O) .delta.: 8.36 (1H, s), 7.68-7.65 (2H,
m), 6.99 (1H, s), 5.83 (1H, d, J=4.9 Hz), 5.47 (1H, d, J=4.9 Hz),
4.90 (1H, d, J=15.2 Hz), 4.56-4.45 (2H, m), 4.25 (1H, d, J=13.9
Hz), 3.59 (1H, br s), 3.39-3.36 (3H, br m), 2.26-2.23 (4H, br m),
1.87 (9H, s), 1.56-1.49 (9H, m).
[1069] [M+H]=798.18.
Example 92
Synthesis of Compound I-92
##STR00311##
[1070] Step (1): Compound 92a.fwdarw.Compound 92b
[1071] To a solution of 92a (4 g, 9.47 mmol) in MeOH (35 ml) was
added O-(4-methoxybenzyl)hydroxylamine (1.45 ml, 9.47 mmol) in MeOH
(5 ml) at 0.degree. C. under N2. The mixture was stirred at
0.degree. C. for 1 h. The mixture was filtered off and the filtrate
was washed IPE and Et.sub.2O to yield compound 92b (3.87 g, 73%,
E/Z=1:15).
[1072] Compound 92b
[1073] .sup.1H-NMR (CDCl3) .delta.: 7.34-7.27 (5H, m), 7.05 (1H,
dd, J=8.4, 1.6 Hz), 6.94-6.84 (9H, m), 5.16 (2H, s), 5.05 (4H, s),
4.63 (1H, s), 3.81 (3H, s), 3.79 (3H, s), 3.77 (3H, s).
Step (2): Compound 92b.fwdarw.Compound 92c
[1074] To a solution of 92b (1.11 g, 2.00 mmol) in DMA (10 ml) was
added HOBt (0.35 g, 2.60 mmol) and WSCD HCl (0.46 g, 2.40 mmol) at
0.degree. C. The mixture was stirred at 0.degree. C. for 1 h. The
reaction mixture was added quinuclidin-4-ylmethanamine (0.33 g,
2.40 mmol) at 0.degree. C. and then the mixture was stirred at
00.degree. C. for overnight. The reaction mixture was diluted with
ethyl acetate, washed with an aqueous sodium hydroxide solution,
water and a saturated salt solution, and dried over magnesium
sulfate. Magnesium sulfate was filtrated off, and then the liquid
was concentrated under reduced pressure. The compound-containing
liquid was subjected to silica gel column chromatography to elute
out the desired compound with hexane/ethyl acetate (containing 10%
triethyl amine). The desired-compound-containing fraction was
concentrated under reduced pressure to yield compound 92c (0.63 g,
46%, single isomer).
[1075] Compound 92c
[1076] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 8.44-8.41 (1H, br m),
7.36-7.32 (6H, m), 7.24 (1H, d, J=1.8 Hz), 7.10 (1H, d, J=8.5 Hz),
6.98 (1H, dd, J=8.5, 1.8 Hz), 6.94-6.91 (6H, m), 5.06 (4H, s), 5.00
(2H, s), 3.75 (9H, s), 2.92 (2H, d, J=6.3 Hz), 2.54 (6H, t, J=7.7
Hz), 1.19 (6H, t, J=7.5 Hz).
Step (3): Compound X-24+Compound 92c.fwdarw.Compound I-92
[1077] Compound X-24 (886 mg, 1 mmol) and compound 92c (680 mg, 1
mmol) were used to synthesize the target compound in the same way
as Example 86.
[1078] Yielded amount: 518 mg (60%)
[1079] .sup.1H-NMR (D.sub.2O) .delta.: 7.15 (1H, d, J=1.8 Hz),
7.00-6.94 (3H, m), 5.85 (1H, d, J=4.9 Hz), 5.45 (1H, d, J=4.9 Hz),
4.63 (1H, d, J=14.3 Hz), 4.08-4.05 (2H, m), 3.54-3.38 (8H, m),
1.96-1.92 (6H, m), 1.56 (3H, d, J=7.2 Hz), 1.53 (3H, s), 1.51 (3H,
s).
[1080] [M+H]=802.14.
Example 93
Synthesis of Compound I-93
##STR00312##
[1081] Step (1): Compound 92a.fwdarw.Compound 93a
[1082] To a solution of 92a (3 g, 7.10 mmol) in MeOH (30 ml) was
added O-4-methylhydroxylammonium chloride (1.54 g, 18.46 mmol) and
Et.sub.3N (2.75 ml, 19.8 mmol) at 0.degree. C. under N2. The
mixture was stirred at 0.degree. C. for 5.5 h. The mixture was
concentrated under reduced pressure. The reaction mixture was
diluted with ethyl acetate, washed with an aqueous hydrochloric
acid, water and a saturated salt solution, and dried over magnesium
sulfate. Magnesium sulfate was filtrated off, and then the liquid
was concentrated under reduced pressure to yield crude compound 93a
(3.21 g)
Step (2): Compound 93a.fwdarw.Compound 93b
[1083] To a solution of 93a (3.21 g, 7.10 mmol) in DMA (20 ml) was
added HOBt (1.24 g, 9.23 mmol) and WSCD HCl (1.63 g, 8.52 mmol) at
0.degree. C. The mixture was stirred at 0.degree. C. for 1 h. The
reaction mixture was added quinuclidin-4-ylmethanamine (1.19 g,
8.52 mmol) at 0.degree. C. and then the mixture was stirred at
0.degree. C. for 1 h. The reaction mixture was diluted with ethyl
acetate, washed with an aqueous sodium hydroxide solution, water
and a saturated salt solution, and dried over magnesium sulfate.
Magnesium sulfate was filtrated off, and then the liquid was
concentrated under reduced pressure. The compound-containing liquid
was subjected to silica gel column chromatography to elute out the
desired compound with hexane/ethyl acetate (containing 10% triethyl
amine). The desired-compound-containing fraction was concentrated
under reduced pressure to yield compound 93b (1.59 g, 39%,
E/Z=1:4).
compound 93b
[1084] .sup.1H-NMR (DMSO-D6) .delta.: 8.46-8.43 (1H, m), 7.40-7.32
(4H, m), 7.27-7.24 (1H, m), 7.13-7.11 (1H, m), 7.01 (1H, dd, J=8.4,
1.9 Hz), 6.96-6.92 (4H, m), 5.07 (2H, s), 4.99 (2H, s), 3.87 (2H,
s), 3.76-3.75 (6H, br m), 3.01-2.97 (2H, m), 2.71-2.68 (6H, m),
1.32-1.29 (6H, m).
Step (3): Compound X-24+Compound 93b.fwdarw.Compound I-93
[1085] Compound X-24 (886 mg, 1 mmol) and compound 93b (680 mg, 1
mmol) were used to synthesize the target compound in the same way
as Example 86.
[1086] Yielded amount: 518 mg (60%)
[1087] .sup.1H-NMR (D.sub.2O) .delta.: 7.17 (1H, s), 7.01-6.95 (3H,
m), 5.85 (1H, d, J=4.8 Hz), 5.46 (1H, d, J=4.8 Hz), 4.64 (1H, d,
J=14.2 Hz), 4.09-4.06 (2H, m), 3.98 (3H, s), 3.55-3.45 (6H, m),
3.38 (2H, br s), 1.95-1.91 (6H, m), 1.57 (3H, d, J=7.0 Hz), 1.52
(3H, s), 1.50 (3H, s).
[1088] [M+H]=815.22.
Example 94 and 95
Synthesis of Compound I-94 and 1-95
##STR00313##
[1089] Step (1): Compound 94a.fwdarw.Compound 94b
[1090] To a solution of 94a (4 g, 8.76 mmol) in MeOH (40 ml) was
added O-(4-methoxybenzyl)hydroxylamine (2.09 g, 9.63 mmol) at
0.degree. C. under N2. The mixture was stirred at 0.degree. C. for
1 h. The mixture was concentrated under reduced pressure. The
reaction mixture was diluted with ethyl acetate, washed with an
aqueous hydrochloric acid, water and a saturated salt solution, and
dried over magnesium sulfate. Magnesium sulfate was filtrated off,
and then the liquid was concentrated under reduced pressure to
yield crude compound 94b (5.02 g, 8.76 mmol, E/Z=1:1.5)
Step (2): Compound 94b.fwdarw.Compound 94c and 94d
[1091] To a solution of 94b (1.77 g, 3 mmol) in DMA (10 ml) was
added HOBt (0.52 g, 3.90 mmol) and WSCD HCl (0.69 g, 3.60 mmol) at
0.degree. C. The mixture was stirred at 0.degree. C. for 1 h. The
reaction mixture was added quinuclidin-4-ylmethanamine (0.50 g,
3.60 mmol) at 0.degree. C. and then the mixture was stirred at
0.degree. C. for 1 h. The reaction mixture was diluted with ethyl
acetate, washed with an aqueous sodium hydroxide solution, water
and a saturated salt solution, and dried over magnesium sulfate.
Magnesium sulfate was filtrated off, and then the liquid was
concentrated under reduced pressure. The compound-containing liquid
was subjected to silica gel column chromatography to elute out the
desired compound with hexane/ethyl acetate (containing 10% triethyl
amine). The desired-compound-containing fraction was concentrated
under reduced pressure to yield compound 94c (0.88 g, 41%,
E/Z=1:10) and compound 94d (0.61. 29%, E/Z=4.5:1).
[1092] Compound 94c
[1093] .sup.1H-NMR (DMSO-D6) .delta.: 8.35 (1H, t, J=6.3 Hz), 7.45
(2H, d, J=7.2 Hz), 7.39 (2H, d, J=8.5 Hz), 7.30 (2H, d, J=8.6 Hz),
7.25-7.18 (2H, m), 6.97 (4H, dd, J=11.7, 8.7 Hz), 6.86 (2H, d,
J=31.6 Hz), 5.16 (2H, s), 5.10 (2H, s), 4.87 (2H, s), 3.78 (3H, s),
3.76 (3H, s), 3.75 (3H, s), 2.91 (2H, d, J=6.3 Hz), 2.58-2.54 (6H,
m), 1.21-1.14 (6H, m).
[1094] Compound 94d
[1095] .sup.1H-NMR (DMSO-D6) .delta.: 7.98 (1H, t, J=6.3 Hz), 7.43
(2H, d, J=8.2 Hz), 7.31-7.24 (4H, m), 7.18 (2H, d, J=7.4 Hz), 6.98
(2H, d, J=8.5 Hz), 6.90 (2H, d, J=8.5 Hz), 6.85 (2H, d, J=8.2 Hz),
5.13 (2H, s), 5.11 (2H, s), 4.85 (2H, s), 3.77 (3H, s), 3.74 (6H,
s), 2.96 (2H, d, J=6.3 Hz), 2.73-2.70 (6H, m), 1.30-1.26 (6H,
m).
Step (3): Compound X-24+Compound 94c.fwdarw.Compound I-94
[1096] Compound X-24 (754 mg, 0.85 mmol) and compound 94c (608 mg,
0.85 mmol) were used to synthesize the target compound in the same
way as Example 86.
[1097] Yielded amount: 410 mg (55%)
[1098] .sup.1H-NMR (D.sub.2O) .delta.: 7.00 (1H, s), 6.97-6.90 (2H,
m), 5.85 (1H, d, J=4.8 Hz), 5.45 (1H, d, J=4.8 Hz), 4.62 (1H, d,
J=14.3 Hz), 4.09-4.04 (2H, m), 3.52-3.30 (8H, m), 1.93-1.90 (6H,
m), 1.56 (3H, d, J=7.3 Hz), 1.52 (3H, s), 1.50 (3H, s).
[1099] [M+H]=835.24.
Step (4): Compound X-24+Compound 94d.fwdarw.Compound I-95
[1100] Compound X-24 (886 mg, 1 mmol) and compound 94d (714 mg, 1
mmol) were used to synthesize the target compound in the same way
as Example 86.
[1101] Yielded amount: 403 mg (46%)
[1102] .sup.1H-NMR (D.sub.2O) .delta.: 7.00 (1H, s), 6.97-6.90 (1H,
m), 6.78 (1H, d, J=8.3 Hz), 5.85 (1H, d, J=4.8 Hz), 5.45-5.42 (1H,
m), 4.64-4.59 (2H, m), 4.07-3.97 (2H, m), 3.52-3.30 (8H, m),
1.94-1.87 (6H, m), 1.57-1.51 (9H, m).
[1103] [M+H]=835.21
Example 96
Synthesis of Compound I-96
##STR00314##
[1104] Step (1): Compound 94a.fwdarw.Compound 96a
[1105] To a solution of 94a (6 g, 13.1 mmol) in MeOH (60 ml) was
added O-4-methylhydroxylammonium chloride (1.64 g, 19.7 mmol) and
Et.sub.3N (2.73 ml, 19.7 mmol) at 0.degree. C. under N2. The
mixture was stirred at 0.degree. C. for 1.5 h. The mixture was
concentrated under reduced pressure. The reaction mixture was
diluted with ethyl acetate, washed with an aqueous hydrochloric
acid, water and a saturated salt solution, and dried over magnesium
sulfate. Magnesium sulfate was filtrated off, and then the liquid
was concentrated under reduced pressure to yield crude compound 96a
(6.38 g, E/Z=1:2.5)
Step (2): Compound 96a.fwdarw.Compound 96b
[1106] To a solution of 96a (6.38 g, 13.1 mmol) in DMA (50 ml) was
added HOBt (2.3 g, 17.0 mmol) and WSCD HCl (3.02 g, 17.7 mmol) at
0.degree. C. The mixture was stirred at 0.degree. C. for 1 h. The
reaction mixture was added quinuclidin-4-ylmethanamine (2.2 g, 15.7
mmol) at 0.degree. C. and then the mixture was stirred at 0.degree.
C. for 1 h. The reaction mixture was diluted with ethyl acetate,
washed with an aqueous sodium hydroxide solution, water and a
saturated salt solution, and dried over magnesium sulfate.
Magnesium sulfate was filtrated off, and then the liquid was
concentrated under reduced pressure. The residue was recrystallized
with hexane/ethyl acetate/a little of methanol to yield compound
96b (0.56 g, 7%, single isomer)
[1107] Compound 96b .sup.1H-NMR (DMSO-D6) .delta.: 8.35 (1H, t,
J=6.3 Hz), 7.44 (2H, d, J=8.5 Hz), 7.29 (2H, d, J=8.5 Hz), 7.23
(1H, d, J=8.9 Hz), 7.20 (1H, d, J=8.9 Hz), 6.98 (2H, d, J=8.5 Hz),
6.86 (2H, d, J=8.5 Hz), 5.15 (2H, s), 4.87 (2H, s), 3.90 (3H, s),
3.77 (3H, s), 3.74 (3H, s), 2.94 (2H, d, J=6.3 Hz), 2.71-2.67 (6H,
m), 1.30-1.26 (6H, m).
Step (3): Compound X-24+Compound 96b.fwdarw.Compound I-96
[1108] Compound X-24 (743 mg, 0.84 mmol) and compound 96b (510 mg,
0.84 mmol) were used to synthesize the target compound in the same
way as Example 86.
[1109] Yielded amount: 226 mg (28%)
[1110] .sup.1H-NMR (D.sub.2O) .delta.: 7.01 (1H, s), 6.97 (1H, d,
J=8.4 Hz), 6.91 (1H, d, J=8.4 Hz), 5.85 (1H, d, J=4.8 Hz), 5.45
(1H, d, J=4.8 Hz), 4.63 (1H, d, J=14.7 Hz), 4.09-4.00 (5H, m),
3.53-3.43 (6H, m), 3.33 (2H, s), 1.92-1.88 (6H, m), 1.54 (3H, d,
J=7.3 Hz), 1.52 (3H, s), 1.50 (3H, s).
[1111] [M+H]=849.25
Example 97
Synthesis of Compound I-97
##STR00315##
[1112] Step (1): Compound X-24+Compound 97a.fwdarw.Compound
1-97
[1113] Compound X-24 (7.40 g, 8.37 mmol) and compound 97a (5.56 g,
8.37 mmol) were used to synthesize the target compound in the same
way as Example 86.
[1114] Yielded amount: 1.81 g (26%)
[1115] .sup.1H-NMR (D.sub.2O) .delta.: 7.98 (1H, s), 6.97 (1H, s),
6.62 (1H, s), 5.82 (1H, d, J=4.5 Hz), 5.50 (1H, d, J=4.5 Hz), 4.90
(1H, d, J=14.4 Hz), 4.36 (2H, s), 4.21-4.12 (2H, m), 3.56 (1H, br
s), 3.36 (3H, br s), 2.24-2.21 (4H, br m), 1.54 (3H, d, J=7.7 Hz),
1.51 (3H, s), 1.49 (3H, s).
[1116] [M+H]=776.18
Example 98
Synthesis of Compound I-98
##STR00316##
[1117] Step (1): Compound 94a+.fwdarw.Compound 98a
[1118] To a solution of 94a (1.37 g, 3 mmol) in MeOH (6 ml) was
added tert-butyl 2-(aminooxy)acetate (0.44 g, 3 mmol) at 0.degree.
C. under N2. The mixture was stirred at rt for 1 h. The mixture was
concentrated under reduced pressure. The reaction mixture was
diluted with ethyl acetate, washed with an aqueous hydrochloric
acid, water and a saturated salt solution, and dried over magnesium
sulfate. Magnesium sulfate was filtrated off, and then the liquid
was concentrated under reduced pressure. The residue was
recrystallized with dichloromethane/diisopropyl ether to yield
compound 98a (0.90 g, 51%, single isomer).
[1119] Compound 98a
[1120] .sup.1H-NMR (CDCl3) .delta.: 7.34 (4H, d, J=8.4 Hz), 7.23
(1H, d, J=8.5 Hz), 6.92 (3H, dd, J=8.4, 5.1 Hz), 6.83 (2H, d, J=8.5
Hz), 5.08 (2H, s), 4.95 (2H, s), 4.73 (2H, s), 3.83 (3H, s), 3.80
(3H, s), 1.51 (9H, s).
Step (2): Compound 98a.fwdarw.Compound 98b
[1121] Compound 98a (0.87 g, 1.49 mmol) and triethylamine (0.29 ml,
2.09 mmol) were dissolved into dimethylacetamide (6 mL), and
thereto was then added Methanesulfonyl chloride (0.15 ml, 1.94
mmol) at -20.degree. C. The mixture was stirred at -20.degree. C.
for 30 minutes. Thereto was then added quinuclidin-4-ylmethanamine
(0.23 g, 1.64 mmol) at 0.degree. C. The mixture was stirred at
0.degree. C. for 1 h. The reaction mixture was diluted with ethyl
acetate, washed with an aqueous sodium hydroxide solution, water
and a saturated salt solution, and dried over magnesium sulfate.
Magnesium sulfate was filtrated off, and then the liquid was
concentrated under reduced pressure. The compound-containing liquid
was subjected to silica gel column chromatography to elute out the
desired compound with hexane/ethyl acetate (containing 10% triethyl
amine). The desired-compound-containing fraction was concentrated
under reduced pressure to yield compound 98b (0.72 g, 69%).
[1122] Compound 98b
[1123] .sup.1H-NMR (DMSO-D6) .delta.: 8.20 (1H, t, J=6.1 Hz), 7.44
(2H, d, J=8.5 Hz), 7.29 (2H, d, J=8.5 Hz), 7.24 (2H, d, J=7.5 Hz),
7.17 (2H, d, J=7.5 Hz), 6.98 (2H, d, J=8.5 Hz), 6.86 (2H, d, J=8.5
Hz), 5.16 (2H, s), 4.87 (2H, s), 4.69 (2H, s), 3.77 (3H, s), 3.74
(3H, s), 2.99 (2H, d, J=6.3 Hz), 2.72-2.68 (6H, m), 1.45 (9H, s),
1.33-1.29 (6H, m).
Step (3): Compound X-24+Compound 98b.fwdarw.Compound I-98
[1124] Compound X-24 (886 mg, 1 mmol) and compound 98b (708 mg, 1
mmol) were used to synthesize the target compound in the same way
as Example 86.
[1125] Yielded amount: 567 mg (59%)
[1126] .sup.1H-NMR (D.sub.2O) .delta.: 7.01-6.99 (2H, m), 6.94-6.91
(1H, m), 5.85 (1H, d, J=4.8 Hz), 5.46 (1H, d, J=4.8 Hz), 4.65-4.62
(3H, m), 4.11-4.05 (2H, m), 3.53-3.37 (9H, m), 1.95-1.91 (6H, m),
1.56 (3H, d, J=7.0 Hz), 1.52 (3H, s), 1.50 (3H, s).
[1127] [M+H]=893.23
Example 99
Synthesis of Compound I-99
##STR00317##
[1128] Step (1): Compound 94a.fwdarw.Compound 99a
[1129] To a solution of tert-butyl 2-(aminooxy)-2-methylpropanoate
(5.25 g, 30 mmol) in MeOH (60 ml) was added 94a (9.16 g, 30 mmol)
at 0.degree. C. under N2. The mixture was stirred at rt for 1 h.
The mixture was concentrated under reduced pressure. The reaction
mixture was diluted with ethyl acetate, washed with an aqueous
hydrochloric acid, water and a saturated salt solution, and dried
over magnesium sulfate. Magnesium sulfate was filtrated off, and
then the liquid was concentrated under reduced pressure. The
residue was recrystallized with dichloromethane/diisopropyl ether
to yield crude compound 99a (16 g, 87%, E/Z=1:1.5).
Step (2): Compound 99a.fwdarw.Compound 99b
[1130] To a solution of 99a (1.6 g, 2.61 mmol) in ethyl acetate (16
ml) was added WSCD HCl (0.55 g, 2.87 mmol) and DMAP (0.03 g, 0.26
mmol) and 2-(trimethylsilyl)ethanol (0.43 ml, 2.87 mmol) at
0.degree. C. The mixture was stirred at rt for 1 h. The reaction
mixture was diluted with ethyl acetate, washed with an aqueous
hydrochloric acid, water and a saturated salt solution, and dried
over magnesium sulfate. Magnesium sulfate was filtrated off, and
then the liquid was concentrated under reduced pressure. The
compound-containing liquid was subjected to silica gel column
chromatography to elute out the desired compound with hexane/ethyl
acetate to chloroform/methanol. The desired-compound-containing
fraction was concentrated under reduced pressure to yield compound
99b (1.23 g, 66%, E/Z=1:10).
[1131] Compound 99b
[1132] .sup.1H-NMR (CDCl3) .delta.: 7.36 (4H, dd, J=8.5, 3.8 Hz),
7.07 (1H, d, J=8.5 Hz), 6.93 (3H, t, J=6.8 Hz), 6.83 (2H, d, J=8.5
Hz), 5.06 (2H, s), 4.97 (2H, s), 4.33 (2H, t, J=8.2 Hz), 3.84 (3H,
s), 3.80 (3H, s), 1.47 (9H, s), 1.03 (2H, t, J=8.2 Hz), 0.02 (9H,
s).
Step (3): Compound 99b.fwdarw.Compound 99c
[1133] To a solution of 99b (1.42 g, 2 mmol) in THF (14 ml) was
added 1M TBAF in THF (4 ml, 4 mmol) at 0.degree. C. The mixture was
stirred at rt for 1 h. The reaction mixture was diluted with ethyl
acetate, washed with an aqueous hydrochloric acid, water and a
saturated salt solution, and dried over magnesium sulfate.
Magnesium sulfate was filtrated off, and then the liquid was
concentrated under reduced pressure to yield compound 99c (1.22
g).
[1134] Compound 99c
[1135] .sup.1H-NMR (CDCl3) .delta.: 7.37-7.33 (4H, m), 6.97 (2H, br
s), 6.93 (2H, d, J=8.6 Hz), 6.83 (2H, d, J=8.6 Hz), 5.07 (2H, s),
4.99 (2H, s), 3.84 (3H, s), 3.80 (3H, s), 1.50 (6H, s), 1.47 (9H,
s).
Step (4): Compound 99c.fwdarw.Compound 99d
[1136] Compound 99c (1.22 g, 2 mmol) and triethylamine (0.38 ml,
2.80 mmol) were dissolved into dimethylacetamide (13 mL), and
thereto was then added Methanesulfonyl chloride (0.20 ml, 2.60
mmol) at -20.degree. C. The mixture was stirred at -20.degree. C.
for 30 minutes. Thereto was then added quinuclidin-4-ylmethanamine
(0.31 g, 2.20 mmol) at 0.degree. C. The mixture was stirred at
0.degree. C. for 1 h. The reaction mixture was diluted with ethyl
acetate, washed with an aqueous sodium hydroxide solution, water
and a saturated salt solution, and dried over magnesium sulfate.
Magnesium sulfate was filtrated off, and then the liquid was
concentrated under reduced pressure. The precipitated solid was
then collected by filtration, and washed with diisopropyl ether to
yield compound 99d (1.01 g, 51%, E/Z=1:10).
[1137] Compound 99d
[1138] .sup.1H-NMR (DMSO-D6) .delta.: 7.73 (1H, t, J=6.5 Hz), 7.45
(2H, d, J=8.2 Hz), 7.29 (2H, d, J=8.2 Hz), 7.24 (1H, d, J=8.5 Hz),
7.06 (1H, d, J=8.5 Hz), 6.99 (2H, d, J=8.2 Hz), 6.85 (2H, d, J=8.2
Hz), 5.15 (2H, s), 4.88 (2H, s), 3.78 (3H, s), 3.74 (3H, s), 2.96
(2H, d, J=6.4 Hz), 2.71-2.68 (6H, m), 1.42 (15H, s), 1.29-1.25 (6H,
m).
Step (5): Compound X-24+Compound 99d.fwdarw.Compound I-99
[1139] Compound X-24 (901 mg, 1.02 mmol) and compound 99d (749 mg,
1.02 mmol) were used to synthesize the target compound in the same
way as Example 86.
[1140] Yielded amount: 431 mg (45%)
[1141] .sup.1H-NMR (D.sub.2O) .delta.: 7.01 (1H, s), 6.95 (1H, d,
J=8.3 Hz), 6.88 (1H, d, J=8.3 Hz), 5.85 (1H, d, J=4.6 Hz), 5.46
(1H, d, J=4.6 Hz), 4.63 (1H, d, J=13.9 Hz), 4.09-4.04 (2H, m),
3.52-3.37 (6H, m), 3.30 (2H, br s), 1.92-1.89 (6H, m), 1.56 (3H, d,
J=6.9 Hz), 1.52 (3H, s), 1.50 (3H, s), 1.44 (6H, s).
[1142] [M+H]=921.46
Example 100
Synthesis of Compound I-100
##STR00318##
[1143] Step (1): Compound 100a+Compound 100b.fwdarw.Compound
100c
[1144] To a solution of 100b (28.9 g, 53 mmol) in THF (250 ml) was
added 100a (6.69 g, 53 mmol) in THF (50 ml) at 0.degree. C. The
mixture was stirred at rt for 1 h. The reaction mixture was diluted
with ethyl acetate, washed with an aqueous sodium hydroxide
solution, water and a saturated salt solution, and dried over
magnesium sulfate. Magnesium sulfate was filtrated off, and then
the liquid was concentrated under reduced pressure. The
precipitated solid was then collected by filtration, and washed
with diisopropyl ether to yield compound 100c (24.1 g, 85%)
[1145] Compound 100c
[1146] .sup.1H-NMR (DMSO-D6) .delta.: 8.40 (1H, t, J=6.0 Hz), 7.43
(2H, d, J=8.5 Hz), 7.33 (2H, d, J=8.5 Hz), 7.19 (1H, d, J=8.7 Hz),
7.13 (1H, d, J=8.7 Hz), 6.98 (2H, d, J=8.5 Hz), 6.89 (2H, d, J=8.5
Hz), 5.16 (2H, s), 4.89 (2H, s), 3.78 (3H, s), 3.76 (3H, s), 3.53
(2H, d, J=6.0 Hz), 2.85-2.78 (2H, m), 2.57-2.54 (2H, m), 2.25 (2H,
s), 1.62-1.57 (2H, m), 1.24-1.18 (2H, m).
Step (2): Compound X-24+Compound 100c.fwdarw.Compound I-100
[1147] Compound X-24 (886 mg, 1 mmol) and compound 100c (537 mg, 1
mmol) were used to synthesize the target compound in the same way
as Example 86.
[1148] Yielded amount: 500 mg (63%)
[1149] .sup.1H-NMR (D.sub.2O) .delta.: 7.01 (1H, s), 6.95 (1H, d,
J=8.4 Hz), 6.89 (1H, d, J=8.4 Hz), 5.82 (1H, d, J=4.8 Hz), 5.45
(1H, d, J=4.8 Hz), 4.92 (1H, d, J=14.6 Hz), 4.28 (1H, d, J=14.6
Hz), 4.07-4.02 (1H, m), 3.71-3.56 (6H, m), 3.44-3.42 (1H, br m),
3.35-3.33 (1H, br m), 2.24 (2H, br s), 2.01 (2H, br s), 1.57 (3H,
d, J=7.2 Hz), 1.52 (3H, s), 1.50 (3H, s).
[1150] [M+H]=778.19
Example 101
Synthesis of Compound I-101
##STR00319##
[1151] Step (1): Compound 100a+Compound 98a.fwdarw.Compound
101a
[1152] Compound 98a (1.17 g, 2 mmol) was used to synthesize the
target compound 101a in the same way as in Step (2) of Example
98.
[1153] Yielded amount: 1.15 g (82%)
[1154] Compound 101a
[1155] .sup.1H-NMR (DMSO-D6) .delta.: 8.41 (1H, t, J=6.1 Hz), 7.43
(2H, d, J=8.4 Hz), 7.29 (2H, d, J=8.4 Hz), 7.25 (2H, d, J=8.9 Hz),
7.17 (2H, d, J=8.9 Hz), 6.98 (2H, d, J=8.5 Hz), 6.86 (2H, d, J=8.5
Hz), 5.16 (2H, s), 4.88 (2H, s), 4.66 (2H, s), 3.77 (3H, s), 3.74
(3H, s), 3.54 (2H, d, J=6.0 Hz), 2.79-2.73 (2H, m), 2.51-2.49 (2H,
m), 2.18 (2H, s), 1.60-1.52 (2H, m), 1.44 (9H, s), 1.18-1.12 (2H,
m).
Step (2): Compound X-24+Compound 101a.fwdarw.Compound I-101
[1156] Compound X-24 (1 g, 1.14 mmol) and compound 101a (788 mg,
1.14 mmol) were used to synthesize the target compound in the same
way as Example 86.
[1157] Yielded amount: 453 mg (43%)
[1158] .sup.1H-NMR (D.sub.2O) .delta.: 7.02-6.99 (2H, m), 6.93 (1H,
d, J=8.4 Hz), 5.83 (1H, d, J=4.8 Hz), 5.47 (1H, d, J=4.8 Hz), 4.89
(1H, d, J=14.4 Hz), 4.62 (2H, s), 4.25 (1H, d, J=14.4 Hz),
3.97-3.92 (1H, m), 3.77-3.50 (6H, m), 3.37 (1H, d, J=8.4 Hz), 3.24
(1H, d, J=8.4 Hz), 2.22 (2H, br s), 1.98 (2H, br s), 1.54-1.51 (9H,
m).
[1159] Elem. Anal.: C35H37ClN8Na2O13S2(H2O) 8.6
[1160] Calcd.: C, 38.99; H, 5.07; N, 10.39; S, 5.95; Na, 4.26; Cl,
3.29(%).
[1161] Found: C, 38.88; H, 4.94; N, 10.53; S, 5.95; Na, 4.40; Cl,
3.57(%).
Example 102 and 103
Synthesis of Compound I-102 and I-103
##STR00320##
[1162] Step (1): Compound 100a+Compound 94b.fwdarw.Compound 102a
and 102b
[1163] Compound 94b (5.76 g, 9.73 mmol) and triethylamine (1.88 ml,
13.6 mmol) were dissolved into dimethylacetamide (35 mL), and
thereto was then added Methanesulfonyl chloride (0.98 ml, 12.6
mmol) at -20.degree. C. The mixture was stirred at -20.degree. C.
for 30 minutes. Thereto was then added compound 100a (1.35 g, 10.7
mmol) in DMA (5 ml) at 0.degree. C. The mixture was stirred at
0.degree. C. for 1 h. The reaction mixture was diluted with ethyl
acetate, washed with an aqueous sodium hydroxide solution, water
and a saturated salt solution, and dried over magnesium sulfate.
Magnesium sulfate was filtrated off, and then the liquid was
concentrated under reduced pressure. The precipitated solid was
then collected by filtration, and washed with ethyl acetate to
yield compound 102a (3.2 g, 47%, single isomer). The residue was
subjected to silica gel column chromatography to elute out the
desired compound with ethyl acetate/methanol (containing 10%
triethyl amine). The desired-compound-containing fraction was
concentrated under reduced pressure to yield compound 102b (2 g,
29%, E/Z=10:1).
[1164] Compound 102a
[1165] .sup.1H-NMR (DMSO-D6) .delta.: 8.51 (1H, t, J=6.1 Hz), 7.44
(2H, d, J=8.5 Hz), 7.35 (2H, d, J=8.5 Hz), 7.28 (2H, t, J=8.5 Hz),
7.23 (1H, d, J=8.8 Hz), 7.18 (1H, d, J=8.8 Hz), 6.98 (2H, d, J=8.5
Hz), 6.93 (2H, d, J=8.5 Hz), 6.86 (2H, d, J=8.5 Hz), 5.15 (2H, s),
5.08 (2H, s), 4.87 (2H, s), 3.77 (3H, s), 3.76 (3H, s), 3.75 (3H,
s), 3.45 (2H, d, J=6.1 Hz), 2.59-2.52 (2H, m), 2.31 (2H, br s),
2.03 (2H, br s), 1.44-1.38 (2H, m), 1.01-0.95 (2H, m).
[1166] Compound 102b
[1167] .sup.1H-NMR (DMSO-D6) .delta.: 8.26 (1H, t, J=6.3 Hz), 7.43
(2H, d, J=8.5 Hz), 7.30 (2H, d, J=8.5 Hz), 7.24 (2H, d, J=7.7 Hz),
7.17 (2H, d, J=7.7 Hz), 6.97 (2H, d, J=8.6 Hz), 6.90 (2H, dd,
J=8.6, 1.9 Hz), 6.85 (2H, d, J=8.5 Hz), 5.12 (2H, s), 5.11 (2H, s),
4.86 (2H, s), 3.77 (3H, s), 3.74 (6H, s), 3.50 (2H, d, J=6.3 Hz),
2.76-2.72 (2H, m), 2.43-2.40 (2H, m), 1.54-1.48 (2H, m), 1.19-1.11
(2H, m).
Step (2): Compound X-24+Compound 102a.fwdarw.Compound I-102
[1168] Compound X-24 (886 mg, 1 mmol) and compound 102a (700 mg, 1
mmol) were used to synthesize the target compound in the same way
as E
[1169] Yielded amount: 432 mg (51%)
[1170] .sup.1H-NMR (D.sub.2O) .delta.: 7.02 (1H, s), 6.94 (2H, dd,
J=14.4, 8.3 Hz), 5.82 (1H, d, J=4.9 Hz), 5.46 (1H, d, J=4.9 Hz),
4.90 (1H, d, J=14.6 Hz), 4.24 (1H, d, J=14.6 Hz), 3.96-3.91 (1H,
m), 3.75-3.51 (6H, m), 3.36 (1H, d, J=8.4 Hz), 3.23 (1H, d, J=8.4
Hz), 2.20 (2H, s), 1.96 (2H, s), 1.54-1.51 (9H, m).
[1171] Elem. Anal.: C33H36ClN8NaO11S2(H2O) 6.7
[1172] Calcd.: C, 41.12; H, 5.17; N, 11.62; S, 6.65; Na, 2.38; Cl,
3.68(%).
[1173] Found: C, 41.02; H, 5.10; N, 11.69; S, 6.67; Na, 2.52; Cl,
3.83(%).
Step (3): Compound X-24+Compound 102b.fwdarw.Compound I-103
[1174] Compound X-24 (886 mg, 1 mmol) and compound 102b (700 mg, 1
mmol) were used to synthesize the target compound in the same way
as Example 86.
[1175] Yielded amount: 365 mg (43%)
[1176] .sup.1H-NMR (D.sub.2O) .delta.: 7.02 (1H, s), 6.96 (1H, d,
J=12.3 Hz), 6.80 (1H, d, J=8.4 Hz), 5.82 (1H, d, J=4.8 Hz), 5.48
(1H, d, J=4.8 Hz), 4.89 (1H, d, J=14.6 Hz), 4.24 (1H, d, J=14.6
Hz), 3.99-3.92 (1H, m), 3.75-3.52 (6H, m), 3.34 (1H, d, J=8.5 Hz),
3.22 (1H, d, J=8.5 Hz), 2.18 (2H, br s), 1.95 (2H, br s), 1.54-1.51
(9H, m).
[1177] Elem. Anal.: C33H36ClN8NaO11S2(H2O) 6.7(NaHCO3) 0.1
[1178] Calcd.: C, 40.89; H, 5.13; N, 11.52; S, 6.59; Na, 2.60; Cl,
3.65(%).
[1179] Found: C, 40.70; H, 5.21; N, 11.60; S, 6.58; Na, 2.60; Cl,
3.84(%).
Example 104 and 105
Synthesis of Compound I-104 and I-105
##STR00321##
[1180] Step (1): Compound 100a+Compound 96a.fwdarw.Compound
104a
[1181] Compound 96b (1.38 g, 11 mmol) was used to synthesize the
target compound in the same way as in Step (1) of Example 102.
[1182] Yielded amount: 3 g (50%, E/Z=1:1.5)
[1183] Compound 104a
[1184] .sup.1H-NMR (DMSO-D6) .delta.: 8.58 (1H, t, J=6.0 Hz), 8.33
(1H, t, J=6.0 Hz), 7.44 (4H, d, J=7.7 Hz), 7.30 (4H, d, J=7.2 Hz),
7.25-7.14 (4H, m), 6.98 (4H, d, J=8.3 Hz), 6.86 (4H, d, J=8.3 Hz),
5.15 (4H, s), 4.88 (4H, s), 3.91 (3H, s), 3.90 (3H, s), 3.77 (6H,
s), 3.74 (6H, s), 2.78-2.73 (4H, m), 2.47-2.42 (2H, m), 2.30 (2H,
s), 2.16 (4H, s), 1.56-1.51 (4H, m), 1.18-1.13 (4H, m).
Step (2): Compound X-24+Compound 104a.fwdarw.Compound I-104 and
I-105
[1185] Compound X-24 (969 mg, 1.1 mmol) and compound 104a (650 mg,
1.1 mmol) were used to synthesize the target compound in the same
way as Example 86.
[1186] Yielded amount of I-104: 140 mg (15%)
[1187] Compound 1-104
[1188] .sup.1H-NMR (D.sub.2O) .delta.: 7.02 (1H, s), 6.92 (2H, dd,
J=20.5, 6.0 Hz), 5.83 (1H, d, J=4.8 Hz), 5.46 (1H, d, J=4.8 Hz),
4.90 (1H, d, J=14.3 Hz), 4.25 (1H, d, J=14.3 Hz), 4.03 (3H, s),
3.96-3.91 (1H, m), 3.72-3.53 (6H, m), 3.33 (1H, d, J=8.5 Hz), 3.21
(1H, d, J=8.5 Hz), 2.18 (2H, s), 1.96 (2H, s), 1.54-1.51 (9H,
m).
[1189] Elem. Anal.: C34H38ClN8NaO11S2(H2O) 7.1(NaHCO3) 0.2
[1190] Calcd.: C, 41.00; H, 5.27; N, 11.18; S, 6.40; Na, 2.75; Cl,
3.54(%).
[1191] Found: C, 40.69; H, 5.23; N, 11.48; S, 6.36; Na, 2.99; Cl,
3.51(%).
[1192] Yielded amount of I-105: 180 mg (19%)
[1193] Compound I-105
[1194] .sup.1H-NMR (D.sub.2O) .delta.: 7.02 (1H, s), 6.95 (1H, d,
J=8.4 Hz), 6.80 (1H, d, J=8.4 Hz), 5.82 (1H, d, J=4.8 Hz), 5.48
(1H, d, J=4.8 Hz), 4.90 (1H, d, J=14.4 Hz), 4.24 (1H, d, J=14.4
Hz), 4.03-3.95 (4H, m), 3.69-3.52 (6H, m), 3.35 (1H, d, J=8.7 Hz),
3.22 (1H, d, J=8.7 Hz), 2.18 (2H, s), 1.95 (2H, s), 1.55-1.51 (9H,
m).
[1195] Elem. Anal.: C34H38ClN8NaO11S2(H2O) 6.8
[1196] Calcd.: C, 41.68; H, 5.31; N, 11.44; S, 6.54; Na, 2.35; Cl,
3.62(%).
[1197] Found: C, 41.46; H, 5.24; N, 11.61; S, 6.80; Na, 2.49; Cl,
3.60(%).
Example 106
Synthesis of Compound I-106
##STR00322##
[1198] Step (1): Compound X-1+Compound 106a.fwdarw.Compound
I-106
[1199] Compound X-1 (1.32 g, 1.32 mmol) and compound 106a (720 mg,
1.32 mmol) were used to synthesize the target compound in the same
way as Example 86.
[1200] Yielded amount: 510 mg (47%)
[1201] .sup.1H-NMR (D.sub.2O) .delta.: 8.26 (1H, s), 7.62 (1H, s),
7.30 (1H, s), 6.99 (1H, s), 5.83 (1H, d, J=4.9 Hz), 5.48 (1H, d,
J=4.9 Hz), 5.01 (1H, t, J=6.6 Hz), 4.89 (1H, d, J=14.3 Hz),
4.54-4.47 (2H, m), 4.26 (1H, d, J=14.3 Hz), 4.16-4.10 (1H, m), 3.59
(1H, s), 2.26-2.23 (4H, m), 1.58 (6H, t, J=6.6 Hz), 1.53-1.49 (9H,
m).
[1202] [M+H]=873.35
Example 107
Synthesis of Compound I-107
##STR00323##
[1203] Step (1): Compound 107a.fwdarw.Compound 107b
[1204] Compound 107a (15.0 g, 99 mmol) was dissolved into
dimethylacetamide (150 mL), and thereto were then added potassium
carbonate (40.9 g, 296 mmol), p-methoxybenzyl chloride (32.2 ml,
237 mmol) and sodium iodide (14.78 g, 99 mmol) in turn. The mixture
was stirred at 50.degree. C. for 1.5 hours. The reaction mixture
was poured into water. The precipitated solid was then collected by
filtration, and washed with water and diisopropyl ether. In this
way, compound 107c was yielded (35.58 g 92%).
[1205] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.60 (1H, s), 7.52 (1H, d,
J=8.4 Hz), 7.36 (4H, m), 6.93-6.89 (5H, m), 5.15 (2H, s), 5.11 (2H,
s), 3.81 (6H, s), 2.51 (3H, s).
Step (2): Compound 107b.fwdarw.Compound 107c
[1206] Compound 107b (35.58 g, 91 mmol) was dissolved into pyridine
(360 mL), and thereto was then added selenium dioxide (25.1 g, 227
mmol). The mixture was stirred at 80.degree. C. for 1 day. The
reaction mixture was filtered and evaporated. The residue was
diluted with an aqueous hydrochloric acid solution and ethyl
acetate, then separated and washed with water and a saturated salt
solution, and dried over magnesium sulfate. Magnesium sulfate was
filtrated off, and then the liquid was concentrated under reduced
pressure. The precipitated solid was then collected by filtration,
and, washed with diisopropyl ether to yield compound 107c (22.0 g,
57%).
[1207] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 7.51-7.50 (2H, m),
7.39-7.35 (4H, m), 7.27 (1H, d, J=8.3 Hz), 6.95-6.93 (4H, m), 5.18
(2H, s), 5.10 (2H, s), 3.75 (3H, s), 3.75 (3H, s).
Step (3): Compound 107c.fwdarw.Compound 107d
[1208] Compound 107c (4.00 g, 9.47 mmol) was dissolved into
tetrahydrofuran (40 mL), and thereto were then added 1-chloro-N, N,
2-trimethyl-1-propenylamine (1.503 ml, 11.36 mmol) at 0.degree. C.
The mixture was stirred at 0.degree. C. for 1 hr. Thereto were was
diluted with ethyl acetate and aqueous sodium hydroxide solution,
then separated and washed with water and a saturated salt solution,
and dried over magnesium sulfate. Magnesium sulfate was filtrated
off, and then the liquid was concentrated under reduced pressure.
The precipitated solid was then collected.
[1209] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 8.69 (1H, t, J=6.3 Hz),
7.56-7.55 (2H, m), 7.38-7.35 (4H, m), 7.25 (1H, d, J=8.8 Hz),
6.95-6.92 (4H, m), 5.17 (2H, s), 5.07 (2H, s), 3.75-3.75 (6H, m),
3.01 (2H, d, J=6.3 Hz), 2.76-2.73 (6H, m), 1.34-1.31 (6H, m).
Step (4): Compound X-1+Compound 107d.fwdarw.Compound
107e.fwdarw.Compound I-107
[1210] Compound X-1 (932 mg, 1.0 mmol) was added to a solution of
compound 107d (545 mg, 1.00 mmol) in dimethylformamide (2 mL) at
0.degree. C., and the resultant solution was stirred at 0.degree.
C. for 3 hours. The reaction mixture was slowly added to a 5% salt
solution (30 ml) (containing 1.5 g of sodium bisulfite) at
0.degree. C. The precipitated solid was collected by filtration,
washed with water, and then suspended into water. The suspension
was freeze-dried to yield compound 107e as an orange solid.
Compound 107e was used in the next reaction without further
purification.
[1211] The total amount of compound 107e yielded was dissolved in
dichloromethane (10 mL), and the solution was cooled to -40.degree.
C. Thereto were then added anisole (1.3 mL, 12 mmol) and a 2 mol/L
aluminum chloride solution (6.00 mL, 12 mmol) in nitromethane in
turn. The resultant was stirred at 0.degree. C. for 30 minutes. The
reaction mixture was dissolved in water, a 2 mol/L aqueous
hydrochloric acid solution, and acetonitrile. The resultant
solution was then washed with diisopropyl ether. To the water phase
was added HP20-SS resin, and then acetonitrile was distilled off
under reduced pressure. The resultant mixed liquid was purified by
ODS column chromatography. To the resultant target-compound
solution was added HP20-SS resin, and then acetonitrile was
distilled off under reduced pressure. The resultant mixed liquid
was purified by HP20-SS column chromatography. To the resultant
target-compound solution was added a 0.2 N aqueous sodium hydroxide
solution until the whole gave a pH of 6.0. Thereafter, a piece of
dry ice was added thereto. The resultant solution was concentrated
under reduced pressure, and then freeze-dried to yield compound
I-107 as a yellow powder.
[1212] Yielded amount: 592.4 mg, (64%).
[1213] .sup.1H-NMR (D.sub.2O) .delta.: 7.54-7.53 (2H, m), 7.00-6.99
(2H, m), 5.84 (1H, d, J=4.8 Hz), 5.44 (1H, d, J=4.8 Hz), 4.65 (1H,
d, J=14.4 Hz), 4.08-4.06 (2H, m), 3.54-3.47 (6H, m), 3.37 (2H, s),
1.95-1.93 (6H, m), 1.56 (3H, d, J=7.1 Hz), 1.53 (3H, s), 1.51 (3H,
s).
[1214] Elem. Anal.: C34H38N7O11S2Na(H2O) 5.2
[1215] Calcd.: C, 45.30; H, 5.41; N, 10.88; S, 7.11; Na,
2.55(%).
[1216] Found: C, 45.00; H, 5.43; N, 11.26; S, 6.98; Na,
2.56(%).
Example 108
Synthesis of Compound I-108
##STR00324##
[1217] Step (1): Compound 107c+Compound 108a.fwdarw.Compound
108b
[1218] Compound 107c (4.00 g, 9.47 mmol) and compound 108a (2.26 g,
11.36 mmol) were used to synthesize compound 108b in the same way
as in Step 3 of Example 107.
[1219] Yielded amount: 1.79 g, (36%)
[1220] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 7.47-7.23 (7H, m),
6.95-6.93 (4H, m), 5.17 (2H, s), 5.10 (2H, s), 4.51 (1H, s),
3.72-3.66 (7H, m), 2.98-2.73 (6H, m), 2.00-1.98 (2H, m), 1.70-1.61
(3H, m).
Step (2): Compound X-1+Compound 108b.fwdarw.Compound
108c.fwdarw.Compound I-108
[1221] Compound X-1 (932 mg, 1.0 mmol) and compound 108b (531 mg,
1.0 mmol) were used to synthesize the target compound in the same
way as in Step (4) of Example 107.
[1222] Yielded amount: 661.3 mg, (67%)
[1223] .sup.1H-NMR (D.sub.2O) .delta.: 7.45-7.42 (2H, m), 7.03-6.99
(2H, m), 5.87-5.83 (1H, m), 5.46-5.43 (1H, m), 4.95 (1H, br s),
4.85-4.81 (1H, m), 4.38-4.27 (1H, m), 4.16-4.07 (2H, m), 3.88-3.46
(7H, m), 2.47-2.22 (4H, m), 1.60-1.56 (3H, m), 1.53-1.50 (6H,
m).
[1224] Elem. Anal.: C33H36N7O11S2Na(H2O) 5.3
[1225] Calcd.: C, 44.57; H, 5.28; N, 11.03; S, 7.21; Na,
2.59(%).
[1226] Found: C, 44.53; H, 5.24; N, 11.33; S, 7.11; Na,
2.68(%).
Example 109
Synthesis of Compound I-109
##STR00325##
[1227] Step (1): Compound 107c+Compound 109a.fwdarw.Compound
109b
[1228] Compound 107c (1.00 g, 2.37 mmol) and compound 109a (0.36
ml, 2.84 mmol) were used to synthesize compound 109b in the same
way as in Step (3) of Example 107.
[1229] Yielded amount: 459.4 mg, (37%)
[1230] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 8.74 (1H, t, J=5.8 Hz),
7.65 (1H, dd, J=8.5, 1.8 Hz), 7.58 (1H, d, J=1.8 Hz), 7.39-7.34
(4H, m), 7.21 (1H, d, J=8.5 Hz), 6.96-6.91 (4H, m), 5.17 (2H, s),
5.08 (2H, s), 3.75 (3H, s), 3.75 (3H, s), 2.54 (2H, t, J=6.7 Hz),
2.49-2.46 (4H, m), 1.70-1.66 (4H, m).
Step (2): Compound X-1+Compound 109b.fwdarw.Compound
109c.fwdarw.Compound I-109
[1231] Compound X-1 (839 mg, 0.9 mmol) and compound 109b (467 mg,
0.9 mmol) were used to synthesize the target compound in the same
way as in Step (4) of Example 107.
[1232] Yielded amount: 415.0 mg, (52%)
[1233] .sup.1H-NMR (D.sub.2O) .delta.: 7.60 (1H, dd, J=8.5, 2.0
Hz), 7.55 (1H, d, J=2.0 Hz), 7.01 (1H, s), 6.99 (1H, d, J=8.5 Hz),
5.80 (1H, d, (2H, m), 3.73-3.67 (1H, m), 3.64-3.46 (5H, m),
2.28-2.20 (4H, m), 1.57 (3H, d, J=7.0 Hz), 1.52 (3H, s), 1.50 (3H,
s).
[1234] Elem. Anal.: C32H36N7O11S2Na(H2O) 4.5
[1235] Calcd.: C, 44.54; H, 5.26; N, 11.36; S, 7.43; Na,
2.66(%).
[1236] Found: C, 44.50; H, 5.18; N, 11.51; S, 7.10; Na,
2.68(%).
Example 110
Synthesis of Compound I-110
##STR00326##
[1237] Step (1): Compound 110a.fwdarw.Compound 110b
[1238] Compound 110a (2.10 g, 5.00 mmol) was dissolved into ethanol
(20 mL), and thereto was then added methyl hydrazine (0.28 ml, 5.25
mmol). The mixture was stirred at rt for 30 minutes, then reflux
for 1 hour. The reaction mixture was evaporated. The precipitated
solid was then collected by filtration, and washed with diisopropyl
ether to yield compound 110b (2.28 g, 102%).
[1239] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 7.68 (1H, s), 7.41-7.39
(5H, m), 6.96-6.94 (4H, m), 5.22 (2H, s), 5.21 (2H, s), 3.75 (6H,
s), 3.53 (3H, s).
Step (2): Compound 110b.fwdarw.Compound 110c
[1240] Compound 110b (1.20 g, 2.68 mmol) was dissolved into
tetrahydrofuran (12 mL), and thereto were then added diisopropyl
azodicarboxylate (0.728 ml, 3.75 mmol) and triphenylphosphine (983
mg, 3.75 mmol) at 0.degree. C. The mixture was stirred at 0.degree.
C. for 10 minutes. Thereto was then added 2-pyrrolidinoethanol
(0.438 ml, 3.75 mmol) at 0.degree. C. The mixture was stirred at rt
for 1 hour. Thereto was then added diisopropyl ether (24 ml). The
precipitated solid was then collected by filtration, and washed
with diisopropyl ether to yield compound 110c (0.93 g, 64%).
[1241] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.82 (1H, s), 7.41-7.34
(5H, m), 6.91-6.89 (4H, m), 5.22 (2H, s), 5.19 (2H, s), 4.42 (2H,
t, J=5.9 Hz), 3.81 (3H, s), 3.81 (3H, s), 3.70 (3H, s), 2.95 (2H,
t, J=5.9 Hz), 2.67-2.62 (4H, m), 1.85-1.78 (4H, m).
Step (3): Compound X-24+Compound 110c.fwdarw.Compound
110d.fwdarw.Compound I-110
[1242] Compound X-24 (886 mg, 1.0 mmol) and compound 110c (546 mg,
1.0 mmol) were used to synthesize the target compound in the same
way as in Step (4) of Example 107.
[1243] Yielded amount: 238.2 mg, (25%)
[1244] .sup.1H-NMR (D.sub.2O) .delta.: 7.45 (1H, s), 7.14 (1H, s),
7.01 (1H, s), 5.83 (1H, d, J=4.6 Hz), 5.47 (1H, d, J=4.6 Hz), 4.34
(1H, d, J=14.6 Hz), 4.08 (1H, q, J=6.9 Hz), 3.96-3.82 (3H, m),
3.74-3.47 (7H, m), 2.26 (4H, br s), 1.54 (3H, d, J=6.9 Hz), 1.51
(3H, s), 1.49 (3H, s).
[1245] Elem. Anal.: C33H37N8O11S2Na(H2O) 5.8
[1246] Calcd.: C, 43.40; H, 5.36; N, 12.27; S, 7.02; Na,
2.52(%).
[1247] Found: C, 43.21; H, 5.29; N, 12.60; S, 6.97; Na,
2.65(%).
Example 111
Synthesis of Compound I-111
##STR00327##
[1248] Step (1): Compound 111a+Compound 111b.fwdarw.Compound
111c
[1249] Compound 111a (10.0 g, 31.8 mmol) was dissolved into
dimethylformamide (100 mL), and thereto was then added sodium
hydride (3.05 g, 76.0 mmol) at 0.degree. C. The mixture was stirred
at 0.degree. C. for 30 minutes. Thereto were then added compound
111b (5.95 g, 35.0 mmol) and sodium iodide (9.54 g, 63.6 mmol) in
turn. The mixture was stirred at 60.degree. C. for 2 hours. The
reaction mixture was diluted with ethyl acetate and water, then
separated and washed with a saturated salt solution, and dried over
magnesium sulfate. Magnesium sulfate was filtrated off, and then
the liquid was concentrated under reduced pressure. The
compound-containing liquid was subjected to silica gel column
chromatography to elute out the desired compound with ethyl acetate
(3% triethylamine). The desired-compound-containing fraction was
concentrated under reduced pressure to yield compound 111c (12.70
g, 97%).
[1250] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 7.39-7.24 (10H, m),
5.19-4.95 (4H, m), 3.83-3.67 (1H, m), 3.13 (1H, s), 3.07 (2H, s),
2.61-2.55 (1H, m), 2.45-2.36 (4H, m), 1.66-1.61 (4H, m).
Step (2): Compound 111c.fwdarw.Compound 111d
[1251] Compound 111c (12.70 g, 30.9 mmol) was dissolved into
methanol (120 mL), and thereto was then added 10% Pd/C (2.54 g, 50%
wet). The mixture was stirred at rt under hydrogen atmosphere for 2
hours. The reaction mixture was filtered through celite, then
concentrated under reduced pressure to yield compound 111d (4.90 g,
111%).
[1252] .sup.1H-NMR (CDCl.sub.3) .delta.: 3.94 (1H, t, J=6.8 Hz),
3.78 (1H, s), 2.96 (2H, t, J=6.8 Hz), 2.66-2.61 (3H, m), 2.58-2.52
(4H, m), 1.81-1.77 (4H, m).
Step (3): Compound 111d+Compound 110a.fwdarw.Compound 111e
[1253] Compound 111d (1.50 g, 10.47 mmol) was dissolved into
ethanol (50 mL), and thereto was then added compound 110a (4.40 g,
10.47 mmol). The mixture was stirred at rt for 1 day, then reflux
for 2 hour. The reaction mixture was evaporated. The
compound-containing liquid was subjected to silica gel column
chromatography to elute out the desired compound with ethyl acetate
(3% triethylamine)/methanol. The
[1254] .sup.1H-NMR (CDCl3) .delta.: 7.73 (1H, s), 7.73 (1H, s),
7.40-7.38 (4H, m), 6.91-6.89 (4H, m), 5.21 (2H, s), 5.21 (2H, s),
4.30 (2H, t, J=7.3 Hz), 3.81 (6H, s), 3.68 (3H, s), 2.73 (2H, t,
J=7.3 Hz), 2.59-2.54 (4H, m), 1.74-1.71 (4H, m).
[1255] Step (4): Compound X-24+Compound 111e.fwdarw.Compound
111f.fwdarw.Compound mmol) were used to synthesize the target
compound in the same way as in Step (4) of Example 107.
[1256] Yielded amount: 444.5 mg, (46%)
[1257] .sup.1H-NMR (D.sub.2O) .delta.: 7.19 (1H, s), 7.14 (1H, s),
6.99 (1H, s), 5.81 (1H, d, J=4.8 Hz), 5.48 (1H, d, J=4.8 Hz), 5.12
(1H, d, J=14.1 Hz), 4.58 (2H, br s), 4.33 (1H, d, J=14.1 Hz), 4.11
(1H, q, J=6.9 Hz), 3.84-3.51 (9H, m), 2.26 (4H, br s), 1.59 (3H d,
J=6.9 Hz), 1.52 (3H, s), 1.50 (3H, s).
[1258] Elem. Anal.: C33H37N8O11S2Na(H2O) 6
[1259] Calcd.: C, 43.23; H, 5.39; N, 12.22; S, 6.99; Na,
2.51(%).
[1260] Found: C, 42.94; H, 5.30; N, 12.54; S, 6.85; Na,
2.64(%).
Example 112
Synthesis of Compound I-112
##STR00328##
[1261] Step (1): Compound 110a.fwdarw.Compound 112a
[1262] Compound 110a (5.00 g, 11.89 mmol) was suspended into
dimethylformamide (25 mL), and thereto were then added
hexamethyldisilazane (24.93 ml, 119 mmol) and methanol (0.48 ml,
11.89 mmol) in turn. The mixture was stirred at rt for 1 day, then
50.degree. C. for 2 hours, 80.degree. C. for 2 hours. The reaction
mixture was slowly added to a 1 mol/L aqueous hydrochloric acid
solution (240 ml) at 0.degree. C. The precipitated solid was
collected by filtration, washed with water and diisopropyl ether to
yield compound 112a (4.89 g, 98%).
[1263] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.35 (4H, d, J=8.6 Hz),
7.33 (2H, s), 6.91 (4H, d, J=8.6 Hz), 5.18 (4H, s), 3.82 (6H,
s).
Step (2): Compound 112a.fwdarw.Compound 112b
[1264] Compound 112a (1.00 g, 2.38 mmol) and paraformaldehyde (0.36
g, 11.92 mmol) were suspended into dimethylformamide (10 mL), and
thereto was then added pyrrolidine (0.99 ml, 11.92 mmol). The
mixture was stirred at rt for 2 hours. Thereto was then added water
(20 ml). The precipitated solid was then collected by filtration,
and washed with water to yield compound 112b (1.16 g, 97%).
[1265] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.37-7.34 (6H, m), 6.90
(4H, d, J=8.6 Hz), 5.18 (4H, s), 4.64 (2H, s), 3.82 (6H, s),
2.71-2.66 (4H, m), 1.74-1.70 (4H, m).
Step (3): Compound X-24+Compound 112b.fwdarw.Compound I-112
[1266] Compound X-24 (886 mg, 1.0 mmol) and compound 112b (503 mg,
1.0 mmol) were used to synthesize the target compound in the same
way as in Step (4) of Example 107.
[1267] Yielded amount: 111.0 mg, (9%)
[1268] .sup.1H-NMR (D.sub.2O) .delta.: 7.29 (2H, s), 7.01 (1H, s),
5.83 (1H, d, J=4.9 Hz), 5.48 (1H, d, J=4.9 Hz), 4.27 (1H, d, J=14.4
Hz), 4.11 (1H, q, J=7.2 Hz), 3.72 (1H, br s), 3.46-3.39 (3H, m),
3.28 (1H, t, J=7.2 Hz), 2.37-2.20 (4H, m), 2.00 (1H, t, J=7.2 Hz),
1.56 (3H, d, J=7.2 Hz), 1.52-1.49 (6H, m).
[1269] Elem. Anal.: C31H32N7O11S2Na(H2O) 5.2(NaHCO3) 0.2
[1270] Calcd.: C, 42.77; H, 4.90; N, 11.19; S, 7.32; Na,
3.15(%).
[1271] Found: C, 42.49; H, 4.85; N, 11.97; S, 7.87; Na,
3.14(%).
Example 113
Synthesis of Compound I-113
##STR00329##
[1272] Step (1): Compound 113a.fwdarw.Compound 113b
[1273] Compound 113a (11.65 g, 51.0 mmol) was dissolved into
dichloromethane (100 mL), and thereto were then added dropwise
boron tribromide (25 g, 100 mmol) and 1 mol/L dichloromethane
solution of boron tribromide (20 ml, 20 mmol) at 0.degree. C. The
mixture was stirred at rt for 1 hour. The reaction mixture was
diluted with ice water, then extracted with ethyl acetate, and
washed with a saturated salt solution, and dried over magnesium
sulfate. Magnesium sulfate was filtrated off, and then the liquid
was concentrated under reduced pressure to yield compound 113b
(10.60 g, 104%). Compound 113b was used in the next reaction
without further purification.
[1274] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 10.54 (2H, br s), 7.09
(1H, s), 5.22 (2H, s).
Step (2): Compound 113b.fwdarw.Compound 113c
[1275] The total amount of compound 113b obtained in Step (1) was
dissolved into dimethylacetamide (110 mL), and thereto were then
added potassium carbonate (21.9 g, 159 mmol), p-methoxybenzyl
chloride (17.3 ml, 127 mmol) and sodium iodide (7.92 g, 52.8 mmol)
in turn. The mixture was stirred at 50.degree. C. for 1 hour. The
reaction mixture was poured into water. The precipitated solid was
then collected by filtration, and washed with water and diisopropyl
ether to yield compound 113c (20.71 g, 89%).
[1276] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.39-7.36 (3H, m), 7.30
(2H, d, J=8.6 Hz), 6.94 (2H, d, J=8.6 Hz), 6.83 (2H, d, J=8.6 Hz),
5.18 (2H, s), 5.11 (2H, s), 5.09 (2H, s), 3.84 (3H, s), 3.80 (3H,
s).
Step (3): Compound 113c.fwdarw.Compound 113d
[1277] A 2 mol/L aqueous sodium hydroxide solution (15 ml, 30 mmol)
was added to a solution of compound 113c (4.41 g, 10 mmol) in
tetrahydrofuran (5 mL) and methanol (5 mL). The resultant solution
was stirred at 70.degree. C. for 1 hour. To the reaction mixture
was added water and 2 mol/L aqueous hydrochloric acid solutions (18
mL) at 0.degree. C. The precipitated solid was then collected by
filtration, and washed with water to yield compound 113d (5.33 g,
116%).
[1278] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.61 (1H, s), 7.37-7.32
(4H, m), 6.92 (2H, d, J=7.9 Hz), 6.83 (2H, d, J=7.4 Hz), 5.09 (2H,
s), 5.04 (2H, s), 4.98 (2H, s), 3.83 (3H, s), 3.80 (3H, s).
Step (4): Compound 113d.fwdarw.Compound 113e
[1279] The total amount of compound 113d yielded (5.33 g, 10 mmol)
was suspended into acetone (50 mL), and thereto was then added
Jone's reagent (2.67 mol/L, 7.5 mL, 20 mmol) at 0.degree. C. The
mixture was stirred at rt for 30 minutes. The reaction mixture was
diluted with water, then added sodium bisulfite at 0.degree. C. The
mixture was evaporated to remove acetone, then the precipitated
solid was collected by filtration, washed with water and
diisopropyl ether to yield compound 113e (3.75 g, 82%).
[1280] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.39-7.37 (3H, m), 7.31
(2H, d, J=8.3 Hz), 6.94 (2H, d, J=8.4 Hz), 6.83 (2H, d, J=8.3 Hz),
5.18 (1H, s), 5.11-5.07 (4H, m), 3.84 (3H, s), 3.80 (3H, s).
Step (5): Compound 113e+Compound 113f.fwdarw.Compound 113g
[1281] Compound 113e (777 mg, 3.40 mmol) was dissolved into
dimethylacetamide (30 mL), and thereto was then added sodium
acetate (1.40 g, 17.0 mmol). The mixture was stirred at rt for 30
minutes. Thereto was then added compound 113f (3.11 g, 6.81 mmol).
The mixture was stirred at rt for 1 hour, then 70.degree. C. for 1
hour. The reaction mixture was diluted with ethyl acetate and
aqueous sodium hydroxide solution, then separated and washed with
water and a saturated salt solution, and dried over sodium sulfate.
Sodium sulfate was filtrated off, and then the liquid was
concentrated under reduced pressure. The compound-containing liquid
was subjected to silica gel column chromatography to elute out the
desired compound with ethyl acetate (10% triethylamine)/methanol
(10% triethylamine). The desired-compound-containing fraction was
concentrated under reduced pressure to yield compound 113g (553 mg,
12%).
[1282] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 8.37 (1H, s), 7.84 (1H,
s), 7.49 (2H, d, J=8.3 Hz), 7.29 (2H, d, J=8.3 Hz), 7.01 (2H, d,
J=8.3 Hz), 6.86 (2H, d, J=8.3 Hz), 5.33 (2H, s), 5.09 (2H, s), 3.96
(2H, s), 3.79 (3H, s), 3.74 (3H, s), 2.71 (6H, br s), 1.39 (6H, br
s).
Step (6): Compound X-24+Compound 113g.fwdarw.Compound
113h.fwdarw.Compound I-113
[1283] Compound X-24 (886 mg, 1.0 mmol) and compound 113g (553 mg,
960 mmol) were used to synthesize the target compound in the same
way as in Step (4) of Example 107.
[1284] Yielded amount: 547.4 mg, (58%)
[1285] .sup.1H-NMR (D.sub.2O) .delta.: 8.38 (1H, s), 7.37 (1H, s),
6.99 (1H, s), 5.83 (1H, d, J=4.9 Hz), 5.43 (1H, d, J=4.9 Hz), 4.61
(1H, d, J=14.4 Hz), 4.17 (2H, s), 4.09-4.02 (2H, m), 3.55-3.38 (6H,
m), 1.99 (6H, s), 1.54 (3H, d, J=7.2 Hz), 1.51 (3H, s), 1.50 (3H,
s).
[1286] Elem. Anal.: C34H36ClN8O10S2Na(H2O) 5(NaHCO3) 0.4
[1287] Calcd.: C, 42.91; H, 4.86; N, 11.64; S, 6.66; Na,
3.34(%).
[1288] Found: C, 42.74; H, 4.97; N, 12.01; S, 6.81; Na,
3.33(%).
Example 114 and 115
Synthesis of Compound I-114 and I-115
##STR00330##
[1289] Step (1): Compound 114a+Compound 113f.fwdarw.Compound
114b
[1290] Compound 113f (311 mg, 1.36 mmol) and sodium acetate (559
mg, 6.82 mmol) were suspended into tetrahydrofuran (6 mL), and
thereto was then added suspension of compound 114a (0.62 g, 1.36
mmol) in tetrahydrofuran (6 mL) at -20.degree. C. The mixture was
stirred at -20.degree. C. for 1 hour. Thereto was then added acetic
acid (0.39 ml, 6.82 mmol). The mixture was stirred at reflux for 1
day. The reaction mixture was diluted with ethyl acetate and
aqueous sodium hydroxide solution, then separated and washed with
water and a saturated salt solution, and dried over sodium sulfate.
Sodium sulfate was filtrated off, and then the liquid was
concentrated under reduced pressure. The precipitated solid was
then collected by filtration, and washed with diisopropyl ether to
yield a mixture of compound 114b and 114c (206 mg, 26%). The
mixture was used in the next reaction without further
purification.
[1291] MS (m+1)=592
Step (2): Compound X-24+Compound 114b and 114c.fwdarw.Compound
I-114 and I-115
[1292] Compound X-24 (354 mg, 0.4 mmol) and compound 114b and 114c
(206 mg, 0.35 mmol) were used to synthesize the target compound in
the same way as in Step (4) of Example 107.
[1293] Yielded amount: Compound I-114 (165.6 mg, 45%), compound
I-115 (16.6 mg, 5.5%)
[1294] Compound I-114
[1295] .sup.1H-NMR (D.sub.2O) .delta.: 7.10 (1H, s), 7.01 (1H, s),
5.85 (1H, d, J=4.6 Hz), 5.45 (1H, d, J=4.6 Hz), 4.63 (1H, d, J=13.9
Hz), 4.12-4.05 (2H, m), 3.59-3.41 (6H, m), 2.98 (2H, s), 1.97 (6H,
t, J=7.2 Hz), 1.57 (3H, d, J=6.9 Hz), 1.52 (3H, s), 1.51 (3H,
s).
[1296] Elem. Anal.: C34H36ClN8O11S2Na(H2O) 6.2(NaHCO3) 0.5
[1297] Calcd.: C, 41.07; H, 4.89; Cl, 3.51; N, 11.11; S, 6.36; Na,
3.42(%).
[1298] Found: C, 40.68; H, 4.96; Cl, 3.53; N, 11.52; S, 6.41; Na,
3.32(%).
[1299] Compound I-115
[1300] .sup.1H-NMR (D.sub.2O) .delta.: 7.33 (1H, s), 6.92 (1H, s),
5.76 (1H, d, J=4.4 Hz), 5.36 (1H, d, J=4.4 Hz), 4.55 (1H, d, J=14.3
Hz), 3.99-3.91 (4H, m), 3.50-3.32 (6H, m), 1.96-1.92 (6H, m),
1.48-1.43 (9H, m).
[1301] MS (m+1)=833
Example 116
Synthesis of Compound I-116
##STR00331##
[1302] Step (1): Compound 110a+Compound 116a.fwdarw.Compound
116b
[1303] Compound 110a (1.26 g, 3.0 mmol) and compound 116a (379 mg,
3.0 mmol) were used to synthesize compound 116b in the same way as
Reference Example 5.
[1304] Yielded amount: 1.35 g, (85%)
[1305] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 7.49 (2H, s), 7.38 (4H,
d, J=8.7 Hz), 6.95 (4H, d, J=8.7 Hz), 5.24 (4H, s), 3.82 (2H, s),
3.75 (6H, s), 2.74-2.68 (2H, m), 2.44-2.38 (2H, m), 2.11 (2H, s),
1.50-1.44 (2H, m), 1.14-1.08 (2H, m).
Step (2): Compound X-24+Compound 116b.fwdarw.Compound
116c.fwdarw.Compound I-116
[1306] Compound X-24 (886 mg, 1.0 mmol) and compound 116b (529 mg,
1.0 mmol) were used to synthesize the target compound in the same
way as in Step (4) of Example 107.
[1307] Yielded amount: 568.0 mg, (62%)
[1308] .sup.1H-NMR (D.sub.2O) .delta.: 7.21 (2H, s), 7.00 (1H, s),
5.79 (1H, d, J=4.9 Hz), 5.40 (1H, d, J=4.9 Hz), 4.23 (1H, d, J=14.6
Hz), 4.06 (1H, q, J=7.2 Hz), 3.91 (2H, s), 3.70-3.47 (4H, m), 3.43
(1H, d, J=8.5 Hz), 3.33 (1H, d, J=8.5 Hz), 2.23-2.13 (2H, m),
2.00-1.92 (2H, m), 1.55 (3H, d, J=7.2 Hz), 1.52 (3H, s), 1.50 (3H,
s).
[1309] Elem. Anal.: C33H34N7O11S2Na(H2O) 6.3
[1310] Calcd.: C, 43.78; H, 5.19; N, 10.83; S, 7.08; Na,
2.54(%).
[1311] Found: C, 43.76; H, 5.19; N, 10.87; S, 7.02; Na,
2.59(%).
Example 117
Synthesis of Compound I-117
##STR00332##
[1312] Step (1): Compound 117a.fwdarw.Compound 117b
[1313] Compound 117a (1.24 g, 3.0 mmol) and 1-hydroxybenzotriazole
(446 mg, 3.3 mmol) were dissolved into dichloromethane (15 mL), and
thereto was then added 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide hydrochloride (690 mg, 3.6 mmol) at 0.degree. C. The
mixture was stirred at rt for 1 hour. The reaction mixture was
diluted with dichloromethane and an aqueous hydrochloric acid
solution, then separated and washed with water, a saturated sodium
bicarbonate solution, and a saturated salt solution, and dried over
magnesium sulfate. Magnesium sulfate was filtrated off, and then
the liquid was concentrated under reduced pressure to yield
compound 117b (1.72 g, 108%).
[1314] Compound 117b was used as it was, without being purified, in
the next reaction.
[1315] .sup.1H-NMR (CDCl.sub.3) .delta.: 8.11 (1H, d, J=8.7 Hz),
7.68-7.62 (2H, m), 7.58-7.54 (1H, m), 7.47-7.44 (2H, m), 7.36 (2H,
d, J=8.5 Hz), 7.31 (2H, d, J=8.5 Hz), 6.93 (2H, d, J=8.5 Hz), 6.85
(2H, d, J=8.5 Hz), 5.23 (2H, s), 5.12 (2H, s), 3.83 (3H, s), 3.81
(3H, s).
Step (2): Compound 117b+Compound 116a.fwdarw.Compound 117c
[1316] Compound 117b (1.59 g, 3.0 mmol) was dissolved into
tetrahydrofuran (10 mL), and thereto was then added compound 116a
(379 mg, 3.0 mmol) in tetrahydrofuran (10 mL) at 0.degree. C. The
mixture was stirred at rt for 1 hour. The reaction mixture was
diluted with ethyl acetate and aqueous sodium hydroxide solution,
then separated and washed with water and a saturated salt solution,
and dried over sodium sulfate. Sodium sulfate was filtrated off,
and then the liquid was concentrated under reduced pressure. The
compound-containing liquid was subjected to silica gel column
chromatography to elute out the desired compound with ethyl acetate
(10% triethylamine)/methanol (10% triethylamine). The
desired-compound-containing fraction was concentrated under reduced
pressure to yield compound 117b (1.54 g, 99%).
[1317] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 8.53 (1H, t, J=5.9 Hz),
7.48 (1H, s), 7.43 (2H, d, J=8.0 Hz), 7.33 (1H, d, J=11.0 Hz), 7.25
(2H, d, J=8.0 Hz), 6.98 (2H, d, J=8.0 Hz), 6.85 (2H, d, J=8.0 Hz),
5.14 (2H, s), 5.01 (2H, s), 3.78 (3H, s), 3.73 (3H, s), 3.58 (2H,
d, J=5.9 Hz), 2.83-2.76 (2H, m), 2.20 (2H, s), 1.58-1.52 (2H, m),
1.21-1.15 (2H, m).
Step (3): Compound X-24+Compound 117c.fwdarw.Compound
117d.fwdarw.Compound I-117
[1318] Compound X-24 (886 mg, 1.0 mmol) and compound 117c (521 mg,
1.0 mmol) were used to synthesize the target compound in the same
way as in Step (4). of Example 107.
[1319] Yielded amount: 202.3 mg, (22%)
[1320] .sup.1H-NMR (D.sub.2O) .delta.: 7.17 (1H, d, J=11.0 Hz),
7.13 (1H, s), 7.00 (1H, s), 5.79 (1H, d, J=4.0 Hz), 5.41 (1H, d,
J=4.0 Hz), 4.89 (1H, d, J=14.7 Hz), 4.25 (1H, d, J=14.2 Hz), 4.05
(1H, q, J=7.2 Hz), 3.69-3.56 (6H, m), 3.40 (1H, d, J=8.4 Hz), 3.31
(1H, d, J=8.4 Hz), 2.25-2.17 (2H, m), 1.99-1.93 (2H, m), 1.55 (3H,
d, J=7.2 Hz), 1.52 (3H, s), 1.50 (3H, s).
[1321] Elem. Anal.: C32H35FN7O10S2Na(H2O) 6.7(NaHCO3) 0.1
[1322] Calcd.: C, 42.23; H, 5.36; F, 2.08; N, 10.74; S, 7.02; Na,
2.77(%).
[1323] Found: C, 42.17; H, 5.21; F, 2.02; N, 10.91; S, 7.06; Na,
2.77(%).
Example 118
Synthesis of Compound I-118
##STR00333##
[1324] Step (1): Compound 118a Compound 118b+Compound
118c.fwdarw.Compound 118d
[1325] Compound 118a was used to synthesize compound 118b in the
same way as in Step (1). Of Example 117.
[1326] Compound 118a (1.67 g, 3.1 mmol) and compound 118b (472 mg,
3.1 mmol) were used to synthesize compound 118c in the same way as
in Step (2) of Example 117.
[1327] Yielded amount: 1.36 g, (79%)
[1328] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 8.23 (1H, t, J=6.2 Hz),
7.43 (2H, d, J=8.5 Hz), 7.33 (2H, d, J=8.5 Hz), 7.18 (1H, d, J=8.5
Hz), 7.12 (1H, d, J=8.5 Hz), 6.97 (2H, d, J=8.5 Hz), 6.88 (2H, d,
J=8.5 Hz), 5.15 (2H, s), 4.88 (2H, s), 3.77 (3H, s), 3.75 (3H, s),
2.97-2.84 (6H, m), 2.60 (2H, s), 2.03-1.90 (2H, m), 1.68-1.53 (4H,
m), 1.46-1.39 (2H, m).
Step (2): Compound X-24+Compound 118d.fwdarw.Compound
118e.fwdarw.Compound I-118
[1329] Compound X-24 (886 mg, 1.0 mmol) and compound 118d (565 mg,
1.0 mmol) were used to synthesize the target compound in the same
way as in Step (4) of Example 107.
[1330] Yielded amount: 579.6 mg, (61%)
[1331] .sup.1H-NMR (D.sub.2O) .delta.: 6.96 (1H, d, J=8.3 Hz), 6.94
(1H, s), 6.90 (1H, d, J=8.3 Hz), 5.80 (1H, d, J=4.8 Hz), 5.43 (1H,
d, J=4.8 Hz), 4.13 (1H, d, J=14.1 Hz), 3.98 (1H, q, J=7.2 Hz),
3.76-3.71 (1H, m), 3.50-3.13 (7H, m), 2.56-2.44 (2H, m), 2.02-1.95
(2H, m), 1.88-1.69 (4H, m), 1.55 (3H, d, J=7.2 Hz), 1.50 (3H, s),
1.48 (3H, s).
[1332] Elem. Anal.: C34H39ClN7O10S2Na(H2O) 6.4
[1333] Calcd.: C, 43.28; H, 5.53; Cl, 3.76; N, 10.39; S, 6.80; Na,
2.44(%).
[1334] Found: C, 43.17; H, 5.41; Cl, 3.69; N, 10.57; S, 6.85; Na,
2.47(%).
Example 119
Synthesis of Compound I-119
##STR00334##
[1335] Step (1): Compound 119a.fwdarw.Compound 119b
[1336] Compound 119a (2.53 g, 10.0 mmol) was dissolved into
methanol (12.5 mL), and thereto was then added 4 mol/L dioxane
solution of hydrochloric acid (12.5 ml, 50 mmol) at 0.degree. C.
The mixture was stirred at rt for 4 hours, then the reaction
mixture was evaporated. The precipitated solid was then collected
by filtration, and washed with ethyl acetate/methanol (1/1) and
ethyl acetate. The precipitated solid was suspended into methanol
(25 mL), and thereto was then added sodium hydroxide (1.20 g, 30
mmol). The mixture was stirred at rt for 30 minutes, then a piece
of dry ice was added thereto. The mixture was filtered, then the
filtrate was concentrated under reduced pressure to yield compound
119b (2.67 g, 174%). The mixture was used in the next reaction
without further purification.
[1337] MS (m+1)=154
Step (2): Compound 119b+Compound 118b.fwdarw.Compound 119c
[1338] Compound 118a (1.09 g, 2.0 mmol) and compound 119b (538 mg,
2.0 mmol) were used to synthesize compound 119c in the same way as
in Step (2) of Example 117.
[1339] Yielded amount: 0.47 g, (42%)
[1340] MS (m+1)=564
Step (3): Compound X-24+Compound 119c.fwdarw.Compound
119d.fwdarw.Compound I-119
[1341] Compound X-24 (722 mg, 0.82 mmol) and compound 119c (460 mg,
0.82 mmol) were used to synthesize the target compound in the same
way as in Step (4) of Example 107.
[1342] Yielded amount: 13 mg, (1.7%)
[1343] .sup.1H-NMR (D.sub.2O) .delta.: 7.58 (1H, s), 7.01 (1H, s),
6.75 (3H, s), 5.85 (1H, s), 5.46 (1H, d, J=5.3 Hz), 4.14-4.10 (4H,
m), 3.62-3.55 (8H, m), 2.18 (6H, br s), 1.60-1.51 (9H, m).
[1344] MS (m+1)=783
Example 120
Synthesis of Compound I-130
##STR00335##
[1345] Step (1): Compound X-24+Compound 120a.fwdarw.Compound
120b.fwdarw.Compound I-120
[1346] A solution of Compound 120a (658 mg, 1.0 mmol) in
dimethylformamide (2.0 mL) was cooled with ice. The reaction vessel
was then degassed under reduced pressure, and thereto was added
Compound X-24 (886 mg, 1.0 mmol). After stirring at 0.degree. C.
for 6 hours, the reaction mixture was slowly added to 5% aqueous
sodium chloride and sodium hydrogen sulfite solution it was cooled
with ice. The precipitated solid was collected by filtration,
washed with water, and suspended into water. The suspension was
freeze-dried to yield Compound 120b as a brown solid. Compound 120b
yielded was used as it was, without being purified, in the next
reaction.
[1347] The total amount of compound 120b yielded was dissolved in
dichloromethane (10 mL), and the solution was cooled to -40.degree.
C. Thereto was then added anisole (1.09 mL, 10 mmol) and a 2 mol/L
aluminum chloride solution (5.0 mL, 10 mmol) in nitromethane in
turn. The liquid was stirred at 0.degree. C. for 30 minutes. To the
reaction liquid was added diisopropyl ether and a small amount of
water, and the resultant was stirred to generate a precipitate. The
supernatant was removed by decantation. To the insoluble matter
adhering to the vessel were added a diluted aqueous hydrochloric
acid solution, and acetonitrile. The resultant was stirred to
dissolve the matter completely. Thereto was then added diisopropyl
ether, and the water phase was separated to be collected. The
organic phase was again subjected to extraction with water, and
then all of the resultant water phases were combined with each
other. Thereto was added HP20-SS resin. Acetonitrile was then
distilled off therefrom under reduced pressure. The resultant mixed
liquid was purified by ODS column chromatography. The
desired-compound-containing fraction was added 0.2 mol/L sodium
hydroxide aqueous solution until it gave a pH of 6.0, and thereto
was added a piece of dry ice. The resultant solution was
concentrated under reduced pressure, and then freeze-dried to yield
compound I-120 as a yellow powder.
[1348] Yielded amount: 534 mg (58%)
[1349] .sup.1H-NMR (D.sub.2O) .delta.: 1.06 (2H, s), 1.29 (2H, d,
J=6.65 Hz), 1.51 (3H, s), 1.53 (3H, s), 1.59 (3H, d, J=6.78 Hz),
2.06 (2H, t, J=13.55 Hz), 2.44-2.83 (5H, m), 3.13 (3H, s), 3.44
(1H, s), 4.01-4.22 (5H, m), 5.47 (1H, d, J=4.77 Hz), 5.83 (1H, d,
J=4.77 Hz), 7.00 (1H, s), 7.23 (1H, s), 8.34 (1H, s).
[1350] Elem. Anal.: C.sub.39H42
ClN.sub.8O.sub.11S.sub.2Na.7.0H.sub.2O.0.1 NaHCO.sub.3
[1351] Calcd.: C, 44.48; H, 5.36; Cl, 3.36; N, 10.61; S, 6.07; Na,
2.40(%).
[1352] Found: C, 44.18; H, 5.34; Cl, 3.27; N, 10.91; S, 6.27; Na,
2.43(%).
[1353] MS (m+1)=899.38
Example 121
Synthesis of Compound I-121
##STR00336##
[1354] Step (1): Compound X-24+Compound 121a.fwdarw.Compound
121b.fwdarw.Compound I-121
[1355] From Compound X-24 (886 mg, 1.0 mmol) and Compound 121a (646
mg, 1.0 mmol), Compound I-121 was obtained as a yellow powder using
the same method as Example 120.
[1356] Yielded amount: 127 mg, (14%)
[1357] .sup.1H-NMR (D.sub.2O) .delta.: 1.41 (3H, t, J=6.90 Hz),
1.51 (3H, s), 1.53 (3H, s), 1.59 (3H, d, J=6.90 Hz), 2.07-2.14 (2H,
m), 2.45-2.87 (6H, m), 3.13 (3H, s), 4.00-4.29 (8H, m), 5.47 (1H,
d, J=4.77 Hz), 5.83 (1H, d, J=4.77 Hz), 6.79 (1H, s), 7.01 (1H, s),
8.44 (1H, s).
[1358] MS (m+1)=887.32
Example 122
Synthesis of Compound I-122
##STR00337##
[1359] Step (1): Compound 122a.fwdarw.Compound 122b.fwdarw.Compound
122c
[1360] A solution of Compound 122a (22.84 g, 168 mmol) in toluene
(114 mL) was cooled to -78.degree. C., and thereto was added
dropwise 1 mol/L DIBAL solution (335 mL, 335 mmol) in toluene for
50 minutes. After stirring at -78.degree. C. for 50 minutes, the
reaction mixture was warmed to 0.degree. C., and thereto was added
dropwise water (13.4 mL), 15% sodium hydroxide aqueous solution
(13.4 mL), and water (33.5 mL) at 0.degree. C. After stirring at
room temperature for 10 minutes thereto was added methanol (114
mL), and tert-butyl hydrazinecarboxylate (26.6 g, 201 mmol). After
stirring at room temperature for overnight, the insoluble substance
was removed by filtration, and then concentrated. The residue was
dissolved ethyl acetate and added saturated citric acid aqueous
solution until it gave a pH of 4.0. The water phase was separated
and added 8 mol/L sodium hydroxide aqueous solution until it gave a
pH of 12.0, followed by extraction with chloroform twice time. The
combined organic layer was dried with anhydrous sodium sulfate. The
inorganic substance was removed by filtration, and then
concentrated under reduced pressure. Thereto was added diisopropyl
ether to precipitate a solid. The solid was collected by
filtration, so as to yield compound 122c as a white solid.
[1361] Yielded amount: 28.7 g (68%)
[1362] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.49 (9H, s), 1.60 (6H, t,
J=7.72 Hz), 2.91 (6H, t, J=7.72 Hz), 6.92 (1H, s), 7.56 (1H,
s).
Step (2): Compound 122c.fwdarw.Compound 122d.fwdarw.Compound
122e
[1363] A solution of Compound 122c (28.7 g, 113 mmol) in methanol
(144 mL) was cooled with ice, and thereto was added sodium
cyanoborohydride (14.24 g, 227 mmol), and then added 2 mol/L
hydrochloric acid aqueous solution until it gave a pH of 4.0. After
stirring at room temperature for 1.5 hours, and thereto was added 8
mol/L sodium hydroxide aqueous solution until it gave a pH of 12.0
at 0.degree. C., and then concentrated, followed by extraction with
ethyl acetate twice time. The combined organic layer was washed
with saturated brine, and then was dried with anhydrous sodium
sulfate. The inorganic substance was removed by filtration, and
then concentrated and subsequently drying under reduced pressure to
yield Compound 122d as a orange oil. Compound 122d yielded was used
as it was, without being purified, in the next reaction.
[1364] The total amount of compound 122d yielded was dissolved in
methanol (144 mL), and the solution was cooled with ice. Thereto
was added slowly 4 mol/L hydrochloric acid solution (141 mL, 565
mmol) in 1,4-dioxane. After stirring at room temperature for
overnight, and the reaction mixture was concentrated under reduced
pressure. Thereto was added 50% methanol/ethyl acetate solution to
precipitate a solid. The solid was collected by filtration, so as
to yield compound 122e as a white solid.
[1365] Yielded amount: 24.6 g (95%)
[1366] .sup.1H-NMR (D.sub.2O) .delta.: 1.90 (6H, t, J=7.97 Hz),
2.99 (2H, s), 3.39 (6H, t, J=7.97 Hz).
Step (3): Compound 122e+Compound 110a.fwdarw.Compound 122f
[1367] A suspension of Compound 122e (17.6 g, 77 mmol) in
1,4-dioxane (144 mL) was added sodium acetate (31.6 g, 385 mmol)
and Compound 110a (38.8 g, 92 mmol). After stirring at room
temperature for 1 hour, thereto was added acetic acid (22.02 ml,
385 mmol). After stirring at room temperature for overnight,
thereto was stirred at 70.degree. C. for 1.5 hours. Then thereto
was added 2 mol/L sodium hydroxide aqueous solution until it gave a
pH of 12.0 at 0.degree. C., followed by extraction with ethyl
acetate twice time. The combined organic layer was washed with
saturated brine, and then was dried with anhydrous sodium sulfate.
The inorganic substance was removed by filtration, and then
concentrated under reduced pressure. Thereto was added 5%
triethylamine and methanol solution in ethyl acetate to precipitate
a solid. The solid was collected by filtration, so as to yield
compound 122f as a white solid.
[1368] Yielded amount: 30.96 g (72%)
[1369] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 1.40 (6H, t, J=7.47 Hz),
2.64 (6H, t, J=7.47 Hz), 3.59 (2H, s), 3.75 (6H, s), 5.11 (2H, s),
5.12 (2H, s), 6.94 (4H, d, J=8.28 Hz), 7.38 (4H, d, J=8.28 Hz),
7.52 (2H, s).
Step (4): Compound X-24+Compound 122f.fwdarw.Compound
122g.fwdarw.Compound I-122
[1370] From Compound X-24 (10.0 g, 11.3 mmol) and Compound 122f
(6.31 g, 11.3 mmol), Compound I-122 was obtained as a white powder
using the same method as Example 120.
[1371] Yielded amount: 3.68 g, (40%)
[1372] .sup.1H-NMR (D.sub.2O) .delta.: 1.50 (3H, s), 1.51 (3H, s),
1.53 (3H, d, J=7.53 Hz), 2.00 (6H, t, J=7.22 Hz), 3.38-3.55 (6H,
m), 3.97-4.06 (4H, m), 4.61 (1H, d, J=14.43 Hz), 5.42 (1H, d,
J=4.77 Hz), 5.83 (1H, d, J=4.77 Hz), 6.97 (1H, s), 7.24 (1H, s),
7.39 (1H, s).
[1373] Elem. Anal.:
C.sub.33H.sub.37N.sub.8O.sub.11S.sub.2Na.sub.1.2.5.9H.sub.2O
[1374] Calcd.: C, 43.83; H, 5.28; N, 12.03; S, 6.88; Na,
2.96(%).
[1375] Found: C, 43.74; H, 5.35; N, 12.27; S, 7.03; Na,
2.86(%).
[1376] MS (m+1)=799.23
Example 123
Synthesis of Compound (I-123)
##STR00338##
[1377] Step (1): Compound 122a.fwdarw.Compound 122b.fwdarw.Compound
123a
[1378] From Compound 122a (10.0 g, 73.4 mmol) and benzyl
hydrazinecarboxylate (21.96 g, 132 mmol), Compound 123a was
obtained as a white powder using the same method as in Step (1) of
Example 122.
[1379] Yielded amount: 14.02 g, (66%)
[1380] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 1.44 (6H, t, J=7.58 Hz),
2.74 (6H, t, J=7.58 Hz), 5.04 (2H, s), 7.09 (1H, s), 7.31-7.40 (6H,
m).
Step (2): Compound 123a.fwdarw.Compound 123b
[1381] A solution of Compound 123a (11.49 g, 40 mmol) in methanol
(180 mL) was added 5% palladium on carbon (3.6 g, 1.7 mmol). After
stirring under hydrogen (1 atm) at room temperature for 2 hours,
the insoluble substance was removed by filtration. Thereto was
concentrated and subsequently drying under reduced pressure to
yield Compound 123b as a white solid.
[1382] Yielded amount: 5.97 g, (97%)
[1383] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 1.40 (6H, t, J=7.65 Hz),
2.73 (6H, t, J=7.65 Hz), 5.88 (2H, s), 6.76 (1H, s).
Step (3): Compound 123b+Compound 110a.fwdarw.Compound 123c
[1384] A suspension of Compound 123b (6.97 g, 45.5 mmol) in
dimethylformamide (70 mL) was added Compound 110f (20.08 g, 47.8
mmol) at 0.degree. C. After stirring at room temperature for 2
hours, thereto was added
O-Benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate
(20.70 g, 54.6 mmol) at 0.degree. C. After stirring at room
temperature for 4 hours, thereto was added acetic acid (26.0 ml,
455 mmol) and sodium cyanoborohydride (4.29 g, 68.2 mmol) at
0.degree. C. After stirring at room temperature for overnight,
thereto was added 2 mol/L sodium hydroxide aqueous solution,
followed by extraction with ethyl acetate twice time. The combined
organic layer was washed with water and saturated brine, and then
was dried with anhydrous sodium sulfate. The inorganic substance
was removed by filtration, and then concentrated under reduced
pressure. Thereto was added diisopropyl ether to precipitate a
solid. The solid was collected by filtration, so as to yield
compound 123c as a yellow solid.
[1385] Yielded amount: 14.19 g, (56%)
[1386] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 1.37 (6H, t, J=7.59 Hz),
2.65 (2H, d, J=6.02 Hz), 2.73 (6H, t, J=7.59 Hz), 3.75 (6H, s),
5.23 (4H, s), 6.95 (4H, d, J=8.66 Hz), 7.37 (4H, d, J=8.66 Hz),
7.46 (2H, s).
Step (4): Compound X-24+Compound 123c.fwdarw.Compound I-123
[1387] From Compound X-24 (11.52 g, 13 mmol) and Compound 123c
(7.25 g, 13 mmol), Compound I-123 was obtained as a white powder
using the same method as Example 120.
[1388] Yielded amount: 3.25 g, (30%)
[1389] .sup.1H-NMR (D.sub.2O) .delta.: 1.51 (3H, s), 1.52 (3H, s),
1.57 (3H, d, J=7.15 Hz), 1.97 (6H, t, J=7.65 Hz), 2.98 (2H, s),
3.41-3.58 (6H, m), 4.05-4.12 (2H, m), 4.63 (1H, d, J=14.81 Hz),
5.45 (1H, d, J=4.89 Hz), 5.85 (1H, d, J=4.89 Hz), 7.00 (1H, s),
7.19 (2H, s).
[1390] MS (m+1)=799.23
Example 124
Synthesis of Compound I-124
##STR00339##
[1391] Step (1): Compound 124a.fwdarw.Compound 124b
[1392] A solution of Compound 124a (30.5 g, 72 mmol) in
tetrahydrofuran (305 mL) was added manganese dioxide (62.5 g, 719
mmol). After stirring at room temperature for overnight, the
insoluble substance was removed by filtration. And thereto was
added 1 mol/L hydrochloric acid aqueous solution, followed by
extraction with ethyl acetate twice time. The combined organic
layer was washed with saturated brine, and then was dried with
anhydrous magnesium sulfate. The inorganic substance was removed by
filtration, and then concentrated under reduced pressure. Thereto
was added diisopropyl ether to precipitate a solid. The solid was
collected by filtration, so as to yield compound 124b as a brown
solid.
[1393] Yielded amount: 22.76 g (75%)
[1394] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 3.75 (3H, s), 3.76 (3H,
s), 5.16 (2H, s), 5.17 (2H, s), 6.92-6.96 (4H, m), 7.35-7.40 (6H,
m).
Step (2): Compound 124b+Compound 122e.fwdarw.Compound 5124cc
[1395] A solution of Compound 124b (30 g, 71 mmol) in
dimethylformamide (300 mL) was added Compound 122e (19.44 g, 85
mmol) and sodium acetate (29.1 g, 355 mmol). After stirring at room
temperature for 1 hour, thereto was added acetic acid (20.3 ml, 355
mmol). After stirring at room temperature for over night, thereto
was added ice water and 2 mol/L sodium hydroxide aqueous solution
until it gave a pH of 10.0 at 0.degree. C. The precipitated solid
was then collected by filtration and dissolved tetrahydrofuran. The
resultant solution was dried with anhydrous sodium sulfate. The
inorganic substance was removed by filtration, and then
concentrated under reduced pressure. Thereto was added ethyl
acetate to precipitate a solid. The solid was collected by
filtration, so as to yield compound 124c as a white solid.
[1396] Yielded amount: 32.66 g (85%)
[1397] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 1.42 (6H, t, J=7.59 Hz),
2.75 (6H, t, J=7.59 Hz), 3.75 (6H, s), 3.94 (2H, s), 5.20 (2H, s),
5.22 (2H, s), 6.94-6.97 (4H, m), 7.39 (2H, d, J=8.53 Hz), 7.42 (2H,
d, J=8.53 Hz), 7.54 (1H, s), 7.71 (1H, s), 8.21 (1H, s).
Step (3): Compound X-24+Compound 124c.fwdarw.Compound I-124
[1398] From Compound X-24 (886 mg, 1.0 mmol) and Compound 124c (541
mg, 1.0 mmol), Compound I-124 was obtained as a yellow powder using
the same method as Example 120.
[1399] Yielded amount: 440 mg, (55%)
[1400] .sup.1H-NMR (D.sub.2O) .delta.: 1.50 (3H, s), 1.52 (3H, s),
1.54 (3H, d, J=7.40 Hz), 1.98 (6H, s), 3.47 (6H, d, J=34.88 Hz),
4.02-4.13 (4H, m), 4.62 (1H, d, J=14.68 Hz), 5.42 (1H, d, J=4.77
Hz), 5.83 (1H, d, J=4.77 Hz), 6.97 (1H, s), 7.08 (1H, s), 7.41 (1H,
s), 8.06 (1H, s).
[1401] Elem. Anal.:
C.sub.34H.sub.37N.sub.8O.sub.10S.sub.2Na.6.5H.sub.2O.0.1NaHCO.sub.3
[1402] Calcd.: C, 44.02; H, 5.43; N, 12.04; S, 6.89; Na,
2.72(%).
[1403] Found: C, 43.83; H, 5.45; N, 12.34; S, 6.81; Na,
2.70(%).
[1404] MS (m+1)=783.34
Example 125
Synthesis of Compound I-125
##STR00340##
[1405] Step (1): Compound 125a.fwdarw.Compound 125b
[1406] A solution of Compound 125a (10.38 g, 45 mmol) in
dichloromethane (100 mL) was cooled with ice, and thereto was added
dropwise boron tribromide (10.3 mL, 109 mmol). After stirring at
0.degree. C. for 1 hour, the reaction mixture was poured to ice,
and thereto was concentrated. Then the precipitated solid was
collected by filtration, so as to yield compound 125b as a brown
solid.
[1407] Yielded amount: 8.89 g, (98%)
[1408] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 5.14 (2H, s), 6.92 (1H,
s).
Step (2): Compound 125b.fwdarw.Compound 125c
[1409] To a solution of compound 125b (9.89 g, 49 mmol) in
dimethylformamide (100 mL) was added potassium carbonate (20.44 g,
148 mmol), 4-methoxybenzylchloride (16.12 mL, 118 mmol) and sodium
iodide (7.39 g, 49 mmol). After stirring at 50.degree. C. for 1
hour, the reaction mixture was poured to ice water. Then the
precipitated solid was collected by filtration, so as to yield
compound 125c as a brown solid.
[1410] Yielded amount: 20.18 g, (93%)
[1411] .sup.1H-NMR (CDCl.sub.3) .delta.: 3.80 (3H, s), 3.84 (3H,
s), 4.99 (2H, s), 5.13 (2H, s), 5.15 (2H, s), 6.82 (2H, d, J=8.66
Hz), 6.90 (1H, s), 6.94 (2H, d, J=8.66 Hz), 7.32 (2H, d, J=8.66
Hz), 7.36 (2H, d, J=8.66 Hz).
Step (3): Compound 125c.fwdarw.Compound 125d
[1412] To a solution of compound 125c (17.35 g, 39 mmol) in
methanol (17 mL) and tetrahydrofuran (17 mL) was added 2 mol/L
sodium hydroxide (59 mL, 118 mmol) aqueous solution. After stirring
at 70.degree. C. for 1 hour, thereto was added ice water. Then the
precipitated solid was collected by filtration, so as to yield
compound 125d as a white solid.
[1413] Yielded amount: 18.60 g, (98%)
[1414] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 3.75 (3H, s), 3.77 (3H,
s), 4.33 (2H, s), 4.81 (2H, s), 5.06 (2H, s), 5.85 (1H, s), 6.87
(2H, d, J=8.66 Hz), 6.96 (2H, d, J=8.66 Hz), 7.05 (1H, s), 7.33
(2H, d, J=8.66 Hz), 7.41 (2H, d, J=8.66 Hz).
Step (4): Compound 125d.fwdarw.Compound 125e
[1415] A solution of Compound 125d (1.92 g, 4.0 mmol) in
dichloromethane (15 mL) and methanol (4 mL) was added manganese
dioxide (3.47 g, 40 mmol). After stirring at room temperature for 1
hour, thereto was concentrated and added ethyl acetate. The
insoluble substance was removed by filtration. And thereto was
added 1 mol/L hydrochloric acid aqueous solution, followed by
extraction with ethyl acetate twice time. The combined organic
layer was washed with saturated brine, and then was dried with
anhydrous magnesium sulfate. The inorganic substance was removed by
filtration, and then concentrated under reduced pressure. Thereto
was added diisopropyl ether to precipitate a solid. The solid was
collected by filtration, so as to yield compound 125e as a white
solid.
[1416] Yielded amount: 1.25 g (69%)
[1417] .sup.1H-NMR (CDCl.sub.3) .delta.: 3.80 (3H, s), 3.84 (3H,
s), 4.96 (2H, dd, J=13.87, 10.10 Hz), 5.14 (2H, dd, J=28.36, 11.04
Hz), 6.40 (1H, s), 6.81 (2H, d, J=8.53 Hz), 6.95 (2H, d, J=8.53
Hz), 7.06 (1H, s), 7.28 (2H, d, J=8.53 Hz), 7.38 (2H, d, J=8.53
Hz).
Step (5): Compound 125e+Compound 122e.fwdarw.Compound 125f
[1418] A solution of Compound 125e (949 mg, 2.08 mmol) in
dimethylacetamide (9.5 mL) was added Compound 122e (521 mg, 2.29
mmol) and sodium acetate (852 mg, 10.4 mmol). After stirring at
room temperature for 1 hour, thereto was added acetic acid (0.594
ml, 10.4 mmol). After stirring at 70.degree. C. for over night,
thereto was added ice water and 2 mol/L sodium hydroxide aqueous
solution until it gave a pH of 10.0 at 0.degree. C. The
precipitated solid was then collected by filtration and dissolved
tetrahydrofuran. The resultant solution was dried with anhydrous
sodium sulfate. The inorganic substance was removed by filtration,
and then concentrated under reduced pressure. Thereto was added
ethyl acetate to precipitate a solid. The resulting crude product
was purified by silica gel column chromatography
(triethylamine/methanol/ethyl acetate), so as to yield compound
125f as a yellow solid.
[1419] Yielded amount: 435 mg (36%)
[1420] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 1.46 (6H, t, J=7.53 Hz),
2.80 (6H, t, J=7.53 Hz), 3.74 (4H, s), 3.79 (3H, s), 3.92 (2H, s),
4.97 (2H, s), 5.27 (2H, s), 6.85 (2H, d, J=8.66 Hz), 7.01 (2H, d,
J=8.66 Hz), 7.29 (2H, d, J=8.66 Hz), 7.50 (2H, d, J=8.66 Hz), 7.67
(1H, s), 8.24 (1H, s).
Step (6): Compound X-24+Compound 125f.fwdarw.Compound I-125
[1421] From Compound X-24 (668 mg, 0.755 mmol) and Compound 125f
(435 mg, 0.755 mmol), Compound I-125 was obtained as a yellow
powder using the same method as Example 120.
[1422] Yielded amount: 196 mg, (31%)
[1423] .sup.1H-NMR (D.sub.2O) .delta.: 1.50 (3H, s), 1.52 (3H, s),
1.54 (3H, d, J=7.15 Hz), 1.99 (6H, t, J=7.47 Hz), 3.39-3.55 (6H,
m), 4.02-4.09 (4H, m), 4.61 (1H, d, J=14.31 Hz), 5.43 (1H, d,
J=4.89 Hz), 5.83 (1H, d, J=4.89 Hz), 6.92 (1H, s), 6.98 (1H, s),
7.94 (1H, s).
[1424] Elem. Anal.:
C.sub.34H.sub.36ClN.sub.8O.sub.10S.sub.2Na.sub.1.4.7.2H.sub.2O
[1425] Calcd.: C, 41.75; H, 5.19; Cl, 3.62; N, 11.46; S, 6.56; Na,
3.29(%).
[1426] Found: C, 41.71; H, 5.15; Cl, 3.46; N, 11.73; S, 6.57; Na,
3.34(%).
[1427] MS (m+1)=817.42
Example 126
Synthesis of Compound I-126
##STR00341##
[1428] Step (1): Compound 124b+Compound 126a.fwdarw.Compound
126b
[1429] From Compound 124b (20.65 g, 49 mmol) and Compound 126a
(14.65 g, 68 mmol), Compound 126b was obtained as a white powder
using the same method as in Step (2) of Example 124.
[1430] Yielded amount: 19.57 g, (76%)
[1431] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 1.14-1.19 (2H, m),
1.48-1.54 (2H, m), 2.19 (2H, s), 2.39-2.45 (2H, m), 2.66-2.72 (2H,
m), 3.75 (6H, s), 4.45 (2H, s), 5.20 (2H, s), 5.23 (2H, s),
6.94-6.97 (4H, m), 7.38-7.43 (4H, m), 7.55 (1H, s), 7.72 (1H, s),
8.24 (1H, s).
Step (2): Compound X-24+Compound 126b.fwdarw.Compound I-126
[1432] From Compound X-24 (886 mg, 1.0 mmol) and Compound 126b (528
mg, 1.0 mmol), Compound I-126 was obtained as a yellow powder using
the same method as Example 120.
[1433] Yielded amount: 457 mg, (58%)
[1434] .sup.1H-NMR (D.sub.2O) .delta.: 1.49 (3H, s), 1.51 (3H, s),
1.53 (3H, d, J=7.15 Hz), 2.00 (2H, s), 2.19 (2H, s), 3.37-3.66 (6H,
m), 4.04 (1H, q, J=7.15 Hz), 4.23 (1H, d, J=14.43 Hz), 4.48 (2H,
dd, J=18.51, 14.62 Hz), 4.87 (1H, d, J=14.43 Hz), 5.34 (1H, d,
J=4.89 Hz), 5.74 (1H, d, J=4.89 Hz), 6.96 (1H, s), 7.10 (1H, s),
7.43 (1H, s), 8.13 (1H, s).
[1435] Elem. Anal.:
C.sub.33H.sub.35N.sub.8O.sub.10S.sub.2Na.5.2H.sub.2O
[1436] Calcd.: C, 44.81; H, 5.17; N, 12.67; S, 7.25; Na,
2.60(%).
[1437] Found: C, 44.77; H, 5.16; N, 12.77; S, 7.52; Na,
2.81(%).
[1438] MS (m+1)=769.48
Example 127
Synthesis of Compound I-127
##STR00342##
[1439] Step (1): Compound X-1+Compound 127a.fwdarw.Compound
I-127
[1440] From Compound X-1 (932 mg, 1.0 mmol) and Compound 127a (528
mg, 1.0 mmol), Compound I-127 was obtained as a yellow powder using
the same method as Example 120.
[1441] Yielded amount: 161 mg, (20%)
[1442] .sup.1H-NMR (D.sub.2O) .delta.: 1.46 (3H, t, J=7.22 Hz),
1.49 (3H, s), 1.52-1.53 (6H, m), 2.22-2.25 (4H, m), 3.36-3.39 (3H,
m), 3.59-3.61 (1H, m), 4.12 (1H, q, J=6.90 Hz), 4.22-4.32 (3H, m),
4.44 (2H, s), 4.90 (1H, d, J=13.93 Hz), 5.48 (1H, d, J=4.89 Hz),
5.83 (1H, d, J=4.89 Hz), 6.98 (1H, s), 7.07 (1H, s), 7.53 (1H, s),
8.20 (1H, s).
[1443] Elem. Anal.:
C.sub.34H38N.sub.7O.sub.10S.sub.2Na.8.1H.sub.2O
[1444] Calcd.: C, 43.55; H, 5.83; N, 10.46; S, 6.84; Na,
2.45(%).
[1445] Found: C, 43.54; H, 5.85; N, 10.72; S, 6.58; Na,
2.48(%).
[1446] MS (m+1)=770.35
Example 128
Synthesis of Compound I-128
##STR00343##
[1447] Step (1): Compound X-1+Compound 128a.fwdarw.Compound
I-128
[1448] From Compound X-1 (932 mg, 1.0 mmol) and Compound 128a (530
mg, 1.0 mmol), Compound I-128 was obtained as a yellow powder using
the same method as Example 120.
[1449] Yielded amount: 331 mg, (42%)
[1450] .sup.1H-NMR (D.sub.2O) .delta.: 1.48-1.54 (12H, m), 2.25
(4H, s), 3.42-3.48 (2H, m), 3.53-3.57 (1H, m), 3.74-3.76 (1H, m),
4.13 (1H, q, J=6.99 Hz), 4.40 (1H, d, J=14.43 Hz), 4.50 (2H, q,
J=7.15 Hz), 4.60 (2H, s), 5.01 (1H, d, J=14.43 Hz), 5.48 (1H, d,
J=4.77 Hz), 5.81 (1H, d, J=4.77 Hz), 6.99 (1H, s), 7.00 (1H, s),
7.33 (1H, s).
[1451] MS (m+1)=771.35
Example 129
Synthesis of Compound I-129
##STR00344##
[1452] Step (1): Compound X-1+Compound 129a.fwdarw.Compound
I-129
[1453] From Compound X-1 (932 mg, 1.0 mmol) and Compound 129a (563
mg, 1.0 mmol), Compound I-129 was obtained as a yellow powder using
the same method as Example 120.
[1454] Yielded amount: 246 mg, (30%)
[1455] .sup.1H-NMR (D.sub.2O) .delta.: 1.40 (3H, t, J=7.03 Hz),
1.50 (3H, s), 1.52 (3H, s), 1.55 (3H, d, J=7.03 Hz), 2.23 (4H, d,
J=10.42 Hz), 3.36 (3H, s), 3.56 (1H, s), 4.11-4.23 (4H, m), 4.37
(2H, s), 4.89 (1H, d, J=14.18 Hz), 5.50 (1H, d, J=4.89 Hz), 5.83
(1H, d, J=4.89 Hz), 6.87 (1H, s), 6.98 (1H, s), 8.09 (1H, s).
[1456] Elem. Anal.:
C.sub.34H.sub.37ClN.sub.7O.sub.10S.sub.2Na.7.4H.sub.2O
[1457] Calcd.: C, 42.56; H, 5.44; Cl, 3.69; N, 10.22; S, 6.68; Na,
2.40(%).
[1458] Found: C, 42.53; H, 5.39; Cl, 3.51; N, 10.41; S, 6.69; Na,
2.56(%).
[1459] MS (m+1)=804.33
Example 130
Synthesis of Compound I-130
##STR00345##
[1460] Step (1): Compound X-24+Compound 130a.fwdarw.Compound
I-130
[1461] From Compound X-24 (709 mg, 0.80 mmol) and Compound 130a
(417 mg, 0.80 mmol), Compound I-130 was obtained as a white powder
using the same method as Example 120.
[1462] Yielded amount: 177 mg, (29%)
[1463] .sup.1H-NMR (D.sub.2O) .delta.: 1.50 (3H, s), 1.52 (3H, s),
1.58 (3H, d, J=7.15 Hz), 2.21-2.25 (4H, m), 3.46-3.97 (8H, m), 4.09
(1H, q, J=7.15 Hz), 4.26 (1H, d, J=14.31 Hz), 5.04 (1H, d, J=14.31
Hz), 5.47 (1H, d, J=4.77 Hz), 5.82 (1H, d, J=4.77 Hz), 7.01 (1H,
s), 7.12 (1H, s), 7.79 (1H, s).
[1464] MS (m+1)=733.35
Example 131
Synthesis of Compound I-131
##STR00346##
[1465] Step (1): Compound 131a+Compound 131b.fwdarw.Compound
131c
[1466] To a solution of Compound 131a (4.57 g, 10.0 mmol) in
methanol (45 mL) was added Compound 131b (877 mg, 10.5 mmol) and
triethylamine (1.46 mL, 10.5 mmol) at 00.degree. C. After stirring
at 00.degree. C. for 1 hour, solvent was removed. The crude product
was dissolved with ethyl acetate and washed with water, aqueous
hydrochloride and brine. The organic layer was filtered, dryed over
magnesium sulfate and concentrated under reduced pressure to yield
Compound 131c as brown oil. Compound 131c was used in the next
reaction without further purification.
[1467] Yielded amount: 4.86 g (100%)
[1468] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.36 (2H, d, J=8.3 Hz),
7.32 (2H, d, J=8.6 Hz), 7.24 (2H, s), 6.92 (2H, d, J=8.6 Hz), 6.82
(2H, d, J=8.6 Hz), 5.06 (2H, s), 5.00 (2H, s), 4.09 (3H, s), 3.83
(3H, s), 3.80 (3H, s).
Step (2): Compound 131c+Compound 131d.fwdarw.Compound 131e
[1469] To a solution of Compound 131c (4.86 g, 10.0 mmol) in
dimethylacetamide (40 mL) was added methanesulfonyl chloride (1.01
mL, 13.0 mmol) at -20.degree. C. After the mixture was stirred at
-20.degree. C. for 30 minutes, the solution of Compound 131d (1.96
g, 14.0 mmol) in dimethylacetamide (10 mL) was added to the mixture
and the reaction mixture was stirred at 00.degree. C. for 30
minutes. Water and ethyl acetate were added to the reaction
mixture, followed by extraction with ethyl acetate. The combined
organic layer was washed with water, aqueous hydrochloric acid
solution and brine. The organic layer was filtered, dryed over
magnesium sulfate and concentrated under reduced pressure. The
crude product was purified by silica gel chromatography to yield
Compound 131e as brown foam.
[1470] Yielded amount: 4.10 g (67%)
[1471] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.36 (2H, d, J=8.1 Hz),
7.31 (2H, d, J=8.3 Hz), 7.22-7.18 (2H, m), 6.92 (2H, t, J=8.6 Hz),
6.82 (2H, t, J=8.3 Hz), 5.94 (1H, t, J=6.6 Hz), 5.03 (2H, s), 4.99
(2H, s), 4.01 (3H, s), 3.83 (3H, s), 3.79 (3H, s), 3.24 (2H, d,
J=6.6 Hz), 2.95 (6H, t, J=7.5 Hz), 1.47 (6H, t, J=7.3 Hz).
Step (3): Compound X-3+Compound 131e.fwdarw.Compound
131f.fwdarw.Compound I-131
[1472] To a solution of Compound X-3 (1.00 g, 1.26 mmol) in
dimethylacetamide (2.0 mL) was added sodium iodide (377 mg, 2.56
mmo) and the mixture was stirred at room temperature for 30
minutes. The mixture was cooled to 0.degree. C. and then a solution
of Compound 131e (766 mg, 1.26 mmol) in dimethylacetamide (2.0 mL)
was dropwised to it. The reaction mixture was slowly added to 5%
aqueous sodium chloride after stirring at 0.degree. C. for 2 hours.
The precipitated solid was collected by filtration, washed with
aqueous hydrochloride and water. The crude product Compound 131f
was dissolved into dichloromethane (12 mL) and the solution was
dryed over magnesium sulfate. Insoluble matter was removed by
filtration to yield Compound 131f as a solution of dichloromethane.
Compound 131f was used in the next reaction without further
purification.
[1473] To a solution of Compound 131f in dichloromethane (12 mL)
was added anisole (1.37 mL, 12.6 mmol) and a 2 mol/L aluminum
chloride solution (6.3 mL, 12.6 mmol) in nitromethane in turn at
-20.degree. C. To the reaction mixture were added diisopropyl ether
and a small amount of water after stirring at 0.degree. C. for 30
minutes, and the resultant was stirred to generate a precipitate.
The supernatant was removed by decantation. To the insoluble matter
adhering to the vessel were added a diluted aqueous hydrochloric
acid solution, and acetonitrile. The resultant was stirred to
dissolve the matter completely. Thereto was added HP20-SS resin.
Acetonitrile was then distilled off therefrom under reduced
pressure. The resultant mixed liquid was purified by ODS column
chromatography. The desired-compound-containing fraction was
concentrated under reduced pressure, and then freeze-dried to yield
compound I-131 as a yellow powder.
[1474] Yielded amount: 250 mg (24%)
[1475] .sup.1H-NMR (D.sub.2O) .delta.: 7.13 (1H, s), 7.06 (1H, s),
7.00 (1H, s), 5.84 (1H, d, J=4.5 Hz), 5.45 (1H, d, J=4.8 Hz), 4.65
(1H, d, J=14.4 Hz), 4.06 (2H, t, J=6.7 Hz), 3.99 (3H, s), 3.54-3.46
(6H, br m), 3.36 (2H, s), 1.92 (6H, s), 1.56 (3H, d, J=7.1 Hz),
1.52 (6H, d, J=7.6 Hz).
[1476] MS (m+1)=849.40
Example 132
Synthesis of Compound I-132
##STR00347##
[1477] Step (1): Compound 132a+Compound 131b.fwdarw.Compound
132b
[1478] To a solution of Compound 132a (4.62 g, 10.0 mmol) in
methanol (22 mL) and tetrahydrofuran (22 mL) was added Compound
131b (877 mg, 10.0 mmol) at 0.degree. C. After stirring at
0.degree. C. for 3 hour, solvent was removed. The crude product was
dissolved with ethyl acetate and washed with water, aqueous
hydrochloride and brine. The organic layer was filtered, dryed over
magnesium sulfate and concentrated under reduced pressure to yield
Compound 132b as brown oil. Compound 132b was used in the next
reaction without further purification.
[1479] Yielded amount: 2.77 g (59%)
[1480] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.34 (2H, d, J=8.5 Hz),
7.29 (2H, d, J=8.7 Hz), 7.08 (1H, s), 6.99 (1H, dd, J=10.9, 3.2
Hz), 6.91 (3H, d, J=8.7 Hz), 6.81 (2H, d, J=8.7 Hz), 5.05 (2H, s),
5.04 (2H, s), 4.06 (3H, s), 3.83 (3H, s), 3.79 (3H, s).
Step (2): Compound 132b+Compound 131d.fwdarw.Compound 132c
[1481] From Compound 132b (2.77 g, 5.9 mmol) and Compound 131d
(1.16 g, 8.3 mmol), Compound 132c was obtained as a yellow foam
using the same method as in Step (2) of Example 131.
[1482] Yielded amount: 1.03 g (29%)
[1483] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.33 (2H, d, J=8.6 Hz),
7.28 (2H, d, J=8.6 Hz), 7.10 (1H, s), 7.01 (1H, dd, J=11.1, 1.5
Hz), 6.91 (2H, d, J=8.3 Hz), 6.81 (2H, d, J=8.3 Hz), 5.96 (1H, s),
5.04 (2H, s), 5.01 (2H, s), 4.01 (3H, s), 3.82 (3H, s), 3.79 (3H,
s), 3.21 (2H, d, J=6.3 Hz), 2.91-2.89 (6H, br m), 1.43-1.41 (6H, br
m).
Step (3): Compound X-3+Compound 132c.fwdarw.Compound I-132
[1484] From Compound X-3 (1.0 g, 1.26 mmol) and Compound 132c (745
mg, 1.26 mmol), Compound I-132 was obtained as a colorless powder
using the same method as in Step (3) of Example 131.
[1485] Yielded amount: 314 mg (27%)
[1486] .sup.1H-NMR (D.sub.2O) .delta.: 7.01 (1H, s), 6.94 (1H, d,
J=11.3 Hz), 6.91 (1H, s), 5.85 (1H, d, J=4.8 Hz), 5.46 (1H, d,
J=4.8 Hz), 4.65 (1H, d, J=14.4 Hz), 4.07 (2H, t, J=7.5 Hz), 3.99
(3H, d, J=8.0 Hz), 3.50 (6H, t, J=18.1 Hz), 3.37 (2H, s), 1.93 (6H,
t, J=7.5 Hz), 1.57 (3H, d, J=7.2 Hz), 1.53 (3H, s), 1.51 (3H,
s).
[1487] MS (m+1)=833.41
Example 133
Synthesis of Compound I-133
##STR00348##
[1488] Step (1): Compound 131a+Compound 133a.fwdarw.Compound
133b
[1489] From Compound 131a (5.03 g, 11 mmol) and Compound 133a (1.62
g, 11 mmol), Compound 133b was obtained as a brown oil using the
same method as in Step (1) of Example 131.
[1490] Yielded amount: 6.45 g (quant.)
[1491] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.36-7.31 (5H, m), 7.17
(1H, d, J=7.3 Hz), 6.92 (2H, d, J=8.3 Hz), 6.82 (2H, d, J=8.3 Hz),
5.04 (2H, s), 5.00 (2H, s), 4.72 (2H, s), 3.83 (3H, s), 3.80 (3H,
s), 1.51 (9H, s).
Step (2): Compound 133b+Compound 131d.fwdarw.Compound 133c
[1492] From Compound 133b (6.45 g, 11 mmol) and Compound 131d (2.16
g, 15.4 mmol), Compound 133c was obtained as a yellow foam using
the same method as in Step (2) Example 131.
[1493] Yielded amount: 5.42 g (70%)
[1494] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.45-7.28 (6H, m),
7.18-7.16 (1H, m), 6.92 (2H, d, J=8.6 Hz), 6.81 (2H, d, J=8.8 Hz),
5.03 (2H, s), 4.97 (2H, s), 4.67 (2H, s), 3.83 (3H, s), 3.79 (3H,
s), 3.26 (2H, d, J=6.3 Hz), 2.93 (6H, t, J=7.1 Hz), 1.48-1.43 (15H,
br m).
Step (3): Compound X-3+Compound 133c.fwdarw.Compound I-133
[1495] From Compound X-3 (1.0 g, 1.26 mmol) and Compound 133c (892
mg, 1.26 mmol), Compound I-133 was obtained as a yellow powder
using the same method as in Step (3) Example 131.
[1496] Yielded amount: 260 mg (22%)
[1497] .sup.1H-NMR (D.sub.2O) .delta.: 7.15 (1H, s), 7.08 (1H, s),
7.01 (1H, s), 5.84 (1H, d, J=4.9 Hz), 5.46 (1H, d, J=4.8 Hz), 4.64
(1H, d, J=14.3 Hz), 4.57 (2H, s), 4.07 (2H, dd, J=10.5, 6.3 Hz),
3.49 (6H, t, J=19.1 Hz), 3.40 (3H, s), 1.95 (6H, t, J=7.6 Hz), 1.57
(3H, d, J=7.0 Hz), 1.52 (3H, s), 1.50 (3H, s).
[1498] MS (m+1)=894.38
Example 134
Synthesis of Compound I-134
##STR00349##
[1499] Step (1): Compound 131a+Compound 134a.fwdarw.Compound
134b
[1500] From Compound 131a (4.57 g, 10 mmol) and Compound 134a (3.03
g, 11 mmol), Compound 134b was obtained as a brown oil using the
same method as in Step (1) of Example 131.
[1501] Yielded amount: 7.1 g (99%)
[1502] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.49 (1H, d, J=1.8 Hz),
7.36-7.27 (20H, m), 6.88 (2H, d, J=8.6 Hz), 6.83 (2H, d, J=8.3 Hz),
5.06 (2H, s), 4.98 (2H, s), 3.81 (3H, s), 3.79 (3H, s).
Step (2): Compound 134b+Compound 131d.fwdarw.Compound 134c
[1503] From Compound 134b (7.1 g, 9.9 mmol) and Compound 131d (1.95
g, 13.9 mmol), Compound 134c was obtained as a brown oil using the
same method as in Step (2) of Example 131.
[1504] Yielded amount: 1.67 g (20%)
[1505] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.41-7.26 (29H, m), 6.86
(2H, d, J=8.3 Hz), 6.82 (2H, d, J=8.3 Hz), 6.31 (1H, t, J=6.3 Hz),
5.02 (2H, d, J=5.6 Hz), 4.95 (2H, d, J=8.6 Hz), 3.82 (3H, s), 3.78
(3H, s), 2.98 (2H, d, J=6.3 Hz), 2.83 (6H, t, J=7.3 Hz), 1.15 (6H,
t, J=7.3 Hz).
Step (3): Compound X-3+Compound 134c.fwdarw.Compound I-134
[1506] From Compound X-3 (1.0 g, 1.26 mmol) and Compound 134c (1.05
g, 1.26 mmol), Compound I-134 was obtained as a colorless powder
using the same method as in Step (3) of Example 131.
[1507] Yielded amount: 390 mg (28%)
[1508] .sup.1H-NMR (D.sub.2O) .delta.: 7.13 (1H, d, J=1.9 Hz), 7.01
(1H, s), 6.98 (1H, d, J=2.0 Hz), 5.84 (1H, d, J=4.9 Hz), 5.44 (1H,
d, J=4.9 Hz), 4.64 (1H, d, J=14.4 Hz), 4.06 (2H, q, J=7.3 Hz),
3.54-3.39 (6H, m), 3.31 (2H, s), 1.91 (6H, t, J=7.8 Hz), 1.56 (3H,
d, J=7.0 Hz), 1.53 (3H, s), 1.51 (3H, s).
[1509] MS (m+1)=835.42
Example 135
Synthesis of Compound I-135
##STR00350##
[1510] Step (1): Compound 132a+Compound 133d.fwdarw.Compound
3bb135a
[1511] To a solution of Compound 132a (4.99 g, 10.8 mmol) and
aqueous hydrochloric acid (5.4 mL, 10.8 mmol) in methanol (25 mL)
and tetrahydrofuran (25 mL) was added Compound 133d (1.77 g, 12.0
mmol) at 0.degree. C. After stirring at 0.degree. C. for 3 hour,
solvent was removed. The crude product was dissolved with ethyl
acetate and washed with water, aqueous hydrochloric acid and brine.
The organic layer was filtered, dryed over magnesium sulfate and
concentrated under reduced pressure to yield Compound 135a as brown
oil. Compound 135a was used in the next reaction without further
purification.
[1512] Yielded amount: 4.41 g (65%)
[1513] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.34 (2H, d, J=8.1 Hz),
7.29 (2H, t, J=7.7 Hz), 7.11 (2H, t, J=13.0 Hz), 6.92 (3H, t, J=8.0
Hz), 6.82 (2H, d, J=8.3 Hz), 5.05 (2H, s), 5.03 (2H, s), 4.71 (2H,
s), 3.83 (3H, s), 3.78 (3H, s), 1.51 (9H, s).
Step (2): Compound 135a+Compound 131d.fwdarw.Compound 135b
[1514] From Compound 135b (4.41 g, 6.5 mmol) and Compound 131d
(1.27 g, 9.1 mmol), Compound 135b was obtained as a yellow foam
using the same method as in Step (2) of Example 131.
[1515] Yielded amount: 2.73 g (62%)
[1516] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.33 (2H, d, J=8.5 Hz),
7.29 (2H, d, J=8.8 Hz), 7.14 (1H, s), 7.04 (1H, dd, J=11.0, 6.5
Hz), 6.91 (2H, dd, J=5.5, 3.1 Hz), 6.81 (2H, d, J=8.7 Hz), 5.04
(2H, s), 5.01 (2H, s), 4.66 (2H, s), 3.83 (3H, s), 3.79 (3H, s),
3.29 (2H, d, J=6.4 Hz), 3.03-2.97 (6H, m), 1.60 (6H, m), 1.48 (9H,
s).
Step (3): Compound X-3+Compound 135b.fwdarw.Compound I-135
[1517] From Compound X-3 (1.0 g, 1.26 mmol) and Compound 135b (853
mg, 1.26 mmol), Compound I-135 was obtained as a yellow powder
using the same method as in Step (3) of Example 131.
[1518] Yielded amount: 175 mg (15%)
[1519] .sup.1H-NMR (D.sub.2O) .delta.: 7.01 (1H, s), 6.98-6.96 (2H,
m), 5.84 (1H, d, J=4.8 Hz), 5.46 (1H, d, J=4.9 Hz), 4.64 (2H, d,
J=13.9 Hz), 4.57 (2H, s), 4.08-4.06 (2H, m), 3.52-3.47 (6H, m),
3.40 (2H, s), 1.95 (6H, t, J=7.7 Hz), 1.57 (3H, s), 1.52 (3H, s),
1.50 (3H, d, J=5.8 Hz).
[1520] MS (m+1)=877.52
Example 136
Synthesis of Compound I-136
##STR00351##
[1521] Step (1): Compound 132a+Compound 136a.fwdarw.Compound
136b
[1522] From Compound 132a (4.99 g, 10 mmol) and Compound 136a (1.90
g, 10 mmol), Compound 136b was obtained as a brown oil using the
same method as in Step (1) of Example 132.
[1523] Yielded amount: 5.11 g (89%) .sup.1H-NMR (CDCl.sub.3)
.delta.: 7.32 (2H, d, J=8.5 Hz), 7.29 (2H, d, J=8.5 Hz), 7.11 (OH,
d, J=188.6 Hz), 7.05 (1H, s), 6.98 (1H, dd, J=11.1, 1.6 Hz),
6.92-6.89 (4H, m), 6.81 (2H, d, J=8.7 Hz), 5.22 (2H, s), 5.05 (2H,
s), 5.03 (2H, s), 3.83 (3H, s), 3.81 (3H, s), 3.79 (3H, s).
Step (2): Compound 136b+Compound 131d.fwdarw.Compound 136c
[1524] From Compound 136a (5.11g, 8.9 mmol) and Compound 136a (1.75
g, 12.5 mmol), Compound 136b was obtained as a yellow foam using
the same method as in Step (2) of Example 131.
[1525] Yielded amount: 2.4 g (39%)
[1526] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.34-7.32 (4H, m), 7.29
(2H, d, J=8.5 Hz), 7.12 (1H, s), 7.03 (1H, dd, J=11.0, 1.8 Hz),
6.91 (4H, d, J=8.7 Hz), 6.81 (2H, d, J=8.5 Hz), 5.91 (1H, t, J=6.4
Hz), 5.15 (2H, s), 5.04 (2H, s), 5.03 (2H, s), 3.83 (3H, s), 3.82
(3H, s), 3.79 (3H, s), 3.14 (2H, d, J=6.5 Hz), 2.75-2.73 (6H, br
m), 1.29-1.24 (6H, m).
Step (3): Compound X-3+Compound 136c.fwdarw.Compound I-136
[1527] From Compound X-3 (1.0 g, 1.26 mmol) and Compound 136c (878
mg, 1.26 mmol), Compound I-136 was obtained as a colorless powder
using the same method as in Step (3) of Example 131.
[1528] Yielded amount: 400 mg (40%)
[1529] .sup.1H-NMR (D.sub.2O) .delta.: 7.00 (1H, s), 6.95 (1H, d,
J=11.3 Hz), 6.92 (1H, s), 5.84 (1H, d, J=4.9 Hz), 5.45 (1H, d,
J=4.8 Hz), 4.64 (1H, d, J=14.2 Hz), 4.06 (2H, t, J=7.0 Hz),
3.51-3.47 (6H, br m), 3.39 (3H, s), 1.96-1.94 (6H, br m), 1.56 (3H,
d, J=7.0 Hz), 1.54 (3H, s), 1.50 (3H, s).
[1530] MS (m+1)=819.54
Example 137
Synthesis of Compound I-137
##STR00352## ##STR00353##
[1531] Step (1): Compound 137a+Compound 134a.fwdarw.Compound
137b
[1532] From Compound 137a (4.39 g, 9.60 mmol) and Compound 134a
(2.64 g, 9.60 mmol), Compound 137b was obtained as a brown oil
using the same method as in Step (1) of Example 131.
[1533] Yielded amount: 2.57 g (38%)
[1534] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.51-7.43 (19H, m),
6.94-6.89 (2H, m), 6.82-6.79 (2H, m), 5.09-4.95 (4H, m), 3.84-3.74
(6H, m).
Step (2): Compound 137b+Compound 137c.fwdarw.Compound 137d
[1535] From Compound 3cc (2.57 g, 3.60 mmol) and Compound 7 (545
mg, 4.32 mmol), Compound 3cc was obtained as a brown oil using the
same method as in Step (2) of Example 131.
[1536] Yielded amount: 940 mg (32%)
[1537] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.34 (7H, dt, J=25.1, 7.5
Hz), 7.23 (13H, br s), 6.93 (2H, d, J=8.3 Hz), 6.77 (2H, d, J=8.3
Hz), 5.11 (2H, s), 4.98 (2H, s), 3.84 (3H, s), 3.73 (3H, s), 3.36
(2H, d, J=5.3 Hz), 2.99-2.79 (6H, m), 1.82-1.64 (6H, br m).
Step (3): Compound X-3+Compound 137d.fwdarw.Compound I-137
[1538] To a solution of Compound X-3 (908 mg, 1.14 mmol) in
dimethylacetamide (2.0 mL) was added sodium iodide (342 mg, 2.29
mmo) and the mixture was stirred at room temperature for 30
minutes. The mixture was cooled to 0.degree. C. and then a solution
of Compound 137d (800 mg, 1.14 mmol) in dimethylacetamide (2.0 mL)
was dropwised to it. The reaction mixture was slowly added to 5%
aqueous sodium chloride after stirring at 0.degree. C. for 2 hours.
The precipitated solid was collected by filtration, washed with
aqueous hydrochloride and water and suspended into water. The
suspension was freeze-dried to yield the crude product as a brown
solid. The crude product yielded was used as it was, without being
purified, in the next reaction.
[1539] To a solution of the crude product in dichloromethane (12
mL) was added anisole (1.25 mL, 11.4 mmol) and a 2 mol/L aluminum
chloride solution (5.7 mL, 11.4 mmol) in nitromethane in turn at
-20.degree. C. To the reaction mixture were added diisopropyl ether
and a small amount of water after stirring at 0.degree. C. for 30
minutes, and the resultant was stirred to generate a precipitate.
The supernatant was removed by decantation. To the insoluble matter
adhering to the vessel were added a diluted aqueous hydrochloric
acid solution, and acetonitrile. The resultant was stirred to
dissolve the matter completely. Thereto was added HP20-SS resin.
Acetonitrile was then distilled off therefrom under reduced
pressure. The resultant mixed liquid was purified by ODS column
chromatography. The desired-compound-containing fraction was
concentrated under reduced pressure, and then freeze-dried to yield
compound I-137 as a yellow powder.
[1540] Yielded amount: 280 mg (29%)
[1541] .sup.1H-NMR (D.sub.2O) .delta.: 7.05-6.97 (3H, m), 5.87-5.86
(1H, m), 5.46-5.45 (1H, m), 4.31-4.07 (5H, m), 3.81-3.51 (7H, m),
2.36-2.31 (4H, m), 1.59 (3H, d, J=6.9 Hz), 1.53 (3H, s), 1.51 (3H,
s).
Example 138
Synthesis of Compound I-138
##STR00354## ##STR00355##
[1542] Step (1): Compound 138a+Compound 136a.fwdarw.Compound
138b
[1543] To a solution of Compound 138a (5.58 g, 10.0 mmol) in
methanol (45 mL) was added acetic acid (0.572 mL, 10.0 mmol),
Compound 136a (1.90 g, 10.0 mmol) and triethylamine (1.39 mL, 10.0
mmol) at 0.degree. C. After stirring at 0.degree. C. for 1 hour,
solvent was removed. The crude product was dissolved with ethyl
acetate and washed with water, aqueous hydrochloride and brine. The
organic layer was filtered, dryed over magnesium sulfate and
concentrated under reduced pressure to yield Compound 138b as brown
oil. Compound 138b was used in the next reaction without further
purification.
[1544] Yielded amount: 5.92 g (100%)
[1545] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.36-7.31 (6H, m), 7.21
(2H, s), 6.92-6.90 (4H, m), 6.82 (2H, d, J=8.7 Hz), 5.23 (2H, s),
5.04 (2H, s), 4.99 (2H, s), 3.83 (3H, s), 3.81 (3H, s), 3.80 (3H,
s).
Step (2): Compound 138b+Compound 137c.fwdarw.Compound 138c
[1546] From Compound 138b (1.78 g, 3.0 mmol) and Compound 137c (492
mg, 3.9 mmol), Compound 138c was obtained as a yellow foam using
the same method as in Step (2) of Example 131.
[1547] Yielded amount: 800 mg (38%)
[1548] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.38-7.30 (6H, m), 7.23
(1H, d, J=5.1 Hz), 7.16 (1H, t, J=4.3 Hz), 6.91-6.84 (6H, m), 5.15
(2H, s), 5.08-5.06 (2H, m), 5.02-5.00 (2H, m), 4.70 (1H, br s),
3.83-3.77 (9H, m), 3.29-2.55 (8H, m), 1.92-1.73 (3H, m), 1.22-1.17
(2H, m).
Step (3): Compound X-3+Compound 138c.fwdarw.Compound I-138
[1549] From Compound X-3 (908 mg, 1.14 mmol) and Compound 138c (800
mg, 1.14 mmol), Compound I-138 was obtained as a white powder using
the same method as in Step (3) of Example 137.
[1550] Yielded amount: 320 mg (33%, E/Z=29:64 or 64:29)
[1551] .sup.1H-NMR (D.sub.2O) .delta.: 7.11-7.09 (2H, m), 7.00 (1H,
s), 5.85-5.84 (1H, m), 5.44 (1H, s), 4.87 (2H, t, J=27.9 Hz), 4.32
(1H, t, J=15.0 Hz), 4.13-4.05 (2H, m), 3.81-3.67 (7H, br m), 2.37
(4H, s), 1.59-1.56 (3H, m), 1.52 (3H, s), 1.50 (3H, s).
[1552] MS (m+1)=822.5
Example 139
Synthesis of Compound I-139
##STR00356##
[1553] Step (1): Compound 139a+Compound 137c.fwdarw.Compound
139b
[1554] From Compound 139a (2.88 g, 5.0 mmol) and Compound 137c (757
mg, 6.0 mmol), Compound 139b was obtained as a yellow foam using
the same method as Step (2) of in Step (2) of Example 131.
[1555] Yielded amount: 861 mg (25%)
[1556] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.34-7.27 (8H, m),
6.90-6.88 (4H, m), 6.82 (2H, d, J=8.6 Hz), 5.14 (2H, s), 5.09-5.00
(4H, m), 4.69 (1H, s), 3.82-3.80 (9H, m), 3.27-3.18 (2H, br m),
3.08-2.82 (4H, m), 2.81-2.70 (2H, m), 2.60-2.53 (1H, m), 2.03-1.70
(3H, m), 1.42 (1H, br s).
Step (2): Compound X-3+Compound 139b.fwdarw.Compound I-139
[1557] From Compound X-3 (1.0 g, 1.26 mmol) and Compound 139b (861
mg, 1.26 mmol), Compound I-139 was obtained as a colorless powder
using the same method as in Step (3) of Example 137.
[1558] Yielded amount: 320 mg (31%, E/Z or Z/E=34:63)
[1559] .sup.1H-NMR (D.sub.2O) .delta.: 7.00 (1H, s), 6.96 (2H, d,
J=11.7 Hz), 5.86-5.84 (1H, m), 5.45-5.44 (1H, m), 4.33 (2H, t,
J=14.7 Hz), 4.13-4.07 (2H, m), 3.87-3.49 (8H, m), 2.38-2.36 (4H, br
m), 1.59-1.57 (3H, m), 1.52 (3H, s), 1.50 (3H, s).
[1560] MS (m+1)=805.82
Example 140
Synthesis of Compound I-140
##STR00357##
[1561] Step (1): Compound X-24+Compound 140a.fwdarw.Compound
140b.fwdarw.Compound I-140
[1562] Compound X-24 (886 mg, 1.0 mmol) and compound 140a (397 mg,
1.0 mmol) which was synthesized into according to the synthesis in
WO2011125966A1 were used to synthesize the target compound in the
same way as in Step (4) of Example 107.
[1563] Yielded amount: 334.2 mg, (37%)
[1564] .sup.1H-NMR (D.sub.2O) .delta.: 7.78 (1H, s), 7.12 (1H, s),
7.00 (1H, s), 5.84 (1H, d, J=4.9 Hz), 5.45 (1H, d, J=4.9 Hz), 4.64
(1H, d, J=14.3 Hz), 4.11-4.05 (2H, m), 3.58-3.42 (6H, m), 3.39 (2H,
s), 1.94 (6H, t, J=7.8 Hz), 1.56 (3H, d, J=7.2 Hz), 1.52 (3H, s),
1.50 (3H, s).
[1565] Elem. Anal.: C32H37N8O10S2Na(H2O) 6.1
[1566] Calcd.: C, 43.15; H, 5.57; N, 12.58; S, 7.20; Na,
2.58(%).
[1567] Found: C, 43.10; H, 5.45; N, 12.82; S, 7.21; Na,
2.64(%).
Example 141
Synthesis of Compound I-141
##STR00358## ##STR00359##
[1568] Step (1): Compound 141a.fwdarw.Compound 141b
[1569] To a cooled (0.degree. C.) solution of compound 141a (17.4
g, 30.0 mmol) in DMA (200 ml) was added 39% peraceticacid (5.69 ml,
33.0 mmol) After stirring for 1 hr at 0.degree. C., the mixture was
quenched by 50 mL of 10% sodium bisulfite aqueous solution. The
resulting solid was collected by filtration and washed with water
and isopropanol to afford 17.4 g of compound 141b (98%).
[1570] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 8.57 (d, J=8.1 Hz, 1H),
7.50 (d, J=7.7 Hz, 2H), 7.42-7.21 (m, 13H), 6.97 (s, 1H), 5.91 (dd,
J=8.1, 4.5 Hz, 1H), 5.03 (d, J=4.5 Hz, 1H), 4.20 (d, J=18.1 Hz,
1H), 4.01 (d, J=18.1 Hz, 1H), 3.69 (d, J=14.0 Hz, 1H), 3.55 (d,
J=14.0 Hz, 1H), 3.12 (s, 3H).
Step (2): Compound 141b.fwdarw.Compound 141c
[1571] To a solution of compound 141b (17 g, 28.6 mmol) in DMF (170
ml) was added dimethylamine hydrochloride (2.33 g, 28.6 mmol) and
36% 38% formalin (4.26 ml, 57.2 mmol). After stirring for 30 min at
50.degree. C., the resulting mixture was poured into water then the
resulting solid was collected by filtration to afford 13.2 g of
compound 141c (76%)
[1572] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 8.59 (d, J=8.3 Hz, 1H),
7.53 (d, J=7.7 Hz, 2H), 7.42-7.23 (m, 14H), 6.95 (s, 1H), 6.51 (s,
1H), 6.45 (s, 1H), 6.05 (dd, J=8.3, 5.0 Hz, 1H), 5.25 (d, J=5.0 Hz,
1H), 3.69 (d, J=14.1 Hz, 1H), 3.58 (d, J=14.1 Hz, 1H), 3.23 (s,
3H).
Step (3): Compound 141c.fwdarw.Compound 141d
[1573] To a cooled (-40.degree. C.) solution of sodium borohydride
(937 mg, 24.8 mmol) in MeOH (300 ml) was added dropwise a solution
of compound 141c (12.5 g, 20.6 mmol) in 250 ml of THF under
-40.degree. C. After the mixture was stirred at -40.degree. C. for
30 min, TFA (0.163 ml, 2.12 mmol) was added. Then the mixture was
concentrated in vacuo. The resulting precipitate was collected by
filtration and washed by MeOH to afford 9.40 g of compound 141d
(75%).
[1574] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 8.61 (d, J=8.1 Hz, 1H),
7.49 (d, J=7.7 Hz, 2H), 7.44-7.22 (m, 13H), 6.95 (s, 1H), 5.94 (dd,
J=3.5, 8.1 Hz, 1H), 5.18 (d, J=3.5 Hz, 1H), 4.06 (q, J=7.7 Hz, 1H),
3.68 (d, J=14.3 Hz, 1H), 3.57 (d, J=14.3 Hz, 1H), 3.04 (s, 3H),
1.55 (d, J=7.7 Hz, 3H).
Step (4): Compound 141d.fwdarw.Compound 141e
[1575] To a cooled (-40.degree. C.) solution of compound 141d (9.39
g, 15.4 mmol) in DMF (100 ml) was added phosphorous tribromide
(1.75 ml, 18.5 mmol). After the reaction mixture was stirred for 15
min at -40.degree. C., the mixture was diluted with water. The
resulting solid was collected by filtration and washed by water to
afford 9.40 g of compound 141e.
[1576] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 9.22 (d, J=8.4 Hz, 1H),
7.48 (d, J=7.8 Hz, 2H), 7.42-7.19 (m, 13H), 6.90 (s, 1H), 5.83 (dd,
J=8.4, 5.0 Hz, 1H), 5.41 (d, J=5.0 Hz, 1H), 4.26 (q, J=7.1 Hz, 1H),
3.60-3.50 (m, 2H), 3.07 (s, 3H), 1.48 (d, J=7.1 Hz, 3H).
Step (5): Compound 141e.fwdarw.Compound 141f
[1577] To a cooled (-20.degree. C.) slurry of phosphorus
pentachloride (4.01 g, 19.2 mmol) in dichloromethane (60.0 ml) was
added pyridine (1.67 ml, 21.2 mmol) followed by compound 141e (5.7
g, 9.62 mmol). After the mixture was stirred for 45 min at
0.degree. C., the mixture was cooled to -40.degree. C. then MeOH
(23.4 ml, 577 mmol) was added to this mixture in one portion. The
mixture was warmed to room temperature and diluted with water and
dichloromethane. The aqueous layer was extracted with
dichloromethane. The combined organic layers were washed with water
and brine, dried over MgSO.sub.4, filtered. To this mixture was
added 4 mmol/l HCl in EtOAc (3.61 ml) then this solution was
concentrated in vaqcuo. The resulting residue compound 141f was
used in next Step without further purification.
Step (6): Compound 141f+Compound 141g.fwdarw.Compound 141h
[1578] To a cooled (-50.degree. C.) solution of compound 141f (9.62
mmol) in dichloro methane (50.0 ml) were added compound 141g (4.96
g, 11.5 mmol) and phenyl dichlorophosphate (1.87 ml, 12.5 mmol)
followed by N-methyl morpholine (4.23 ml, 38.5 mmol). After 1 hr at
-50.degree. C., the reaction mixture was poured into water. Then
the aqueous layer was extracted with ethyl acetate and the combined
extracts were washed with water and brine, dried (MgSO4), filtered,
and concentrated in vacuo. The residue was purified by silica gel
chromatography to afford 1.25 g of compound 141h (25%).
[1579] .sup.1H-NMR (CDCl.sub.3) .delta.: 8.29 (d, J=9.0 Hz, 1H),
7.42-7.28 (m, 11H), 6.94 (s, 1H), 6.06 (dd, J=9.0, 5.1 Hz, 1H),
5.29 (d, J=5.0 Hz, 1H), 4.15-4.02 (m, 1H), 2.62 (s, 3H), 1.63 (d,
J=10.0 Hz, 3H), 1.52 (s, 15H), 1.41 (s, 9H).
Step (7): Compound 141h.fwdarw.Compound 141i
[1580] To a cooled (0.degree. C.) solution of compound 141h (4.93
g, 5.57 mmol) in tetrahydrofuran (50.0 ml) were added magnesium
bromide diethyl etherate (7.19 g, 27.9 mmol), pyridine-4-thiol
(1.36 g, 12.3 mmol) and potassium carbonate (1.69 g, 12.3 mmol).
After stirring for 2 hr at 00.degree. C., the reaction mixture was
poured into water. Then the aqueous layer was extracted with ethyl
acetate and the combined extracts were washed with water and brine,
dried (MgSO4), filtered, and concentrated in vacuo. The residue was
purified by silica gel chromatography to afford 1.25 g of compound
5i (25%).
[1581] .sup.1H-NMR (CDCl3) .delta.: 8.39-8.32 (m, 1H), 7.44-7.21
(m, 13H), 7.08 (d, J=5.9 Hz, 2H), 6.98 (s, 1H), 6.05 (dd, J=8.8,
5.1 Hz, 1H), 5.38 (d, J=5.1 Hz, 1H), 3.82 (q, J=7.2 Hz, 1H), 1.63
(d, J=9.7 Hz, 6H), 1.53 (s, 9H), 1.42 (s, 9H).
Step (8): Compound 141i+Compound 141j.fwdarw.Compound 141k
[1582] To a cooled (00.degree. C.) solution of compound 141i (0.90
g, 1.00 mmol) in DMF (3.00 ml) was added compound 141j (0.56 g,
1.10 mmol; ref. WO2013002215A1). After stirring overnight at
0.degree. C., the reaction mixture was poured into water. Then the
aqueous layer was extracted with ethyl acetate and the combined
extracts were washed with water and brine, dried (MgSO4), filtered,
and concentrated in vacuo. The resulting residue compound 141k was
used in next Step without further purification.
Step (9): Compound 141k.fwdarw.Compound I-141
[1583] To a cooled (-20.degree. C.) solution of compound 141k in
dichloromethane (15.0 ml) was added anisole (1.09 ml, 10.0 mmol)
followed by 2 mol/L aluminum chloride solution (5.00 mL, 10.0 mmol)
in nitromethane in one portion. After stirring for 30 min at
-20.degree. C., the mixture was quenched with water (15.0 ml). The
resulting precipitate was dissolved in 2 mol/L aqueous hydrochloric
acid solution and acetonitrile. The water phase was washed with
diisopropyl ether. To this water phase was added HP20SS resin and
involved acetonitrile was distilled off under reduced pressure. The
residual suspension was loaded HP20SS precolum connected ODS column
and purified. To the resultant target-compound solution was added a
0.2 mol/L aqueous sodium hydroxide solution until the whole gave a
pH of 6.0. Then a piece of dry ice was added thereto. The resultant
solution was concentrated under reduced pressure, and then
freeze-dried to afford 508 mg of compound I-141 (65% from compound
141i)
[1584] .sup.1H-NMR (D.sub.2O) .delta.: 8.38 (d, J=6.6 Hz, 2H), 7.87
(d, J=6.6 Hz, 2H), 7.53 (d, J=8.6 Hz, 1H), 6.99 (s, 1H), 6.93 (d,
J=8.6 Hz, 1H), 5.85 (d, J=5.1 Hz, 1H), 5.65 (d, J=5.1 Hz, 1H), 4.22
(q, J=7.2 Hz, 1H), 1.54-1.50 (m, 9H).
[1585] Elemental Analysis: C30H26ClN6NaO10S3(H2O) 5
[1586] Calcd.: C, 41.17; H, 4.15; N, 9.60; S, 10.99; Cl, 4.05; Na,
2.63(%).
[1587] Found: C, 40.88; H, 4.16; N, 9.72; S, 11.00; Cl, 4.26; Na,
2.93(%).
Example 142
Synthesis of Compound I-142
##STR00360##
[1588] Step (1): Compound 142a.fwdarw.Compound 142b
[1589] Compound 142a (12.8 g, 30.0 mmol) was used to synthesized
the compound 142b in the same way as in Step (1) of example
117.
[1590] Yielded amount: 14.1 g, (86%)
[1591] .sup.1H-NMR (CDCl.sub.3) .delta.: 8.11 (d, J=8.6 Hz, 1H),
7.97 (s, 1H), 7.74 (s, 1H), 7.60-7.53 (m, 1H), 7.49-7.43 (m, 2H),
7.39 (d, J=8.3 Hz, 2H), 7.33 (d, J=8.3 Hz, 2H), 6.94 (d, J=8.3 Hz,
2H), 6.85 (d, J=8.3 Hz, 2H), 5.17 (s, 2H), 5.14 (s, 2H), 3.84 (s,
3H), 3.81 (s, 3H).
Step (2): Compound 142b.fwdarw.Compound 142c
[1592] Compound 142b (1.63 g, 3.00 mmol) was used to synthesized
the compound 142c in the same way as in Step (2) of example
117.
[1593] Yielded amount: 1.53 g (95%)
[1594] .sup.1H-NMR (CDCl.sub.3) .delta.: 7.41 (d, J=1.6 Hz, 1H),
7.37 (d, J=8.5 Hz, 2H), 7.32 (d, J=8.5 Hz, 2H), 6.93 (d, J=8.4 Hz,
2H), 6.82 (d, J=8.4 Hz, 2H), 6.09 (t, J=5.8 Hz, 1H), 5.10 (s, 2H),
5.03 (s, 2H), 3.83 (s, 3H), 3.80 (s, 3H), 3.78 (d, J=6.3 Hz, 2H),
3.04-2.92 (m, 2H), 2.66-2.60 (m, 2H), 2.34 (s, 2H), 1.35-1.22 (m,
2H).
Step (3): Compound 142c+Compound X-24.fwdarw.Compound I-142
[1595] Compound X-24 (0.886 g, 1.00 mmol) and compound 142c (0.537
g, 1.00 mmol) were used to synthesized the target compound in the
same way as in Step (4) of example 107.
[1596] Yidlded amount: 0.291 g (36%)
[1597] .sup.1H-NMR (D.sub.2O) .delta.: 7.38 (d, J=1.8 Hz, 1H), 7.22
(d, J=1.8 Hz, 1H), 6.99 (s, 1H), 5.77 (d, J=4.7 Hz, 1H), 5.40 (d,
J=4.7 Hz, 1H), 4.90 (d, J=14.4 Hz, 1H), 4.24 (d, J=14.4 Hz, 1H),
4.04 (q, J=7.1 Hz, 1H), 3.74-3.51 (m, 6H), 3.41 (d, J=8.5 Hz, 1H),
3.31 (d, J=8.5 Hz, 1H), 2.29-2.15 (m, 2H), 2.02-1.92 (m, 2H), 1.55
(d, J=7.1 Hz, 3H), 1.52-1.48 (m, 6H).
[1598] Elemental Analysis: C32H35ClN7NaO10S2(H2O) 6.4
[1599] Calcd.: C, 41.98; H, 5.26; N, 10.71; Cl, 3.87; Na,
2.51(%).
[1600] Found: C, 41.94; H, 5.16; N, 10.87; Cl, 3.72; Na,
2.61(%).
Example 143
Synthesis of Compound I-143
Step (1): Compound X-24.fwdarw.Compound 143a)
[1601] Compound 143a:
1-((6,7-bis((4-methoxybenzyl)oxy)-1-methyl-4-oxo-1,4-dihydroquinolin-3-yl-
)methyl)-1-(((4S,6R,7R)-7-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-
-yl)oxy)imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2--
(((4-methoxybenzyl)
oxy)carbonyl)-4-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)meth-
yl)pyrrolidin-1-ium, Iodide
##STR00361##
[1602]
6,7-bis((4-methoxybenzyl)oxy)-1-methyl-3-(pyrrolidin-1-ylmethyl)qui-
nolin-4(1H)-one (WO2013052568A1 0.588 g, 1.14 mmol) in DMF (5 mL)
at 0.degree. C. under nitrogen was added compound X-24 (1.063 g,
1.200 mmol) (in DMF (5 mL). The mixture was stirred at the same
temperature over 3 h, and was left in a freezer overnight. The
solution was poured into ice-cooled 5% NaCl aq (100 mL) containing
NaHSO.sub.3 (1 g) and was stirred for 15 min. The solid was
collected by filtration, washed with water and dried, and purified
by automated silica gel chromatography (Combiflash RF), eluting
with MeOH/DCM (0-20%) to afford compound 143a (0.269 g, 15% yield)
as a brown solid. LCMS: (M+H).sup.+: 1273.5.
Step (2): Compound 143a.fwdarw.Compound I-143
[1603] Compound I-143:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((1-((6,7-dihydroxy-1-methyl-4-oxo-1,4-dihydroquinolin-3-
-yl)methyl)pyrrolidin-1-ium-1-yl)methyl)-4-methyl-8-oxo-5-thia-1-azabicycl-
o[4.2.0]oct-2-ene-2-carboxylate, Sodium salt
##STR00362##
[1604] Compound 143a (0.269 g, 0.142 mmol) in DCM (1.5 mL) at
0.degree. C. was added anisole (0.16 mL, 1.42 mmol), followed by
TFA (0.50 mL, 6.5 mmol). The mixture was warmed up to rt and then
stirred overnight. Diisopropyl ether (30 mL) was added, and the
mixture was stirred for 10 min. The resulting precipitate was
collected by filtration, and washed twice with diisopropyl ether
(2.times.5 mL). The solid was dissolved in a mixture of MeCN (6
mL), water (6 mL), and 2 M HCl aq (1.5 mL), and HP20SS resin (6 g)
was added. The mixture was concentrated to dryness, and the resin
was loaded onto a pre-column containing HP20SS resin (10 g), and
purified by automated reverse phase chromatography eluting with
0-20% MeCN/water to afford
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((1-((6,7-dihydroxy-1-methyl-4-oxo-1,4-dihydroquinolin-3-
-yl)methyl)pyrrolidin-1-ium-1-yl)methyl)-4-methyl-8-oxo-5-thia-1-azabicycl-
o[4.2.0]oct-2-ene-2-carboxylate (67 mg, 62% yield) as an off-white
solid. A portion of this product (56 mg, 0.074 mmol) was suspended
in water (HPLC grade, 10 mL) and cooled to 0.degree. C. To the
vigorously stirring suspension was added 0.1 N NaOH aq (0.74 mL,
0.074 mmol) slowly using an Eppendorf pipette. After the addition
was complete, a small piece of dry ice was added to quench any
extra NaOH. The pale yellow solution was then frozen and
lyophilized to afford compound I-143 (57 mg) as an off-white
solid.
[1605] LCMS: (M+H).sup.+: 756.2. .sup.1H NMR (400 MHz, D.sub.2O)
.delta. ppm 1.32-1.43 (m, 9H) 2.10 (d, J=10.86 Hz, 4H) 3.25 (br.
s., 3H) 3.48 (br. s., 1H) 3.80 (s, 3H) 4.00 (d, J=6.57 Hz, 1H) 4.11
(d, J=14.40 Hz, 1H) 4.33 (s, 2H) 4.78-4.81 (m, 1H) 5.35 (d, J=4.80
Hz, 1H) 5.70 (d, J=4.80 Hz, 1H) 6.87 (s, 1H) 6.96 (s, 1H) 7.48 (s,
1H) 8.05 (s, 1H).
[1606] The compounds shown below were obtained from Compound X-24
and the each corresponding amine which was synthesized according to
the synthesis in WO2013052568A1 in the same way as example 143.
Example 144
Synthesis of Compound I-144
[1607] Compound I-144:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((1-((1-ethyl-5-fluoro-6,7-dihydroxy-4-oxo-1,4-dihydroqu-
inolin-3-yl)methyl)pyrrolidin-1-ium-1-yl)methyl)-4-methyl-8-oxo-5-thia-1-a-
zabicyclo[4.2.0]oct-2-ene-2-carboxylate, Sodium salt
##STR00363##
[1608] LCMS: (M+H).sup.+: 788.1. .sup.1H NMR (400 MHz, D.sub.2O)
.delta. ppm 1.24-1.48 (m, 12H) 1.99-2.23 (m, 4H) 3.22 (br. s., 3H)
3.46 (d, J=3.28 Hz, 1H) 3.96-4.17 (m, 4H) 4.27 (br. s., 2H) 4.79
(d, J=7.33 Hz, 1H) 5.35 (d, J=4.80 Hz, 1H) 5.70 (d, J=4.80 Hz, 1H)
6.70 (s, 1H) 6.85 (s, 1H) 8.03 (s, 1H).
Example 145
Synthesis of Compound I-145
[1609] Compound I-145:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((1-((5-chloro-6,7-dihydroxy-1-methyl-4-oxo-1,4-dihydroq-
uinolin-3-yl)methyl)pyrrolidin-1-ium-1-yl)methyl)-4-methyl-8-oxo-5-thia-1--
azabicyclo[4.2.0]oct-2-ene-2-carboxylate, Sodium salt
##STR00364##
[1610] LCMS: (M+H).sup.+: 790.0. .sup.1H NMR (400 MHz, D.sub.2O)
.delta. ppm 1.27-1.50 (m, 9H) 2.08 (br. s., 4H) 3.21 (d, J=6.32 Hz,
3H) 3.45 (br. s., 1H) 3.63 (br. s., 3H) 3.95-4.12 (m, 2H) 4.21 (br.
s., 2H) 4.78 (d, J=11.62 Hz, 1H) 5.36 (d, J=4.80 Hz, 1H) 5.70 (d,
J=4.80 Hz, 1H) 6.65 (br. s., 1H) 6.85 (s, 1H) 7.91 (br. s.,
1H).
Example 146
Synthesis of Compound I-146
[1611] Step (1): 6,7-dimethoxyquinazolin-4(3H)-one.fwdarw.Compound
146a
[1612] Compound 146a: 3-(2-chloroethyl)-6,7-dimethoxyquinazolin-4
(3H)-one
##STR00365##
[1613] To a solution of 6,7-dimethoxyquinazolin-4(3H)-one (5.0 g,
24 mmol) in DMF (100 mL) was added 1-chloro-2-iodoethane (3.48 mL,
48.5 mmol) dropwise at 50.degree. C., and the mixture was stirred
overnight.
[1614] Water was added, the mixture was extracted with ethyl
acetate.
[1615] The organic layer was dried (Na.sub.2SO.sub.4), concentrated
and purified by automated silica gel chromatography (10% MeOH in
DCM) to afford compound 146a (6.5 g, 96% yield) as a yellow solid.
LCMS: (M+H).sup.+: 269.0.
Step (2): Compound 146a.fwdarw.Compound 146b
[1616] Compound 146b:
3-(2-chloroethyl)-6,7-dihydroxyquinazolin-4(3H)-one
##STR00366##
[1617] To a solution of compound 146a in DCM (100 mL) was added
BBr.sub.3 dropwise at -70.degree. C., and the mixture was allowed
to warm up to room temperature and stirred for 1 h. MeOH was added
to the mixture dropwise at 0.degree. C., and then the solvent was
removed in vacuo. The residue was purified by silica gel
chromatography (20% MeOH in DCM) to afford compound 146b (5.7 g,
91% yield). LCMS: (M+H).sup.+: 241.2.
Step (3): Compound 146b.fwdarw.Compound 146c
[1618] Compound 146c:
3-(2-chloroethyl)-6,7-bis((4-methoxybenzyl)oxy)quinazolin-4(3H)-one
##STR00367##
[1619] To a solution of 1-(chloromethyl)-4-methoxybenzene (14.8 g,
95.0 mmol) in DMF (100 mL) was added potassium carbonate (16.4 g,
118 mmol) and 1-(chloromethyl)-4-methoxybenzene (14.8 g, 95.0
mmol), and this mixture was stirred at 50.degree. C. overnight.
Water was added, and the mixture was extracted with ethyl acetate.
The organic layer was dried (Na.sub.2SO.sub.4), filtered, and
concentrated, and the residue was purified using silica gel
chromatography (Combiflash RF) to afford compound 146c (7.8 g, 69%
yield). LCMS: (M+H).sup.+: 480.9.
Step (4): Compound 146c.fwdarw.Compound 146d
[1620] Compound 146d:
6,7-bis((4-methoxybenzyl)oxy)-3-(2-(pyrrolidin-1-yl)ethyl)quinazolin-4(3H-
)-one
##STR00368##
[1621] To a solution of compound 146c (7.00 g, 14.6 mmol) in DCM
(150 mL) were added DIPEA (6.36 mL, 36.4 mmol) and pyrrolidine
(3.01 mL, 36.4 mmol), and the mixture was heated to 80.degree. C.
The reaction mixture was washed with 5% NaHCO.sub.3 aq (40 mL),
brine, and H.sub.2O, and the organic layer was dried
(Na.sub.2SO.sub.4), filtered, and concentrated, and the residue was
purified by automated silica gel chromatography (20% MeOH in DCM)
to afford compound 146d (2.9 g, 39% yield). LCMS: (M+H).sup.+:
516.3.
Step (5): Compound X-24+Compound 146d.fwdarw.Compound I-146
[1622] Compound I-146
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((1-(2-(6,7-dihydroxy-4-oxoquinazolin-3(4H)-yl)ethyl)pyr-
rolidin-1-ium-1-yl)methyl)-4-meth
yl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, Sodium
salt
##STR00369##
[1623] This compound was prepared according to the two-step
sequence of Example 143, using compound 146d and compound X-24.
[1624] .sup.1H NMR (400 MHz, D.sub.2O) .delta. ppm 1.37 (s, 3H)
1.39 (s, 3H) 1.47 (d, J=7.07 Hz, 3H) 2.13 (br. s., 4H) 3.35-3.60
(m, 5H) 3.68 (d, J=10.61 Hz, 1H) 3.99 (q, J=6.99 Hz, 1H) 4.19 (d,
J=14.15 Hz, 1H) 4.24-4.41 (m, 2H) 5.00 (d, J=14.15 Hz, 1H) 5.34 (d,
J=5.05 Hz, 1H) 5.69 (d, J=4.80 Hz, 1H) 6.72 (s, 1H) 6.86 (s, 1H)
7.11 (s, 1H) 8.00 (s, 1H).
Example 147
Synthesis of Compound I-147
[1625] Step (1):
6,7-dimethoxyquinazoline-2,4(1H,3H)-dione.fwdarw.Compound 147a
[1626] Compound 147a: 6,7-dimethoxy-1-methylquinazoline-2,4(1H,
3H)-dione
##STR00370##
[1627] To a suspension of 6,7-dimethoxyquinazoline-2,4(1H,3H)-dione
(40.0 g, 180 mmol) in anhydrous chloroform (300 mL) was added
(E)-trimethylsilyl N-(trimethylsilyl)acetimidate (156 mL, 630
mmol), and the mixture was stirred at room temperature until a
clear solution was obtained (2 h). Iodomethane (168 mL, 2700 mmol)
was then added. The reaction mixture was heated to reflux
temperature for 48 h. After the solution was cooled to room
temperature, sat. NaHCO.sub.3 aq (30 mL) was added, and the
precipitate was collected by filtration to afford compound 147a (38
g, 89% yield) as a white solid. LCMS: (M+H).sup.+: 237.1.
Step (2): Compound 147a.fwdarw.Compound 147b
[1628] Compound 147b:
3-(2-chloroethyl)-6,7-dimethoxy-1-methylquinazoline-2,4(1H,3H)-dione
##STR00371##
[1629] To a solution of compound 147a (28.0 g, 119 mmol) in DMF (20
mL) was added cesium carbonate (77.0 g, 237 mmol), followed by
1-chloro-2-iodoethane (21.6 mL, 237 mmol). The reaction mixture was
stirred at 50.degree. C. overnight. Water was added and the mixture
was stirred at rt for 15 min. The white precipitate was collected
by filtration and washed with water to afford compound 147b (29 g,
82% yield). The crude mixture was used in next Step without
purification. LCMS: (M+H).sup.+: 299.0.
Step (3): compound 147b.fwdarw.Compound 147c
[1630] Compound 147c
5-chloro-3-(2-chloroethyl)-6,7-dimethoxy-1-methylquinazoline-2,4(1H,
3H)-dione
##STR00372##
[1631] 3-(2-chloroethyl)-6,7-dimethoxy-1-methylquinazoline-2,4(1H,
3H)-dionecompound 147b (29 g, 97 mmol) and
1-chloropyrrolidine-2,5-dione (19.5 g, 146 mmol) were suspended in
DMF (40 mL) and heated at 95.degree. C. for 0.5 h. Water and ethyl
acetate (300 mL) were added to the mixture. The organic phase was
separated, and the aqueous phase was extracted with ethyl acetate
(2.times.300 mL). The combined organic phases were dried, filtered
and concentrated. The residue was purified by silica gel
chromatography (0-15%, EtOAc in hexane) to afford compound 147c (10
g, 31% yield). LCMS: (M+H).sup.-: 333.0.
Step (4): compound 147c.fwdarw.Compound 147d
[1632] Compound 147d:
5-chloro-3-(2-chloroethyl)-6,7-dihydroxy-1-methylquinazoline-2,4(1H,
3H)-dione
##STR00373##
[1633] To a solution of compound 147c (10g, 30.0 mmol) in DCM (25
mL) was added BBr.sub.3 (14.2 mL, 150 mmol) at -78.degree. C. The
mixture was allowed to warm up to rt, and stirred for 2 h. The
mixture was diluted with MeOH and stripped several times to afford
compound 147d (8.8 g, 96% yield) as a yellow solid. The crude
product was used in next Step without further purification. LCMS:
(M+H).sup.+: 304.9.
Step (5): compound 147d.fwdarw.Compound 147e
[1634] Compound 147e:
5-chloro-3-(2-chloroethyl)-6,7-bis((4-methoxybenzyl)oxy)-1-m
ethylquinazoline-2,4(1H, 3H)-dione
##STR00374##
[1635] To a solution of compound 147d (4.40 g, 10.1 mmol) in DMF
(120 mL) was added cesium carbonate (9.87 g, 30.3 mmol), followed
by 1-(chloromethyl)-4-methoxybenzene (5.50 mL, 40.4 mmol). The
reaction mixture was stirred at 50.degree. C. for 5 h. Water was
added and the mixture was stirred at rt for 15 min. The yellow
precipitate was collected by filtration and washed with water. The
crude material was purified by automated silica gel chromatography,
using a 40 g column and eluting with EA/Hexane (0-30%) to afford
compound 147e (2.3 g, 42% yield) as a yellow solid. LCMS:
(M+H).sup.+: 545.1.
Step (6): compound 147e.fwdarw.Compound 147f
[1636] Compound 147f:
5-chloro-6,7-bis((4-methoxybenzyl)oxy)-1-methyl-3-(2-(pyrrolidin-1-yl)eth-
yl)quinazoline-2,4(1H, 3H)-dione
##STR00375##
[1637] A solution, of compound 147e (2.3 g, 4.2 mmol), DIPEA (1.363
g, 10.54 mmol), and pyrrolidine (0.750 g, 10.5 mmol) in
acetonitrile (100 mL) was heated at reflux temperature for 6 h.
Water was added, and the product was extracted with DCM. The
organic phase was washed with NaHCO.sub.3 aq, brine and then dried
over Na.sub.2SO.sub.4, filtered and concentrated. The crude
material was purified by automated silica gel chromatography using
a 24 g column and eluting with 0-5% MeOH in DCM to afford compound
147f (1 g, 41% yield) as a yellow solid. LCMS: (M+H).sup.+:
580.3.
Step (7): compound X-24+Compound 147f.fwdarw.Compound I-147
[1638] Compound I-147:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((1-(2-(5-chloro-6,7-dihydroxy-1-methyl-2,4-dioxo-1,2-di-
hydroquinazolin-3(4H)-yl)ethyl)pyrrolidin-1-ium-1-yl)methyl)-4-methyl-8-ox-
o-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, Sodium
salt
##STR00376##
[1639] This compound was prepared according to the two-step
sequence of Example 143, using compound 147f and compound X-24.
[1640] LCMS: (M+H).sup.+: 821.0. .sup.1H NMR (400 MHz, D.sub.2O)
.delta. ppm 1.38 (s, 3H) 1.40 (s, 3H) 1.48 (d, J=6.82 Hz, 3H) 2.12
(br. s., 4H) 3.32 (br. s., 3H) 3.35-3.66 (m, 6H) 3.98-4.07 (m, 1H)
4.16-4.36 (m, 3H) 4.98 (d, J=14.15 Hz, 1H) 5.37 (d, J=4.80 Hz, 1H)
5.68 (d, J=4.29 Hz, 1H) 6.48 (s, 1H) 6.91 (s, 1H).
Example 148
Synthesis of Compound I-148
[1641] Step (1): Methyl
2-amino-4,5-difluorobenzoate.fwdarw.Compound 148a
[1642] Compound 148a: Methyl
2-amino-3-chloro-4,5-difluorobenzoate
##STR00377##
[1643] Methyl 2-amino-4,5-difluorobenzoate (40.0 g, 214 mmol) and
NCS (25.9 g, 194 mmol) were suspended in DMF (10 mL) and heated at
95.degree. C. for 30 min. Water and DCM were added to the mixture.
The organic phase was separated. The water phase was extracted with
DCM (2.times.10 mL). The combined organic phase was dried, filtered
and concentrated. The resulting residue was purified via normal
phase chromatography (0-40% EtOAc in hexane) to afford Compound
148a (11 g, 26% yield) as a white solid. LCMS: (M+H).sup.+:
221.9.
Step (2): compound 148a.fwdarw.Compound 148b
[1644] Compound 148b:
8-chloro-2-(chloromethyl)-6,7-difluoroquinazolin-4(3H)-one
##STR00378##
[1645] Hydrogen chloride gas was bubbled through a solution of
compound 148a (150 mL, 2380 mmol) until the precipitate that
initially formed had dissolved. This mixture was stirred at rt
overnight. Water was added to the reaction mixture, and the
resulting precipitate was collected by filtration and dried under
high vacuum to afford Compound 148b (8.0 g, 67% yield) as gray
solid.
[1646] LCMS: (M+H).sup.+: 264.9.
Step (3): compound 148b.fwdarw.Compound 148c
[1647] Compound 148c:
8-chloro-6,7-difluoro-2-(pyrrolidin-1-ylmethyl)quinazolin-4(3H)-one
##STR00379##
[1648] To a solution of Compound 148b (5.00 g, 18.9 mmol) in DCM
(120 mL) was added a solution of pyrrolidine (3.90 mL, 47.2 mmol)
in DCM dropwise, and this mixture was stirred at rt for 2 h. The
reaction mixture was washed with brine (3.times.), and the organic
layer was dried with Na.sub.2SO.sub.4, filtered, and concentrated
to Compound 148c (5.0 g, 88% yield) as a white solid. LCMS:
(M+H).sup.+: 300.3.
Step (4): Compound 148c.fwdarw.Compound 148d
[1649] Compound 148d:
8-chloro-6,7-bis((4-methoxybenzyl)oxy)-2-(pyrrolidin-1-ylmethyl)quinazoli-
n-4(3H)-one
##STR00380##
[1650] A mixture of (4-methoxyphenyl)methanol (46.1 g, 334 mmol)
and Compound 148c (5.00 g, 16.7 mmol) was heated at 80.degree. C.
over the weekend. Water was added to the reaction mixture, and the
pH was adjusted to 2 using 2 N HCl aq, and the product was
extracted with DCM. The organic layer was washed with brine and
concentrated, and the residue was purified by automated reverse
phase chromatography (70% MeCN in H.sub.2O containing 0.1% TFA).
The combined fractions were then neutralized using 2 N NaOH, and
the product was extracted with DCM. The organic layer was dried,
filtered, concentrated and then repurified by automated silica gel
chromatography to afford Compound 148d (350 mg, 3.9% yield).
[1651] LCMS: (M+H).sup.+: 536.0.
Step (5): Compound X-24+Compound 148d.fwdarw.Compound I-148
[1652] Compound I-148:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((1-((8-chloro-6,7-dihydroxy-4-oxo-3,4-dihydroquinazolin-
-2-yl)methyl)pyrrolidin-1-ium-1-yl)methyl)-4-methyl-8-oxo-5-thia-1-azabicy-
clo[4.2.0]oct-2-ene-2-carboxylate, Sodium salt
##STR00381##
[1653] This compound was prepared according to the two-Step
sequence of Example 143, using compound 148d and compound X-24.
[1654] LCMS: (M+H).sup.+: 777.1. .sup.1H NMR (400 MHz, D.sub.2O)
.delta. ppm 1.35 (s, 9H) 2.14 (br. s., 4H) 3.51-4.03 (m, 6H) 4.43
(q, J=15.49 Hz, 2H) 4.93 (d, J=13.89 Hz, 2H) 5.10 (d, J=5.05 Hz,
1H) 5.63 (d, J=4.80 Hz, 1H) 6.86 (s, 1H) 7.29 (s, 1H).
Example 149
Synthesis of Compound I-149
[1655] Step (1): 2,4,5-trifluorobenzoyl chloride.fwdarw.Compound
149a
[1656] Compound 149a: Ethyl
3-(dimethylamino)-2-(2,4,5-trifluorobenzoyl) acrylate
##STR00382##
[1657] A solution of 2,4,5-trifluorobenzoyl chloride (50 g, 257
mmol) in toluene was added dropwise to a solution of triethylamine
(107 mL, 771 mmol) and ethyl 3-(dimethylamino)acrylate (44.2 g, 308
mmol) in toluene (500 mL). The mixture was stirred at 90.degree. C.
for 3 h. The reaction mixture was cooled down and then was washed
with water and extracted with EtOAc. The organic layer was dried
over Na.sub.2SO.sub.4, filtered and concentrated to afford compound
149a (75 g, 97% yield) as brown oil. The crude product was used in
next Step without further purification. LCMS: (M+H).sup.+:
302.0,
Step (2): compound 149a.fwdarw.Compound 149b
[1658] Compound 149b: Ethyl
6,7-difluoro-1-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate
##STR00383##
[1659] A solution of compound 149a (70 g, 232 mmol) in ethanol (200
mL) and diethyl ether (400 mL) was added to methanamine (54.7 mL,
465 mmol). After the mixture was stirred for 2 h at rt, analysis of
the mixture by LCMS indicated that the reaction was complete. The
reaction mixture was concentrated under reduced pressure, the oily
residue was dissolved in DMF (500 mL) and potassium carbonate (96.0
g, 697 mmol) was added. The mixture was stirred at 100.degree. C.
for 2 h. Cold water was added to the reaction mixture. The
resulting precipitate was collected by filtration and dried to
afford compound 149b (45 g, 73% yield). LCMS: (M+H).sup.+:
267.9.
Step (3): compound 149b.fwdarw.Compound 149c
[1660] Compound 149c:
6,7-Dimethoxy-1-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic
acid
##STR00384##
[1661] A mixture of compound 149b (45.0 g, 168 mmol), potassium
hydroxide (472 g, 8420 mmol) and methanol (1 L) was heated at
reflux temperature for 6 h. The pH of the solution was adjusted to
2, and the mixture was concentrated in vacuo. The obtained residue
was triturated with water to afford compound 149c (35 g, 79% yield)
as a pale yellow solid. The crude product was used in next Step
without further purification. LCMS: (M+H).sup.+: 264.0.
Step (4): compound 149c.fwdarw.Compound 149d
[1662] Compound 149d:
6,7-Dimethoxy-1-methyl-5-nitro-4-oxo-1,4-dihydroquinoline-3-carboxylic
acid
##STR00385##
[1663] A thick, dark solution of compound 149c (35 g, 133 mmol)
dissolved in sulfuric acid (354 mL, 6648 mmol) was cooled to
0.degree. C. and potassium nitroperoxous acid (16.1 g, 160 mmol)
was added in small portions. The temperature of the reaction
mixture was maintained below 10.degree. C. by use of an ice-water
bath. After the addition was complete, the mixture was maintained
under 10.degree. C. for 1 h, and was then allowed to warm up to rt.
The mixture was stirred at this temperature for 2 h, after which
time it was poured onto ice-water (800 mL). The yellow solid that
precipitated was collected by filtration, and washed with water and
ethanol. The solid was dried in vacuo to afford compound 148d (30
g, 73% yield) as a pale yellow solid. The crude product was used in
next Step without further purification. LCMS: (M+H).sup.+:
337.4
Step (5): compound 149d.fwdarw.Compound 149e
[1664] Compound 149e:
5-Amino-6,7-dimethoxy-1-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic
acid
##STR00386##
[1665] A solution of ethyl compound 149d (30 g, 89 mmol) in a
mixture of ethanol (300 mL) and water (300 mL) was treated with
sodium sulfide.9H.sub.2O (214 g, 892 mmol) for 2 h at 90.degree. C.
After the mixture was cooled down, it was poured into cold water,
and the solution was adjusted to pH 2. The resulting yellow
precipitate was collected by filtration, washed with water and
dried to afford compound 148e (24 g, 97% yield) as a yellow solid.
The crude product was used in next Step without further
purification.
[1666] LCMS: (M+H).sup.+: 279.0
Step (6): compound 149e.fwdarw.Compound 149f
[1667] Compound 149f:
5-Chloro-6-hydroxy-7-methoxy-1-methyl-4-oxo-1,4-dihydroquinoline-3-carbox-
ylic acid
##STR00387##
[1668] To a pale brown suspension of compound 149e (24 g, 69 mmol)
in conc. HCl aq (120 mL) was added dropwise a solution of sodium
nitrosoamide (4.69 g, 69.0 mmol) in water (40 mL) at 0.degree. C.
The mixture was stirred at 0.degree. C. for 1 h. To the orange
suspension was added HCl aq (180 mL), and the mixture was heated at
95.degree. C. for 6 h. The reaction mixture was cooled down to rt
and then poured into water, and the precipitate was collected by
filtration and dried to afford compound 149f (13 g, 66% yield) as a
pale yellow solid. The crude product was used in next Step without
further purification. LCMS: (M+H).sup.+: 283.9.
Step (7): compound 149f.fwdarw.Compound 149g
[1669] Compound 149g:
5-Chloro-6,7-dihydroxy-1-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic
acid
##STR00388##
[1670] To a solution of compound 149f (17.6 mL, 45.8 mmol) in DCM
(300 mL) was added BBr.sub.3 (15.2 mL, 160 mmol) at -78.degree. C.
The mixture was allowed to warm up to rt, and stirred overnight.
The mixture was diluted with MeOH and stripped several times to
afford compound 149g (11 g, 89% yield) as a yellow solid. The crude
product was used in next Step reaction without further
purification. LCMS: (M+H).sup.+: 269.9.
Step (8): compound 149g.fwdarw.Compound 149h
[1671] Compound 149h: 4-Methoxybenzyl
5-chloro-6,7-bis((4-methoxybenzyl)oxy)-1-methyl-4-oxo-1,4-di
hydroquinoline-3-carboxylate
##STR00389##
[1672] To a solution of compound 149g (11 g, 40.8 mmol) in DMF (250
mL) was added cesium carbonate (39.9 g, 122 mmol), followed by
1-(chloromethyl)-4-methoxybenzene (22.2 mL, 163 mmol). The reaction
mixture was stirred at 55.degree. C. for 5 h. Water was added, and
the mixture was stirred at rt for 15 min. The yellow precipitate
was collected by filtration and washed with water to afford
compound 149h (20 g, 78% yield) as a yellow solid. The crude
mixture was used in next Step without purification. LCMS:
(M+H).sup.+: 630.3.
Step (9): compound 149h.fwdarw.Compound 149j
[1673] Compound 149j:
5-Chloro-6,7-bis((4-methoxybenzyl)oxy)-1-methyl-4-oxo-1,4-dihydroquinolin-
e-3-carboxylic acid
##STR00390##
[1674] To a suspension of compound 149h (20.0 g, 31.7 mmol) in a
mixture of methanol (120 mL) and water (60 mL) was added KOH (3.56
g, 63.5 mmol) portionwise. The resulting mixture was stirred at
90.degree. C. for 3 h. The reaction mixture was cooled down to rt
and concentrated. The residue was then diluted with water and the
solution was adjusted to pH 1 using 2 N HCl aq. The precipitate was
collected by filtration and dried to afford compound 149j (13.5 g,
83% yield) as a pale yellow solid. The crude product was used in
the next Step without further purification. LCMS: (M+H).sup.+:
510.2
Step (10): compound 149j.fwdarw.Compound 149k
[1675] Compound 149k:
5-Chloro-6,7-bis((4-methoxybenzyl)oxy)-1-methyl-4-oxo-N-(2-(pyrrolidin-1--
yl)ethyl)-1,4-dihydroquinoline-3-carboxamide
##STR00391##
[1676] To a solution of compound 149j (2.0 g, 2.7 mmol) in DMF (100
mL) were added HATU (1.03 g, 2.71 mmol) and DIPEA (1.42 mL, 8.12
mmol), and the mixture was stirred for 0.5 h. To this mixture was
added 2-(pyrrolidin-1-yl)ethanamine (0.34 mL, 2.7 mmol). Analysis
of the reaction mixture by LCMS indicated that the reaction was
complete in 1 h. Water was added, and the mixture was extracted
with DCM and washed with brine. The crude material was purified by
automated silica gel chromatography using a 24 g column and eluting
with 0-20% MeOH/DCM. The pure product was then washed by sodium
bicarbonate aq, and further purified using a 4 g silica gel column
and eluting with 0-20% MeOH/DCM to afford compound 149k (1.3 g, 79%
yield) as a yellow solid. LCMS: (M+H).sup.+: 606.3
Step (11): compound X-24+Compound 149k.fwdarw.Compound I-149
[1677] Compound I-149:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((1-(2-(5-chloro-6,7-dihydroxy-1-methyl-4-oxo-1,4-dihydr-
oquinoline-3-carboxamido)ethyl)pyrrolidin-1-ium-1-yl)methyl)-4-methyl-8-ox-
o-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, Sodium
salt
##STR00392##
[1678] This compound was prepared according to the two-Step
sequence of Example 143, using compound 149k and compound X-24.
[1679] LCMS: (M+H).sup.+: 777.1. .sup.1H NMR (400 MHz, D.sub.2O)
.delta. ppm 1.36 (s, 3H) 1.40 (s, 3H) 1.47 (br. s., 3H) 1.99-2.22
(m, 4H) 3.27-4.28 (m, 13H) 4.90 (br. s., 1H) 5.37 (d, J=4.80 Hz,
1H) 5.76 (br. s., 1H) 6.47 (br. s., 1H) 6.85 (s, 1H) 8.10 (br. s.,
1H).
Example 150
Synthesis of Compound I-150
[1680] Step (1): 4,5-dihydroxy-2-nitrobenzaldehyde.fwdarw.Compound
150a
[1681] Compound 150a:
4,5-Bis((4-methoxybenzyl)oxy)-2-nitrobenzaldehyde
##STR00393##
[1682] To a solution of 4,5-dihydroxy-2-nitrobenzaldehyde (79.0 g,
431 mmol) in DMF (500 mL) was added K.sub.2CO.sub.3 (179 g, 1300
mmol), followed by 1-(chloromethyl)-4-methoxybenzene (129 mL, 949
mmol). The reaction mixture was stirred at 50.degree. C. for 2 h.
The mixture was poured into ice-water, and the resulting suspension
was filtered to afford a yellow solid that was dried and used in
the next Step without further purification (152 g, 83% yield).
Step (2): compound 150a.fwdarw.Compound 150b
[1683] Compound 150b: Methyl
4,5-bis((4-methoxybenzyl)oxy)-2-nitrobenzoate
##STR00394##
[1684] To a suspension of compound 150a (152 g, 359 mmol) in MeOH
(1.2 L) and DCM (300 mL), were added KOH (101 g, 1800 mmol) and
I.sub.2 (182 g, 718 mmol). The reaction mixture was stirred for 1.5
h. A saturated aqueous sodium bisulphite solution (300 mL) was
added, and it was noted that the chestnut color of the mixture
disappeared. The organic phase was concentrated and then EtOAc (500
mL) was added to the mixture. The organic phase was separated, and
the aqueous phase was extracted with EtOAc (2.times.500 mL). The
combined organic phase was dried, filtered and concentrated to
afford compound 150b (128 g, 79% yield) as a red oil. LCMS:
(M+H).sup.+: 454.1.
Step (3): compound 150b.fwdarw.Compound 150c
[1685] Compound 150c: Methyl
2-amino-4,5-bis((4-methoxybenzyl)oxy)benzoate
##STR00395##
[1686] A mixture of compound 150b (128 g, 282 mmol), iron (126 g,
2260 mmol) and ammonium chloride (151 g, 2820 mmol) in water (400
mL) and methanol (1200 mL) was heated at reflux for 1 h. The
mixture was filtered, and the collected solid was washed with DCM.
The filtrate was concentrated in vacuo to remove organic solvents.
Then DCM (500 mL) was added to the resulting aqueous solution, the
organic phase was separated, and the aqueous phase was extracted
with DCM (2.times.300 mL). The combined organic extracts were
concentrated to afford compound 150c (100 g, 84% yield) as a grey
solid. LCMS: (M+H).sup.+: 424.0.
Step (4): compound 150c.fwdarw.Compound 150d
[1687] Compound 150d: 2-Amino-4,5-bis((4-methoxybenzyl)oxy)benzoic
acid
##STR00396##
[1688] To a solution of compound 150c (10.0 g, 23.6 mmol) in water
(100 mL) and methanol (100 mL) was added sodium hydroxide (4.72 g,
118 mmol). The mixture was stirred at 80.degree. C. for 1 h. The
methanol was removed under vacuum, and citric acid was added to
adjust the pH of the solution to 6. The mixture was then extracted
with DCM (3.times.100 mL). The combined organic extracts were
washed with water, dried (Na.sub.2SO.sub.4), filtered and
concentrated to afford compound 150d (8.2 g, 85% yield) as a slight
yellow solid. LCMS: (M+H).sup.+: 410.3.
Step (5): compound 150d.fwdarw.Compound 150e
[1689] Compound 150e:
2-amino-4,5-bis((4-methoxybenzyl)oxy)-N-(quinuclidin-4-ylmethyl)benzamide
##STR00397##
[1690] To a solution of compound 150d (3.00 g, 7.33 mmol) in DMF
(50 mL) was added HATU (3.34 g, 8.79 mmol) and DIPEA (3.84 mL, 22.0
mmol), and the resulting mixture was stirred at rt for 30 min.
Then, quinuclidin-4-ylmethanamine (WO2011125966Ai, 1.13 g, 8.06
mmol) was added, and the resulting mixture was stirred at rt for 1
h. Water and EtOAc were added to the mixture. The organic phase was
separated, the aqueous phase was extracted with EtOAc three times.
The combined organic extracts were washed with brine, dried
(Na.sub.2SO.sub.4), filtered, and concentrated under vacuum. The
residue was purified by automated silica gel chromatography (0-10%
solvent B in solvent A; solvent A=DCM, solvent B=10:90:1
MeOH:DCM:NH.sub.4OH, 40 g column) to afford compound 150e (2.88 g,
74% yield) as a brown solid. LCMS: (M+H).sup.+: 532.5.
Step (6): compound 150e.fwdarw.Compound 150f
[1691] Compound 150f:
6,7-bis((4-methoxybenzyl)oxy)-3-(quinuclidin-4-ylmethyl)quinazolin-4(3H)--
one
##STR00398##
[1692] A mixture of compound 150e (2.88 g, 5.42 mmol) and
trimethoxymethane (2.97 mL, 27.1 mmol) in methanol (100 mL) was
heated to 120.degree. C. overnight. The solvent was removed under
vacuum, and the residue was purified by Combiflash silica gel
chromatography (0-10% solvent B in solvent A; solvent A=DCM,
solvent B=10:90:1 MeOH:DCM:NH.sub.4OH, 24 g column). The collected
brown solid was dissolved in DCM and washed with water. The organic
layer was concentrated, and the residue was further purified by
automated silica gel chromatography (0-10% MeOH/DCM, 4 g column) to
afford compound 150f (0.68 g, 23% yield) as a white yellow solid.
LCMS: (M+H).sup.+: 542.5.
Step (11): compound X-24+Compound 150f.fwdarw.Compound I-150
[1693] Compound I-150:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((4-((6,7-dihydroxy-4-oxoquinazolin-3(4H)-yl)methyl)quin-
uclidin-1-ium-1-yl)methyl)-4-meth
yl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, Sodium
salt
##STR00399##
[1694] This compound was prepared according to the two-Step
sequence of Example 143, using compound 150f and compound X-24.
[1695] LCMS: (M+H).sup.+: 783.7. .sup.1H NMR (400 MHz, D.sub.2O)
.delta. ppm 1.36 (s, 3H) 1.38 (s, 3H) 1.40 (d, J=7.07 Hz, 3H) 1.84
(t, J=7.58 Hz, 6H) 3.23-3.47 (m, 6H) 3.85-3.99 (m, 4H) 4.48 (d,
J=14.40 Hz, 1H) 5.29 (d, J=5.05 Hz, 1H) 5.70 (d, J=4.80 Hz, 1H)
6.84 (d, J=2.02 Hz, 2H) 7.25 (s, 1H) 7.91 (s, 1H).
Example 151
Synthesis of Compound I-151
[1696] Step (1): Compound 150d.fwdarw.Compound 151a
[1697] Compound 151a
2-Amino-4,5-bis((4-methoxybenzyl)oxy)-N-(2-(pyrrolidin-1-yl)
ethyl)benzamide
##STR00400##
[1698] To a solution of compound 150d (1.57 g, 3.83 mmol) in MeCN
(20 mL) were added HATU (1.60 g, 4.22 mmol) and DIPEA (1.27 mL,
7.67 mmol). The mixture was stirred for 0.5 h, and then
2-(pyrrolidin-1-yl)ethanamine (0.58 mL, 4.6 mmol) was added. The
mixture was stirred for 1 h, and then a standard aqueous work-up
afforded compound 151a (1.8 g, 93% yield). The crude product was
directly used for the next Step without any purification.
[1699] LCMS: (M+H).sup.+: 506.5
Step (2): compound 151a.fwdarw.Compound 151b
[1700] Compound 151b:
6,7-bis((4-methoxybenzyl)oxy)-3-(2-(pyrrolidin-1-yl)ethyl)quinazoline-2,4-
(1H, 3H)-dione
##STR00401##
[1701] A mixture of compound 151a (1.8 g, 3.6 mmol) and CDI (1.155
g, 7.120 mmol) in THF (30 mL) was heated at reflux temperature for
4 h. The solution was cooled down and was partitioned between DCM
and water. The organic layer was washed with aq NaHCO.sub.3, brine,
dried over Na.sub.2SO.sub.4, filtered and concentrated. The crude
material was purified by automated silica gel chromatography
(Combiflash RF), using a 40 g column and eluting with 0-10%
MeOH/DCM with each solvent containing 0.1% NEt.sub.3. The desired
product was washed with water, and further purified by normal phase
chromatography, using a 4 g column and eluting with 0-10% MeOH/DCM
to afford compound 151b (700 mg, 37% yield) as a yellow solid.
LCMS: (M+H).sup.+: 532.5
Step (3): compound X-24+Compound 151b.fwdarw.Compound I-151
[1702] Compound I-151:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((1-(2-(6,7-dihydroxy-2,4-dioxo-1,2-dihydroquinazolin-3(-
4H)-yl)ethyl)pyrrolidin-1-ium-1-yl)methyl)-4-methyl-8-oxo-5-thia-1-azabicy-
clo[4.2.0]oct-2-ene-2-carboxylate, Sodium salt
##STR00402##
[1703] This compound was prepared according to the two-Step
sequence of Example 143, using compound 151b and compound X-24.
[1704] LCMS: (M+H).sup.+: 773.0. .sup.1H NMR (400 MHz, D.sub.2O)
.delta. ppm 1.38 (s, 3H) 1.40 (s, 3H) 1.47 (d, J=7.07 Hz, 3H) 2.10
(br. s., 4H) 3.30-3.64 (m, 6H) 4.02 (q, J=7.07 Hz, 1H) 4.16-4.36
(m, 3H) 4.95 (d, J=14.15 Hz, 1H) 5.34 (d, J=4.55 Hz, 1H) 5.68 (d,
J=4.55 Hz, 1H) 6.39 (s, 1H) 6.89 (s, 1H) 7.13 (s, 1H).
[1705] The compounds shown below were obtained from Compound X-24
and the each corresponding amine which was synthesized according to
the synthesis in WO2013052568A1 in the same way as example 143.
Example 152
Synthesis of Compound I-152
[1706] Compound I-152:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((1-(2-(l-ethyl-6,7-dihydroxy-4-oxo-1,4-dihydrocinnoline-
-3-carboxamido)ethyl)pyrrolidin-1-ium-1-yl)methyl)-4-methyl-8-oxo-5-thia-1-
-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, Sodium salt
##STR00403##
[1707] LCMS: (M+H).sup.+: 828.0. .sup.1H NMR (400 MHz, D.sub.2O)
.delta. ppm 1.32-1.39 (m, 9H) 1.45 (d, J=6.82 Hz, 3H) 2.11 (br. s.,
4H) 3.29-3.69 (m, 6H) 3.75-3.91 (m, 2H) 3.98 (q, J=7.07 Hz, 1H)
4.18 (d, J=14.15 Hz, 1H) 4.41 (q, J=6.99 Hz, 2H) 4.94 (d, J=14.15
Hz, 1H) 5.35 (d, J=4.80 Hz, 1H) 5.69 (d, J=4.80 Hz, 1H) 6.86 (s,
1H) 6.91 (s, 1H) 7.24 (s, 1H).
Example 153
Synthesis of Compound I-153
[1708] Compound I-153:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((1-(2-(1-ethyl-6,7-dihydroxy-4-oxo-1,4-dihydroquinoline-
-3-carboxamido)ethyl)pyrrolidin-1-ium-1-yl)methyl)-4-methyl-8-oxo-5-thia-1-
-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, Sodium salt
##STR00404##
[1709] LCMS: (M+H).sup.+: 826.9. .sup.1H NMR (400 MHz, D.sub.2O)
.delta. ppm 1.28 (t, J=7.07 Hz, 3H) 1.34 (s, 3H) 1.36 (s, 3H) 1.44
(d, J=7.07 Hz, 3H) 2.11 (br. s., 4H) 2.99-3.03 (m, 1H) 3.29-3.54
(m, 5H) 3.60 (br. s., 1H) 3.68-3.86 (m, 2H) 3.97 (d, J=7.07 Hz, 1H)
4.05 (d, J=7.07 Hz, 2H) 4.16 (d, J=14.15 Hz, 1H) 4.93 (d, J=14.15
Hz, 1H) 5.35 (d, J=4.80 Hz, 1H) 5.68 (d, J=4.55 Hz, 1H) 6.77 (s,
1H) 6.85 (s, 1H) 7.23 (s, 1H) 8.29 (s, 1H).
Example 154
Synthesis of Compound I-154
[1710] Compound I-154:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((4-((6,7-dihydroxy-2,4-dioxo-1,2-dihydroquinazolin-3(4H-
)-yl)methyl)quinuclidin-1-ium-1-yl)methyl)-4-methyl-8-oxo-5-thia-1-azabicy-
clo[4.2.0]oct-2-ene-2-carboxylate, Sodium salt
##STR00405##
[1711] LCMS: (M+H).sup.+: 798.9. .sup.1H NMR (400 MHz, D.sub.2O)
.delta. ppm 1.36 (s, 3H) 1.38 (s, 3H) 1.41 (d, J=7.07 Hz, 3H) 1.82
(t, J=7.58 Hz, 6H) 3.20-3.44 (m, 6H) 3.78-3.98 (m, 4H) 4.46 (d,
J=14.40 Hz, 1H) 5.29 (d, J=5.05 Hz, 1H) 5.70 (d, J=4.80 Hz, 1H)
6.42 (s, 1H) 6.85 (s, 1H) 7.15 (s, 1H).
Example 155
Synthesis of Compound I-155
[1712] Step (1): 2-chloro-3,4-dimethoxybenzaldehyde.fwdarw.Compound
155a
[1713] Compound 155a:
2-Chloro-3,4-dimethoxy-6-nitrobenzaldehyde
##STR00406##
[1714] Trifluoromethanesulfonic acid (26.6 mL, 299 mmol) was added
to a solution of 2-chloro-3,4-dimethoxybenzaldehyde (20 g, 100
mmol) and potassium nitrate (30.2 g, 299 mmol) in acetic acid (80
mL) with stirring at 0.degree. C., and the resulting mixture was
stirred at room temperature overnight. The reaction mixture was
then poured into water, neutralized with a saturated aqueous sodium
hydrogencarbonate solution. The precipitate was collected by
filtration and dried to afford compound 155a (19 g, 78% yield).
[1715] LCMS: (M+H).sup.+: 246.1.
Step (2): compound 155a.fwdarw.Compound 155b
[1716] Compound 155b: 2-Chloro-3,4-dimethoxy-6-nitrobenzoic
acid
##STR00407##
[1717] To a solution of compound 155a (19 g, 77 mmol) in THF (100
mL) and t-Butanol (100 mL) was added 2-methylbut-2-ene (387 mL, 774
mmol) at 10.degree. C. Subsequently, a solution of sodium chlorite
(21.0 g, 232 mmol) and sodium dihydrogenphosphate (27.8 g, 232
mmol) in water (50 mL) was added dropwise to the solution and the
suspension was stirred vigorously for 1 h at rt. The mixture was
then diluted with saturated NH.sub.4Cl aq and the product was
extracted with DCM. The combined organic extracts were washed with
brine, dried over Na.sub.2SO.sub.4, filtered, and concentrated in
vacuo to afford a yellow solid that was used in the next Step
without further purification (20 g, 99%). LCMS:
(M+H--H.sub.2O).sup.+: 244.1.
Step (3): compound 155b.fwdarw.Compound 155c
[1718] Compound 155c: 6-Amino-2-chloro-3,4-dimethoxybenzoic
acid
##STR00408##
[1719] A mixture of compound 155b (10 g, 38 mmol) and Pd/C (1.0 g,
38 mmol) in methanol (100 mL) was stirred overnight under an
atmosphere of hydrogen. The mixture was filtered, and the solvent
was evaporated to afford compound 155c (8 g, 90% yield) as a brown
solid. LCMS: (M+H).sup.+: 232.1.
Step (4): compound 155c.fwdarw.Compound 155d
[1720] Compound 155d: 5-Chloro-6,7-dimethoxyquinazolin-4(3H-one
##STR00409##
[1721] In a 100 mL flask were placed compound 155c (7.0 g, 30
mmol), trimethoxymethane (64.1 g, 604 mmol), ammonium acetate (23.3
g, 302 mmol) and methanol (20 mL). The reaction mixture was stirred
at 120.degree. C. for 3 h. The reaction mixture was concentrated.
Water (100 mL) was added to the reaction mixture, and the resulting
mixture was stirred for 15 min and filtered to afford compound 155d
(6.5 g, 89% yield) as a brown crystalline product.
[1722] LCMS: (M+H).sup.+: 241.1.
Step (5): compound 155d.fwdarw.Compound 155e
[1723] Compound 155e:
5-chloro-3-(2-chloroethyl)-6,7-dimethoxyquinazolin-4(3H)-one
##STR00410##
[1724] To a solution of compound 155d (3.0 g, 12.5 mmol) in DMF (5
mL) was added cesium carbonate (8.12 g, 24.9 mmol), followed by
1-chloro-2-iodoethane (2.27 mL, 24.9 mmol). The reaction mixture
was stirred at 50.degree. C. for 0.5 h. Water was added and the
mixture was stirred at rt for 15 min. The white precipitate was
collected by filtration and washed with water to afford compound
155e (3 g, 79% yield). The crude mixture was used in next Step
without purification. LCMS: (M+H).sup.+: 303.2.
Step (6): compound 155e.fwdarw.Compound 155f
[1725] Compound 155f:
5-Chloro-3-(2-chloroethyl)-6,7-dihydroxyquinazolin-4(3H)-one
##STR00411##
[1726] To a solution of compound 155e (3.0 g, 9.9 mmol) in DCM (10
mL) was added tribromoborane (3.40 mL, 34.6 mmol) at -78.degree. C.
The mixture was allowed to warm up to rt, and was stirred
overnight. The mixture was diluted with MeOH and concentrated, and
this procedure was repeated several times to afford compound 155f
(2.5 g, 92% yield). The crude product was used in next Step without
further purification. LCMS: (M+H).sup.+: 275.1.
Step (7): compound 155f.fwdarw.Compound 155g
[1727] Compound 155g:
5-chloro-3-(2-chloroethyl)-6,7-bis((4-methoxybenzyl)oxy)quinazolin-4(3H)--
one
##STR00412##
[1728] To a solution of compound 155f (2.5 g, 9.1 mmol) in DMF (30
mL) was added K.sub.2CO.sub.3 (5.02 g, 36.4 mmol), followed by
1-(chloromethyl)-4-methoxybenzene (5.12 mL, 36.4 mmol). The
reaction mixture was stirred at 50.degree. C. for 2 h. Water was
added, and the mixture was stirred at rt for 15 min. The yellow
precipitate was collected by filtration and washed with water to
afford compound 155g (4 g, 73% yield) as a yellow solid. The crude
mixture was used in next Step without purification. LCMS:
[1729] (M+H).sup.+: 515.4.
Step (8): compound 155g.fwdarw.Compound 155h
[1730] Compound 155h:
5-Chloro-6,7-bis((4-methoxybenzyl)oxy)-3-(2-(pyrrolidin-1-ylquinazolin-4(-
3H)-one
##STR00413##
[1731] A solution of compound 155g (4.0 g, 7.8 mmol), DIPEA (2.57
mL, 15.5 mmol), and pyrrolidine (1.28 mL, 15.5 mmol) in
acetonitrile (100 mL) was heated to reflux temperature for 12 h.
Water was added to the reaction mixture, which was then extracted
with DCM. The organic layer was washed with NaHCO.sub.3, brine and
dried over Na.sub.2SO.sub.4, filtered and concentrated in vacuo.
The crude material was purified by automated silica gel
chromatography using an 80 g column and eluting with 0-5% MeOH in
DCM over 45 min, to provide 1 g of pure product as a grey solid.
Contaminated fractions were concentrated and washed by MeCN to give
another 800 mg product, affording a total of 1.8 g product (42%
yield). LCMS: (M+H).sup.+: 550.5.
Step (9): compound X-24+Compound 155h.fwdarw.Compound I-155
[1732] Compound I-155:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((1-(2-(5-chloro-6,7-dihydroxy-4-oxoquinazolin-3(4H)-yl)-
ethyl)pyrrolidin-1-ium-1-yl)methy
1)-4-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate,
Sodium salt
##STR00414##
[1733] This compound was prepared according to the two-Step
sequence of Example 143, using compound 155h and compound X-24.
[1734] LCMS: (M+H).sup.+: 791.4. .sup.1H NMR (400 MHz, D.sub.2O)
.delta. ppm 1.37 (s, 3H) 1.39 (s, 3H) 1.47 (d, J=7.07 Hz, 3H) 2.14
(br. s., 4H) 3.34-3.59 (m, 5H) 3.68 (br. s., 1H) 3.99 (q, J=6.65
Hz, 1H) 4.13-4.36 (m, 3H) 5.00 (d, J=14.15 Hz, 1H) 5.36 (d, J=4.80
Hz, 1H) 5.70 (d, J=4.80 Hz, 1H) 6.58 (s, 1H) 6.87 (s, 1H) 7.99 (s,
1H).
Example 156
Synthesis of Compound I-156
Step (1):
[1735] 6,7-bis((4-methoxybenzyl)oxy)-1-methyl-4-oxo-,
4-dihydroquinoline-3-carboxylic acid.fwdarw.Compound 156a
[1736] Compound 156a:
6,7-Bis((4-methoxybenzyl)oxy)-1-methyl-4-oxo-N-(quinuclidin-4-ylmethyl)-1-
,4-dihydroquinoline-3-carboxamide
##STR00415##
[1737] To a solution of
6,7-bis((4-methoxybenzyl)oxy)-1-methyl-4-oxo-,
4-dihydroquinoline-3-carboxylic acid (WO2013052568A1, 3.0 g, 5.5
mmol) in DMF (100 mL) were added HATU (3.13 g, 8.23 mmol) and DIPEA
(2.88 mL, 16.5 mmol), and the mixture was stirred for 0.5 h.
Quinuclidin-4-ylmethanamine (WO2011125966A1, 1.28 mL, 8.23 mmol)
was then added, and the mixture was stirred for 2 h. Sodium
bicarbonate was added, and the mixture was stirred for 15 min. The
yellow precipitate was collected by filtration, washed with water
and purified by automated silica gel chromatography using a 24 g
column and eluting with 0-20% MeOH in DCM to afford compound 156a
(2 g, 61% yield) as a yellow solid. LCMS: (M+H).sup.+: 598.6.
Step (2): compound X-24+Compound 156a.fwdarw.Compound I-156
[1738] Compound I-156:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((4-((6,7-dihydroxy-1-methyl-4-oxo-1,4-dihydroquinoline--
3-carboxamido)methyl)quinuclidin-1-ium-1-yl)methyl)-4-methyl-8-oxo-5-thia--
1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, Sodium salt
##STR00416##
[1739] This compound was prepared according to the two-Step
sequence of Example 143, using compound 156a and compound X-24.
[1740] LCMS: (M+H).sup.+: 839.3. .sup.1H NMR (400 MHz, D.sub.2O)
.delta. ppm 1.37 (s, 3H) 1.39 (s, 3H) 1.43 (d, J=7.07 Hz, 3H) 1.82
(br. s., 6H) 3.17-3.53 (m, 8H) 3.64 (s, 3H) 3.89-4.02 (m, 2H) 4.52
(d, J=14.40 Hz, 1H) 5.31 (d, J=4.55 Hz, 1H) 5.71 (d, J=4.80 Hz, 1H)
6.64 (br. s., 1H) 6.85 (s, 1H) 7.16 (s, 1H) 8.20 (s, 1H).
Example 157
Synthesis of Compound I-157
[1741] Compound I-157:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((1-(2-(6,7-dihydroxy-1-methy
1-4-oxo-1,4-dihydroquinoline-3-carboxamido)ethyl)pyrrolidin-1-ium-1-yl)me-
thyl)-4-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate,
Sodium salt
##STR00417##
[1742] This compound was prepared according to the two-Step
sequence of Example 143, using
6,7-bis((4-methoxybenzyl)oxy)-1-methyl-4-oxo-N-(2-(pyrrolidin-1-yl)ethyl)-
-1,4-dihydroquinoline-3-carboxamide (which was synthesized
according to the synthesis in WO2013052568A1) and compound X-24.
LCMS: (M+H).sup.+: 813.2. H NMR (400 MHz, D.sub.2O) .delta. ppm
1.34 (s, 3H) 1.37 (s, 3H) 1.47 (d, J=6.82 Hz, 3H) 2.11 (br. s., 4H)
3.42 (br. s., 4H) 3.49 (br. s., 3H) 3.56-3.82 (m, 4H) 4.00 (d,
J=6.82 Hz, 1H) 4.15 (d, J=14.15 Hz, 1H) 4.95 (d, J=14.15 Hz, 1H)
5.37 (d, J=4.55 Hz, 1H) 5.73 (d, J=4.80 Hz, 1H) 6.46 (br. s., 1H)
6.82 (s, 1H) 6.97 (s, 1H) 7.96 (s, 1H).
Example 158
Synthesis of Compound I-158
[1743] Step (1): compound 155d.fwdarw.Compound 158a
[1744] Compound 158a:
5-Chloro-3-(3-chloropropyl)-6,7-dimethoxyquinazolin-4(3H)-one
##STR00418##
[1745] To a solution of compound 155d (2.50 g, 10.4 mmol) in DMF
(100 mL) was added 1-chloro-3-iodopropane (1.60 mL, 20.8 mmol)
dropwise at 50.degree. C., and the mixture was stirred overnight.
Water was added, and the mixture was extracted with EtOAc. The
organic layer was dried over Na.sub.2SO.sub.4, filtered and
concentrated. The residue was purified by automated silica gel
chromatography (10% MeOH in DCM) to afford compound 158a (2.0 g,
61% yield) as a yellow solid. LCMS: (M+H).sup.+: 316.8.
Step (2): compound 158a.fwdarw.Compound 158b
[1746] Compound 158b:
5-Chloro-3-(3-chloropropyl)-6,7-dihydroxyquinazolin-4(3H)-one
##STR00419##
[1747] To a solution of compound 158a (2.0 g, 6.3 mmol) in DCM (100
mL) was added boron tribromide (2.98 mL, 31.5 mmol) dropwise at
-78.degree. C. The reaction mixture was allowed to warm up slowly
to rt and was stirred overnight. The mixture was diluted with MeOH
and concentrated, and this process was repeated three times to
afford compound 158b (1.7 g, 93% yield). LCMS: (M+H).sup.+:
288.8.
Step (3): compound 158b.fwdarw.Compound 158c
[1748] Compound 158c:
5-Chloro-3-(3-chloropropyl)-6,7-bis((4-methoxybenzyl)oxy)quinazolin-4(3H)-
-one
##STR00420##
[1749] To a solution of compound 158b (3.68 g, 23.5 mmol) in DMF
(100 mL) was added potassium carbonate (4.06 g, 29.4 mmol) and
1-(chloromethyl)-4-methoxybenzene (3.68 g, 23.5 mmol), and this
mixture was stirred at 50.degree. C. overnight. Water was added,
and the mixture was extracted with EtOAc. The organic layer was
dried (Na.sub.2SO.sub.4), filtered and concentrated. The residue
was purified by automated silica gel chromatography to afford
compound 158c (3 g, 96% yield). LCMS: (M+H).sup.+: 529.1.
Step (4): compound 158c.fwdarw.Compound 158d
[1750] Compound 158d:
5-Chloro-6,7-bis((4-methoxybenzyl)oxy)-3-(3-(pyrrolidin-1-yl)propyl)quina-
zolin-4(3H)-one
##STR00421##
[1751] To a solution of compound 158c (3.3 g, 6.2 mmol) in MeCN
(100 mL) were added DIPEA (2.72 mL, 15.6 mmol) and pyrrolidine
(1.29 mL, 15.6 mmol), and this mixture was heated to 80.degree. C.
Analysis of the reaction mixture by LCMS indicated that the
starting material was not fully consumed. Sodium iodide (1.121 g,
7.480 mmol) was added to the reaction mixture, which was then
stirred overnight at the same temperature. The volatiles were
removed, and the residue was dissolved in EtOAc, washed with brine,
NaHCO.sub.3 aq, and water, dried over Na.sub.2SO.sub.4, filtered
and then purified by automated silica gel chromatography (10% MeOH
in DCM) to afford compound 158d (0.9 g, 26% yield). LCMS:
(M+H).sup.+: 564.5.
Step (5): compound X-24+Compound 158d.fwdarw.Compound I-158
[1752] Compound I-158:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((1-(3-(5-chloro-6,7-dihydroxy-4-oxoquinazolin-3(4H)-yl)-
propyl)pyrrolidin-1-ium-1-yl)methyl)-4-methyl-8-oxo-5-thia-1-azabicyclo[4.-
2.0]oct-2-ene-2-carboxylate, Sodium salt
##STR00422##
[1753] This compound was prepared according to the two-Step
sequence of Example 143, using compound 158d and compound X-24.
[1754] LCMS: (M+H).sup.+: 804.9. .sup.1H NMR (400 MHz, D.sub.2O)
.delta. ppm 1.27 (d, J=7.07 Hz, 3H) 1.34 (s, 3H) 1.36 (s, 3H) 2.06
(br. s., 4H) 2.17 (br. s., 2H) 3.27 (s, 2H) 3.31-3.50 (m, 6H)
3.89-4.12 (m, 3H) 5.07 (d, J=4.80 Hz, 1H) 5.57 (d, J=4.80 Hz, 1H)
6.78 (s, 1H) 6.81 (s, 1H) 8.04 (s, 1H).
Example 159
Synthesis of Compound I-159
Step (1):
[1755]
6,7-bis((4-methoxybenzyl)oxy)-4-oxo-1,4-dihydroquinoline-3-carboxyl-
ate.fwdarw.Compound 159a
[1756] Compound 159a: Ethyl
6,7-bis((4-methoxybenzyl)oxy)-1-methyl-4-oxo-1,4-dihydroquinoline-3-carbo-
xylate
##STR00423##
[1757] To a suspension of ethyl
6,7-bis((4-methoxybenzyl)oxy)-4-oxo-1,4-dihydroquinoline-3-carboxylate
(10.0 g, 20.4 mmol) in DMF (100 mL) was added K.sub.2CO.sub.3 (7.06
g, 51.1 mmol) and iodomethane (3.18 mL, 51.1 mmol). The mixture was
stirred at 50.degree. C. for 2 h. Water was added, the precipitate
was collected by filtration to afford compound 159a (9 g, 87%
yield) as a yellow solid that was used for the next Step without
further purification.
[1758] LCMS: (M+H).sup.+: 504.1.
Step (2): compound 159a.fwdarw.Compound 159b
[1759] Compound 159b:
6,7-Bis((4-methoxybenzyl)oxy)-1-methyl-4-oxo-1,4-dihydroquinoline-3-carbo-
xylic acid
##STR00424##
[1760] To a suspension of compound 159a (9.0 g, 17.9 mmol) in a
mixture of methanol (10 mL) and water (5 mL) was added KOH (5.0 g,
89 mmol) portionwise. The resulting mixture was stirred at
90.degree. C. for 3 h. The reaction mixture was cooled down to rt
and concentrated. The residue was diluted with water and the pH of
the solution was adjusted to 1 using 2 N HCl aq. The precipitate
was collected by filtration and dried to afford compound 159b (9 g,
92% yield) as a pale yellow solid. The crude product was used in
next Step without further purification. LCMS: (M+H).sup.+:
476.4.
Step (3): compound 159b.fwdarw.Compound 159c
[1761] Compound 159c:
3-(1,4-diazabicyclo[3.2.2]nonane-4-carbonyl)-6,7-bis((4-meth
oxybenzyl)oxy)-1-methylguinolin-4(1H)-one
##STR00425##
[1762] To a solution of compound 159b (3.0 g, 5.5 mmol) in DMF (30
mL) were added HATU (3.13 g, 8.23 mmol) and DIPEA (2.88 mL, 16.5
mmol). The mixture was stirred for 0.5 h, and
1,4-diazabicyclo[3.2.2]nonane (1.16 mL, 8.23 mmol) was added. The
reaction mixture was stirred for 1 h. Water was added and the
product was extracted with DCM and washed with sodium bicarbonate.
The crude material was purified by automated silica gel
chromatography using a 24 g column and eluting with 0-20% MeOH in
DCM to afford compound 159c (1.8 g, 56% yield) as a yellow solid.
LCMS: (M+H).sup.+: 584.6
Step (4): compound X-24+Compound 159c.fwdarw.Compound I-159
[1763] Compound I-159:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((4-(6,7-dihydroxy-1-methyl-4-oxo-1,4-dihydroquinoline-3-
-carbonyl)-1,4-diazabicyclo[3.2.2]nonan-1-ium-1-yl)methyl)-4-methyl-8-oxo--
5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, Sodium salt
##STR00426##
[1764] This compound was prepared according to the two-Step
sequence of Example 143, using compound 159c and compound X-24.
LCMS: (M+H).sup.+: 825.1. .sup.1H NMR (400 MHz, D.sub.2O) .delta.
ppm 1.33-1.51 (m, 9H) 2.27 (br. s., 4H) 3.31-3.87 (m, 10H)
3.92-4.07 (m, 2H) 4.11-4.28 (m, 2H) 4.75-4.80 (m, 1H) 5.32 (d,
J=5.05 Hz, 1H) 5.68-5.76 (m, 1H) 6.84-6.90 (m, 1H) 6.98 (br. s.,
1H) 7.46-7.54 (m, 1H) 7.96-8.06 (m, 1H).
Example 160
Synthesis of Compound I-160
[1765] Step (1): compound 149j.fwdarw.Compound 160a
[1766] Compound 160a:
3-(1,4-diazabicyclo[3.2.2]nonane-4-carbonyl)-5-chloro-6,7-bis((4-methoxyb-
enzyl)oxy)-1-methylquinolin-4(1H)-one
##STR00427##
[1767] To a solution of compound 149j (2.5 g, 4.9 mmol) in DMF (50
mL) were added HATU (2.80 g, 7.35 mmol) and DIPEA (3.43 mL, 19.6
mmol), and the resulting mixture was stirred at rt for 30 min. Then
1,4-diazabicyclo[3.2.2]nonane (0.804 g, 6.37 mmol) was added, and
the resulting mixture was stirred at rt for 1 h. Water and EtOAc
were added to the mixture. The organic phase was separated, and the
aqueous phase was extracted with EtOAc three times. The combined
organic extracts were washed with brine, dried over
Na.sub.2SO.sub.4, filtered, and concentrated under vacuum. The
residue was purified by automated silica gel chromatography (0-10%
solvent Bin solvent A; solvent A=DCM, solvent
B=10:90:1MeOH:DCM:NH.sub.4OH, 24 g column). The collected brown
solid was dissolved in DCM and washed with water, and then the
organic layer was concentrated. The residue was further purified by
automated silica gel chromatography (0-10% MeOH in DCM, 4 g column)
to afford compound 160a (1.17 g, 39% yield) as a brown solid. LCMS:
(M+H).sup.+: 618.5.
Step (2): compound X-24+Compound 160a.fwdarw.Compound I-160
[1768] Compound I-160:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((4-(5-chloro-6,7-dihydroxy-1-methyl-4-oxo-1,4-dihydroqu-
inoline-3-carbonyl)-1,4-diazabicyclo[3.2.2]nonan-1-ium-1-yl)methyl)-4-meth-
yl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, Sodium
salt
##STR00428##
[1769] This compound was prepared according to the two-Step
sequence of Example 143, using compound 160a and compound X-24.
[1770] LCMS: (M+H).sup.+: 859.2. H NMR (400 MHz, D.sub.2O) .delta.
ppm 1.33-1.55 (m, 9H) 2.07-2.34 (m, 4H) 3.31-3.91 (m, 11H) 4.20
(br. s., 3H) 4.76 (d, J=6.32 Hz, 1H) 5.32 (d, J=4.80 Hz, 1H) 5.72
(d, J=4.80 Hz, 1H) 6.84 (s, 1H) 6.85-6.88 (m, 1H) 7.86-7.95 (m,
1H).
Example 161
Synthesis of Compound I-161
[1771] Step (1): compound 155d.fwdarw.Compound 147a
[1772] Compound 161a:
5-chloro-6,7-dimethoxy-3-methylquinazolin-4(3H)-one
##STR00429##
[1773] To a mixture of K.sub.2CO.sub.3 (24.5 g, 177 mmol) and
compound 155d (21.3 g, 89.0 mmol) in DMF (100 mL) was added
iodomethane (11.02 mL, 177 mmol) at rt, and the resluting mixture
was stirred at 50.degree. C. for 1 h. The mixture was cooled down
to room temperature and poured into ice-water (700 mL). The
resulting aqueous mixture was stirred for 15 min and filtered to
afford compound 161a (19.3 g, 86% yield) as a yellow solid. LCMS:
(M+H).sup.+: 255.2.
Step (2): compound 161a.fwdarw.Compound 161b
[1774] Compound 161b:
5-chloro-6,7-dihydroxy-3-methylquinazolin-4(3H)-one
##STR00430##
[1775] To a solution of compound 161a (18.0 g, 70.7 mmol) in DCM
(150 mL) was added tribromoborane (24.30 mL, 247.0 mmol) at
-78.degree. C. The mixture was allowed to warm up to rt, and
stirred overnight. The mixture was diluted with MeOH and
concentrated, diluted again with MeOH and concentrated, and this
procedure was repeated several times to afford compound 161b (16.3
g, 99% yield). LCMS: (M+H).sup.+: 227.1.
Step (3): compound 161b.fwdarw.Compound 161c
[1776] Compound 161c:
5-chloro-6,7-bis((4-methoxybenzyl)oxy)-3-methylquinazolin-4(3H)-one
##STR00431##
[1777] To a solution of compound 161b (16.3 g, 71.9 mmol) in DMF
(250 mL) was added K.sub.2CO.sub.3 (29.8 g, 216 mmol), followed by
1-(chloromethyl)-4-methoxybenzene (29.4 mL, 216 mmol). Then the
reaction mixture was stirred at 50.degree. C. for 2 h. Water was
added and the mixture was stirred at rt for 15 min. The yellow
precipitate was collected by filtration and washed with water to
afford compound 161c (40 g, 98% yield). LCMS: (M+H).sup.+:
467.2.
Step (4): compound 161c.fwdarw.Compound 161d
[1778] Compound 161d: Potassium
6-amino-2-chloro-3,4-bis((4-methoxybenzyl)oxy)benzoate
##STR00432##
[1779] To a solution of compound 161c (36 g, 63 mmol) in methanol
(300 mL) and water (200 mL) was added KOH (355 g, 6320 mmol). The
mixture was heated at reflux temperature overnight. The mixture was
cooled to rt and water (100 mL) was added. The resulting yellow
precipitate was collected by filtration and washed with water (20
mL). The residue was diluted with diisopropyl ether and DCM (2:1
ratio, 900 mL), and the solid was collected by filtration, rinsing
with the same solvent mixture (2.times.60 mL), to afford compound
161d (23.6 g, 77% yield) as a light brown solid.
[1780] LCMS: (M+H).sup.+: 444.2.
Step (5): compound 161ad.fwdarw.Compound 161e
[1781] Compound 161e:
5-chloro-6,7-bis((4-methoxybenzyl)oxy)-3-(quinuclidin-4-ylmethyl)quinazol-
in-4(3H)-one
##STR00433##
[1782] To a mixture of compound 161e (5.0 g, 10.4 mmol) in DMF (25
mL) were added trimethoxymethane (56.7 mL, 519 mmol), DIPEA (18.12
mL, 104.0 mmol) and quinuclidin-4-ylmethanamine, 2 Hydrochloride
(ref: WO2011125966A1, 3.29 g, 15.6 mmol). The mixture was stirred
at 115.degree. C. for 6 h. Water was added, and the mixture was
extracted with DCM and washed with 2 N NaOH aq. The organic extract
was purified by automated normal phase chromatography using a 160 g
basic alumina column and eluting with 30-80% solvent A in solvent B
(solvent A=EtOAc/EtOH/Et.sub.3N, 76:24:1 ratio; solvent B=Hexane)
to afford compound 161e (3.0 g, 50% yield) as a yellow solid. LCMS:
(M+H).sup.+: 576.4.
Step (6): compound X-24+Compound 161e.fwdarw.Compound I-161
[1783] Compound I-161:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((4-((5-chloro-6,7-dihydroxy-4-oxoquinazolin-3(4H)-yl)me-
thyl)quinuclidin-1-ium-1-yl)methy
1)-4-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate,
Sodium salt
##STR00434##
[1784] This compound was prepared according to the two-Step
sequence of Example 143, using compound 161e and compound X-24.
LCMS: (M+H): 817.4. .sup.1H NMR (400 MHz, D.sub.2O) .delta. ppm
1.37 (s, 3H) 1.39 (s, 3H) 1.42 (d, J=7.07 Hz, 3H) 1.86 (t, J=7.71
Hz, 6H) 3.25-3.46 (m, 6H) 3.85-4.00 (m, 4H) 4.49 (d, J=14.40 Hz,
1H) 5.30 (d, J=5.05 Hz, 1H) 5.71 (d, J=4.80 Hz, 1H) 6.84 (br. s.,
1H) 6.86 (s, 1H) 7.96 (s, 1H).
Example 162
Synthesis of Compound I-162
Step (1):
[1785] 6-amino-2-chloro-3,4-bis((4-methoxybenzyl)oxy)benzoate
[1786] Compound 162a
[1787] Compound 162a:
6-amino-2-chloro-3,4-bis((4-methoxybenzyl)oxy)-N-(quinuclidin-4-ylmethyl)-
benzamide
##STR00435##
[1788] To a solution of potassium
6-amino-2-chloro-3,4-bis((4-methoxybenzyl)oxy)benzoate (5.0 g, 10.4
mmol) in acetonitrile (400 mL) were added HATU (3.94 g, 10.4 mmol)
and DIPEA (9.06 mL, 51.9 mmol), and the mixture was stirred for 0.5
h at rt. Quinuclidin-4-ylmethanamine, 2 Hydrochloride
(WO2011125966A1, 2.65 g, 12.5 mmol) was then added, and the mixture
was stirred for 1 h at rt. Water was added, and the mixture was
extracted with DCM and washed with aq sodium bicarbonate. The crude
material was purified by automated silica column chromatography
using a 24 g column and eluting with 40-90% solvent A in solvent B
(solvent A=EtOAc/EtOH/Et.sub.3N, 76:24:1 ratio; solvent B=Hexane)
to afford compound 162a (2.46 g, 42% yield) as a yellow solid.
LCMS: (M+H).sup.+: 566.4.
Step (2): compound 162a.fwdarw.Compound 162b
[1789] Compound 162b:
5-chloro-6,7-bis((4-methoxybenzyl)oxy)-3-(quinuclidin-4-ylmethyl)quinazol-
ine-2,4(1H,3H)-dione
##STR00436##
[1790] A mixture of compound 162a (100 mg, 0.177 mmol) and CDI (86
mg, 0.53 mmol) in THF (20 mL) was heated to reflux temperature for
24 h. The solution was cooled to rt and was partitioned between
EtOAc and water. The organic phase was dried over Na.sub.2SO.sub.4,
filtered and concentrated. The crude material was purified by
automated silica gel chromatography using a 24 g column and eluting
with 0-20% MeOH (containing 1% NH.sub.4OH) in DCM to afford
compound 162b (100 mg, 96% yield). LCMS: (M+H).sup.+: 592.4.
Step (3): compound X-24+Compound 162b.fwdarw.Compound 162c
[1791] Compound 162c:
1-(((4S,6R,7R)-7-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)
oxy)imino)-2-(2-((tert-butoxycarbonyl)amino)
thiazol-4-yl)acetamido)-2-(((4-methoxybenzyl)oxy)carbonyl)-4-methyl-8-oxo-
-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl)-4-((5-chloro-6,7-bis((4-m-
ethoxybenzyl)oxy)-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)methyl)quinucli-
din-1-ium, Iodide
##STR00437##
[1792] To a mixture of compound 162b (0.101 g, 0.171 mmol) in DMF
(2 mL) at 0.degree. C. was added compound X-24 (0.166 g, 0.188
mmol). The mixture was stirred at the same temperature over 1 h.
The solution was poured into ice-cooled 5% NaCl aq (20 mL) and the
resulting slurry was stirred for .about.15 min. The solid was
collected by filtration, rinsed with water (2.times.), and dried
under high vacuum to afford the desired product as a yellow solid
(0.27 g, 70% yield).
[1793] LCMS: (M+H).sup.+: 1349.6.
Step (4): compound 162c.fwdarw.Compound I-162
[1794] Compound I-162:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl-2-(((2-carboxypropan-2-yl)oxy)im-
ino)acetamido)-3-((4-((5-chloro-6,7-dihydroxy-2,4-dioxo-1,2-dihydroquinazo-
lin-3(4H)-yl)methyl)quinuclidin-1-ium-1-yl)methyl)-4-methyl-8-oxo-5-thia-1-
-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, Sodium salt
##STR00438##
[1795] To a solution of compound 162c (0.233 g, 0.102 mmol) in DCM
(1 mL) at 0.degree. C. was added anisole (0.11 mL, 1.03 mmol),
followed by TFA (0.30 mL, 3.89 mmol). The mixture was stirred
overnight at rt. Diisopropyl ether (10 mL) was then added. The
mixture was stirred for 10 min, and the precipitate was collected
by filtration, and rinsed twice with diisopropyl ether (2.times.2
mL) The solid was dissolved in a mixture of MeCN (2 mL), water (2
mL), and 2 M HCl aq (0.5 mL), and HP20SS resin (2 g) was added. The
mixture was concentrated to dryness, and the resin was loaded onto
a pre-column containing HP20SS resin (4 g). The pre-column was
installed on the Combiflash instrument and washed with water (flow
rate=75 mL/min) until the eluting fractions were at pH 4.5
(.about.5 min). The product was then purified by automated reverse
phase chromatography (100 g C18 Gold column, 10% MeCN/water for 8
min, then 18% MeCN/water for 15 min) to afford
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((4-((5-chloro-6,7-dihydroxy-2,4-dioxo-1,2-dihydroquinaz-
olin-3(4H)-yl)methyl)quinuclidin-1-ium-1-yl)methyl)-4-methyl-8-oxo-5-thia--
1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate (53 mg) as an off white
solid. This compound was suspended in water (HPLC grade, 10 mL),
and cooled to 0.degree. C. To the vigorously stirring suspension
was added 0.1 N NaOH aq slowly using an Eppendorf pipette until the
pH of the solution was .about.5.5, and a small piece of dry ice was
added to quench any excess NaOH. The resulting clear solution was
then frozen and lyophilized to afford compound I-162 (53 mg, 59%
yield) as an off-white solid. LCMS: (M+H).sup.+: 833.1. .sup.1H NMR
(400 MHz, D.sub.2O) .delta. ppm 1.36 (s, 3H) 1.38 (s, 3H) 1.41 (d,
J=6.57 Hz, 3H) 1.83 (br. s., 6H) 3.14-3.48 (m, 6H) 3.91 (d, J=15.92
Hz, 4H) 4.46 (d, J=13.89 Hz, 1H) 5.30 (br. s., 1H) 5.71 (d, J=4.55
Hz, 1H) 6.17-6.33 (m, 1H) 6.86 (s, 1H).
Example 163
Synthesis of Compound I-163
[1796] Step (1): compound 150d.fwdarw.Compound 163a
[1797] Compound 163a:
2-amino-4,5-bis((4-methoxybenzyl)oxy)-N-(8-methyl-8-azabicyclo[3.2.1]octa-
n-3-yl)benzamide
##STR00439##
[1798] To a solution of compound 150d (4.0 g, 9.8 mmol) in
acetonitrile (300 mL) were added HATU (4.46 g, 11.7 mmol) and DIPEA
(8.53 mL, 48.8 mmol), and the mixture was stirred for 0.5 h at rt.
(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-amine, 2 Hydrochloride
(2.499 g, 11.72 mmol) was then added, and the mixture was stirred
for 2 h at rt. Water was added and the mixture was extracted with
DCM and washed with sodium bicarbonate. The organic extract was
purified by automated silica gel chromatography using a 24 g column
and eluting with 0-20% MeOH (containing 1% NH.sub.4OH) in DCM to
afford compound 163a (3.4 g, 66% yield) as a yellow solid. LCMS:
(M+H)+: 532.4.
Step (2): compound 163a.fwdarw.Compound 163b
[1799] Compound 163b:
6,7-Bis((4-methoxybenzyl)oxy)-3-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)
quinazolin-4(3H-one
##STR00440##
[1800] A mixture of compound 163a (1.5 g, 2.8 mmol),
trimethoxymethane (30.9 mL, 282 mmol) and methanol (30 mL) was
heated to 100.degree. C. for 7 d. Water was added, and the mixture
was extracted with DCM and washed with aq sodium bicarbonate. The
organic extract was purified by automated silica gel chromatography
using a 24 g column and eluting with 0-15% MeOH (containing 1%
NH.sub.4OH) in DCM to afford compound 163b (1.2 g, 79% yield) as a
yellow solid.
[1801] LCMS: (M+H).sup.+: 542.4
Step (3): compound X-24+Compound 163b.fwdarw.Compound I-163
[1802] Compound I-163:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-(((1R,5S,8s)-3-(6,7-dihydroxy-4-oxoquinazolin-3(4H)-yl)--
8-methyl-8-azabicyclo[3.2.1]octan-8-ium-8-yl)methyl)-4-methyl-8-oxo-5-thia-
-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, Sodium salt
##STR00441##
[1803] This compound was prepared according to the two-step
sequence of Example 162, using compound 163b and compound X-24.
LCMS: (M+H).sup.+: 783.4. .sup.1H NMR (400 MHz, D.sub.2O) .delta.
ppm 1.38 (s, 3H) 1.40 (s, 3H) 1.46 (d, J=7.07 Hz, 3H) 2.18 (t,
J=16.42 Hz, 2H) 2.25-2.36 (m, 2H) 2.37-2.55 (m, 2H) 2.82-3.00 (m,
2H) 3.03 (s, 3H) 3.84-4.09 (m, 5H) 4.80-4.92 (m, 1H) 5.35 (d,
J=4.80 Hz, 1H) 5.71 (d, J=4.80 Hz, 1H) 6.82 (s, 1H) 6.88 (s, 1H)
7.27 (s, 1H) 8.09 (s, 1H).
Example 164
Synthesis of Compound I-164
[1804] Step (1): 2-amino-4,5-bis((4-methoxybenzyl)oxy)benzoic
acid.fwdarw.Compound 164a
[1805] Compound 164a:
3-(1-azabicyclo[2.2.1]heptan-4-ylmethyl)-6,7-bis((4-methoxybenzyl)oxy)qui-
nazolin-4(3H)-one
##STR00442##
[1806] To a solution of
2-amino-4,5-bis((4-methoxybenzyl)oxy)benzoic acid (1.0 g, 2.4 mmol)
in DMF (10 mL) were added trimethoxymethane (24.05 mL, 220.0 mmol),
DIPEA (1.280 mL, 7.33 mmol) and
1-azabicyclo[2.2.1]heptan-4-ylmethanamine, 2 Hydrochloride (0.730
g, 3.66 mmol). The mixture was stirred at 115.degree. C. for 2 h.
Water was added, and the mixture was extracted with DCM and washed
with 2 N NaOH aq. The organic extract was purified by automated
silica gel chromatography, using a 24 g column and eluting with
0-15% MeOH (containing 1% NH.sub.4OH) in DCM to afford compound
164a (0.43 g, 33% yield) as a slightly yellow solid. LCMS:
(M+H).sup.+: 528.4.
Step (2): compound X-24+Compound 164a.fwdarw.Compound I-141
[1807] Compound I-164:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((4-((6,7-dihydroxy-4-oxoquinazolin-3(4H)-yl)methyl)-1-a-
zabicyclo[2.2.1]heptan-1-ium-1-yl)methyl)-4-methyl-8-oxo-5-thia-1-azabicyc-
lo[4.2.0]oct-2-ene-2-carboxylate, Sodium salt
##STR00443##
[1808] This compound was prepared according to the two-step
sequence of Example 162, using compound 164a and compound X-24.
LCMS: (M+H).sup.+: 769.4. .sup.1H NMR (400 MHz, D.sub.2O) .delta.
ppm 1.36 (s, 3H) 1.38 (s, 3H) 1.41 (d, J=7.07 Hz, 3H) 1.90 (br. s.,
2H) 2.08 (br. s., 2H) 3.21-3.62 (m, 6H) 3.92 (d, J=7.07 Hz, 1H)
4.12 (d, J=14.40 Hz, 1H) 4.27 (br. s., 2H) 4.74-4.77 (m, 1H) 5.24
(d, J=4.80 Hz, 1H) 5.65 (d, J=4.80 Hz, 1H) 6.86 (s, 1H) 6.91 (s,
1H) 7.34 (s, 1H) 8.03 (s, 1H).
Example 165
Synthesis of Compound I-165
[1809] Step (1): compound 161d.fwdarw.Compound 165a
[1810] Compound 165a:
3-(1-azabicyclo[2.2.1]heptan-4-ylmethyl)-5-chloro-6,7-bis((4-methoxybenzy-
l)oxy)quinazolin-4(3H)-one
##STR00444##
[1811] To a mixture of compound 161d (1.0 g, 2.07 mmol) in DMF (10
mL) were added trimethoxymethane (20.43 mL, 187.0 mmol), DIPEA
(1.09 mL, 6.22 mmol) and 1-azabicyclo[2.2.1]heptan-4-ylmethanamine,
2 Hydrochloride (0.620 g, 3.11 mmol). Then, the mixture was stirred
at 115.degree. C. for 2 h. Water was added, and the mixture was
extracted with DCM and washed with 2 N NaOH aq. The crude product
was purified by automated silica gel chromatography using a 24 g
column and eluting with 0-15% MeOH (containing 1% NH.sub.4OH) in
DCM to afford compound 165a (0.36 g, 31% yield) as a slight yellow
solid. LCMS: (M+H).sup.+: 562.4.
Step (2): compound X-24+Compound 165a.fwdarw.Compound I-165
[1812] Compound I-165:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((4-((5-chloro-6,7-dihydroxy-4-oxoquinazolin-3(4H)-yl)me-
thyl)-1-azabicyclo[2.2.1]heptan-1-ium-1-yl)methyl)-4-methyl-8-oxo-5-thia-1-
-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, Sodium salt
##STR00445##
[1813] This compound was prepared according to the two-step
sequence of Example 162, using compound 165a and compound X-24.
[1814] LCMS: (M+H).sup.+: 802.8. .sup.1H NMR (400 MHz, D.sub.2O)
.delta. ppm 1.36 (s, 3H) 1.38 (s, 3H) 1.41 (d, J=7.33 Hz, 3H) 1.92
(d, J=16.17 Hz, 2H) 2.08 (br. s., 2H) 3.20-3.62 (m, 6H) 3.93 (q,
J=6.99 Hz, 1H) 4.11 (d, J=14.40 Hz, 1H) 4.23 (s, 2H) 4.75 (s, 1H)
5.26 (d, J=4.80 Hz, 1H) 5.65 (d, J=4.55 Hz, 1H) 6.80 (s, 1H) 6.87
(s, 1H) 8.02 (s, 1H).
Example 166
Synthesis of Compound I-166
[1815] Step (1): 4-nitrobenzene-1,2-diol.fwdarw.Compound 166a
[1816] Compound 166a:
4,4'-(((4-nitro-1,2-phenylene)bis(oxy))bis(methylene))bis(methoxybenzene)
##STR00446##
[1817] To a solution of 4-nitrobenzene-1,2-diol (9.6 g, 62 mmol) in
DMF (100 mL) was added K.sub.2CO.sub.3 (25.7 g, 186 mmol) followed
by 1-(chloromethyl)-4-methoxybenzene (21.0 mL, 155 mmol). The
reaction mixture was stirred at 50.degree. C. for 2 h. Water was
added, and the mixture was stirred at room temperature for 15 min.
The resulting yellow precipitate was collected by filtration and
washed with water to afford compound 166a (25.8 g, 95% yield) as a
yellow solid. This material was used in the next Step without
purification. LCMS: (M+H+Na).sup.+: 418.1.
Step (2): compound 166a.fwdarw.Compound 166b
[1818] Intermediate 3,4-bis((4-methoxybenzyl)oxy)aniline
##STR00447##
[1819] Under an atmosphere of nitrogen, a mixture of compound 166a
(29.5 g, 74.6 mmol), ethanol (150 mL), and water (150 mL) was
treated with Na.sub.2S.9H.sub.2O (179 g, 746 mmol) for 2 h at
100.degree. C. The mixture was allowed to cool down, and then was
poured into cold water. The resulting yellow precipitate was
collected by filtration, washed with water and dried to afford
compound 166b (26.3 g, 96% yield) as a yellow solid. This material
was used in next Step without purification. LCMS: (M+H).sup.+:
366.1.
Step (3): compound 166b.fwdarw.Compound 166c
[1820] Compound 166c:
5-(((3,4-bis((4-methoxybenzyl)oxy)phenyl)amino)methylene)-2,2-dimethyl-1,-
3-dioxane-4,6-dione
##STR00448##
[1821] To a solution of compound 166b (19.5 g, 53.4 mmol) in iPrOH
(150 mL) was added
5-(methoxymethylene)-2,2-dimethyl-1,3-dioxane-4,6-dione (9.64 mL,
55.9 mmol) at room temperature. The resulting mixture was heated to
80.degree. C. for 20 min. Over this time, the mixture became a
thick slurry that was difficult to stir. The reaction mixture was
cooled to room temperature, diluted with a small amount of iPrOH to
afford a more fluid slurry, and then filtered through a Buchner
funnel rinsing with iPrOH. The collected yellow solid was used in
the next Step without further purification. LCMS: (M+H+Na).sup.+:
542.2.
Step (4): compound 166c.fwdarw.Compound 166d
[1822] Compound 166d: 6,7-bis((4-methoxybenzyl)oxy)quinolin-4
(1H)-one
##STR00449##
[1823] Diphenylether (60 mL) was heated to a boil using a heating
mantle. Solid compound 166c (14.0 g, 26.9 mmol) was added
portionwise, and the resulting solution was heated for 5 min. The
mixture was cooled until it was lukewarm, and then hexane was
added. The mixture was stirred well, and then filtered through a
Buchner funnel. The collected solid was again suspended in hexane,
stirred for 30 min, and then filtered to afford compound 166d (11
g, 82% yield). This material was used in the next Step without
further purification. LCMS: (M+H).sup.+: 418.1.
Step (5): compound 166d.fwdarw.Compound 166e
[1824] Compound 166e:
3-(hydroxymethyl)-6,7-bis((4-methoxybenzyl)oxy)quinolin-4(1H)-one
##STR00450##
[1825] A slurry of compound 166d (5.10 g, 12.2 mmol) in ethanol (30
mL) was heated to 80.degree. C. for 20 min to aid solubility of the
starting material. (Note: the starting material does not completely
dissolve at elevated temperature, but all clumps are broken up.)
The mixture was removed from the oil bath to add 1 M sodium
hydroxide aq (30.5 mL, 30.5 mmol) and formaldehyde (37% aq
solution, 25.5 mL, 342 mmol), and this mixture was heated at
80.degree. C. for 4 h. The reaction mixture was cooled to room
temperature by adding ice, and the resulting slurry was stirred for
20 min to break up the clumps. The product was collected by
filtration through a Buchner funnel. The solid was washed with
water followed by hexanes, and was dried under vacuum overnight to
afford compound 166e (4.69 g, 86% yield) as a tan solid. This
material was used without purification. LCMS: (M+H).sup.+:
448.2.
Step (6): compound 166e.fwdarw.Compound 166f
[1826] Compound 166f:
3-(hydroxymethyl)-6,7-bis((4-methoxybenzyl)oxy)-1-((2-(trimethylsilyl)eth-
oxy)methyl)quinolin-4(1H)-one
##STR00451##
[1827] To a suspension of sodium hydride (0.326 g, 8.14 mmol) in
THF (72.6 mL) was added compound 166e (4.6 g, 7.4 mmol), and the
mixture was stirred at room temperature for 30 min. Then, SEMCl
(1.44 mL, 8.14 mmol) was added, and the mixture was stirred at room
temperature for 3 h. The mixture was concentrated onto silica gel,
and the resulting residue was purified by automated silica gel
chromatography (100% DCM, then 0-10% MeOH/DCM over 10 min, 40 g
column) to afford compound 166f (2.2 g, 51% yield) as a dark brown
solid. LCMS: (M+H).sup.+: 578.2.
Step (7): compound 166f.fwdarw.Compound 166g
[1828] Compound 166g:
6,7-bis((4-methoxybenzyl)oxy)-4-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)--
1,4-dihydroquinoline-3-carbaldehyde
##STR00452##
[1829] To a solution of compound 166f (2.2 g, 3.8 mmol) in DCM (50
mL) was added manganese dioxide (4.97 g, 57.1 mmol), and the
mixture was stirred at room temperature overnight. The mixture was
filtered through a celite cake rinsing with DCM, and the filtrate
was concentrated to afford compound 166g (2.1 g, 96% yield) as a
yellow solid. This material was used in the next Step without
purification. LCMS: (M+H).sup.+: 576.2.
Step (8): compound 166g.fwdarw.Compound 166h
[1830] Compound 166h:
6,7-bis((4-methoxybenzyl)oxy)-3-(pyrrolidin-1-ylmethyl)-1-((2-(trimethyls-
ilyl)ethoxy)methyl)quinolin-4(1H)-one
##STR00453##
[1831] To a solution of compound 166g (2.1 g, 3.7 mmol) in DCM (40
mL) was added pyrrolidine (0.452 mL, 5.47 mmol) and acetic acid
(10.4 .mu.L, 0.182 mmol), and the homogeneous solution was stirred
at room temperature for 30 min. Then, NaBH(OAc).sub.3 (1.55 g, 7.30
mmol) was added, and the mixture was stirred for 1.5 h. The
reaction mixture was diluted with DCM, and then washed successively
with saturated NaHCO.sub.3 (aq), NaOH (aq), and brine. The organic
layer was concentrated, and then MeOH (30 mL) and 5 N NaOH (2 mL)
were added. The resulting mixture was stirred at room temperature
for 0.5 h. The volatiles were removed, and the residue was purified
twice via automated silica gel chromatography to afford compound
166h (1.65 g, 72% yield) as a pale yellow solid. LCMS: (M+H).sup.+:
631.3. .sup.1H NMR (DMSO-d.sub.6): 7.96 (s, 1H), 7.64 (s, 1H), 7.41
(d, J=8.6 Hz, 2H), 7.38 (d, J=8.6 Hz, 2H), 6.96 (d, J=6.6 Hz, 2H),
6.94 (d, J=6.6 Hz, 2H), 5.61 (s, 2H), 5.19 (s, 2H), 5.12 (s, 2H),
3.76 (s, 3H), 3.75 (s, 3H), 3.51 (t, J=8.3 Hz, 2H), 3.47 (s, 2H),
2.44-2.50 (m, 4H), 1.62-1.74 (m, 4H), 0.78-0.89 (m, 2H), -0.08 (s,
9H).
Step (9): compound X-24+Compound 166h.fwdarw.Compound I-166
[1832] Compound I-166:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((1-((6,7-dihydroxy-4-oxo-1,4-dihydroquinolin-3-yl)methy-
l)pyrrolidin-1-ium-1-yl)methyl)-4-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]o-
ct-2-ene-2-carboxylate, Sodium salt
##STR00454##
[1833] This compound was prepared according to the two-step
sequence of Example 162, using compound 166h and compound X-24.
LCMS: (M+H).sup.+: 742.1. 742.4. .sup.1H NMR (D.sub.2O): 8.05 (s,
1H), 7.41 (s, 1H), 6.89 (s, 1H), 6.86 (s, 1H), 5.70 (d, J=4.8 Hz,
1H), 5.34 (d, J=4.8 Hz, 1H), 4.76-4.83 (m, 2H), 4.27-4.44 (m, 2H),
4.11 (d, J=13.9 Hz, 1H), 3.91-4.04 (m, 1H), 3.39-3.55 (m, 1H),
3.16-3.34 (m, 3H), 1.96-2.20 (m, 4H), 1.34-1.39 (m, 9H).
Example 167
Synthesis of Compound I-167
[1834] Step (1): 6,7-dimethoxyquinolin-4(1H)-one.fwdarw.Compound
167a compound 167a: 6,7-dimethoxy-5-nitroquinolin-4(1H)-one
##STR00455##
[1835] A thick, dark solution of 6,7-dimethoxyquinolin-4(1H)-one
(10 g, 48.7 mmol) in sulfuric acid (40 mL, 750 mmol) was cooled to
0.degree. C., and potassium nitrate (4.93 g, 48.7 mmol) was added
in small portions, maintaining the temperature below 10.degree. C.
After the addition was complete, the mixture was stirred for 10 min
and was poured onto ice-water (300 mL). A yellow solid precipitated
which was collected by filtration and washed with water and
ethanol. The solid was collected and dried in vacuo to afford
compound 167a (13.2 g, 108% yield) as a pale yellow solid. This
crude material was used in next Step without purification. LCMS:
(M+H).sup.+: 250.9.
Step (2): compound 167a.fwdarw.Compound 167b
[1836] Compound 167b: 5-amino-6,7-dimethoxyquinolin-4(1H)-one
##STR00456##
[1837] A solution of compound 166a (13.2 g, 52.8 mmol) in EtOH (40
mL) and DCM (80 mL) was placed under vacuum, flushed with an
atmosphere of hydrogen, and this process was repeated six times.
Then, 10% Pd/C (5.61 g, 5.28 mmol) was added. The mixture was
stirred for 12 h and then filtered rinsing with generous amounts of
ethanol. The filtrate was concentrated to afford compound 167b e
(11.3 g, 88% yield) as a yellow solid. LCMS: (M+H).sup.+:
220.9.
Step (3): compound 167b.fwdarw.Compound 167c
[1838] Compound 167c:
5-chloro-6-hydroxy-7-methoxyquinolin-4(1H)-one
##STR00457##
[1839] To a stirring mixture of compound 167b (12.2 g, 55.4 mmol)
in conc. HCl aq (50 mL, 1650 mmol) at 0.degree. C. was added a
solution of sodium nitrite (4.01 g, 58.2 mmol) in water (17 mL),
dropwise. The mixture was stirred at 0.degree. C. for 10 min, at
which point LCMS indicated the formation of a diazo-intermediate
having one methoxy group de-methylated. To the orange suspension
was added conc. HCl aq (50 mL), and the resulting mixture was
heated to 95.degree. C. for 1 h. The reaction mixture was cooled
down to room temperature, and was filtered and dried to afford
compound 167c (10.2 g, 76% yield) as a pale yellow solid. The crude
product was used in next Step without purification. LCMS:
(M+H).sup.+: 225.9.
Step (4): compound 167c.fwdarw.Compound 167d
[1840] Compound 167d: 5-chloro-6,7-dihydroxyquinolin-4(1H)-one
##STR00458##
[1841] To a solution of compound 167c (9.0 g, 40 mmol) in DCM (100
mL) was added tribromoborane (5.66 mL, 59.8 mmol) at -78.degree. C.
The mixture was stirred for 2 h at room temperature. The mixture
was diluted with MeOH (50 mL) and concentrated, and this process
was repeated five times to afford compound 167d (12.5 g, 148%
yield) as a brown solid. This material was carried forward to the
next Step without purification. LCMS: (M+H).sup.+: 211.9.
Step (5): compound 167d.fwdarw.Compound 167e
[1842] Compound 167e
5-chloro-6,7-bis((4-methoxybenzyl)oxy)quinolin-4 (1H)-one
##STR00459##
[1843] To a solution of compound 167f (10.5 g, 29.8 mmol) in DMF
(100 mL) was added K.sub.2CO.sub.3 (8.23 g, 59.5 mmol), followed by
1-(chloromethyl)-4-methoxybenzene (8.07 mL, 59.5 mmol). The
reaction mixture was stirred at 50.degree. C. for 2 h. Water (200
mL) and DCM (150 mL) were added, and the mixture was stirred at
room temperature for 15 min. The aqueous phase was extracted with
DCM (two times). The combined organic phases were dried, filtered,
and concentrated to afford a residue that was purified via
automated normal phase chromatography (0-10% MeOH in DCM) to afford
compound 167e (5.3 g, 39% yield) as a crimson solid. LCMS:
(M+H).sup.+: 452.1.
Step (6): compound 167e.fwdarw.Compound 167f
[1844] Compound 167f:
5-chloro-3-(hydroxymethyl)-6,7-bis((4-methoxybenzyl)oxy)quinolin-4(1H)-on-
e
##STR00460##
[1845] A slurry of compound 167e (25 g, 55 mmol) in ethanol (200
mL) was heated to 80.degree. C. to aid solubility of the starting
material. (Note: the starting material does not completely dissolve
at elevated temperature, but all clumps are broken up.) The mixture
was removed from the oil bath to add 1 M sodium hydroxide (aq) (277
mL, 277 mmol) and formaldehyde (37% aq solution, 82 mL, 1100 mmol),
and this mixture was heated at 80.degree. C. for 3 h. The reaction
mixture was cooled to room temperature, and the resulting slurry
was filtered through a Buchner funnel. The solid was washed with
water, followed by hexanes to afford compound 167f (20.4 g, 77%
yield) as a tan solid. LCMS: (M+H).sup.+: 482.0. .sup.1H NMR
(DMSO-d.sub.6): 11.55 (d, J=5.8 Hz, 1H), 7.70 (d, J=5.8 Hz, 1H),
7.48 (d, J=8.6 Hz, 2H), 7.30 (d, J=8.8 Hz, 2H), 7.09 (s, 1H), 7.01
(d, J=8.6 Hz, 2H), 6.85 (d, J=8.6 Hz, 2H), 5.17 (s, 2H), 4.86 (s,
2H), 4.32 (d, J=5.1 Hz, 2H), 3.79 (s, 3H), 3.74 (s, 3H).
Step (7): compound 167f.fwdarw.Compound 167g
[1846] Compound 167g:
5-chloro-3-(hydroxymethyl)-6,7-bis((4-methoxybenzyl)oxy)-1-((2-(trimethyl-
silyl)ethoxy)methyl)quinolin-4 (H)-one
##STR00461##
[1847] To a suspension of compound 167f (28 g, 51.1 mmol) in DMF
(800 mL) was added sodium hydride (2.05 g, 51.1 mmol) and the
mixture was stirred at room temperature for 30 min. Then,
(2-(chloromethoxy)ethyl)trimethylsilane (9.05 mL, 51.1 mmol) was
added, and the mixture was stirred at room temperature for 1 h.
Analysis of the reaction mixture by LC-MS indicated that some
starting material was still present. Water was added to the
reaction mixture, and the precipitate was collected by filtration.
Silica gel and DCM were added to the precipitate, and the resulting
mixture was concentrated and purified by automated silica gel
chromatography (100% DCM, then 0-10% MeOH/DCM) to afford compound
167g (11 g, 19% yield) as a brown oil. LCMS: (M+H).sup.+:
612.2.
Step (8): compound 167g.fwdarw.Compound 167h
[1848] Compound 167h:
5-chloro-6,7-bis((4-methoxybenzyl)oxy)-4-oxo-1-((2-(trimethylsilyl)ethoxy-
)methyl)-1,4-dihydroquinoline-3-carbaldehyde
##STR00462##
[1849] To a solution of
5-chloro-3-(hydroxymethyl)-6,7-bis((4-methoxybenzyl)oxy)-1-((2-(trimethyl-
silyl)ethoxy)methyl)quinolin-4(1H)-one (5.48 g, 6.62 mmol) in DCM
(90 mL) was added manganese(IV) oxide (8.64 g, 99.0 mmol), and the
mixture was stirred at room temperature overnight. The mixture was
filtered through a celite cake, rinsed with DCM, and the filtrate
was concentrated in vacuo to afford compound 167h (4.2 g, 80%
yield). This material was used in the next Step without further
purification. LCMS: (M+H).sup.+: 610.2.
Step (9): compound 167h.fwdarw.Compound 167i
[1850] Compound 167i:
5-chloro-6,7-bis((4-methoxybenzyl)oxy)-4-oxo-1-((2-(trimethylsilyl)ethoxy-
)methyl)-1,4-dihydroquinoline-3-carboxylic acid
##STR00463##
[1851] To a solution of compound 167h (3.64 g, 4.59 mmol) in THF
(140 mL) and t-Butanol (140 mL) was added 2-methylbut-2-ene (22.97
mL, 45.90 mmol) at 10.degree. C. Subsequently, a solution of sodium
chlorite (1.246 g, 13.78 mmol) and sodium dihydrogenphosphate
(1.653 g, 13.78 mmol) in water (45 mL) was added dropwise to the
first solution, and the mixture was stirred overnight at room
temperature. The mixture was then diluted with sat NH.sub.4C1 (aq)
and extracted with DCM. The combined organic extracts were washed
with brine, dried over Na.sub.2SO.sub.4, filtered, and concentrated
in vacuo to afford compound 167i (2.56 g, 89% yield) as a white
solid that was used in the next Step without further purification.
LCMS: (M+H).sup.+: 626.1. .sup.1H NMR (DMSO-d.sub.6): 9.08 (s, 1H),
7.57 (s, 1H), 7.49 (d, J=8.6 Hz, 2H), 7.30 (d, J=8.6 Hz, 2H), 7.01
(d, J=8.6 Hz, 2H), 6.86 (d, J=8.6 Hz, 2H), 5.91 (s, 2H), 5.33 (s,
2H), 4.95 (s, 2H), 3.79 (s, 3H), 3.75 (s, 3H), 3.62 (t, J=8.0 Hz,
2H), 0.88 (t, J=8.0 Hz, 2H), -0.05 (s, 9H).
Step (10): compound 167i.fwdarw.Compound 167j
[1852] Compound 167j:
5-chloro-6,7-bis((4-methoxybenzyl)oxy)-4-oxo-N-(2-(pyrrolidin-1-yl)ethyl)-
-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4-dihydroquinoline-3-carboxamide
##STR00464##
[1853] To a solution of compound 167i (2.20 g, 3.51 mmol) in DMF
(50 mL) was added HATU (1.60 g, 4.22 mmol) and DIPEA (1.84 mL, 10.5
mmol), and the resulting mixture was stirred at room temperature
for 30 min. Then, 2-(pyrrolidin-1-yl)ethanamine (0.47 mL, 3.7 mmol)
was added, and the resulting mixture was stirred at room
temperature for 1 h. Water and EtOAc were added to the mixture, and
the aqueous phase was extracted with EtOAc three times. The
combined organic extracts were washed with brine, dried over
Na.sub.2SO.sub.4, filtered, and concentrated in vacuo. The
resulting residue was purified via automated normal phase
chromatography (24 g column, 0-10% solvent B in solvent A; solvent
A=DCM, solvent B=10:90:1 MeOH:DCM:NH.sub.4OH). The collected solid
was dissolved in DCM and washed with water, and then the organic
layer was concentrated in vacuo. The residue was passed through a
small (4 g) silica gel column (0-10% MeOH in DCM) to afford
compound 167j (1.31 g, 52% yield) as a brown solid. LCMS:
(M+H).sup.+: 722.3.
[1854] .sup.1H NMR (DMSO-d.sub.G): 9.88 (t, J=5.6 Hz, 1H), 8.84 (s,
1H), 7.48 (d, J=8.6 Hz, 2H), 7.45 (s, 1H), 7.30 (d, J=8.6 Hz, 2H),
7.01 (d, J=8.8 Hz, 2H), 6.85 (d, J=8.6 Hz, 2H), 5.81 (s, 1H), 5.28
(s, 2H), 4.91 (s, 2H), 3.79 (s, 3H), 3.75 (s, 3H), 3.59 (t, J=7.8
Hz, 2H), 3.44 (q, J=6.3 Hz, 2H), 2.58 (t, J=6.4 Hz, 2H), 2.44-2.50
(m, 4H), 1.64-1.74 (m, 4H), 0.87 (t, J=7.8 Hz, 2H), -0.06 (s,
9H).
Step (11): compound X-24+Compound 167j.fwdarw.Compound I-167
[1855] Compound I-167:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((1-(2-(5-chloro-6,7-di
hydroxy-4-oxo-1,4-dihydroquinoline-3-carboxamido)ethyl)pyrrolidin-1-ium-1-
-yl)methyl)-4-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxyla-
te, Sodium salt
##STR00465##
[1856] This compound was prepared according to the two-step
sequence of Example 162, using compound 167j and compound X-24.
[1857] LCMS: (M+H).sup.+: 833.2. .sup.1H NMR (D.sub.2O): 8.26 (br.
s., 1H), 6.87 (s, 1H), 6.47-6.57 (m, 1H), 5.70 (d, J=4.5 Hz, 1H),
5.35 (d, J=4.5 Hz, 1H), 4.90 (d, J=14.9 Hz, 1H), 4.17 (d, J=14.1
Hz, 1H), 3.96 (d, J=5.3 Hz, 1H), 3.69-3.90 (m, 2H), 3.56-3.67 (m,
1H), 3.26-3.55 (m, 6H), 2.10 (br. s., 4H), 1.45 (d, J=6.6 Hz, 3H),
1.38 (s, 3H), 1.36 (s, 3H).
Example 168
Synthesis of Compound I-168
[1858] Step (1):
5-chloro-1-ethyl-6,7-bis((4-methoxybenzyl)oxy)-4-oxo-1,4-dihydroquinoline-
-3-carboxylic acid.fwdarw.Compound 168a
[1859] Compound 168a:
5-chloro-1-ethyl-6,7-bis((4-methoxybenzyl)oxy)-4-oxo-N-(quinuclidin-4-ylm-
ethyl)-1,4-dihydroquinoline-3-carboxamide
##STR00466##
[1860] To a solution of
5-chloro-1-ethyl-6,7-bis((4-methoxybenzyl)oxy)-4-oxo-1,4-dihydroquinoline-
-3-carboxylic acid (ref: WO2013052568, 6.11g, 11.7 mmol) and
quinuclidin-4-ylmethanamine (1.799 g, 12.83 mmol) in DCM (700 mL)
was added DIPEA (3.05 mL, 17.5 mmol) and PyBOP (7.28 g, 14.0 mmol)
at room temperature, and the reaction mixture was stirred
overnight. The mixture was concentrated and the residue was
purified via automated silica gel chromatography (120 g column,
0-10% MeOH in DCM), and the isolated product was washed with
saturated NaHCO.sub.3 aq, brine, and water successively. The
resulting material was eluted through a smaller (24 g) silica gel
column (0-10% MeOH in DCM) to afford product (2.28 g, 30% yield) as
a white solid. This material was not very reactive in the
subsequent Step and was determined by .sup.1H NMR to exist in a
salt form, presumably with some form of silica gel as the
counterion. The material was suspended in MeOH and 1 equiv of 5 N
NaOH (aq) was added. The mixture was stirred for 15 min and then
filtered and rinsed with MeOH to afford compound 168a (1.82 g).
LCMS: (M+H).sup.+: 646.1. .sup.1H NMR (DMSO-d.sub.6): 10.04 (t,
J=6.1 Hz, 1H), 8.74 (s, 1H), 7.51 (d, J=8.8 Hz, 2H), 7.31 (d, J=8.6
Hz, 2H), 7.29 (br. s., 1H), 7.02 (d, J=8.6 Hz, 2H), 6.86 (d, J=8.6
Hz, 2H), 5.36 (s, 2H), 4.91 (s, 2H), 4.50 (q, J=6.8 Hz, 2H), 3.79
(s, 3H), 3.75 (s, 3H), 3.11 (d, J=5.8 Hz, 2H), 2.69-2.79 (m, 6H),
1.28-1.37 (m, 9H).
Step (2): compound X-24+Compound 168a.fwdarw.Compound I-168
[1861] Compound I-168:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((4-((5-chloro-1-ethyl-6,7-dihydroxy-4-oxo-1,4-dihydroqu-
inoline-3-carboxamido)methyl)quinuclidin-1-ium-1-yl)methyl)-4-methyl-8-oxo-
-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, Sodium salt
##STR00467##
[1862] This compound was prepared according to the two-Step
sequence of Example 162, using compound 168a and compound X-24.
[1863] LCMS: (M+H).sup.+: 887.4. .sup.1H NMR (D.sub.2O): 8.31 (s,
1H), 6.85 (s, 1H), 6.70 (br. s., 1H), 5.70 (d, J=4.5 Hz, 1H), 5.30
(d, J=4.8 Hz, 1H), 4.52 (d, J=14.1 Hz, 1H), 3.99-4.16 (m, 2H),
3.86-3.98 (m, 2H), 3.24-3.50 (m, 8H), 1.83 (br. s., 6H), 1.42 (d,
J=6.8 Hz, 3H), 1.38 (s, 3H), 1.36 (s, 3H), 1.22-1.30 (m, 3H).
Example 169
Synthesis of Compound I-169
[1864] Step (1): compound 167i.fwdarw.Compound 169a
[1865] Compound 169a:
5-chloro-6,7-bis((4-methoxybenzyl)oxy)-4-oxo-N-(quinuclidin-4-ylmethyl)-1-
-((2-(trimethylsilyl)ethoxy)methyl)-1,4-dihydro
quinoline-3-carboxamide
##STR00468##
[1866] To a solution of compound 167i (980 mg, 1.56 mmol) in DMF
(25 mL) was added HATU (714 mg, 1.88 mmol) and DIPEA (1.09 mL, 6.26
mmol), and the resulting mixture was stirred at room temperature
for 30 min. Then quinuclidin-4-ylmethanamine, 2 Hydrochloride (WO
2011125966A1, 367 mg, 1.72 mmol) was added and the resulting
mixture was stirred at room temperature for 1 h. Water and EtOAc
were added to the mixture, and the aqueous phase was extracted with
EtOAc three times. The combined organic extracts were washed with
brine, dried over Na.sub.2SO.sub.4, filtered, and concentrated in
vacuo. The residue was purified via automated normal phase
chromatography (24 g column, 45-90% solvent B in solvent A; solvent
A=hexanes, solvent B=3:1 EtOAc/EtOH containing 2% NH.sub.4OH) to
afford the desired product as a brown solid. The 1H NMR of this
material suggested that the product exists as a salt form. To the
solid suspended in MeOH was added 200 .mu.L of 6 N NaOH aq, at
which point the mixture became homogeneous. After stirring the
solution for 5 min, it was then passed through an SCX column,
eluting with MeOH. The product was then recovered by eluting with
MeOH containing 1% NH.sub.4OH. The collected material was
concentrated, then redissolved in MeOH and concentrated another two
times to ensure all the NH.sub.4OH was removed. This process
afforded compound 169a (0.896 g, 76% yield) as a brown solid. LCMS:
(M+H).sup.+: 748.7. .sup.1H NMR (DMSO-d.sub.6): 9.94 (t, J=6.1 Hz,
1H), 8.86 (s, 1H), 7.48 (d, J=8.8 Hz, 2H), 7.46 (s, 1H), 7.30 (d,
J=8.6 Hz, 2H), 7.01 (d, J=8.8 Hz, 2H), 6.85 (d, J=8.8 Hz, 2H), 5.82
(s, 2H), 5.28 (s, 2H), 4.91 (s, 2H), 3.79 (s, 3H), 3.75 (s, 3H),
3.59 (t, J=8.0 Hz, 2H), 3.13 (d, J=6.1 Hz, 2H), 2.72-2.82 (m, 6H),
1.30-1.40 (m, 6H), 0.87 (t, J=7.8 Hz, 2H), -0.06 (s, 9H).
Step (2): compound X-24+Compound 169a.fwdarw.Compound I-169
[1867] Compound I-169:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((4-((5-chloro-6,7-dihydroxy-4-oxo-1,4-dihydroquinoline--
3-carboxamido)methyl)quinuclidin-1-ium-1-yl)methyl)-4-methyl-8-oxo-5-thia--
1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, Sodium salt
##STR00469##
[1868] This compound was prepared according to the two-Step
sequence of Example 162, using compound 169a and compound X-24.
[1869] LCMS: (M+H).sup.+: 859.5. .sup.1H NMR (D.sub.2O)
.quadrature.: 8.10 (s, 1H), 6.85 (s, 1H), 6.41 (s, 1H), 5.71 (d,
J=4.8 Hz, 1H), 5.32 (d, J=4.8 Hz, 1H), 4.52 (d, J=14.1 Hz, 1H),
3.82-4.03 (m, 2H), 3.29-3.53 (m, 6H), 3.23 (br. s., 2H), 1.76-1.89
(m, 6H), 1.43 (d, J=6.8 Hz, 3H), 1.39 (s, 3H), 1.37 (s, 3H).
[1870] The compounds shown below were obtained from Compound X-24
and the each corresponding amine which was synthesized in the same
way as example 163 to 169.
Example 170
Synthesis of Compound I-170
[1871] Compound I-170:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((4-((5-chloro-1-cyclopropyl-6,7-dihydroxy-4-oxo-1,4-dih-
ydroquinoline-3-carboxamido)methyl)quinuclidin-1-ium-1-yl)methyl)-4-methyl-
-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, Sodium
salt
##STR00470##
[1872] LCMS: (M+H).sup.+: 899.5. .sup.1H NMR (D.sub.2O): 8.29 (s,
1H), 7.14 (s, 1H), 6.85 (s, 1H), 5.66-5.73 (m, 1H), 5.70 (d, J=4.8
Hz, 1H), 5.30 (d, J=4.8 Hz, 1H), 4.51 (d, J=14.4 Hz, 1H), 3.88-4.00
(m, 2H), 3.30-3.50 (m, 7H), 3.23 (br. s., 2H), 1.82 (br. s., 6H),
1.42 (d, J=6.8 Hz, 3H), 1.38 (s, 3H), 1.36 (s, 3H), 1.16 (d, J=6.3
Hz, 2H), 0.92 (br. s., 2H).
Example 171
Synthesis of Compound I-171
[1873] Compound I-171:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-(((1R,5S,8s)-3-(5-chloro-6,7-dihydroxy-4-oxo-1,4-dihydro-
quinoline-3-carboxamido)-8-methyl-8-azabicyclo[3.2.1]octan-8-ium-8-yl)meth-
yl)-4-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate,
Sodium salt
##STR00471##
[1874] LCMS: (M+H).sup.+: 859.2. .sup.1H NMR (D.sub.2O): 8.19 (br.
s., 1H), 6.88 (s, 1H), 6.54 (br. s., 1H), 5.70 (d, J=4.8 Hz, 1H),
5.34 (d, J=4.5 Hz, 1H), 4.07-4.26 (m, 1H), 3.91-4.04 (m, 3H), 3.86
(br. s., 1H), 2.98 (br. s., 3H), 2.41-2.81 (m, 5H), 2.22-2.40 (m,
3H), 1.90-2.05 (m, 2H), 1.45 (d, J=6.3 Hz, 3H), 1.40 (s, 3H), 1.38
(s, 3H).
Example 172
Synthesis of Compound I-172
[1875] Compound I-172:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((4-((5-chloro-6,7-dihydroxy-1-methyl-4-oxo-1,4-dihydroq-
uinoline-3-carboxamido)methyl)quinuclidin-1-ium-1-yl)methyl)-4-methyl-8-ox-
o-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, Sodium
salt
##STR00472##
[1876] LCMS: (M+H).sup.+: 873.5. .sup.1H NMR (D.sub.2O)
.quadrature.: 8.11 (br. s., 1H), 6.86 (s, 1H), 6.45 (br. s., 1H),
5.71 (d, J=4.0 Hz, 1H), 5.33 (m, 1H), 4.53 (d, J=14.1 Hz, 1H), 3.94
(m, 2H), 3.54 (m, 3H), 3.32-3.50 (m, 7H), 3.23 (m, 2H), 1.83 (m,
6H), 1.43 (d, J=6.3 Hz, 3H), 1.39 (s, 3H), 1.38 (s, 3H).
Example 173
Synthesis of Compound I-173
[1877] Compound I-171:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-(((1R,5S,8s)-3-(5-chloro-6,7-dihydroxy-1-methyl-4-oxo-1,-
4-dihydroquinoline-3-carboxamido)-8-methyl-8-azabicyclo[3.2.1]octan-8-ium--
8-yl)methyl)-4-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxyl-
ate, Sodium salt
##STR00473##
[1878] LCMS: (M+H).sup.+: 873.5. .sup.1H NMR (D.sub.2O): 8.28 (s,
1H), 6.89 (s, 1H), 6.64 (br. s., 1H), 5.67-5.74 (m, 1H), 5.71 (d,
J=4.5 Hz, 1H), 5.35 (d, J=4.5 Hz, 1H), 4.64-4.67 (m, 1H), 4.13-4.20
(m, 1H), 3.94-4.05 (m, 3H), 3.83-3.91 (m, 1H), 3.68 (s, 3H), 3.01
(s, 3H), 2.58-2.80 (m, 3H), 2.44-2.57 (m, 2H), 2.30-2.41 (m, 2H),
1.93-2.06 (m, 3H), 1.46 (d, J=6.8 Hz, 3H), 1.40 (s, 3H), 1.38 (s,
3H).
Example 174
Synthesis of Compound I-174
[1879] Step (1): compound 166b.fwdarw.Compound 174a
[1880] Compound 174a: Diethyl
2-(((3,4-bis((4-methoxybenzyl)oxy)phenyl)amino)methylene)
malonate
##STR00474##
[1881] To a solution of compound 166b (100 g, 274 mmol) in iPrOH
(800 mL) was added diethyl 2-(ethoxymethylene)malonate (60.3 mL,
301 mmol) at room temperature. The resulting solution was heated to
80.degree. C. for 40 min. Over this time, the suspension became
much thicker and was difficult to stir. The mixture was cooled to
room temperature, diluted with a small amount of iPrOH to make the
slurry more fluid, and filtered through a Buchner funnel rinsing
with iPrOH to afford compound 174a (140 g, 96% yield). LCMS:
(M+H).sup.+: 536.4.
Step (2): compound 174a.fwdarw.Compound 174b
[1882] Compound 174b: ethyl
6,7-bis((4-methoxybenzyl)oxy)-4-oxo-1,4-dihydroquinoline-3-carboxylate
##STR00475##
[1883] Diphenyl ether (167 mL) was heated to a boil using a heating
mantle. compound 174a (15.6 g, 29.0 mmol) was added portionwise and
the resulting solution was heated for 10 min. The resulting dark
solution was cooled to room temperature, diluted with hexane. This
entire procedure was performed 8 more times (a total of 140 g of
starting material was processed), and the hexane mixtures from each
batch were combined and filtered to afford crude product as a grey
solid. The solid was diluted again with hexane, and the resulting
slurry was stirred for 30 min and filtered. The collected solid was
diluted with MeOH, heated to 80.degree. C. for 30 min, and then
filtered to afford compound 174b (75 g, 59% yield) LCMS:
(M+H).sup.+: 490.3.
Step (3): compound 174b.fwdarw.Compound 174c
[1884] Compound 174c: ethyl
6,7-bis((4-methoxybenzyl)oxy)-4-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)--
1,4-dihydroquinoline-3-carboxylate
##STR00476##
[1885] To a suspension of compound 174b (20.0 g, 40.9 mmol) in THF
(300 mL) was added K.sub.2CO.sub.3 (8.47 g, 61.3 mmol) and SEMCl
(7.97 ml, 44.9 mmol). The mixture was stirred at room temperature
for 3 h. Water was added to the mixture and the THF was evaporated.
The remaining mixture was extracted with DCM (3.times.200 mL). The
combined organic phases were dried, filtered and concentrated to
afford compound 174c (23 g, 91% yield) as a dark red oil. This
material was used in the next Step without purification. LCMS:
(M+H).sup.+: 620.5.
Step (4): compound 174c.fwdarw.Compound 174d
[1886] Compound 174d:
6,7-bis((4-methoxybenzyl)oxy)-4-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)--
1,4-dihydroquinoline-3-carboxylic acid
##STR00477##
[1887] To a solution of compound 174c (23 g, 37 mmol) in water (200
mL) and MeOH (200 mL) was added NaOH (7.42 g, 186 mmol). The
mixture was stirred at 80.degree. C. for 1 h. The methanol was
evaporated, and HCl aq was added to the solution to adjust the pH
to 6. The precipitated solid was collected by filtration to afford
compound 174d (19.8 g, 90% yield) as a grey solid. LCMS:
(M+H).sup.+: 592.2.
[1888] .sup.1H NMR (DMSO-d.sub.6): 8.63 (s, 1H), 7.75 (s, 1H), 7.41
(d, J=8.6 Hz, 2H), 7.37 (d, J=8.6 Hz, 2H), 7.34 (s, 1H), 6.92-6.97
(m, J=8.6 Hz, 2H), 6.92-6.97 (m, J=9.0 Hz, 2H), 5.66 (s, 2H), 5.19
(s, 2H), 5.09 (s, 2H), 3.76 (s, 3H), 3.75 (s, 3H), 3.54 (t, J=7.8
Hz, 2H), 0.84 (t, J=7.8 Hz, 2H), -0.07 (s, 9H).
Step (5): compound 174d.fwdarw.Compound 174e
[1889] Compound 174e:
3-(1,4-diazabicyclo[3.2.2]nonane-4-carbonyl)-6,7-bis((4-methoxybenzyl)oxy-
)-1-((2-(trimethylsilyl)ethoxy)methyl)quinolin-4 (1H)-one
##STR00478##
[1890] To a solution of compound 174d (24.0 g, 40.6 mmol) in DMF
(250 mL) was added HATU (18.5 g, 48.7 mmol) and DIPEA (28.3 mL, 162
mmol), and the resulting mixture was stirred at room temperature
for 30 min. Then, 1,4-diazabicyclo[3.2.2]nonane (5.63 g, 44.6 mmol)
was added, and the mixture was stirred at room temperature for 1 h.
Water and EtOAc were added and the aqueous phase was extracted with
EtOAc three times. The combined organic extracts were washed with
brine, dried over Na.sub.2SO.sub.4, filtered, and concentrated in
vacuo. The residue was purified via normal phase chromatography (24
g column, 0-10% solvent B in solvent A; solvent A=DCM, solvent
B=10:90:1 MeOH:DCM:NH.sub.4OH). The isolated solid was dissolved in
DCM, washed with water, and then the organic later was
concentrated. The residue was eluted through a small silica gel
column (4 g, 0-10% MeOH/DCM) to afford compound 174e (16.4 g, 58%
yield) as a brown solid. LCMS: (M+H).sup.+: 700.6. .sup.1H NMR
(DMSO-d.sub.6): 8.22 (s, 1H), 7.67 (s, 1H), 7.41 (d, J=8.8 Hz, 2H),
7.39 (d, J=9.1 Hz, 2H), 7.35 (s, 1H), 6.95 (d, J=8.8 Hz, 2H), 6.95
(d, J=8.8 Hz, 2H), 5.63 (s, 2H), 5.21 (s, 2H), 5.14 (s, 2H), 4.53
(br. s., 1H), 3.76 (s, 6H), 3.46-3.59 (t, J=8.1 Hz, 2H), 3.36-3.42
(m, 1H), 2.78-3.04 (m, 6H), 1.43-2.02 (m, 4H), 0.88-1.34 (m, 3H),
0.84 (t, J=8.0 Hz, 2H), -0.07 (s, 9H). Note: This intermediate
exists as a mixture of amide rotamers, as observed by .sup.1H NMR.
Only the shifts for the major rotamer are reported.
Step (4): compound X-24+Compound 174e.fwdarw.Compound I-174
[1891] Compound I-174:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((4-(6,7-dihydroxy-4-oxo-1,4-dihydroquinoline-3-carbonyl-
)-1,4-diazabicyclo[3.2.2]nonan-1-ium-1-yl)methyl)-4-methyl-8-oxo-5-thia-1--
azabicyclo[4.2.0]oct-2-ene-2-carboxylate, Sodium salt
##STR00479##
[1892] This compound was prepared according to the two-Step
sequence of Example 162, using compound 174e and compound X-24.
[1893] LCMS: (M+H).sup.+: 811.3. .sup.1H NMR (D.sub.2O)
.quadrature.: 8.00 (s, 1H), 7.42 (s, 1H), 6.91 (s, 1H), 6.85 (s,
1H), 5.71 (d, J=4.8 Hz, 1H), 5.32 (d, J=5.1 Hz, 1H), 4.77 (br. s.,
1H), 4.17 (d, J=14.1 Hz, 1H), 3.87-4.08 (m, 2H), 3.26-3.85 (m, 8H),
2.26 (m, 3H), 1.45 (d, J=7.3 Hz, 3H), 1.39 (s, 3H), 1.37 (s, 3H).
Note: This analog exists as a mixture of amide rotamers, as
observed by .sup.1H NMR. Only the shifts for the major rotamer are
reported.
[1894] The compounds shown below were obtained from Compound X-24
and the each corresponding amine which was synthesized according to
the synthesis in WO2013052568A1 in the same way as above
example.
Example 175
Synthesis of Compound I-175
[1895] Compound I-175:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((4-((6,7-dihydroxy-4-oxo-1,4-dihydroquinoline-3-carboxa-
mido)methyl)quinuclidin-1-ium-1-yl)methyl)-4-methyl-8-oxo-5-thia-1-azabicy-
clo[4.2.0]oct-2-ene-2-carboxylate, Sodium salt
##STR00480##
[1896] LCMS: (M+H).sup.+: 825.6. .sup.1H NMR (D.sub.2O): 8.39 (s,
1H), 7.34 (s, 1H), 6.86 (s, 1H), 6.68 (br. s., 1H), 5.71 (d, J=4.8
Hz, 1H), 5.31 (d, J=4.5 Hz, 1H), 4.50 (d, J=14.4 Hz, 1H), 3.85-4.02
(m, 2H), 3.38-3.54 (m, 3H), 3.22-3.37 (m, 5H), 1.82 (br. s., 6H),
1.42 (d, J=6.6 Hz, 3H), 1.39 (s, 3H), 1.37 (s, 3H).
Example 176
Synthesis of Compound I-176
[1897] Compound I-176:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((1-(2-(6,7-dihydroxy-4-oxo-1,4-dihydroquinoline-3-carbo-
xamido)ethyl)pyrrolidin-1-ium-1-yl)methyl)-4-methyl-8-oxo-5-thia-1-azabicy-
clo[4.2.0]oct-2-ene-2-carboxylate, Sodium salt
##STR00481##
[1898] LCMS: (M+H).sup.+: 799.6. .sup.1H NMR (D.sub.2O): 8.19 (s,
1H), 7.14 (s, 1H), 6.84 (s, 1H), 6.63 (s, 1H), 5.70 (d, J=4.5 Hz,
1H), 5.35 (d, J=4.8 Hz, 1H), 4.91 (d, J=14.1 Hz, 1H), 4.16 (d,
J=14.4 Hz, 1H), 3.92-4.01 (m, 1H), 3.66-3.88 (m, 2H), 3.56-3.65 (m,
1H), 3.31-3.52 (m, 5H), 1.98-2.19 (m, 4H), 1.45 (d, J=7.1 Hz, 3H),
1.37 (s, 3H), 1.35 (s, 3H).
Example 177
Synthesis of Compound I-177
[1899] Compound I-177:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((4-(5-chloro-6,7-dihydroxy-4-oxo-1,4-dihydroquinoline-3-
-carbonyl)-1,4-diazabicyclo[3.2.2]nonan-1-ium-1-yl)methyl)-4-methyl-8-oxo--
5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, Sodium salt
##STR00482##
[1900] LCMS: (M+H).sup.+: 845.3. .sup.1H NMR (D.sub.2O): 7.87 (br.
s., 1H), 6.84 (s, 1H), 6.70 (br. s., 1H), 5.71 (d, J=4.8 Hz, 1H),
5.31 (d, J=4.8 Hz, 1H), 4.74-4.81 (m, 1H), 4.14-4.28 (m, 2H),
3.92-4.08 (m, 1H), 3.28-3.91 (m, 8H), 2.03-2.34 (m, 4H), 1.44 (d,
J=7.1 Hz, 3H), 1.38 (s, 3H), 1.36 (s, 3H). Note: This analog exists
as a mixture of amide rotamers, as observed by .sup.1H NMR. Only
the shifts for the major rotamer are reported.
Example 178
Synthesis of Compound I-178
[1901] Step (1): compound 167i.fwdarw.Compound 178a
[1902] Compound 178a:
N-(1-azabicyclo[2.2.1]heptan-4-ylmethyl)-5-chloro-6,7-bis((4-methoxybenzy-
l)oxy)-4-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4-dihydroquinoline-3-c-
arboxamide
##STR00483##
[1903] To a solution of compound 167i (2.56 g, 3.27 mmol) in DMF
(80 mL) was added HATU (1.49 g, 3.92 mmol) and DIPEA (2.29 mL, 13.1
mmol), and the resulting mixture was stirred at room temperature
for 30 min. Then, 1-azabicyclo[2.2.1]heptan-4-ylmethanamine, 2
Hydrochloride (WO 2011125966A1, 0.716 g, 3.60 mmol) was added, and
the resulting mixture was stirred at room temperature for 1 h.
Water and EtOAc were added to the mixture, and the aqueous phase
was extracted with EtOAc three times. The combined organic extracts
were washed with brine, dried over Na.sub.2SO.sub.4, filtered, and
concentrated in vacuo. The residue was purified on a Combiflash
instrument using a Biotage KP-NH column (45-90% 3:1 EtOAc/EtOH in
hexanes) to afford compound 178a (560 mg, 23% yield) as a pale
yellow solid. LCMS: (M+H).sup.+: 734.4. .sup.1H NMR (DMSO-d.sub.6):
10.01 (t, J=5.8 Hz, 1H), 8.87 (s, 1H), 7.48 (d, J=8.6 Hz, 2H), 7.46
(s, 1H), 7.30 (d, J=8.3 Hz, 2H), 7.01 (d, J=8.6 Hz, 2H), 6.85 (d,
J=8.6 Hz, 2H), 5.82 (s, 2H), 5.28 (s, 2H), 4.91 (s, 2H), 3.79 (s,
3H), 3.74 (s, 3H), 3.67 (d, J=5.8 Hz, 2H), 3.55-3.62 (m, 4H),
2.70-2.84 (m, 2H), 2.16 (s, 2H), 1.73-1.81 (m, 2H), 1.46-1.58 (m,
2H), 1.13-1.28 (m, 2H), 0.87 (t, J=8.0 Hz, 2H), -0.06 (s, 9H).
Step (2): compound X-24+Compound 178a.fwdarw.Compound 178b
[1904] Compound 178b:
1-(((4S,6R,7R)-7-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)-
imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-(((4-met-
hoxybenzyl)oxy)carbonyl)-4-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-
-3-yl)methyl)-4-((5-chloro-6,7-bis((4-methoxybenzyl)oxy)-4-oxo-1-((2-(trim-
ethylsilyl)ethoxy)methyl)-1,4-dihydroquinoline-3-carboxamido)methyl)-1-aza-
bicyclo[2.2.1]heptan-1-ium
##STR00484##
[1905] To a solution of compound 178a (0.840 g, 1.075 mmol) in DMF
(3.60 mL) at 0.degree. C., was added a solution of compound X-24
(1.00 g, 1.13 mmol) in DMF (3.60 mL), and the mixture was stirred
for 30 min at 0.degree. C. An ice-cold solution of NaCl (5% aq, 30
mL) was added, and the resulting slurry was stirred at 0.degree. C.
for 15 min, filtered and dried in vacuo to afford compound 178b
(1.64 g, 72% yield). This material was used in the next Step
without purification.
[1906] LCMS: (M+H).sup.+: 1492.5.
Step (3): compound 178b.fwdarw.Compound 178c
[1907] Compound 178c:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((4-((5-chloro-6,7-dihydroxy-4-oxo-1,4-dihydroquinoline--
3-carboxamido)methyl)-1-azabicyclo[2.2.1]heptan-1-ium-1-yl)methyl)-4-methy-
l-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
##STR00485##
[1908] To a solution of compound 178b (1.64 g, 0.769 mmol) in DCM
(15 mL) at -40.degree. C., was added anisole (0.840 mL, 7.69 mmol)
and 1 M AlCl.sub.3 in nitromethane (7.69 mL, 7.69 mmol). The
resulting clumpy mixture was stirred at 0.degree. C. for 30 min,
and a solution of MeCN, water, and 1 N HCl aq (1:1:0.25 ratio, 30
mL) was added followed by 30 mL of iPr.sub.2O. The organic layer
was extracted with a solution of 20% MeCN in 0.5 M HCl aq
(2.times.30 mL). To the combined aqueous layers was added HP20SS
resin (8 g), and the mixture was concentrated until all the MeCN
was removed. This sample was filtered through a loading cartridge
that was pre-loaded with more HP20SS resin (15 g). The cartridge
was attached to a Combiflash and 100% water was eluted through the
cartridge until the fractions were pH>4. A reverse phase
Combiflash column was attached (100 g C18 column) and the product
was eluted using 0-20% MeCN/water for 10 min, and then 30%
MeCN/water over 15 min. Pure fractions were collected to afford
compound 178c (370 mg, 55% yield). LCMS: (M+H).sup.+: 845.3.
.sup.1H NMR (DMSO-d.sub.6): 10.38-10.54 (m, 1H), 9.86 (br. s., 1H),
8.43 (s, 1H), 7.31 (br. s., 2H), 6.92 (br. s., 1H), 6.72 (s, 1H),
5.71-5.84 (m, 1H), 5.26 (d, J=5.1 Hz, 1H), 4.93 (m, 1H), 3.92-4.00
(m, 1H), 3.81-3.92 (m, 1H), 3.48-3.63 (m, 6H), 3.22-3.28 (m, 2H),
1.94-2.10 (m, 2H), 1.71 (br. s., 2H), 1.47 (s, 3H), 1.44 (s, 3H),
1.11-1.33 (m, 3H).
Step (4): compound 178c.fwdarw.Compound I-178
[1909] Compound I-178:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((4-((5-chloro-6,7-dihydroxy-4-oxo-1,4-dihydroquinoline--
3-carboxamido)methyl)-1-azabicyclo[2.2.1]heptan-1-ium-1-yl)methyl)-4-methy-
l-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, Sodium
salt
##STR00486##
[1910] A vigorously stirring solution of compound 178c (140 mg,
0.164 mmol) in water (11 mL) and acetonitrile (5.52 mL) was cooled
to 0.degree. C. using an ice bath, and 0.1 M NaOH aq was added
dropwise until the pH was 5.5. A small piece of dry ice was added
to quench any excess sodium hydroxide, and then the acetonitrile
was removed in vacuo. The remaining solution was concentrated by
lyophilization to afford compound I-178 (139 mg, 97% yield).
[1911] LCMS: (M+H).sup.+: 845.3. .sup.1H NMR (D.sub.2O): 8.12 (s,
1H), 6.80 (s, 1H), 6.40 (s, 1H), 5.63 (d, J=4.8 Hz, 1H), 5.24 (d,
J=4.5 Hz, 1H), 4.75-4.80 (m, 1H), 4.15 (d, J=14.7 Hz, 1H), 3.98 (m,
1H), 3.60 (m, 6H), 3.33 (d, J=7.6 Hz, 1H), 3.21 (d, J=7.8 Hz, 1H),
2.11 (m, 2H), 1.87 (m, 2H), 1.42 (d, J=6.8 Hz, 3H), 1.36 (s, 3H),
1.34 (s, 3H).
Example 179
Synthesis of Compound I-179
[1912] Step (1): compound 151d.fwdarw.Compound 179a
[1913] Compound 179a:
N-(1-azabicyclo[2.2.1]heptan-4-ylmethyl)-6,7-bis((4-methoxybenzyl)oxy)-4--
oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-1,4-dihydroquinoline-3-carboxamid-
e
##STR00487##
[1914] To a solution of compound 151d (1.00 g, 1.69 mmol) in DMF
(25 mL) was added HATU (0.771 g, 2.03 mmol) and DIPEA (1.18 mL,
6.76 mmol), and the resulting mixture was stirred at room
temperature for 30 min. Then,
1-azabicyclo[2.2.1]heptan-4-ylmethanamine (WO 2011125966A1, 0.337
g, 1.690 mmol) was added, and the resulting mixture was stirred at
room temperature for 1 h. Water and EtOAc were added to the
mixture, and the aqueous phase was extracted three times with
EtOAc. The combined organic extracts were washed with brine, dried
over Na.sub.2SO.sub.4, filtered and concentrated in vacuo. The
residue was purified by automated chromatography (100% hexanes,
then 0-45% 3:1 EtOAc/EtOH in hexanes, 55 g Biotage.RTM.KP-NH
column) to afford compound 179a (560 mg, 47% yield) as a brown
solid. LCMS: (M+H).sup.+: 700.4. .sup.1H NMR (DMSO-d.sub.6): 10.21
(t, J=5.3 Hz, 1H), 8.86 (s, 1H), 7.78 (s, 1H), 7.44 (s, 1H), 7.42
(d, J=8.6 Hz, 2H), 7.38 (d, J=8.6 Hz, 2H), 6.95 (d, J=8.1 Hz, 2H),
6.96 (d, J=7.8 Hz, 2H), 5.81 (s, 2H), 5.23 (s, 2H), 5.18 (s, 2H),
3.76 (s, 3H), 3.75 (s, 3H), 3.67 (d, J=5.3 Hz, 2H), 3.55 (t, J=7.8
Hz, 2H), 2.69-2.87 (m, 2H), 2.43-2.50 (m, 2H), 2.18 (s, 2H),
1.46-1.62 (m, 2H), 1.21-1.28 (m, 2H), 0.83 (t, J=7.8 Hz, 2H), -0.08
(s, 9H).
Step (2): compound X-24+Compound 179a.fwdarw.Compound 179b
[1915] Compound 179b:
4-((6,7-bis((4-methoxybenzyl)oxy)-4-oxo-1-((2-(trimethylsilyl)ethoxy)meth-
yl)-1,4-dihydroquinoline-3-carboxamido)methyl)-1-(((4S,6R,7R)-7-((Z)-2-(((-
1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-butoxycar-
bonyl)amino)thiazol-4-yl)acetamido)-2-(((4-methoxybenzyl)oxy)carbonyl)-4-m-
ethyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl)-1-azabicyclo[2-
.2.1]heptan-1-ium
##STR00488##
[1916] To a solution of compound 179a (560 mg, 0.784 mmol) in DMF
(2.61 mL) at 0.degree. C., was added a solution of compound X-24
(729 mg, 0.823 mmol) in DMF (2.61 mL) and the mixture was stirred
for 30 min at 0.degree. C. A cold solution of NaCl (5% aq, 30 mL)
was added, and the resulting slurry was stirred at 0.degree. C. for
15 min, filtered and dried under vacuum to afford compound 179b
(1.15 g, 92% yield). This material was used in the next Step
without purification.
[1917] LCMS: (M+H).sup.+: 1457.5.
Step (3): compound 179b.fwdarw.Compound 179c
[1918] Compound 179c:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((4-((6,7-dihydroxy-4-oxo-1,4-dihydroquinoline-3-carboxa-
mido)methyl)-1-azabicyclo[2.2.1]heptan-1-ium-1-yl)methyl)-4-methyl-8-oxo-5-
-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
##STR00489##
[1919] To a solution of compound 179b (1.13 g, 0.646 mmol) in DCM
(15 mL) at -40.degree. C., were added anisole (0.84 mL, 7.7 mmol)
and 1 M AlCl.sub.3 in nitromethane (6.46 mL, 6.46 mmol). The
resulting clumpy mixture was stirred at 0.degree. C. for 30 min. A
mixture of MeCN, water, and 1 N HCl aq (1:1:0.25 ratio, 30 mL) was
added, followed by 30 mL of iPr.sub.2O. The organic layer was
extracted with a solution of 20% MeCN in 0.5 M HCl aq (2.times.30
mL). To the combined aqueous layers was added HP20SS resin (10 g),
and the mixture was concentrated to remove the acetonitrile. The
remaining slurry was filtered through a loading cartridge that was
pre-loaded with HP20SS resin (20 g). The cartridge was attached to
a Combiflash instrument and flushed with 100% water until the
fractions were pH>4. A Yamazen Ultrapack ODS-S-50C glass column
was attached, and the product was eluted with 100% H.sub.2O, 5 min,
0-18% MeCN/H.sub.2O over 30 min, and 18% MeCN/H.sub.2O for 10 min.
The purest fractions were collected to afford compound 179c (200
mg, 38% yield). LCMS: (M+H).sup.+: 811.4. .sup.1H NMR
(DMSO-d.sub.6): 12.82 (br. s., 1H), 10.53 (t, J=5.3 Hz, 1H), 10.37
(br. s., 1H), 10.06 (br. s., 1H), 9.44 (br. s., 1H), 8.47 (br. s.,
1H), 7.52 (s, 1H), 7.33 (br. s., 2H), 7.00 (s, 1H), 6.70 (s, 1H),
5.75 (dd, J=7.3, 5.3 Hz, 1H), 5.26 (d, J=5.1 Hz, 1H), 4.99-5.18 (m,
1H), 3.91-4.09 (m, 2H), 3.43-3.62 (m, 8H), 1.92-2.13 (m, 2H),
1.64-1.78 (m, 2H), 1.46 (s, 3H), 1.44 (s, 3H), 1.19-1.38 (m,
3H).
Step (4): compound 179c.fwdarw.Compound I-179
[1920] Compound I-179:
(4S,6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)i-
mino)acetamido)-3-((4-((6,7-dihydroxy-4-oxo-1,4-dihydroquinoline-3-carboxa-
mido)methyl)-1-azabicyclo[2.2.1]heptan-1-ium-1-yl)methyl)-4-methyl-8-oxo-5-
-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, Sodium salt
##STR00490##
[1921] Compound 179c (200 mg, 0.245 mmol) in water (11 mL) and
acetonitrile (5.50 mL) was cooled to 0.degree. C. using an ice
bath, and 0.2 M NaOH aq was added dropwise until the pH was 5.5. A
small piece of dry ice was added to quench any excess sodium
hydroxide, and then the acetonitrile was removed in vacuo. The
remaining solution was concentrated by lyophilization to afford
compound 1-179 (203 mg, 99% yield). LCMS: (M+H).sup.+: 811.2.
.sup.1H NMR (D.sub.2O): 8.30 (s, 1H), 7.18 (s, 1H), 6.80 (s, 1H),
6.64 (s, 1H), 5.61 (d, J=4.8 Hz, 1H), 5.20 (d, J=4.8 Hz, 1H),
4.73-4.78 (m, 1H), 4.14 (d, J=14.4 Hz, 1H), 3.97 (q, J=7.3 Hz, 1H),
3.64 (d, J=6.8 Hz, 2H), 3.42-3.60 (m, 4H), 3.31 (d, J=8.3 Hz, 1H),
3.23 (d, J=8.6 Hz, 1H), 2.01-2.20 (m, 2H), 1.79-1.93 (m, 2H), 1.41
(d, J=7.1 Hz, 3H), 1.35 (s, 3H), 1.33 (s, 3H).
Example 180
Synthesis of Compound I-180
##STR00491##
[1922] Step (1): Compound 180a.fwdarw.Compound 180b
[1923] Compound 180a (1.45 g, 7.9 mmol) was dissolved into
tetrahydrofuran (15 mL), and thereto was then added lithium
aluminium hydride (0.3 g, 7.9 mmol) at 0.degree. C. The mixture was
stirred at 0.degree. C. for 1 hour. To the reaction mixture was
then added sodium sulfate decahydrate at 0.degree. C. The mixture
was stirred at rt for 1 hour. To the reaction mixture was then
added tert-butyl hydrazinecarboxylate (2.1 g, 15.7 mmol). After
stirring at room temperature for overnight, the insoluble substance
was removed by filtration, and then dissolved ethyl acetate and
added saturated citric acid aqueous solution. The water phase was
separated and extracted with chloroform. The combined organic layer
was dried with anhydrous magnesium sulfate. Magnesium sulfate was
filtrated off, and then the liquid was under reduced pressure to
yield compound 180b (2.28 g, 113%). Compound 180b yielded was used
as it was, without being purified, in the next reaction.
[1924] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 10.52 (1H, s), 7.55 (1H,
s), 2.85-2.77 (2H, m), 2.29 (2H, s), 1.78-1.70 (2H, m), 1.42 (9H,
s), 1.38 (2H, s), 1.26-1.16 (2H, m).
Step (2): Compound 180b.fwdarw.Compound 180c
[1925] The total amount of compound 180b yielded (2.28 g) was
dissolved into methanol (25 mL), and thereto was then added sodium
cyanoborohydride (1.2 g, 19.1 mmol) at 0.degree. C. The mixture was
stirred at 0.degree. C. for 10 minutes, and then added 2 mol/L
hydrochloric acid aqueous solution until it gave a pH of 4.0. After
stirring at room temperature for 2 hours, the mixture was
concentrated and thereto was added 8 mol/L sodium hydroxide aqueous
solution, and then extracted with ethyl acetate. The combined
organic layer was dried with anhydrous sodium sulfate. Sodium
sulfate was filtrated off, and then the liquid was under reduced
pressure to yield compound 180c (2.99 g, 130%). Compound 180c
yielded was used as it was, without being purified, in the next
reaction.
[1926] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 8.22 (1H, s), 4.30 (1H,
s), 2.98 (2H, d, J=4.0 Hz), 2.75-2.69 (2H, m), 2.47-2.41 (2H, m),
2.14 (2H, s), 1.53-1.38 (13H, m).
Step (3): Compound 180c.fwdarw.Compound 180d
[1927] The total amount of compound 180c yielded (2.99 g) was
dissolved in methanol (24 mL), and thereto was then added 4 mol/L
hydrochloric acid solution (23.8 mL, 95 mmol) in 1,4-dioxane at
0.degree. C. After stirring at room temperature for over night, and
the reaction mixture was concentrated under reduced pressure. The
precipitated solid was then collected by filtration, and washed
with 50% methanol/ethyl acetate solution to yield compound 180d
(2.31 g, 113%)
[1928] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 10.78 (1H, s), 7.45-7.20
(4H, m), 3.28-3.22 (2H, m), 3.18 (2H, s), 3.07 (2H, s), 1.97-1.91
(2H, m), 1.72-1.66 (2H, m).
Step (4): Compound X-180d+Compound 180e.fwdarw.Compound 180f
[1929] To a suspension of the total amount of compound 180d yielded
(2.31 g) in 1,4-dioxane (45 mL) was added sodium acetate (3.91 g,
47.7 mmol) and compound 180e (4.81 g, 11.4 mmol). After stirring at
room temperature for 1 hour, thereto was stirred at 70.degree. C.
for 2 hours. The reaction mixture was diluted with a mixture of
ethyl acetate/tetrahydrofuran and aqueous sodium hydroxide
solution, then separated and washed with water and a saturated salt
solution, and dried over sodium sulfate. Sodium sulfate was
filtrated off, and then the liquid was concentrated under reduced
pressure. The compound-containing liquid was subjected to silica
gel column chromatography to elute out the desired compound with
ethyl acetate (10% triethylamine)/methanol (10% triethylamine). The
desired-compound-containing fraction was concentrated under reduced
pressure to yield compound 180f (1.79 g, 35%).
[1930] .sup.1H-NMR (DMSO-D.sub.6) .delta.: 7.60 (1H, s), 7.49 (1H,
s), 7.40-7.36 (4H, m), 6.96-6.93 (4H, m), 5.16 (2H, s), 5.15 (2H,
s), 4.18 (2H, s), 3.75 (3H, s), 3.75 (3H, s), 2.74-2.68 (2H, m),
2.47-2.41 (2H, m), 2.30 (2H, s), 1.57-1.51 (2H, m), 1.20-1.14 (2H,
m).
Step (4): Compound X-24+Compound 180f.fwdarw.Compound
180f.fwdarw.Compound I-180
[1931] Compound X-24 (886 mg, 1.0 mmol) and compound 180f (544 mg,
1.0 mmol) were used to synthesize the target compound in the same
way as Example 120.
[1932] Yielded amount: 225 mg, (28%)
[1933] .sup.1H-NMR (D.sub.2O) .delta.: 7.47 (1H, s), 7.27 (1H, s),
6.98 (1H, s), 5.76 (1H, d, J=4.3 Hz), 5.37 (1H, d, J=4.3 Hz), 4.88
(1H, d, J=14.4 Hz), 4.34 (2H, s), 4.24 (1H, d, J=14.4 Hz), 4.06
(1H, q, J=7.0 Hz), 3.64-3.43 (6H, m), 2.23-2.15 (2H, m), 2.04-1.97
(2H, m), 1.54 (3H, d, J=7.0 Hz), 1.51 (3H, s), 1.49 (3H, s).
[1934] LCMS (m+1)=785
[1935] The compounds shown in the following tabels can be obtained
in the same way exemplified above.
TABLE-US-00001 TABLE 1 Example No. Structure II-1 ##STR00492## II-2
##STR00493## II-3 ##STR00494## II-4 ##STR00495## II-5 ##STR00496##
II-6 ##STR00497## II-7 ##STR00498## II-8 ##STR00499##
TABLE-US-00002 TABLE 2 Example No. Structure II-9 ##STR00500##
II-10 ##STR00501## II-11 ##STR00502## II-12 ##STR00503## II-13
##STR00504## II-14 ##STR00505## II-15 ##STR00506## II-16
##STR00507##
TABLE-US-00003 TABLE 3 Example No. Structure II-17 ##STR00508##
II-18 ##STR00509## II-19 ##STR00510## II-20 ##STR00511## II-21
##STR00512## II-22 ##STR00513## II-23 ##STR00514## II-24
##STR00515##
TABLE-US-00004 TABLE 4 Example No. Structure II-25 ##STR00516##
II-26 ##STR00517## II-27 ##STR00518## II-28 ##STR00519## II-29
##STR00520## II-30 ##STR00521## II-31 ##STR00522## II-32
##STR00523##
TABLE-US-00005 TABLE 5 Example No. Structure II-33 ##STR00524##
II-34 ##STR00525## II-35 ##STR00526## II-36 ##STR00527## II-37
##STR00528## II-38 ##STR00529## II-39 ##STR00530## II-40
##STR00531##
TABLE-US-00006 TABLE 6 Example No. Structure II-41 ##STR00532##
II-42 ##STR00533## II-43 ##STR00534## II-44 ##STR00535## II-45
##STR00536## II-46 ##STR00537## II-47 ##STR00538## II-48
##STR00539##
TABLE-US-00007 TABLE 7 Example No. Structure II-49 ##STR00540##
II-50 ##STR00541## II-51 ##STR00542## II-52 ##STR00543## II-53
##STR00544## II-54 ##STR00545## II-55 ##STR00546##
Test Example 1
[1936] Compound (I) of the invention was evaluated for in vitro
antimicrobial activity thereof.
(Method)
[1937] Measurement of Minimum Inhibitory Concentration (MIC:
.mu.g/mL) was conducted according to CLSI (Clinical and Laboratory
Standards Institute) method, and the amount of bacteria for
inoculation was 5.times.10.sup.5 cfu/mL, and cation-adjusted
Iso-Sensitest broth containing human Apo-transferrin was used as a
test medium, and the experiment was conducted using broth
microdilution method. The bacteria used are listed below.
TABLE-US-00008 TABLE 8 Strain Enzyme No. Species Name Produced
Strain Type 1 E. Coli JMI1890 PER-1, ESBL producing TEM-1 strain 2
A. baumannii JMI7 PER-1, ESBL and OXA-type OXA-23, carbapenemase 51
producing strain 3 A. baumannii JMI2346 OXA-51, ESBL and OXA-type
TEM carbapenemase producing strain 4 K. pneumoniae SR01358 KPC-2
ESBL and KPC-type carbapenemase producing strain
(Results)
[1938] The test results are shown in Tables below. The values of
inhibitory activity are expressed in microgram/mL (.mu.g/ml).
TABLE-US-00009 TABLE 9 Com- E. Coli A. baumannii A. baumannii K.
pneumoniae pound JMI:890 JMI:7 JMI:2346 SR01358 I-1 1 1 16
.ltoreq.0.031 I-3 0.5 0.5 2 .ltoreq.0.031 I-8 1 1 16 0.25 I-10 1 1
8 .ltoreq.0.031 I-11 2 2 16 0.063 I-12 0.25 1 4 .ltoreq.0.031 I-13
1 2 8 0.063 I-14 1 2 8 .ltoreq.0.031 I-15 1 4 16 I-16 0.5 1 8
.ltoreq.0.031 I-17 2 4 16 .ltoreq.0.031 I-20 0.063 0.125 0.5
.ltoreq.0.031 I-21 0.5 0.5 2 0.063 I-22 0.5 0.5 4 .ltoreq.0.031
I-23 1 1 4 0.063 I-24 2 1 8 0.125 I-25 0.25 0.5 2 .ltoreq.0.031
I-26 0.5 0.5 4 .ltoreq.0.031 I-27 0.5 0.5 4 .ltoreq.0.031 I-32 1
0.5 2 0.125 I-33 0.25 1 4 0.063 I-35 0.5 1 16 .ltoreq.0.031 I-36
0.5 0.5 4 0.125 I-37 0.5 1 4 0.125 I-38 0.25 0.25 0.5 0.063 I-39
0.25 0.125 1 0.063 I-40 0.5 1 4 0.063 I-41 1 1 4 0.063 I-42 0.5 0.5
2 0.063 I-43 0.5 1 4 0.063
TABLE-US-00010 TABLE 10 Com- E. Coli A. baumannii A. baumannii K.
pneumoniae pound JMI:1890 JMI:7 JMI:2346 SR01358 I-51 0.5 2 8 0.125
I-52 0.25 1 4 .ltoreq.0.031 I-53 0.25 2 4 0.25 I-60 1 1 4
.ltoreq.0.031 I-61 2 2 16 0.063 I-62 0.063 0.5 2 .ltoreq.0.031 I-63
1 1 .ltoreq.0.031 I-64 0.125 2 4 .ltoreq.0.031 I-65 0.125 0.5 2
.ltoreq.0.031 I-66 0.063 0.25 1 .ltoreq.0.031 I-67 0.25 1 2
.ltoreq.0.031 I-68 0.5 2 8 .ltoreq.0.031 I-69 0.25 1 8
.ltoreq.0.031 I-71 0.25 0.5 2 .ltoreq.0.031 I-72 0.125 1 4
.ltoreq.0.031 I-73 0.063 0.25 2 .ltoreq.0.031 I-74 0.25 0.25 4
.ltoreq.0.031 I-75 0.125 0.25 4 .ltoreq.0.031 I-76 0.25 0.5 4
.ltoreq.0.031 I-77 0.25 0.5 1 .ltoreq.0.031 I-78 0.25 0.5 8
.ltoreq.0.031 I-83 0.063 0.5 2 .ltoreq.0.031 I-84 2 1 16
.ltoreq.0.031 I-85 0.5 2 8 0.25
TABLE-US-00011 TABLE 11 Com- E. Coli A. baumannii A. baumannii K.
pneumoniae pound JMI:1890 JMI:7 JMI:2346 SR01358 I-90 1 0.5 8
.ltoreq.0.031 I-92 2 4 16 0.125 I-94 0.5 1 4 0.063 I-96 0.125 1 8
.ltoreq.0.031 I-98 0.063 0.5 4 .ltoreq.0.031 I-99 1 2 16
.ltoreq.0.031 I-100 0.125 0.5 1 0.063 I-101 0.063 0.25 0.5
.ltoreq.0.031 I-102 0.125 0.5 2 .ltoreq.0.031 I-103 0.25 0.5 2
.ltoreq.0.031 I-104 0.125 1 1 .ltoreq.0.031 I-105 0.25 2 4
.ltoreq.0.031 I-107 0.5 2 4 .ltoreq.0.031 I-108 0.5 0.5 2
.ltoreq.0.031 I-109 0.5 1 8 0.063 I-113 0.25 0.25 4 .ltoreq.0.031
I-114 0.125 0.5 4 .ltoreq.0.031 I-115 0.25 0.25 2 .ltoreq.0.031
I-116 .ltoreq.0.031 0.25 1 .ltoreq.0.031 I-117 .ltoreq.0.031 0.5 1
0.25 I-118 .ltoreq.0.031 0.25 0.5 0.063 I-120 0.063 0.5 2
.ltoreq.0.031 I-121 0.063 0.5 2 .ltoreq.0.031 I-122 0.25 0.5 2
.ltoreq.0.031 I-123 0.125 0.5 4 .ltoreq.0.031 I-124 0.125 0.5 2
.ltoreq.0.031 I-125 0.125 0.5 8 .ltoreq.0.031
TABLE-US-00012 TABLE 12 Com- E. Coli A. baumannii A. baumannii K.
pneumoniae pound JMI:890 JMI:7 JMI:2346 SR01358 I-4 2 1
.ltoreq.0.031 I-54 0.125 0.5 1 .ltoreq.0.031 I-81 0.5 2 8
.ltoreq.0.031 I-126 0.063 0.25 0.5 .ltoreq.0.031 I-130 8
.ltoreq.0.031 I-131 0.125 2 2 0.063 I-132 0.25 1 4 .ltoreq.0.031
I-133 0.063 0.5 2 .ltoreq.0.031 I-134 0.125 1 2 .ltoreq.0.031 I-135
0.125 1 4 .ltoreq.0.031 I-136 0.5 1 2 .ltoreq.0.031 I-137 0.25 0.5
2 .ltoreq.0.031 I-138 0.25 0.5 4 .ltoreq.0.031 I-140 0.5 4
.ltoreq.0.031 I-142 0.25 0.5 2 .ltoreq.0.031 I-150 2 0.5 2
.ltoreq.0.031 I-160 .ltoreq.0.031 0.25 0.5 0.063 I-161 0.125 0.25 4
.ltoreq.0.031 I-164 .ltoreq.0.031 0.5 2 .ltoreq.0.031 I-165
.ltoreq.0.031 0.5 1 .ltoreq.0.031 I-169 0.063 0.25 0.5
.ltoreq.0.031 I-174 4 0.25 1 .ltoreq.0.031 I-177 0.063 0.25 0.5
.ltoreq.0.031 I-180 .ltoreq.0.031 0.5 1 .ltoreq.0.031
[1939] As shown above, Compounds (I) of the invention have a wide
antimicrobial spectrum, in particular, potent antimicrobial
spectrum against Gram negative bacteria, and/or effectiveness
against multidrug-resistant bacteria, and further to exhibit high
stability against beta-lactamase producing Gram negative
bacteria.
Formulation Example 1
[1940] Powder of a compound of the present invention is formulated
to prepare an injecting agent.
INDUSTRIAL APPLICABILITY
[1941] The compounds of the present invention have a wide
antimicrobial spectrum against Gram negative bacteria and Gram
positive bacteria, and are effective as an antimicrobial drug
having high stability against beta-lactamase producing Gram
negative bacteria. Moreover, the present compounds have good
disposition, and high water solubility, and thus particularly
effective as an injecting agent.
* * * * *